<SEC-DOCUMENT>0001193125-17-155092.txt : 20170503
<SEC-HEADER>0001193125-17-155092.hdr.sgml : 20170503
<ACCEPTANCE-DATETIME>20170503080603
ACCESSION NUMBER:		0001193125-17-155092
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170503
DATE AS OF CHANGE:		20170503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		17807201

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d371808d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-Q</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended March&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>or </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">0-24260</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g371808g48q23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">11-3131700</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3854 American Way, Suite A, Baton Rouge, LA 70816 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(225) <FONT STYLE="white-space:nowrap">292-2031</FONT> or <FONT STYLE="white-space:nowrap">(800)&nbsp;467-2662</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has
submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167;232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; <FONT
STYLE="white-space:nowrap">in&nbsp;Rule&nbsp;12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is a shell company (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares outstanding of each of the issuer&#146;s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001
par value, 33,728,276 shares outstanding as of April&nbsp;28, 2017. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><A HREF="#tx371808_1">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><A HREF="#tx371808_2">PART I. FINANCIAL INFORMATION </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM 1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_3">FINANCIAL STATEMENTS:</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_4">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH&nbsp;31, 2017 (UNAUDITED) AND DECEMBER&nbsp;31, 2016</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_5">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE-MONTH PERIODS ENDED MARCH&nbsp;31, 2017 AND 2016 (UNAUDITED)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_6">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE-MONTH PERIODS ENDED MARCH&nbsp;31, 2017 AND 2016 (UNAUDITED)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM 2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_7">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM 3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_8">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM&nbsp;4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_9">CONTROLS AND PROCEDURES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><A HREF="#tx371808_10">PART II. OTHER INFORMATION </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM&nbsp;1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_11">LEGAL PROCEEDINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM&nbsp;1A.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_12">RISK FACTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM 2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_13">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_14">DEFAULTS UPON SENIOR SECURITIES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM&nbsp;4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_15">MINE SAFETY DISCLOSURES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM&nbsp;5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_16">OTHER INFORMATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ITEM&nbsp;6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx371808_17">EXHIBITS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><A HREF="#tx371808_18">SIGNATURES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><A HREF="#tx371808_19">INDEX TO EXHIBITS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_1"></A>SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>When included in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> or in other documents that we file with the Securities and
Exchange Commission (&#147;SEC&#148;) or in statements made by or on behalf of the Company, words like &#147;believes,&#148; &#147;belief,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148;
&#147;projects,&#148; &#147;estimates,&#148; &#147;may,&#148; &#147;might,&#148; &#147;would,&#148; &#147;should&#148; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform
Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the
following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing federal
and state laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business, changes in the case mix of
patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in
payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt
agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to comply with requirements stipulated in our corporate integrity agreement and
changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely
on any forward-looking statement as a prediction of future events.&nbsp;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements
or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&nbsp;For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, filed with the SEC on March&nbsp;1, 2017, particularly, Part I, Item&nbsp;1A - Risk Factors therein, which are incorporated herein by reference and Part
II, Item 1A. Risk Factors of this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Additional risk factors may also be described in reports that we file from time to time with the SEC. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our company website address is
www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and
accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#147;Investors&#148; on our website home page. Visitors to our website can also register to receive automatic <FONT
STYLE="white-space:nowrap">e-mail</FONT> and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website
(under the link &#147;SEC filings&#148;) free of charge our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and
Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available
on the Investor Relations subpage of our website (under the link &#147;Corporate Governance&#148;). </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additionally, the public may read and copy any
of the materials we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at <FONT
STYLE="white-space:nowrap">(800)&nbsp;SEC-0330.</FONT> Our electronically filed reports can also be obtained on the SEC&#146;s internet site at http://www.sec.gov. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_2"></A>PART I. FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_3"></A>ITEM 1. FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_4"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2017<BR>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patient accounts receivable, net of allowance for doubtful accounts of $19,249 and
$17,716</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net of accumulated depreciation of $142,185 and $138,650</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net of accumulated amortization of $28,557 and $27,864</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">756,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">734,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>LIABILITIES AND EQUITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term obligations, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and Contingencies&#151;Note 5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 60,000,000 shares authorized; 35,364,752 and 35,253,577 shares
issued; and 33,693,027 and 33,597,215 shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock at cost 1,671,725 and 1,656,362 shares of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Amedisys, Inc. stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">756,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">734,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_5"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Periods&nbsp;Ended&nbsp;March&nbsp;31</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of service, excluding depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity in loss from equity method investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,923</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to Amedisys, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings per common share:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to Amedisys, Inc. common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings per common share:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to Amedisys, Inc. common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_6"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Periods&nbsp;Ended&nbsp;March&nbsp;31</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash provided by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">401(k) employer match</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity in loss from equity method investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of deferred debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities, net of impact of acquisitions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patient accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of deferred compensation plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions of businesses, net of cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of stock upon exercise of stock options and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of stock to employee stock purchase plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares withheld upon stock vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax benefit from stock options exercised and restricted stock vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest distribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from revolving line of credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments of revolving line of credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments of long-term obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of company stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental Disclosures of Cash Flow Information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes, net of refunds received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. NATURE OF OPERATIONS,
CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries
(&#147;Amedisys,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148;) are a multi-state provider of home health, hospice and personal care services with approximately 75% and 79% of our revenue derived from Medicare for the three-month periods
ended March&nbsp;31, 2017 and 2016, respectively. As of March&nbsp;31, 2017, we owned and operated 326 Medicare-certified home health care centers, 79 Medicare-certified hospice care centers and 16 personal-care care centers in 34 states within the
United States and the District of Columbia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring
adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. Generally Accepted Accounting Principles (&#147;U.S. GAAP&#148;). Our results of operations for the interim periods
presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our
consolidated financial statements and related notes included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, as filed with the Securities and Exchange Commission (&#147;SEC&#148;)
on March&nbsp;1, 2017 (the &#147;Form <FONT STYLE="white-space:nowrap">10-K&#148;),</FONT> which includes information and disclosures not included herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our accounting and reporting
policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and
accompanying notes. Actual results could materially differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reclassifications and Comparability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain reclassifications have been made to prior periods&#146; financial statements in order to conform to the current period&#146;s presentation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited
condensed consolidated financial statements include the accounts of Amedisys, Inc., and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated
financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we
also have certain equity investments that are accounted for as set forth below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity,
which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the
voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $27.8&nbsp;million as of March&nbsp;31, 2017 and
December&nbsp;31, 2016. We account for investments in entities in which we have less than a 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We earn net service revenue
through our home health, hospice and personal-care care centers by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit
basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a <FONT STYLE="white-space:nowrap">60-day</FONT> episode of care as
episodic-based revenue. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we record our service revenue, we record it net of estimated revenue adjustments and contractual
adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the
accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially
impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Home Health Revenue
Recognition </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Medicare Revenue </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net service revenue
is recorded under the Medicare prospective payment system (&#147;PPS&#148;) based on a <FONT STYLE="white-space:nowrap">60-day</FONT> episode payment rate that is subject to adjustment based on certain variables including, but not limited to:
(a)&nbsp;an outlier payment if our patient&#146;s care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&nbsp;a low utilization payment adjustment (&#147;LUPA&#148;) if the number of visits was fewer than five;
(c)&nbsp;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&nbsp;a payment adjustment based upon the level of therapy services required (with various
incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments;
(f)&nbsp;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&nbsp;changes in the base episode payments established by the Medicare Program;
(h)&nbsp;adjustments to the base episode payments for case mix and geographic wages; and (i)&nbsp;recoveries of overpayments. In addition, we make adjustments to Medicare revenue if we find that we are unable to produce appropriate documentation of
a face to face encounter between the patient and physician. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We make adjustments to Medicare revenue to reflect differences between estimated and actual
payment amounts, our discovered inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily
includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable.
Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are
<FONT STYLE="white-space:nowrap">60-day</FONT> episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors
underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on the number of days elapsed during an episode of
care. As of March&nbsp;31, 2017 and 2016, the difference between the cash received from Medicare for a request for anticipated payment (&#147;RAP&#148;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the
resulting credits were recorded as a reduction to our outstanding patient accounts receivable in our condensed consolidated balance sheets for such periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Episodic-based Revenue. </I>We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other
insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">Non-episodic</FONT> based Revenue. </I>Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated <FONT STYLE="white-space:nowrap">per-visit</FONT> rates,
as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine
net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance <FONT
STYLE="white-space:nowrap">co-payment.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hospice Revenue Recognition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Hospice Medicare Revenue </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross revenue is recorded on an
accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general
inpatient care, continuous home care and respite care. Routine care accounts for 98% of our total net Medicare hospice service revenue for each of the three-month periods ended March&nbsp;31, 2017, and 2016. Beginning January&nbsp;1, 2016, the
Centers for Medicare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Medicaid Services (&#147;CMS&#148;) has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two
routine rates, beginning January&nbsp;1, 2016, Medicare is also reimbursing for a service intensity <FONT STYLE="white-space:nowrap">add-on</FONT> (&#147;SIA&#148;). The SIA is based on visits made in the last seven days of life by a registered
nurse (&#147;RN&#148;) or medical social worker (&#147;MSW&#148;) for patients in a routine level of care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We make adjustments to Medicare revenue for an
inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes a historical
collection rate of over 99% on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and
estimate amounts due back to Medicare if we estimate a cap has been exceeded.&nbsp;We record these adjustments as a reduction to revenue and an increase in other accrued liabilities. Beginning for the cap year ending October&nbsp;31, 2014, providers
are required to self-report and pay their estimated cap liability by March 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the following year. As of March&nbsp;31, 2017, we have settled our Medicare hospice reimbursements for all fiscal
years through October&nbsp;31, 2012. As of March&nbsp;31, 2017, we have recorded $0.9&nbsp;million for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October&nbsp;31, 2013 through October&nbsp;31,
2017. As of December&nbsp;31, 2016, we had recorded $0.8&nbsp;million for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October&nbsp;31, 2013 through October&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Hospice <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable.
Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net
service revenue and patient accounts receivable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Personal Care Revenue Recognition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Personal Care Revenue </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We generate net service revenues by
providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our payor clients, including state and local governmental agencies, managed care organizations, commercial
insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation, which are recognized as net
service revenue at the time services are rendered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patient Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of
March&nbsp;31, 2017, there is only one single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables (approximately 13.2%). Thus we believe there are no other significant concentrations of
receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at 365 days or greater. We write off accounts on a monthly basis once we have
exhausted our collection efforts and deem an account to be uncollectible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the credit risk associated with our Medicare accounts, which
represent 58% and 61% of our net patient accounts receivable at March&nbsp;31, 2017 and December&nbsp;31, 2016, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government
payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. During the
three-month periods ended March&nbsp;31, 2017 and 2016, we recorded $3.4&nbsp;million and $1.7&nbsp;million, respectively, in estimated revenue adjustments to Medicare revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe there is a certain level of credit risk associated with <FONT STYLE="white-space:nowrap">non-Medicare</FONT> payors. To provide for our <FONT
STYLE="white-space:nowrap">non-Medicare</FONT> patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Medicare Home Health </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our home health patients, our <FONT
STYLE="white-space:nowrap">pre-billing</FONT> process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are
accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for any subsequent episodes of care contiguous
with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#147;final billed&#148;). The RAP received for that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was
paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Medicare Hospice </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our hospice patients, our <FONT
STYLE="white-space:nowrap">pre-billing</FONT> process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are
accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Home Health, Hospice and Personal Care </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> patients, our <FONT STYLE="white-space:nowrap">pre-billing</FONT> process primarily begins with
verifying a patient&#146;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of <FONT
STYLE="white-space:nowrap">non-Medicare</FONT> accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics
that would subject us to any significant credit risk. We estimate an allowance for doubtful accounts based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of
collectability based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
details our financial instruments where the carrying value and the fair value differ (amounts in millions): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value at Reporting Date Using</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:72.55pt; font-size:8pt; font-family:Times New Roman"><B>Financial Instrument</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value&nbsp;as<BR>of</B><br><B>March&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in&nbsp;Active<BR>Markets for Identical<BR>Items</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable&nbsp;Inputs<BR>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value. The three levels of inputs are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level&nbsp;1 &#150; Quoted prices in active markets for identical assets and liabilities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level&nbsp;2 &#150; Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other
inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level&nbsp;3 &#150; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our
cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts&#146; approximate fair value. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Weighted-Average Shares Outstanding </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net income
per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares
used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-<BR>Month Periods<BR>Ended March&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares outstanding - basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock and stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares outstanding - diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilutive securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;)
<FONT STYLE="white-space:nowrap">2014-09,</FONT> <I>Revenue from Contracts with Customers (Topic 606)</I>, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services
to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">2015-14,</FONT> <I>Revenue from Contracts with Customers (Topic 606): Deferral of the
Effective Date</I>, to defer the effective date of the standard from January&nbsp;1, 2017 to January&nbsp;1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the
decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company does not
expect an impact on its consolidated financial statements upon implementation of ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> and ASU <FONT STYLE="white-space:nowrap">2015-14</FONT> on January&nbsp;1, 2018, but is still evaluating the effect
the standard will have on its related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases
(Topic 842)</I>, which will require lessees to recognize a lease liability and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases (with the exception of short-term leases) at the
commencement date. The ASU is effective for annual and interim periods beginning on or after December&nbsp;15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new
guidance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still evaluating the overall impact on our consolidated
financial statements and related disclosures and the effect of the standard on our ongoing financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2016-09,</FONT> <I>Compensation &#150; Stock Compensation (Topic 718):</I> <I>Improvements to Employee Share-Based Payment Accounting</I>, which will simplify the accounting for share-based payment award transactions,
including income tax consequences, classification of awards as either equity or liability and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December&nbsp;15, 2016. We adopted this
ASU effective January&nbsp;1, 2017, and as a result, we recorded a $0.4&nbsp;million increase to our <FONT STYLE="white-space:nowrap">non-current</FONT> deferred tax asset and retained earnings for tax benefits that were not previously recognized
under the prior rules. Additionally, on a prospective basis, we recorded excess tax benefits as a discrete item in our income tax provision within our condensed consolidated statement of operations for the three-month period ended March&nbsp;31,
2017. Historically these amounts were recorded as additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital in our condensed consolidated balance sheet. We also elected to prospectively apply the change to the presentation of cash payments
made to taxing authorities on the employees&#146; behalf for shares withheld upon stock vesting on our condensed consolidated statements of cash flows for the three-month period ended March&nbsp;31, 2017. We have also elected to continue our current
policy of estimating forfeitures of stock-based compensation awards at grant date and revising in subsequent periods to reflect actual forfeitures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> <I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</I>, which provides specific guidance on eight cash flow
classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December&nbsp;15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition
method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU <FONT
STYLE="white-space:nowrap">2016-15</FONT> will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-01,</FONT> <I>Business Combinations (Topic 805): Clarifying the Definition of a
Business</I>, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The ASU is effective for annual and interim periods beginning after
December&nbsp;15, 2017. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-04,</FONT> <I>Intangibles&#151;Goodwill and Other (Topic 350)&#151;Simplifying the
Test for Goodwill Impairment</I>, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the
difference of the carrying amount to the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December&nbsp;15, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU <FONT
STYLE="white-space:nowrap">2017-04</FONT> will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. ACQUISITIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our
position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#146;s length transactions, with consideration based on our analysis
of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from
acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms
to assist in the fair value determination of identifiable intangible assets. Preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset
valuations and liabilities assumed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;1, 2017, we acquired the assets of Home Staff, L.L.C. which owns and operates three personal-care
care centers servicing the state of Massachusetts for a total purchase price of $4.0&nbsp;million (subject to certain adjustments), of which $0.4&nbsp;million was placed in a promissory note to be paid over 24 months, subject to any offsets or
withholds for indemnification purposes. The purchase price was paid with cash on hand on the date of the transaction. During the three-month period ended March&nbsp;31, 2017, we recorded goodwill ($3.8 million), other intangibles &#150; <FONT
STYLE="white-space:nowrap">non-compete</FONT> agreements ($0.2 million) and other assets and liabilities, net ($0.5 million) in connection with the acquisition. The <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements will be amortized
over a weighted-average period of 2.8 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. LONG-TERM OBLIGATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term debt consisted of the following for the periods indicated (amounts in millions): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$100.0&nbsp;million Term Loan; principal payments plus accrued interest payable quarterly;
interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (2.98% at March&nbsp;31, 2017); due August&nbsp;28, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">95.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$200.0&nbsp;million Revolving Credit Facility; interest only payments; interest rate at ABR Rate
plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August&nbsp;28, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our weighted average interest rate for our $100.0&nbsp;million Term Loan, under our Credit Agreement, was 2.8% and 2.4% for
the three-month periods ended March&nbsp;31, 2017 and 2016, respectively. Our weighted average interest rate for our $200.0&nbsp;million Revolving Credit Facility was 2.7% for the three-month period ended March&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, our consolidated leverage ratio was 0.9, our consolidated fixed charge coverage ratio was 4.1 and we are in compliance with our
Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the <FONT STYLE="white-space:nowrap">non-compliance,</FONT> which might
include, among other things, seeking debt covenant waivers or amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, our availability under our $200.0&nbsp;million
Revolving Credit Facility was $170.4&nbsp;million as we had $29.6&nbsp;million outstanding letters of credit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings - Ongoing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are involved in the
following legal actions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Securities Class&nbsp;Action Lawsuits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, between June&nbsp;10 and July&nbsp;28, 2010, several putative securities class action complaints were filed in the United States
District Court for the Middle District of Louisiana (the &#147;District Court&#148;) against the Company and certain of our former senior executives. The cases were consolidated into the first-filed action <I>Bach, et al. v. Amedisys, Inc., et
al.</I> Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:10-cv-00395,</FONT></FONT> and the District Court appointed as <FONT STYLE="white-space:nowrap">co-lead</FONT> plaintiffs the Public Employees&#146; Retirement
System of Mississippi and the Puerto Rico Teachers&#146; Retirement System (the <FONT STYLE="white-space:nowrap">&#147;Co-Lead</FONT> Plaintiffs&#148;). They filed a consolidated, amended complaint which all defendants moved to dismiss. The District
Court granted the defendants&#146; motions to dismiss on June&nbsp;28, 2012, and the <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Plaintiffs appealed that ruling to the United States Court of Appeals for the Fifth Circuit (the &#147;Fifth
Circuit&#148;). On October&nbsp;2, 2014, a three-judge panel of the Fifth Circuit reversed the District Court&#146;s dismissal and remanded the case to the District Court for further proceedings. The defendants request for an <I>en banc</I> review
was denied on December&nbsp;29, 2014 and their Petition for a Writ of Certiorari from the United States Supreme Court was denied on June&nbsp;29, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After remand to the District Court, the Plaintiffs were granted leave to file a First Amended Consolidated Complaint (the &#147;First Amended Securities
Complaint&#148;) on behalf of all purchasers or acquirers of Amedisys&#146; securities between August&nbsp;2, 2005 and September&nbsp;30, 2011. The First Amended Securities Complaint alleges that the Company and seven individual defendants violated
Section 10(b), Section 20(a), and Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> of the Securities Exchange Act of 1934 by materially misrepresenting the Company&#146;s financial results and concealing a scheme to obtain higher Medicare
reimbursements and additional patient referrals by (1)&nbsp;providing medically unnecessary care to patients, including certifying and <FONT STYLE="white-space:nowrap">re-certifying</FONT> patients for medically unnecessary <FONT
STYLE="white-space:nowrap">60-day</FONT> treatment episodes; (2)&nbsp;implementing clinical tracks such as &#147;Balanced for Life&#148; and wound care programs that provided a <FONT STYLE="white-space:nowrap">pre-set</FONT> number of therapy visits
irrespective of medical need; (3) &#147;upcoding&#148; patients&#146; Medicare forms to attribute a &#147;primary diagnosis&#148; to a medical condition associated with higher billing rates; and (4)&nbsp;providing improper and illegal remuneration
to physicians to obtain patient certifications or <FONT STYLE="white-space:nowrap">re-certifications.</FONT> The First Amended Securities Complaint seeks certification of the case as a class action and an unspecified amount of damages, as well as
interest and an award of attorneys&#146; fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All defendants moved to dismiss the First Amended Securities Complaint on December&nbsp;15, 2015. While
that motion was pending the parties agreed to mediate the case. This mediation was not successful. On August&nbsp;19, 2016, the District Court issued its ruling on the defendants&#146; motions to dismiss, dismissing with prejudice all claims against
two former officers, dismissing all except Section 20(a) claims against three former officers, and denying all other relief. The Company and four individual defendants then filed their answers to the First Amended Securities Complaint on
October&nbsp;20, 2016. The independent executrix of the estate of William F. Borne, who was substituted as a defendant in the case after Mr.&nbsp;Borne&#146;s death, filed her answer on February&nbsp;6, 2017. The case is currently in the early
stages of discovery. The parties have agreed to mediate the case again on June&nbsp;12, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the case is in the early stages of litigation, we
are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the securities litigation described above.&nbsp;The Company intends to continue to vigorously defend itself in the securities litigation
matter but, if decided adverse to the Company, its impact could be material.&nbsp;No assurances can be given as to the timing or outcome of the securities matter described above or the impact of any of the inquiry or litigation matters on the
Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Subpoena Duces Tecum Issued by the U.S. Department of Justice </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;21, 2015, we received a Subpoena Duces Tecum (&#147;Subpoena&#148;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of
information regarding 53 identified hospice patients to the United States Attorney&#146;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related
compliance activities. The Subpoena generally covers the period from January&nbsp;1, 2011, through May&nbsp;21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently
available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Civil Investigative Demand Issued by the U.S. Department of Justice </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2015, we received a civil investigative demand (&#147;CID&#148;) issued by the U.S. Department of Justice pursuant to the federal False
Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney&#146;s
Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from
January&nbsp;1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this
investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal
False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States
Attorney&#146;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period
from January&nbsp;1, 2011 through June&nbsp;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of
this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the matters
referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and
determined, will have a material impact on our consolidated financial condition, results of operations or cash flows. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Investigative Matters -
Ongoing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Integrity Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this
agreement, we entered into a corporate integrity agreement (&#147;CIA&#148;) with the Office of Inspector <FONT STYLE="white-space:nowrap">General-HHS</FONT> (&#147;OIG&#148;). The CIA formalizes various aspects of our already existing ethics and
compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive
compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an
independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk
mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received from federal health care programs, as
well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The corporate integrity
agreement has a term of five years. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Computer Inventory and Data Security Reporting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;1 and March&nbsp;2, 2015, we provided official notice under federal and state data privacy laws concerning the outcome of an extensive risk
management process to locate and verify our large computer inventory. The process identified approximately 142 encrypted computers and laptops for which reports were required under federal and state data privacy laws. The devices at issue were
originally assigned to Company clinicians and other team members who left the Company between 2011 and 2014. We reported these devices to the U.S. Department of Health and Human Services, state agencies, and individuals whose information may be
involved, as required under applicable law because we could not rule out unauthorized access to patient data on the devices. The Office of Civil Rights, U.S. Department of Health and Human Services (&#147;OCR&#148;) is reviewing our compliance with
applicable laws, as is typical for any data breach involving more than 500 individuals. We are cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate with applicable regulatory authorities. In
accordance with our CIA, we have notified the OIG of this matter. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Idaho and Wyoming Self-Report </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2016, the Company engaged an independent auditing firm to perform a clinical audit of the hospice care centers acquired by Frontier Home Health and
Hospice in April 2014. No assurances can be given as to the timing or outcome of the audit on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third Party Audits - Ongoing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time,
in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by the Centers for Medicare and Medicaid Services (&#147;CMS&#148;) conduct extensive review of claims data to
identify potential improper payments under the Medicare program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone
Program Integrity Contractor (&#147;ZPIC&#148;) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&nbsp;1, 2008 through March&nbsp;31, 2010 (the &#147;Review
Period&#148;) to determine whether the underlying services met pertinent Medicare payment requirements.&nbsp;We acquired the hospice operations subject to this review on August&nbsp;1, 2009; the Review Period covers time periods both before and
after our ownership of these hospice operations.&nbsp;Based on the ZPIC&#146;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on
June&nbsp;6, 2011, the Medicare Administrative Contractor (&#147;MAC&#148;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has
filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An ALJ hearing was held in early January 2015. On January&nbsp;18, 2016, we received a letter dated January&nbsp;6, 2016
referencing the ALJ hearing decision for the overpayment issued on June&nbsp;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7&nbsp;million with a balance owed of $5.6&nbsp;million including interest based on 9
disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&nbsp;No assurances can be given as to the
timing or outcome of the Medicare Appeals Council decision. As of June&nbsp;30, 2016, Medicare has withheld payments of $5.7&nbsp;million (including additional interest) as part of their standard procedures once this level of the appeal process has
been reached. In the event we are not able to recoup this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&nbsp;1, 2009. As of March&nbsp;31, 2017, we have an
indemnity receivable for the amount withheld related to the period prior to August&nbsp;1, 2009. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2016, the Company received a request for medical
records from SafeGuard Services, L.L.C (&#147;SafeGuard&#148;), a ZPIC related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our
ownership of the care centers, which were acquired on December&nbsp;31, 2015. Subsequent to the initial ZPIC letter, the Company received additional requests for information regarding its care centers in Florida including post payment claims
reviews, communications regarding suspensions of payment, and letters notifying the Company that various care centers have been placed on prepayment review. As these matters continue to develop, the Company is cooperating with SafeGuard, responding
to all requests for information, and working to resolve these matters. Based on the information currently available to the Company and the uncertainty regarding the scope of this audit, the Company cannot predict the timing or outcome of this audit
or reasonably estimate the amount or range of potential losses, which may arise from this matter. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#146; compensation and professional liability.
While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in
which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves,
are reviewed and updated by us on a quarterly basis. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our health insurance has a retention limit of $0.9&nbsp;million, our workers&#146; compensation
insurance has a retention limit of $0.5&nbsp;million and our professional liability insurance has a retention limit of $0.3&nbsp;million. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. SEGMENT
INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home
health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides
palliative care and comfort to terminally ill patients and their families. Our personal care segment, which was established with the acquisition of Associated Home Care during the three-month period ended March&nbsp;31, 2016, provides patients with
assistance with the essential activities of daily living. The &#147;other&#148; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting,
finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate
expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#146;s chief operating decision maker and therefore are
not disclosed below (amounts in millions). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-Month Period Ended March&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Home<BR>Health</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Hospice</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Personal<BR>Care</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">271.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of service, excluding depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-Month Period Ended March&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Home<BR>Health</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Hospice</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Personal<BR>Care (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">272.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of service, excluding depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="20"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(1) Acquired March&nbsp;1, 2016.</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.&nbsp;SUBSEQUENT EVENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2017, we acquired certain home health and hospice operations from Tenet Healthcare in Arizona, Illinois, Massachusetts, and Texas for a purchase
price of $20.5&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_7"></A>ITEM&nbsp;2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our
results of operations and financial condition for the three-month period ended March&nbsp;31, 2017. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the
consolidated financial statements and notes and the related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2016 filed with the Securities and Exchange Commission (&#147;SEC&#148;) on March&nbsp;1, 2017 (the &#147;Form <FONT STYLE="white-space:nowrap">10-K&#148;),</FONT> which are incorporated herein by this reference. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless otherwise provided, &#147;Amedisys,&#148; &#147;we,&#148; &#147;our,&#148; and the &#147;Company&#148; refer to Amedisys, Inc. and our consolidated
subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a provider of
high-quality <FONT STYLE="white-space:nowrap">in-home</FONT> healthcare and related services to the chronic, <FONT STYLE="white-space:nowrap">co-morbid,</FONT> aging American population, with approximately 75% and 79% of our revenue derived from
Medicare for the three-month periods ended March&nbsp;31, 2017 and 2016, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations involve servicing patients through our three
reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care
that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. As of March&nbsp;31, 2017, we owned and operated
326 Medicare-certified home health care centers, 79 Medicare-certified hospice care centers and 16 personal-care care centers in 34 states within the United States and the District of Columbia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Owned and Operated Care Centers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Home<BR>Health</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Hospice</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Personal<BR>Care</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions/Startups</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closed/Consolidated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At March&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governmental Inquiries and Investigations and Other Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 5 &#150; Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding our corporate integrity
agreement and for a discussion of and updates regarding class action litigation and other legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items.<B><I> </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2017, the Centers for Medicare
and Medicaid Services (&#147;CMS&#148;) issued a proposed rule to update hospice payment rates and the wage index for fiscal year 2018.&nbsp;CMS estimates hospices serving Medicare beneficiaries would see an estimated 1.0% increase in
payments.&nbsp;CMS notes that minus the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), the rate increase would have been a 2.9% market basket adjustment, less the 0.4% productivity adjustment, less 0.3% as required under the ACA (or
+2.2% net).&nbsp;CMS also proposes increasing the aggregate cap by 1.0% to $28,689.04. We expect our impact of the 2018 proposed rule to be in line with that of the hospice industry. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Three-Month Period Ended March&nbsp;31, 2017 Compared to the Three-Month Period Ended March&nbsp;31, 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Consolidated </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results
from continuing operations (amounts in millions): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-<BR>Month Periods<BR>Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin, excluding depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>% of revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>41.8</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>42.1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>% of revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>35.0</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>39.0</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Effective income tax rate</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>39.5</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>41.0</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to Amedisys, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall our operating income increased $14&nbsp;million on a revenue increase of $22&nbsp;million and a $6&nbsp;million
decrease in operating expenses which were offset by a $14&nbsp;million increase in cost of service. The significant improvement was driven by the performance of our hospice division and reductions in corporate operating expenses as the result of <FONT
STYLE="white-space:nowrap">non-recurring</FONT> costs incurred during the three-month period ended March&nbsp;31, 2016. The reduction in corporate operating expenses was partially offset by an increase in our provision for doubtful accounts. For
additional information regarding our provision for doubtful accounts, see &#147;Outstanding Patient Accounts Receivable.&#148; Our home health division was down slightly but overcame the majority of the $4&nbsp;million Centers for Medicare and
Medicaid Services (&#147;CMS&#148;) rate cut effective January&nbsp;1, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Home Health Division </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our home health segment results from continuing operations: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-Month Periods<BR>Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial Information </B><B><I>(in millions)</I></B><B>:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicare</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key Statistical Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Medicare:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Same Store (1):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Admissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recertifications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total (2):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Admissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recertifications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Completed episodes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Visits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,263,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,311,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average revenue per completed episode (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Visits per completed episode (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Medicare:</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Same Store (1):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Admissions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Episodic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Episodic</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recertifications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total (2):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Admissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recertifications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Visits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total (2):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Visiting Clinician Cost per Visit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Manager Cost per Visit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost per Visit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Visits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,818,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,839,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Same store information represents the percent increase (decrease) in our Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue, admissions or recertifications for the period as a percent of the
Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue, admissions or recertifications of the prior period. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Total includes acquisitions. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Operating Results </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, our operating income remained
flat as the result of a $4&nbsp;million decrease in gross margin, offset by a $3&nbsp;million decrease in other operating expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Net Service
Revenue </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Medicare revenue decreased approximately $8&nbsp;million. Approximately $6&nbsp;million of the decrease is due to lower volumes and
increases in contractual reserves. Additionally, we experienced a $4&nbsp;million decrease in revenue per episode as a result of the 2017 CMS rate cut which was offset by a $2&nbsp;million increase related to the acuity level of our patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> revenue increased $7&nbsp;million with revenues and
admissions from episodic payors increasing 35% while our per visit payors decreased 1%. We continue to focus on contract payors with significant concentrations in our markets and those that add incremental margin to our operations as we continue to
evaluate our portfolio of managed care contracts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cost of Service, Excluding Depreciation and Amortization </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cost per visit consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor
the overall delivery of care. Our cost of service increased $2&nbsp;million due to a $2.16 increase in cost per visit as our total visits decreased approximately 1%. The costs associated with our clinicians increased $1.94 driven by a $1.00 increase
related to planned wage increases in July 2016 and $1.00 due to health insurance increases. We continue to focus on improving this metric, and we have seen a $2.86 sequential improvement from the three-month period ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other Operating Expenses </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other operating expenses
decreased $3&nbsp;million due to decreases in other care center related expenses, primarily salaries and benefits as the result of planned decreases during our Homecare Homebase (&#147;HCHB&#148;) rollout. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Hospice Division </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes
our hospice segment results from continuing operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-Month<BR>Periods Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial Information</B><B><I> (in millions):</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicare</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key Statistical Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Same Store (1):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicare revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hospice admissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average daily census</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total (2):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hospice admissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average daily census</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue per day, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of service per day</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average discharge length of stay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Same store information represents the percent increase (decrease) in our Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue, Hospice admissions or average daily census for the period as a percent
of the Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue, Hospice admissions or average daily census of the prior period. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Total includes acquisitions. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Operating Results </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, our operating income increased $6&nbsp;million on a $9&nbsp;million increase in gross margin offset by a $3&nbsp;million increase in other operating
expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Net Service Revenue </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our hospice revenue
increased $13&nbsp;million, primarily due to an increase in our average daily census as a result of a 20% increase in hospice admissions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cost of
Service, Excluding Depreciation and Amortization </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our hospice cost of service increased $4&nbsp;million as the result of a 16% increase in average
daily census. Our cost of service per day decreased $3.28 primarily due to significant improvement in salary cost per day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other Operating Expenses </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other operating expenses increased $3&nbsp;million due to increases in other care center related expenses, primarily salaries and benefits expense and
provision for doubtful accounts. The $2&nbsp;million increase in provision for doubtful accounts is due to continued aging of <FONT STYLE="white-space:nowrap">non-Medicare</FONT> receivables post our HCHB implementation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Personal Care Division </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
summarizes our personal care segment results from continuing operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-Month<BR>Periods Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial Information</B><B><I> (in millions):</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicare</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key Statistical Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Billable hours</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clients served</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2016, we acquired Associated Home Care, a personal care home health care company with nine care centers. On
September&nbsp;1, 2016, we acquired the assets of Professional Profiles, Inc. which owned and operated four personal-care care centers. In addition during the three-month period ended September&nbsp;30, 2016, we opened a <FONT
STYLE="white-space:nowrap">start-up</FONT> personal-care care center. On February&nbsp;1, 2017, we acquired the assets of Home Staff LLC, which owned and operated three personal-care care centers, one of which was subsequently consolidated with one
of our existing personal-care care centers. Operating loss related to our personal care division was less than $1&nbsp;million on net service revenue of $14&nbsp;million and cost of service of $10&nbsp;million; other operating expenses were
approximately $3&nbsp;million. Acquisitions are included in our consolidated financial statements from their respective acquisition dates. As a result, our personal care operating results for the three-month periods ended March&nbsp;31, 2017 and
2016 are not fully comparable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Corporate </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table summarizes our corporate results from continuing operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-<BR>Month Periods<BR>Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial Information</B><B><I> (in millions):</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate expenses consist of costs relating to our executive management and corporate and administrative support functions,
primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. Excluding $2&nbsp;million related to
HCHB implementation and $2&nbsp;million related to various legal matters in 2016, corporate expenses decreased $5&nbsp;million as a result of a reduction in restructuring costs including salaries and benefits, IT fees and personnel costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash
flows for the periods indicated (amounts in millions): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three-<BR>Month Periods<BR>Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by operating activities increased $14.9&nbsp;million during the three-month period ended March 31, 2017 compared
to the three-month period ended March 31, 2016 primarily due to an increase in our cash collections as compared to 2016. For additional information regarding our operating performance and our days revenue outstanding, see &#147;Results of
Operations&#148; and &#147;Outstanding Patient Accounts Receivable&#148;, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities decreased $25.9&nbsp;million
during the three-month period ended March 31, 2017 compared to the three-month period ended March 31, 2016 primarily due to a decrease in our acquisition activity ($23.6 million) and a decrease in capital expenditures ($2.3 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in financing activities increased $3.0&nbsp;million during the three-month period ended March 31, 2017 compared to the three-month period ended
March 31, 2016 primarily due to a decrease in borrowing on our revolving line of credit offset by repurchases of company stock pursuant to our stock repurchase program during the three-month period ended March&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Typically, our principal source of
liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the
incurrence of additional indebtedness or through sales of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three-month period ended March&nbsp;31, 2017, we spent $4.4&nbsp;million in
capital expenditures as compared to $6.7&nbsp;million during the three-month period ended March&nbsp;31, 2016. Our capital expenditures for 2017 are expected to be approximately $10.0 - $12.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, we had $48.3&nbsp;million in cash and cash equivalents and $170.4&nbsp;million in availability under our $200.0&nbsp;million
Revolving Credit Facility. Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Patient Accounts Receivable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
patient accounts receivable, net increased $6.6&nbsp;million from December&nbsp;31, 2016 to March&nbsp;31, 2017. Our cash collection as a percentage of revenue was 100% and 94% for the three-month periods ended March&nbsp;31, 2017 and 2016,
respectively. Our days revenue outstanding, net at March&nbsp;31, 2017 was 40.5 days which is an increase of 0.3 days from December&nbsp;31, 2016. We have experienced a slowdown in collections primarily as the result of our shift from our legacy
platforms (AMS2 and AMS3) to HCHB. We anticipate reductions in days revenue outstanding during 2017 now that we have completed our HCHB implementation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care
center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in
additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the date the episode was completed and varies by state for Medicaid-reimbursable services and among insurance companies and other
private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our provision for estimated revenue adjustments (which is deducted from our service revenue to determine net service revenue) and
provision for doubtful accounts were as follows for the periods indicated (amounts in millions). We fully reserve for both our Medicare and other patient accounts receivable that are aged over 365 days. For those patient accounts that are not aged
over 365 days, we make adjustments to Medicare revenue or our provision for doubtful accounts based on our aging of accounts and historical collection experience. We have experienced a $4&nbsp;million increase in our provision for doubtful accounts
and contractual reserves due to increased write-offs and accounts receivable aging as a result of our conversion to HCHB. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Periods&nbsp;Ended</FONT><BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for estimated revenue adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As a percent of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following schedules detail our patient accounts receivable, net of estimated revenue adjustments, by payor class, aged
based upon initial date of service (amounts in millions, except days revenue outstanding, net): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">0-90</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">91-180</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">181-365</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Over&nbsp;365</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>At March&nbsp;31, 2017:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicare patient accounts receivable, net (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other patient accounts receivable:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicaid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for doubtful accounts (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> patient accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total patient accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Days revenue outstanding, net (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">0-90</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">91-180</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">181-365</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Over 365</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>At December&nbsp;31, 2016:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicare patient accounts receivable, net (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other patient accounts receivable:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medicaid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for doubtful accounts (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> patient accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total patient accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Days revenue outstanding, net (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The following table summarizes the activity and ending balances in our estimated revenue adjustments (amounts in millions), which is recorded to reduce our Medicare outstanding patient accounts receivable to their
estimated net realizable value, as we do not estimate an allowance for doubtful accounts for our Medicare claims. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Period</FONT><BR>Ended&nbsp;March&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Period</FONT><BR>Ended&nbsp;December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for estimated revenue adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write offs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Our estimated revenue adjustments were 4.6% and 3.9% of our outstanding Medicare patient accounts receivable
at March&nbsp;31, 2017 and December&nbsp;31, 2016, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The following table summarizes the activity and ending balances in our allowance for doubtful accounts (amounts in millions), which is recorded to reduce only our Medicaid and private payer outstanding patient accounts
receivable to their estimated net realizable value. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Period</FONT><BR>Ended&nbsp;March&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Period</FONT><BR>Ended&nbsp;December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write offs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Our allowance for doubtful accounts was 21.0% and 21.5% of our outstanding Medicaid and private patient
accounts receivable at March&nbsp;31, 2017 and December&nbsp;31, 2016, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts receivable (i.e., net of estimated revenue adjustments and allowance for doubtful accounts ) at March&nbsp;31, 2017
and December&nbsp;31, 2016 by our average daily net patient revenue for the three-month periods ended March&nbsp;31, 2017 and December&nbsp;31, 2016, respectively. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indebtedness </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our weighted average interest rate
for our $100.0&nbsp;million Term Loan, under our Credit Agreement, was 2.8% and 2.4% for the three-month periods ended March&nbsp;31, 2017 and 2016, respectively. Our weighted average interest rate for our $200.0&nbsp;million Revolving Credit
Facility was 2.7% for the three-month period ended March&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, our consolidated leverage ratio was 0.9, our
consolidated fixed charge coverage ratio was 4.1 and we are in compliance with our Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, our availability under
our $200.0&nbsp;million Revolving Credit Facility was $170.4&nbsp;million as we had $29.6&nbsp;million outstanding in letters of credit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 4 to
our condensed consolidated financial statements and Note 7 of the financial statements included in our Form <FONT STYLE="white-space:nowrap">10-K</FONT> for additional details on our outstanding long-term obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inflation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe inflation has significantly
impacted our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Part II, Item 7 &#150; Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2016 Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of
operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting estimates include revenue recognition; patient accounts receivable; insurance; goodwill and other intangible assets; and
income taxes. There have not been any changes to our significant accounting policies or their application since we filed our 2016 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_8"></A>ITEM&nbsp;3.&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility and Term Loan carry a floating interest rate which is tied to
the Eurodollar rate (<I>i.e.</I> LIBOR) and the Prime Rate and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of March&nbsp;31,
2017, the total amount of outstanding debt subject to interest rate fluctuations was $93.7&nbsp;million. A 1.0% interest rate change would cause interest expense to change by approximately $0.9&nbsp;million annually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_9"></A>ITEM&nbsp;4.&nbsp;CONTROLS AND PROCEDURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 as
amended (the &#147;Exchange Act&#148;) is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC&#146;s rules and forms. This information is also accumulated and communicated to our management and Board
of Directors to allow timely decisions regarding required disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the preparation of this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT>
as of March&nbsp;31, 2017, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and
procedures, as such term is defined under Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective
at a reasonable assurance level as of March&nbsp;31, 2017, the end of the period covered by this Quarterly Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Controls
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule
<FONT STYLE="white-space:nowrap">13a-15(f))</FONT> that have occurred during the quarter ended March&nbsp;31, 2017, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inherent Limitations on Effectiveness of Controls </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal
controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be
met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that
judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of
the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Projections of any evaluation of controls&#146; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies
and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial
officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of March&nbsp;31, 2017, the end of the period covered by this Quarterly Report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_10"></A>PART II. OTHER INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_11"></A>ITEM&nbsp;1. LEGAL PROCEEDINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 5 to the condensed consolidated financial statements for information concerning our legal proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_12"></A>ITEM&nbsp;1A. RISK FACTORS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition to other information set forth in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> you should carefully consider the risk factors included in Part I, Item 1A. &#150; Risk Factors of our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> These risk factors could materially impact our business, financial condition and/or operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial
also may materially adversely impact our business, financial condition and/or operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_13"></A>ITEM&nbsp;2. UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the information with respect to purchases made by us of shares of our
common stock during each of the months during the three-month period ended March&nbsp;31, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(a)&nbsp;Total&nbsp;Number<BR>of&nbsp;Shares&nbsp;(or&nbsp;Units)<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(b)&nbsp;Average&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Paid&nbsp;per&nbsp;Share&nbsp;(or<BR>Unit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(c)&nbsp;Total&nbsp;Number&nbsp;of<BR>Shares (or Units)<BR>Purchased&nbsp;as&nbsp;Part&nbsp;of<BR>Publicly Announced<BR>Plans or Programs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(d)&nbsp;Maximum&nbsp;Number&nbsp;(or<BR>Approximate Dollar<BR>Value) of Shares (or<BR>Units) That May Yet Be<BR>Purchased Under the<BR>Plans or Programs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;1,&nbsp;2017&nbsp;to&nbsp;January&nbsp;31,&nbsp;2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;1,&nbsp;2017&nbsp;to&nbsp;February&nbsp;28,&nbsp;2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;1, 2017 to March&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,363</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock previously awarded
to such employees under our 2008 Omnibus Incentive Compensation Plan. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_14"></A>ITEM&nbsp;3. DEFAULTS UPON SENIOR
SECURITIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_15"></A>ITEM&nbsp;4. MINE SAFETY DISCLOSURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_16"></A>ITEM&nbsp;5. OTHER
INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx371808_17"></A>ITEM&nbsp;6. EXHIBITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits marked with the cross symbol (&#134;) are filed and the exhibits marked with a double cross (&#134;&#134;) are furnished with this Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT>
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Document Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Report or Registration Statement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SEC File or<BR>Registration<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>or Other<BR>Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&nbsp;14, 2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">0-24260</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Composite of <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Company inclusive of all amendments through April&nbsp;20, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">0-24260</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;*10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Composite Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan (inclusive of Plan amendments dated June&nbsp;7, 2012 and October&nbsp;25, 2012, April&nbsp;23, 2015 and June&nbsp;4, 2015, January&nbsp;20, 2017 and
February&nbsp;22, 2017 and the full text of the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">0-24260</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;31.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;31.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Gary D. Willis, Chief Financial Officer (principal financial officer), pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;&#134;32.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;&#134;32.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Gary D. Willis, Chief Financial Officer (principal financial officer), pursuant to 18&nbsp;U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.INS</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Instance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.SCH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.CAL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.DEF</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.LAB</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Labels Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.PRE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_18"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A<SMALL>MEDISYS</SMALL>, I<SMALL>NC</SMALL>.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ SCOTT G. GINN</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Scott G. Ginn,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Principal Accounting Officer and</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Duly Authorized Officer</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;3, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx371808_19"></A>EXHIBIT INDEX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits marked with the cross symbol (&#134;) are filed and the exhibits marked with a double cross (&#134;&#134;) are furnished with this Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT>
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Document Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Report or Registration Statement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SEC File or<BR>Registration<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>or Other<BR>Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&nbsp;14, 2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">0-24260</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Composite of <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Company inclusive of all amendments through April&nbsp;20, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">0-24260</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;*10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Composite Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan (inclusive of Plan amendments dated June&nbsp;7, 2012 and October&nbsp;25, 2012, April&nbsp;23, 2015 and June&nbsp;4, 2015, January&nbsp;20, 2017 and
February&nbsp;22, 2017 and the full text of the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">0-24260</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;31.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;31.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Gary D. Willis, Chief Financial Officer (principal financial officer), pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;&#134;32.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;&#134;32.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Gary D. Willis, Chief Financial Officer (principal financial officer), pursuant to 18&nbsp;U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.INS</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Instance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.SCH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.CAL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.DEF</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.LAB</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Labels Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#134;101.PRE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d371808dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Paul B. Kusserow,
certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
March&nbsp;31, 2017, of Amedisys, Inc.; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b. Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">c. Evaluated the effectiveness of
the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">d. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;3, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ Paul B. Kusserow</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Paul B. Kusserow</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>President and Chief Executive Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(Principal Executive Officer)</B></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d371808dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Gary D. Willis, certify
that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31,
2017, of Amedisys, Inc.; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b. Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">c. Evaluated the effectiveness of
the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">d. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;3, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ Gary D. Willis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gary D. Willis</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Chief Financial
Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(Principal Financial Officer)</B></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d371808dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of Amedisys, Inc. (the &#147;Company&#148;) on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
March&nbsp;31, 2017 (the &#147;Report&#148;), I, Paul B. Kusserow, President and Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities
Exchange Act of 1934; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;3, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ Paul B. Kusserow</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paul B. Kusserow</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>President and
Chief Executive Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(Principal Executive Officer)</B></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d371808dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of Amedisys, Inc. (the &#147;Company&#148;) on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
March&nbsp;31, 2017 (the &#147;Report&#148;), I, Gary D. Willis, Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of
2002, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;3, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ Gary D. Willis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gary D. Willis</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Chief Financial
Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(Principal Financial Officer)</B></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>amed-20170331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Prepared by IBM Cognos FSR v6.7.5.34 using Fujitsu Interstage XWand -->
<xbrli:xbrl xmlns:amed="http://www.amedisys.com/20170331" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric">
  <link:schemaRef xlink:type="simple" xlink:href="amed-20170331.xsd" />
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Apr28_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_ConcentrationRiskByTypeAxis_MedicareRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_ConcentrationRiskByTypeAxis_MedicareRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_amed_CapYearAxis_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_CapYearAxis_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandSixteenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amed:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Feb01_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:HomeStaffLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-02-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:HomeStaffLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:HomeStaffLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:HomeStaffLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Feb01_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:HomeStaffLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:HomeStaffLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2011_TO_Jun06_2011_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-06-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2008_TO_Mar31_2010_amed_StateAxis_SouthCarolinaMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>
      <xbrli:endDate>2010-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:ComputerInventoryAndDataSecurityReportingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:ComputerInventoryAndDataSecurityReportingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:ComputerInventoryAndDataSecurityReportingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_May21_2015_amed_StateAxis_MassachusettsMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-05-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Nov03_2015_amed_StateAxis_MorgantownWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-11-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-01-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Aug02_2005_TO_Sep30_2011_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:SecuritiesClassActionLawsuitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-08-02</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Aug19_2016_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:SecuritiesClassActionLawsuitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:FavorableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-08-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Aug19_2016_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInPartMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:SecuritiesClassActionLawsuitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:FavorableInPartMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-08-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Aug19_2016_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:SecuritiesClassActionLawsuitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-08-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Jun27_2016_amed_StateAxis_ParkersburgWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun30_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_May01_2017_us-gaap_BusinessAcquisitionAxis_TenetHealthcareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:TenetHealthcareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-05-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDollar">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDperShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Agencies">
    <xbrli:measure>amed:Agencies</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Day">
    <xbrli:measure>amed:D</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Number_of_Visits">
    <xbrli:measure>amed:Number_of_Visits</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Beneficiary">
    <xbrli:measure>amed:Beneficiary</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Computers">
    <xbrli:measure>amed:Computers</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Residents">
    <xbrli:measure>amed:Residents</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Claims">
    <xbrli:measure>amed:Claims</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Segments">
    <xbrli:measure>amed:Segments</xbrli:measure>
  </xbrli:unit>
  <dei:DocumentType id="ID_0" contextRef="FROM_Jan01_2017_TO_Mar31_2017">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="ID_1" contextRef="FROM_Jan01_2017_TO_Mar31_2017">2017-03-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="ID_2" contextRef="FROM_Jan01_2017_TO_Mar31_2017">false</dei:AmendmentFlag>
  <dei:DocumentFiscalPeriodFocus id="ID_3" contextRef="FROM_Jan01_2017_TO_Mar31_2017">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="ID_4" contextRef="FROM_Jan01_2017_TO_Mar31_2017">2017</dei:DocumentFiscalYearFocus>
  <dei:TradingSymbol id="ID_5" contextRef="FROM_Jan01_2017_TO_Mar31_2017">AMED</dei:TradingSymbol>
  <dei:CurrentFiscalYearEndDate id="ID_6" contextRef="FROM_Jan01_2017_TO_Mar31_2017">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCentralIndexKey id="ID_7" contextRef="FROM_Jan01_2017_TO_Mar31_2017">0000896262</dei:EntityCentralIndexKey>
  <dei:EntityFilerCategory id="ID_8" contextRef="FROM_Jan01_2017_TO_Mar31_2017">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="ID_9" contextRef="FROM_Jan01_2017_TO_Mar31_2017">AMEDISYS INC</dei:EntityRegistrantName>
  <dei:EntityCommonStockSharesOutstanding id="ID_10" decimals="0" contextRef="AS_OF_Apr28_2017" unitRef="Shares">33728276</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus id="ID_11" contextRef="FROM_Jan01_2017_TO_Mar31_2017">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="ID_12" contextRef="FROM_Jan01_2017_TO_Mar31_2017">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer id="ID_13" contextRef="FROM_Jan01_2017_TO_Mar31_2017">Yes</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_14" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">48334000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="ID_15" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">172707000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseCurrent id="ID_16" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">10097000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent id="ID_17" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">11964000</us-gaap:OtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="ID_18" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">36676000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Goodwill id="ID_19" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">292793000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_20" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">46220000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:DeferredTaxAssetsNetNoncurrent id="ID_21" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">98943000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="ID_22" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">38894000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="ID_23" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">756628000</us-gaap:Assets>
  <us-gaap:PropertyPlantAndEquipmentNet id="ID_24" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">36999000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_25" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">46755000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:OtherAssetsNoncurrent id="ID_26" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">38468000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent id="ID_27" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">166056000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent id="ID_28" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">107940000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Goodwill id="ID_29" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">288957000</us-gaap:Goodwill>
  <us-gaap:Assets id="ID_30" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">734029000</us-gaap:Assets>
  <us-gaap:PrepaidExpenseCurrent id="ID_31" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">7397000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent id="ID_32" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">11260000</us-gaap:OtherAssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_33" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">30197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableCurrent id="ID_34" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">30358000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="ID_35" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">82480000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="ID_36" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">63290000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent id="ID_37" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">5220000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <us-gaap:LiabilitiesCurrent id="ID_38" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">181348000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations id="ID_39" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">87809000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:OtherLiabilitiesNoncurrent id="ID_40" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">3730000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="ID_41" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">272887000</us-gaap:Liabilities>
  <us-gaap:OtherLiabilitiesNoncurrent id="ID_42" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">4306000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations id="ID_43" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">85472000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:LiabilitiesCurrent id="ID_44" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">183904000</us-gaap:LiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="ID_45" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">81909000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrent id="ID_46" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">29444000</us-gaap:AccountsPayableCurrent>
  <us-gaap:Liabilities id="ID_47" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">273682000</us-gaap:Liabilities>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent id="ID_48" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">6888000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="ID_49" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">65663000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PreferredStockValueOutstanding id="ID_50" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">0</us-gaap:PreferredStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding id="ID_51" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">35000</us-gaap:CommonStockValueOutstanding>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="ID_52" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">544428000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:TreasuryStockValue id="ID_53" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">47531000</us-gaap:TreasuryStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="ID_54" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="ID_55" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">-14967000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="ID_56" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">481980000</us-gaap:StockholdersEquity>
  <us-gaap:MinorityInterest id="ID_57" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">966000</us-gaap:MinorityInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_58" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">482946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity id="ID_59" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">756628000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="ID_60" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">537472000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:MinorityInterest id="ID_61" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">939000</us-gaap:MinorityInterest>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="ID_62" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">-30545000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="ID_63" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">460203000</us-gaap:StockholdersEquity>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="ID_64" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:LiabilitiesAndStockholdersEquity id="ID_65" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">734029000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_66" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">461142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:CommonStockValueOutstanding id="ID_67" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">35000</us-gaap:CommonStockValueOutstanding>
  <us-gaap:TreasuryStockValue id="ID_68" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">46774000</us-gaap:TreasuryStockValue>
  <us-gaap:PreferredStockValueOutstanding id="ID_69" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</us-gaap:PreferredStockValueOutstanding>
  <us-gaap:CommitmentsAndContingencies id="ID_70" xsi:nil="true" contextRef="AS_OF_Dec31_2016" unitRef="USDollar" />
  <us-gaap:CommitmentsAndContingencies id="ID_71" xsi:nil="true" contextRef="AS_OF_Mar31_2017" unitRef="USDollar" />
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent id="ID_72" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">19249000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent id="ID_73" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">17716000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="ID_74" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">142185000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="ID_75" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">138650000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="ID_76" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">28557000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="ID_77" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">27864000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="ID_78" decimals="3" contextRef="AS_OF_Mar31_2017" unitRef="USDperShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="ID_79" decimals="3" contextRef="AS_OF_Dec31_2016" unitRef="USDperShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="ID_80" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="ID_81" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="ID_82" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="ID_83" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="ID_84" decimals="3" contextRef="AS_OF_Mar31_2017" unitRef="USDperShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="ID_85" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="ID_86" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Shares">35364752</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="ID_87" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Shares">33693027</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:TreasuryStockShares id="ID_88" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Shares">1671725</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare id="ID_89" decimals="3" contextRef="AS_OF_Dec31_2016" unitRef="USDperShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued id="ID_90" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">35253577</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="ID_91" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued id="ID_92" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="ID_93" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">33597215</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized id="ID_94" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TreasuryStockShares id="ID_95" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">1656362</us-gaap:TreasuryStockShares>
  <us-gaap:AssetsCurrent id="ID_96" decimals="-3" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">243102000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="ID_97" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">214910000</us-gaap:AssetsCurrent>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_98" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">370458000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_99" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">215785000</us-gaap:CostOfServices>
  <us-gaap:LaborAndRelatedExpense id="ID_100" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">74459000</us-gaap:LaborAndRelatedExpense>
  <us-gaap:ShareBasedCompensation id="ID_101" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">3874000</us-gaap:ShareBasedCompensation>
  <us-gaap:OtherGeneralAndAdministrativeExpense id="ID_102" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">40417000</us-gaap:OtherGeneralAndAdministrativeExpense>
  <us-gaap:InvestmentIncomeInterestAndDividend id="ID_103" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">19000</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InterestExpense id="ID_104" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">1068000</us-gaap:InterestExpense>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="ID_105" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">-106000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherNonoperatingIncomeExpense id="ID_106" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">1112000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="ID_107" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">-43000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="ID_108" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">25122000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="ID_109" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">69000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLoss id="ID_110" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">15130000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic id="ID_111" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDperShare">0.45</us-gaap:EarningsPerShareBasic>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_112" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">348817000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_113" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">201837000</us-gaap:CostOfServices>
  <us-gaap:OtherGeneralAndAdministrativeExpense id="ID_114" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">46717000</us-gaap:OtherGeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="ID_115" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">11063000</us-gaap:OperatingIncomeLoss>
  <us-gaap:LaborAndRelatedExpense id="ID_116" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">76717000</us-gaap:LaborAndRelatedExpense>
  <us-gaap:CostsAndExpenses id="ID_117" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">337754000</us-gaap:CostsAndExpenses>
  <us-gaap:ShareBasedCompensation id="ID_118" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">4070000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="ID_119" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">10703000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:InvestmentIncomeInterestAndDividend id="ID_120" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">22000</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:NonoperatingIncomeExpense id="ID_121" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-360000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="ID_122" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-5000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:InterestExpense id="ID_123" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">1112000</us-gaap:InterestExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="ID_124" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">735000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:EarningsPerShareBasic id="ID_125" decimals="2" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDperShare">0.19</us-gaap:EarningsPerShareBasic>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_126" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">6341000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_127" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">4417000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_128" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">3940000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_129" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">4473000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:ProfitLoss id="ID_130" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">15199000</us-gaap:ProfitLoss>
  <us-gaap:IncomeTaxExpenseBenefit id="ID_131" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">9923000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CostsAndExpenses id="ID_132" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">345293000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_133" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">25165000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="ID_134" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">102000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLoss id="ID_135" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">6213000</us-gaap:NetIncomeLoss>
  <us-gaap:ProfitLoss id="ID_136" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">6315000</us-gaap:ProfitLoss>
  <us-gaap:IncomeTaxExpenseBenefit id="ID_137" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">4388000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:EarningsPerShareDiluted id="ID_138" decimals="2" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDperShare">0.19</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="ID_139" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDperShare">0.44</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="ID_140" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="Shares">32920000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="ID_141" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Shares">33443000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="ID_142" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Shares">34073000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="ID_143" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="Shares">33508000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ProceedsFromSaleOfRestrictedInvestments id="ID_144" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">565000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="ID_145" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">4385000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised id="ID_146" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">653000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities id="ID_147" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:RepaymentsOfLongTermDebt id="ID_148" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">1250000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="ID_149" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">-785000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="ID_150" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">18137000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:InterestPaid id="ID_151" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">706000</us-gaap:InterestPaid>
  <us-gaap:IncomeTaxesPaidNet id="ID_152" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">284000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="ID_153" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">2775000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncomeTaxesPaidNet id="ID_154" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-7000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities id="ID_155" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">159000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="ID_156" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">9098000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="ID_157" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">801000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="ID_158" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">6702000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="ID_159" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">12244000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="ID_160" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-34154000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_161" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">185000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:InterestPaid id="ID_162" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">648000</us-gaap:InterestPaid>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="ID_163" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">4038000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="ID_164" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-360000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised id="ID_165" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">0</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromSaleOfRestrictedInvestments id="ID_166" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">230000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="ID_167" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-7845000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_168" decimals="-3" contextRef="AS_OF_Mar31_2016" unitRef="USDollar">7824000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="ID_169" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">2232000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockPlans id="ID_170" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">638000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:RepaymentsOfLongTermDebt id="ID_171" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">1250000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="ID_172" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-19678000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EquityMethodInvestmentDividendsOrDistributions id="ID_173" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">362000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="ID_174" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">27689000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_175" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">27502000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_176" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">3940000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:RepaymentsOfShortTermDebt id="ID_177" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">0</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:ProceedsFromShortTermDebt id="ID_178" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">40500000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="ID_179" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">-521000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:DepreciationDepletionAndAmortization id="ID_180" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">4473000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:RepaymentsOfShortTermDebt id="ID_181" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">25500000</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired id="ID_182" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">4099000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired id="ID_183" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">27682000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="ID_184" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="ID_185" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">12315000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="ID_186" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">-8175000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:DepreciationDepletionAndAmortization id="ID_187" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">4417000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_188" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">6341000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="ID_189" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">16000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="ID_190" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">9445000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_191" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">185000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:EquityMethodInvestmentDividendsOrDistributions id="ID_192" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">150000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="ID_193" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">12493000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="ID_194" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">3403000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="ID_195" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">990000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="ID_196" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">93000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="ID_197" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">1386000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="ID_198" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">576000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="ID_199" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">27097000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsForProceedsFromInvestments id="ID_200" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">256000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PaymentsForProceedsFromInvestments id="ID_201" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">0</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:ProceedsFromStockPlans id="ID_202" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">612000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="ID_203" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">758000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="ID_204" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <amed:CashDistributionToNoncontrollingInterest id="ID_205" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">42000</amed:CashDistributionToNoncontrollingInterest>
  <amed:CashDistributionToNoncontrollingInterest id="ID_206" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">0</amed:CashDistributionToNoncontrollingInterest>
  <us-gaap:ProceedsFromShortTermDebt id="ID_207" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">0</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:PensionExpense id="ID_208" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">2227000</us-gaap:PensionExpense>
  <us-gaap:PensionExpense id="ID_209" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">1737000</us-gaap:PensionExpense>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="ID_210" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. NATURE OF OPERATIONS&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;CONSOLIDATION &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;AND PRESENTATION &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;OF FINANCIAL STATEMENTS &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (&amp;#8220;Amedisys,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; or &amp;#8220;our&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; a multi-state provider of home health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;personal care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; services with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;79&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; our revenue derived from Medicare for&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-month period&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; ended March 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;owned and operated&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;326&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare-certified home health care centers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;79&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare-certified hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care centers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; personal&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care care centers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; states within the United St&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ates&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; the District of Columbia&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Basis of Presentation&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. Generally Accepted Accounting Principles (&amp;#8220;U.S. GAAP&amp;#8221;). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated finan&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cial statements and related notes included in our Annual Report on Form 10-K for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the year ended December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on March 1, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (the &amp;#8220;Form 10-K&amp;#8221;), which includes information and disclosures not included herein.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Use of Estimates&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our accounting and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reporting policies conform with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;GAAP. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In preparing the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Reclassifications and Comparability &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Certain reclassifications have been made to prior periods' financial statements in order to conform to the current period'&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; presentation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;These &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;c&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;onsolidated financial statements include the accounts of Amedisys, Inc.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements, and business combinations accounted for as purchases have been included in our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;accounted for as set forth below&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Equity &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;Investments &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Third party equity interests in our consolidated joint ventures are reflected as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;noncontrolling&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; interests in our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% or less of the voting stock and the entity is not a variable interest entity in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as of March &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We account for investments in entities in which we have less than a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% ownership interest under the cost method&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of accounting if we do not have the ability to exercise significant influence over the investee&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:UseOfEstimates id="ID_211" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Use of Estimates&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our accounting and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reporting policies conform with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;GAAP. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In preparing the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ComparabilityOfPriorYearFinancialData id="ID_212" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Reclassifications and Comparability &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Certain reclassifications have been made to prior periods' financial statements in order to conform to the current period'&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; presentation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:ComparabilityOfPriorYearFinancialData>
  <us-gaap:ConsolidationPolicyTextBlock id="ID_213" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;These &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;c&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;onsolidated financial statements include the accounts of Amedisys, Inc.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements, and business combinations accounted for as purchases have been included in our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;unaudited condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;accounted for as set forth below&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:EquityMethodInvestmentsPolicy id="ID_214" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Equity &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;Investments &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Third party equity interests in our consolidated joint ventures are reflected as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;noncontrolling&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; interests in our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% or less of the voting stock and the entity is not a variable interest entity in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as of March &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We account for investments in entities in which we have less than a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% ownership interest under the cost method&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of accounting if we do not have the ability to exercise significant influence over the investee&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="ID_215" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Basis of Presentation&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. Generally Accepted Accounting Principles (&amp;#8220;U.S. GAAP&amp;#8221;). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated finan&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cial statements and related notes included in our Annual Report on Form 10-K for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the year ended December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on March 1, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (the &amp;#8220;Form 10-K&amp;#8221;), which includes information and disclosures not included herein.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <amed:MinimumPercentOwnershipForControllingInterestPercent id="ID_216" decimals="2" contextRef="AS_OF_Mar31_2017" unitRef="Pure">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
  <amed:OperatingCareCenters id="ID_217" decimals="0" contextRef="AS_OF_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">326</amed:OperatingCareCenters>
  <amed:OperatingCareCenters id="ID_218" decimals="0" contextRef="AS_OF_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Agencies">79</amed:OperatingCareCenters>
  <us-gaap:ConcentrationRiskPercentage1 id="ID_219" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_ConcentrationRiskByTypeAxis_MedicareRevenueMember" unitRef="Pure">0.75</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="ID_220" decimals="2" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_ConcentrationRiskByTypeAxis_MedicareRevenueMember" unitRef="Pure">0.79</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:EquityMethodInvestmentAggregateCost id="ID_221" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">27800000</us-gaap:EquityMethodInvestmentAggregateCost>
  <amed:MaximumPercentOwnershipForCostMethodPercent id="ID_222" decimals="2" contextRef="AS_OF_Mar31_2017" unitRef="Pure">0.20</amed:MaximumPercentOwnershipForCostMethodPercent>
  <amed:MaximumPercentOwnershipForEquityMethodPercent id="ID_223" decimals="2" contextRef="AS_OF_Mar31_2017" unitRef="Pure">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
  <amed:OperatingCareCenters id="ID_224" decimals="0" contextRef="AS_OF_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Agencies">16</amed:OperatingCareCenters>
  <us-gaap:EquityMethodInvestmentAggregateCost id="ID_225" decimals="-5" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">27800000</us-gaap:EquityMethodInvestmentAggregateCost>
  <us-gaap:NumberOfStatesInWhichEntityOperates id="ID_226" decimals="0" contextRef="AS_OF_Mar31_2017" unitRef="Agencies">34</us-gaap:NumberOfStatesInWhichEntityOperates>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="ID_227" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We earn net service revenue through our home health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;personal-care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care center&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for services provided. We refer to home health revenue earned and billed on a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episode of care as episodic-based revenue. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Home Health Revenue Recognition&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net service revenue is recorded under the Medicare prospective payment system (&amp;#8220;PPS&amp;#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&amp;#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&amp;#160;a low utilization payment adjustment (&amp;#8220;LUPA&amp;#8221;) if the number of visits was fewer than five; (c)&amp;#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&amp;#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&amp;#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&amp;#160;changes in the base episode payments established by the Medicare Program; (h)&amp;#160;adjustments to the base episode payments for case mix and geographic wages; and (i)&amp;#160;recoveries of overpayments.   In addition, we make adjustments to Medicare revenue if we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;find that we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are unable to produce &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;appropriate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;documentation of a face to face encounter between the patient and physician.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;   &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reflect&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; differences between estimated and actual payment amounts, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;discovered &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; on&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to patient accounts receivable. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the number of days elapsed during an episode of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the difference between the cash received from Medicare for a request for anticipated payment (&amp;#8220;RAP&amp;#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;tient accounts receivable in our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated balance sheets for such periods. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Episodic-based Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-episodic &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;b&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;ased Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Hospice Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver.  The four levels of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are routine care, general inpatient care, continu&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ous home care and respite care. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Routine care accounts &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;98&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of our total net Medic&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are hospice service revenue for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;each of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;month&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; period&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; ended March 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Beginning&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; January 1, 2016, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the Centers for Medicare and Medicaid Services (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;CMS&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&amp;#8220;SIA&amp;#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&amp;#8220;RN&amp;#8221;) or medical social worker (&amp;#8220;MSW&amp;#8221;) for patients in a routine level of care.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;acceptable authorizations &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; historical collection rate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of over 99% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we estimate a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap has been exceeded.&amp;#160;We record these adjustments as a reduction to revenue and an increase &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in other accrued liabilities. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their estimated cap liability by March 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;st&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of the following year. As of March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;e have settled our Medicare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hospice reimbursements for all fiscal years through October 31, 20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we have recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;f&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;or&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; estimated amounts due back to Medicare in other accrued liabilities for the Federal &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap years ended October 31, 2013 through October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; As of December 31, 2016, we had recorded $0.8 million for&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31, 2013 through October 31, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;day &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;able&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Personal Care Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Personal Care Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation, which are recognized as net service revenue at the time services are rendered&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Patient Accounts Receivable &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and patients. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of March 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;here is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;only &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, other than Medicare, that accounts for more than &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our total&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; outstanding patient receivables&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%). T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of our patient accounts receivable. We fully reserve for accounts which are aged at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe the credit risk associated with our Medicare accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;represent &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;58&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; net patient accounts receivable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively, is limited due to our historical collection rate of over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;from Medicare and the fact that Medicare is a U.S. government &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;adjustments as discussed above&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;month periods ended March 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, in estimated revenue adjustments to Medicare revenue.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe there is a certain level of credit risk associated with non-Medicare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Home Health &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our estimated payment for the initial episode at the start of care or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&amp;#8220;final billed&amp;#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;120&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the start of the episode, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Hospice &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;W&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;e bill Medicare on a monthly basis for the services provided to the patient&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-Medicare Home Health, Hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Personal Care&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Once the patient has been confirmed for eligibility, we will provide services to the patient &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and bill the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; or groups of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; with similar characteristics that would subject us to any significant credit risk.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We estimate an allowance for doubtful accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;collectability&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Fair Value at Reporting Date Using&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Financial Instrument&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Carrying Value as of
March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Quoted Prices in Active Markets for Identical Items
(Level 1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Other Observable Inputs (Level 2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;94.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;96.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;fair value hierarchy&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; is&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1 &amp;#8211; Quoted prices in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2 &amp;#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3 &amp;#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, payroll and employee benefits&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and accrued expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we estimate the carrying amounts' approximate fair value&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Weighted-Average Shares Outstanding&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; per share attributable to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Amedisys&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, Inc. common stockholders, calculated on the treasury stock method, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;is&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based on the weighted average&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;used in our computation of the weighted-average shares outstanding, which are used to calc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ulate our basic and diluted net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;attributable to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Amedisys&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, Inc. common stockholders (amounts in thousands):&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Three-Month Periods Ended March 31&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,443&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,920&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;239&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;82&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Non-vested stock and stock units&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;391&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;506&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;34,073&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,508&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Anti-dilutive securities&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;332&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;319&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ASU &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015-14, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, to defer the effective date of the standard from January 1, 2017 to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;does not expect an impact on its consolidated financial statements upon implementation of ASU 2014-09 and ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;disclosures&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which will require&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still evaluating the overall impact on our consolidated financial statements and related disclosures and the effect of the standard on our ongoing financial reporting.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 718):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which will simplify the accounting for share-based payment award transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;including income tax consequences, classification of awards as either equity or liability and classification on the statement of cash flows. The ASU is effective for annual and interim&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;periods &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;beginning after December 15, 2016. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We adopted this ASU &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;effective Ja&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;nuary 1, 2017, and as a result, we recorded a $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million increase to our non-current deferred tax asset and retained earnings for tax benefits that were not previously recognized under the prior rules. Additionally, on a prospective basis, we recorded excess tax benefits as a discrete item in our income tax provision within our condensed consolidated statement of operations for the three-mo&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;nth period ended March 31, 2017. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Historically these amounts were recorded as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;addition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;al&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; paid-in capital &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; our condensed consolidated balance sheet&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also elected to prospectively apply the change to the presentation of cash payments made to taxing authorities on the employees' behalf for shares withheld upon stock vesting on our condensed consolidated statements of cash flows for the three-month period ended March 31, 2017. We have also elected to continue our current policy of estimating forfeitures of stock-based compensation awards at grant date and revising in subsequent periods to reflect actual forfeitures&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In A&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ugust 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and related disclosures and the effect of the standard on its ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In January 2017, the FASB issued ASU 2017-01, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The ASU is effective for annual and interim periods beginning after December 15, 2017. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In January 2017, the FASB issued ASU 2017-04, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference of the carrying amount to the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2017-04 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="ID_228" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We earn net service revenue through our home health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;personal-care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care center&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for services provided. We refer to home health revenue earned and billed on a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episode of care as episodic-based revenue. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Home Health Revenue Recognition&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net service revenue is recorded under the Medicare prospective payment system (&amp;#8220;PPS&amp;#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&amp;#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&amp;#160;a low utilization payment adjustment (&amp;#8220;LUPA&amp;#8221;) if the number of visits was fewer than five; (c)&amp;#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&amp;#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&amp;#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&amp;#160;changes in the base episode payments established by the Medicare Program; (h)&amp;#160;adjustments to the base episode payments for case mix and geographic wages; and (i)&amp;#160;recoveries of overpayments.   In addition, we make adjustments to Medicare revenue if we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;find that we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are unable to produce &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;appropriate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;documentation of a face to face encounter between the patient and physician.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;   &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reflect&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; differences between estimated and actual payment amounts, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;discovered &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; on&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to patient accounts receivable. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the number of days elapsed during an episode of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the difference between the cash received from Medicare for a request for anticipated payment (&amp;#8220;RAP&amp;#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;tient accounts receivable in our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;condensed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated balance sheets for such periods. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Episodic-based Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-episodic &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;b&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;ased Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Hospice Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver.  The four levels of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are routine care, general inpatient care, continu&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ous home care and respite care. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Routine care accounts &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;98&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of our total net Medic&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are hospice service revenue for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;each of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;month&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; period&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; ended March 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Beginning&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; January 1, 2016, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the Centers for Medicare and Medicaid Services (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;CMS&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&amp;#8220;SIA&amp;#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&amp;#8220;RN&amp;#8221;) or medical social worker (&amp;#8220;MSW&amp;#8221;) for patients in a routine level of care.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;acceptable authorizations &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; historical collection rate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of over 99% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we estimate a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap has been exceeded.&amp;#160;We record these adjustments as a reduction to revenue and an increase &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in other accrued liabilities. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their estimated cap liability by March 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;st&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of the following year. As of March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;e have settled our Medicare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hospice reimbursements for all fiscal years through October 31, 20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we have recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;f&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;or&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; estimated amounts due back to Medicare in other accrued liabilities for the Federal &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap years ended October 31, 2013 through October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; As of December 31, 2016, we had recorded $0.8 million for&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31, 2013 through October 31, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;day &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;able&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Personal Care Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Personal Care Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation, which are recognized as net service revenue at the time services are rendered&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <amed:EpisodeOfCareAsEpisodicBasedRevenue id="ID_229" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Day">60</amed:EpisodeOfCareAsEpisodicBasedRevenue>
  <amed:EpisodesInProgressThatBeginDuringReportingPeriod id="ID_230" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Day">60</amed:EpisodesInProgressThatBeginDuringReportingPeriod>
  <amed:PercentageOfTotalReimbursementOfOutlierPayment id="ID_231" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Pure">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
  <amed:FirstThresholdOfTherapyServicesRequired id="ID_232" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Number_of_Visits">6</amed:FirstThresholdOfTherapyServicesRequired>
  <amed:SecondThresholdOfServicesRequired id="ID_233" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Number_of_Visits">14</amed:SecondThresholdOfServicesRequired>
  <amed:ThirdThresholdOfTherapyServicesRequired id="ID_234" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Number_of_Visits">20</amed:ThirdThresholdOfTherapyServicesRequired>
  <amed:LowUtilizationPaymentAdjustmentNumberOfVisits id="ID_235" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Number_of_Visits">5</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
  <amed:HospiceMedicareRevenueRateAccountedForRoutineCare id="ID_236" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Pure">0.98</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
  <amed:HospiceMedicareRevenueRateAccountedForRoutineCare id="ID_237" decimals="2" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="Pure">0.98</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
  <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities id="ID_238" decimals="-5" contextRef="AS_OF_Mar31_2017_amed_CapYearAxis_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" unitRef="USDollar">900000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
  <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities id="ID_239" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_CapYearAxis_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" unitRef="USDollar">800000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
  <amed:HistoricalCollectionRateFromMedicare id="ID_240" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Pure">0.99</amed:HistoricalCollectionRateFromMedicare>
  <amed:HistoricalCollectionRateFromMedicare id="ID_241" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Pure">0.99</amed:HistoricalCollectionRateFromMedicare>
  <amed:HistoricalCollectionRateFromMedicare id="ID_242" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Pure">0.99</amed:HistoricalCollectionRateFromMedicare>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy id="ID_243" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Patient Accounts Receivable &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and patients. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of March 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;here is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;only &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, other than Medicare, that accounts for more than &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our total&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; outstanding patient receivables&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%). T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of our patient accounts receivable. We fully reserve for accounts which are aged at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe the credit risk associated with our Medicare accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;represent &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;58&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; net patient accounts receivable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively, is limited due to our historical collection rate of over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;from Medicare and the fact that Medicare is a U.S. government &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;adjustments as discussed above&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;month periods ended March 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, in estimated revenue adjustments to Medicare revenue.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe there is a certain level of credit risk associated with non-Medicare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Home Health &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our estimated payment for the initial episode at the start of care or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&amp;#8220;final billed&amp;#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;120&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the start of the episode, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Hospice &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;W&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;e bill Medicare on a monthly basis for the services provided to the patient&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-Medicare Home Health, Hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Personal Care&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Once the patient has been confirmed for eligibility, we will provide services to the patient &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and bill the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; or groups of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; with similar characteristics that would subject us to any significant credit risk.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We estimate an allowance for doubtful accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;collectability&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <amed:PercentageOfPatientReceivablesOutstanding id="ID_244" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Pure">0.1</amed:PercentageOfPatientReceivablesOutstanding>
  <amed:Percentageofpatientreceivablesoutstandingovertenpercent id="ID_245" decimals="3" contextRef="AS_OF_Mar31_2017" unitRef="Pure">0.132</amed:Percentageofpatientreceivablesoutstandingovertenpercent>
  <amed:MinimumDaysAccountsReceivableOutstandingFullyReserved id="ID_246" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Day">365</amed:MinimumDaysAccountsReceivableOutstandingFullyReserved>
  <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare id="ID_247" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Pure">0.58</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
  <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare id="ID_248" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.61</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
  <amed:RevenueAdjustmentToMedicareRevenue id="ID_249" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">3400000</amed:RevenueAdjustmentToMedicareRevenue>
  <amed:RevenueAdjustmentToMedicareRevenue id="ID_250" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">1700000</amed:RevenueAdjustmentToMedicareRevenue>
  <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare id="ID_251" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Pure">0.6</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare>
  <amed:RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare id="ID_252" decimals="2" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Pure">0.5</amed:RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare>
  <amed:MaximumDaysToSubmitFinalBillFromStartOfEpisode id="ID_253" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Day">120</amed:MaximumDaysToSubmitFinalBillFromStartOfEpisode>
  <amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid id="ID_254" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Day">60</amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid>
  <amed:FinancialInstrumentDetailsTextBlock id="ID_255" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Fair Value at Reporting Date Using&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Financial Instrument&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Carrying Value as of
March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Quoted Prices in Active Markets for Identical Items
(Level 1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Other Observable Inputs (Level 2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;94.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;96.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="ID_256" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Fair Value at Reporting Date Using&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Financial Instrument&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Carrying Value as of
March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Quoted Prices in Active Markets for Identical Items
(Level 1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Other Observable Inputs (Level 2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;94.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;96.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;fair value hierarchy&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; is&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1 &amp;#8211; Quoted prices in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2 &amp;#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3 &amp;#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, payroll and employee benefits&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and accrued expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we estimate the carrying amounts' approximate fair value&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:LiabilitiesFairValueDisclosure id="ID_257" decimals="-5" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">94800000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="ID_258" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USDollar">96400000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="ID_259" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USDollar">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="ID_260" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USDollar">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:EarningsPerSharePolicyTextBlock id="ID_261" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Weighted-Average Shares Outstanding&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; per share attributable to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Amedisys&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, Inc. common stockholders, calculated on the treasury stock method, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;is&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based on the weighted average&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;used in our computation of the weighted-average shares outstanding, which are used to calc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ulate our basic and diluted net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;attributable to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Amedisys&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, Inc. common stockholders (amounts in thousands):&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Three-Month Periods Ended March 31&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,443&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,920&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;239&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;82&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Non-vested stock and stock units&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;391&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;506&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;34,073&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,508&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Anti-dilutive securities&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;332&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;319&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="ID_262" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Shares">239000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <amed:NonVestedStockAndStockUnits id="ID_263" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Shares">391000</amed:NonVestedStockAndStockUnits>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="ID_264" decimals="-3" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Shares">332000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <amed:NonVestedStockAndStockUnits id="ID_265" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="Shares">506000</amed:NonVestedStockAndStockUnits>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="ID_266" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="Shares">319000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="ID_267" decimals="-3" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="Shares">82000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock id="ID_268" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Three-Month Periods Ended March 31&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,443&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,920&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;239&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;82&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Non-vested stock and stock units&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;391&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;506&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;34,073&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,508&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Anti-dilutive securities&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;332&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;319&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="ID_269" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ASU &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015-14, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, to defer the effective date of the standard from January 1, 2017 to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;does not expect an impact on its consolidated financial statements upon implementation of ASU 2014-09 and ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;disclosures&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which will require&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still evaluating the overall impact on our consolidated financial statements and related disclosures and the effect of the standard on our ongoing financial reporting.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 718):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which will simplify the accounting for share-based payment award transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;including income tax consequences, classification of awards as either equity or liability and classification on the statement of cash flows. The ASU is effective for annual and interim&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;periods &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;beginning after December 15, 2016. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We adopted this ASU &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;effective Ja&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;nuary 1, 2017, and as a result, we recorded a $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million increase to our non-current deferred tax asset and retained earnings for tax benefits that were not previously recognized under the prior rules. Additionally, on a prospective basis, we recorded excess tax benefits as a discrete item in our income tax provision within our condensed consolidated statement of operations for the three-mo&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;nth period ended March 31, 2017. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Historically these amounts were recorded as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;addition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;al&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; paid-in capital &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; our condensed consolidated balance sheet&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also elected to prospectively apply the change to the presentation of cash payments made to taxing authorities on the employees' behalf for shares withheld upon stock vesting on our condensed consolidated statements of cash flows for the three-month period ended March 31, 2017. We have also elected to continue our current policy of estimating forfeitures of stock-based compensation awards at grant date and revising in subsequent periods to reflect actual forfeitures&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In A&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ugust 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and related disclosures and the effect of the standard on its ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In January 2017, the FASB issued ASU 2017-01, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The ASU is effective for annual and interim periods beginning after December 15, 2017. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In January 2017, the FASB issued ASU 2017-04, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference of the carrying amount to the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2017-04 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_270" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:BusinessCombinationDisclosureTextBlock id="ID_271" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. ACQUISITIONS &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;personal care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;services. The purchase price paid for acquisitions is negotiated through arm's length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets. Preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On February&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 1, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we acquired the assets of Home Staff, L.L.C. which owns and operates three personal-care care centers servicing the state of Massachusetts for a total purchase price of $4.0 million (subject to certain adjustments), of which $0.4 million was placed in a promissory note to be paid over 24 months, subject to any offsets or withhold&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for indemnification purposes. The purchase price was paid with cash on hand on the date of the transaction. During the three-month period ended March 31, 2017, we recorded goodwill ($3.8 million), &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;other&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; intangibles &amp;#8211; non-compete agreements ($0.2 million) and other assets and liabilities, net ($0.5 million) in connection with the acquisition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The non-compete agreements will be amortized over a weighted-average period of 2.8 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:NumberOfBusinessesAcquired id="ID_272" decimals="0" contextRef="FROM_Jan01_2017_TO_Feb01_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Agencies">3</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_273" decimals="-5" contextRef="FROM_Jan01_2017_TO_Feb01_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_274" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">3800000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="ID_275" decimals="-5" contextRef="AS_OF_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet id="ID_276" decimals="-5" contextRef="AS_OF_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <us-gaap:LongTermDebt id="ID_277" decimals="-5" contextRef="AS_OF_Feb01_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">400000</us-gaap:LongTermDebt>
  <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife id="ID_278" contextRef="FROM_Jan01_2017_TO_Mar31_2017_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">P2Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
  <us-gaap:DebtDisclosureTextBlock id="ID_279" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;4. LONG-TERM OBLIGATIONS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="width: 90px; text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$100.0 million Term Loan; principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.98% at March 31, 2017); due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;93.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;95.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$200.0 million Revolving Credit Facility; interest only payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Promissory notes&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred debt issuance costs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (2.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (2.7)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;92.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;93.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Current portion of long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(6.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;85.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;87.8&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our weighted average interest rate for our $100.0 million Term Loan, under our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Credit Agreement, was 2.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.4%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for the three-month period&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; ended March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and 2016, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Our weighted average interest rate for our $200.0 millio&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;n Revolving Credit Facility was&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% for the three-month period ended March 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of March &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; leverage ratio was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;fixed charge coverage ratio was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we are in compliance with our Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of March 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;availability under our $2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;00.0 million Revolving Credit Facility was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;17&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million as we had $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;29&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million outstanding letters of credit.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock id="ID_280" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;4. LONG-TERM OBLIGATIONS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="width: 90px; text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$100.0 million Term Loan; principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.98% at March 31, 2017); due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;93.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;95.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$200.0 million Revolving Credit Facility; interest only payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Promissory notes&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred debt issuance costs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (2.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (2.7)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;92.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;93.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Current portion of long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(6.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;85.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;87.8&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <us-gaap:LongTermDebt id="ID_281" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="USDollar">93700000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_282" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="USDollar">95000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_283" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">93000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_284" decimals="-5" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">92400000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_285" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">0</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_286" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">0</us-gaap:LongTermDebt>
  <us-gaap:DebtInstrumentFaceAmount id="ID_287" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="USDollar">100000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentMaturityDate id="ID_288" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">2020-08-28</us-gaap:DebtInstrumentMaturityDate>
  <amed:InterestRateOnNotesPayableToBank id="ID_289" decimals="4" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="Pure">0.0298</amed:InterestRateOnNotesPayableToBank>
  <amed:WeightedAverageInterestRate id="ID_290" decimals="3" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="Pure">0.0240</amed:WeightedAverageInterestRate>
  <amed:TotalLeverageRatio id="ID_291" decimals="1" contextRef="AS_OF_Mar31_2017" unitRef="Pure">0.9</amed:TotalLeverageRatio>
  <amed:FixedChargeCoverageRatio id="ID_292" decimals="1" contextRef="AS_OF_Mar31_2017" unitRef="Pure">4.1</amed:FixedChargeCoverageRatio>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity id="ID_293" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">170400000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LettersOfCreditOutstandingAmount id="ID_294" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">29600000</us-gaap:LettersOfCreditOutstandingAmount>
  <us-gaap:LongTermDebtNoncurrent id="ID_295" decimals="-5" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">85500000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="ID_296" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">87800000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:DebtInstrumentFaceAmount id="ID_297" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">200000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentMaturityDate id="ID_298" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">2020-08-28</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:UnamortizedDebtIssuanceExpense id="ID_299" decimals="-5" contextRef="AS_OF_Mar31_2017" unitRef="USDollar">2400000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:UnamortizedDebtIssuanceExpense id="ID_300" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">2700000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:LongTermDebt id="ID_301" decimals="-5" contextRef="AS_OF_Mar31_2017_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember" unitRef="USDollar">1100000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_302" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember" unitRef="USDollar">700000</us-gaap:LongTermDebt>
  <amed:WeightedAverageInterestRate id="ID_303" decimals="3" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="Pure">0.0270</amed:WeightedAverageInterestRate>
  <amed:WeightedAverageInterestRate id="ID_304" decimals="4" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="Pure">0.0280</amed:WeightedAverageInterestRate>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="ID_305" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Legal Proceedings &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;- Ongoing&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We are involved in the following legal actions: &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Securities Class Action Lawsuits &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As previously disclosed, between&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; June&amp;#160;10 and July 28, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2010, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;several&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; putative securities class action complaint&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;were&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; filed in the United States District Court for the Middle District of Louisiana (the &amp;#8220;District Court&amp;#8221;) against the Company and certain of our former senior executives.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; The cases were consolidated into the first-filed action &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Bach, et al. v. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Amedisys&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;, Inc., et al.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Case No. 3:10-cv-00395, and the District Court appointed as co-lead plaintiffs the Public Employees' Retirement System of Mississippi and the Puerto Rico Teachers' Retirement System (the &amp;#8220;Co-Lead Plaintiffs&amp;#8221;). They filed a consolidated, amended complaint which all defendants moved to dismiss. The District Court granted the defendants' motions to dismiss on June 28, 20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2, and the Co-Lead Plaintiffs appealed that ruling to the United States Court of Appeals for the Fifth Circuit (the &amp;#8220;Fifth Circuit&amp;#8221;). On October 2, 2014, a three-judge panel of the Fifth Circuit reversed the District Court's dismissal and remanded the case to the District Court for further proceedings. The defendants request for an &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;en banc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; review was denied on December 29, 2014 and their Petition for a Writ of Certiorari from the United States Supreme Court was denied on June 29, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;After remand to the District Court, the Plaintiffs were granted leave to file a First Amended Consolidated Complaint (the &amp;#8220;First Amended Securities Complaint&amp;#8221;) on behalf of all purchasers or acquirers of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Amedisys&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;' securities between August 2, 2005 and September 30, 2011.  The First Amended Securities Complaint alleges that the Company and seven individual defendants violated Section 10(b), Section 20(a), and Rule 10b-5 of the Securities Exchange Act of 1934 by materially misrepresenting the Company's financial results and concealing a scheme to obtain higher Medicare reimbursements and additional patient referrals by (1) providing medically unnecessary care to patients, including certifying and re-certifying patients for medically unnecessary 60-day treatment episodes; (2) implementing clinical tracks such as &amp;#8220;Balanced for Life&amp;#8221; and wound care programs that provided a pre-set number of therapy visits irrespective of medical need; (3) &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;upcoding&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221; patients' Medicare forms to attribute a &amp;#8220;primary diagnosis&amp;#8221; to a medical condition associated with higher billing rates; and (4) providing improper and illegal remuneration to physicians to obtain patient certifications or re-certifications.  The First Amended Securities Complaint seeks certification of the case as a class action and an unspecified amount of damages, as well as interest and an award of attorneys' fees.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;All defendants moved to dismiss the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; First Amended Securities Complaint on December 15, 2015. While that motion was pending the parties agreed to mediate the case. This mediation was not successful. On August 19, 2016, the District Court issued its ruling on the defendants' motions to dismiss, dismissing with prejudice all claims against two former officers, dismissing all except Section 20(a) claims against three former officers, and denying all other relief. The Company and four individual defendants then filed their answers to the First Amended Securities Complaint on October 20, 2016. The independent executrix of the estate of William F. Borne, who was substituted as a defendant in the case after Mr. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Borne's&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; death, filed her answer on February 6, 2017. The case is currently in the early stages of discovery. The parties have agreed to mediate the case again on June 12, 2017.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Because the case is in the early stages of litigation, w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;e are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the securities litigation described above.&amp;#160; The Company intends to continue to vigorously defend itself in the securities litigation matter but, if decided adverse to the Company, its impact could be material.&amp;#160; No assurances can be given as to the timing or outcome of the securities matter described above or the impact of any of the inquiry or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Subpoena &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Duces&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Tecum&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; Issued by the U.S. Department of Justice&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On May 21, 2015, we received a Subpoena &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Duces&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Tecum&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#8220;Subpoena&amp;#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney's Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;May 21, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Civil Investigative Demand Issued by the U.S. Department of Justice&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On November 3, 2015, we received a civil investigative demand (&amp;#8220;CID&amp;#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Based on the information currently available to us, we cannot predict the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;timing or outcome of this investigation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On June 27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January 1, 2011 through June 20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Other Investigative Matters&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; - Ongoing&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Corporate Integrity Agreement&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of&lt;/font&gt;&lt;font style="font-family:Calibri;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Justice relating to certain of our clinical and business operations.  Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&amp;#8220;CIA&amp;#8221;) with the Office of Inspector General-HHS (&amp;#8220;OIG&amp;#8221;). The CIA formalizes various aspects of our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs.  The corporate integrity agreement has a term of five years.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Computer Inventory and Data Security Reporting&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On March 1 and March 2, 2015, we provided official notice under federal and state data privacy laws concerning the outcome of an &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;extensive risk management process to locate and verify our large computer inventory. The process identified approximately 142 encrypted computers and laptops for which reports were required under federal and state data privacy laws. The devices at issue were originally assigned to Company clinicians and other team members&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; who left the Company between 2011 and 2014. We reported these devices to the U.S. Department of Health and Human Services, state agencies, and individuals whose information may be involved, as required under applicable law because we could not rule out unauthorized access to patient data on the devices. The Office of Civil Rights, U.S. Department of Health and Human Services (&amp;#8220;OCR&amp;#8221;) is reviewing our compliance with applicable laws, as is typical for any data breach involving more than 500 individuals. We are cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate with applicable regulatory authorities. In accordance with our CIA, we have notified the OIG of this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Idaho and Wyoming Self-Report&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 2016, the Company engaged an independent auditing firm to perform a clinical audit of the hospice care centers acquired by Frontier Home Health and Hospice in April 2014. No assurances can be given as to the timing or outcome of the audit on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Third Party Audits&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; - Ongoing&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;From &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;time to time, in the ordinary course of business, we are subject to audits under various governmental programs in whic&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;h third party firms engaged by the Centers for Medicare and Medicaid Services (&amp;#8220;CMS&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; conduct extensive review of claims data to identify potential improper payments under the Medicare program.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor (&amp;#8220;ZPIC&amp;#8221;) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the &amp;#8220;Review Period&amp;#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&amp;#160; We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&amp;#160; Based on the ZPIC's findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare Administrative Contractor (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;MAC&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment.  We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An ALJ hearing was held in early January 2015. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;On January 18, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&amp;#160; No assurances can be given as to the timing or outcome of the Me&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;dicare Appeals Council decision. As of June 30, 2016, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In the event we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are not able to recoup &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009.  As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we have &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;an indemnity receivable for the amount withheld related to the period prior to August 1, 2009.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In July 2016, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the Company received a request for medical records from &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;SafeGuard&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Services, L.L.C (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;SafeGuard&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;), a ZPIC related to services provided by some of the care cente&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;rs that the Company acquired fro&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;m Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. Subsequent to the initial ZPIC letter, the Company received additional requests for information regarding its care centers in Florida including post &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payment claims reviews, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;communications regarding suspensions of payment, and letters notifying the Company that various care centers have been placed on prepayment review. As these matters continue to develop, the Company is cooperating with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;SafeGuard&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, responding to all requests for information, and working to resolve these matters.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Based on the information currently&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; available to the Company&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and the uncertainty regarding the scope of this audit&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the Company cannot predict the timing or outcome of this audit or reasonably estimate the amount or range of potential losses, which may arise from this matter&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Insurance &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers' compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;specified deductible limits&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; reported&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our health insurance has a retention limit of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, our workers' compensation insurance has a retention limit of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and our professional liability insurance has a retention limit of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;  &lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <amed:NumberOfBeneficiaries id="ID_306" decimals="0" contextRef="FROM_Jan01_2011_TO_Jun06_2011_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Beneficiary">16</amed:NumberOfBeneficiaries>
  <amed:NumberOfBeneficiaries id="ID_307" decimals="0" contextRef="FROM_Jan01_2008_TO_Mar31_2010_amed_StateAxis_SouthCarolinaMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Beneficiary">30</amed:NumberOfBeneficiaries>
  <amed:CorporateIntegrityAgreementTerm id="ID_308" contextRef="FROM_Jan01_2017_TO_Mar31_2017">P5Y</amed:CorporateIntegrityAgreementTerm>
  <amed:YearOfDeparture id="ID_309" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MinimumMember">2011</amed:YearOfDeparture>
  <amed:YearOfDeparture id="ID_310" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MaximumMember">2014</amed:YearOfDeparture>
  <amed:NumberOfMissingComputersAndLaptops id="ID_311" decimals="0" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember" unitRef="Computers">142</amed:NumberOfMissingComputersAndLaptops>
  <amed:ThresholdOfIndividualsInDataBreach id="ID_312" decimals="0" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember" unitRef="Residents">500</amed:ThresholdOfIndividualsInDataBreach>
  <amed:NumberOfPatients id="ID_313" decimals="0" contextRef="FROM_Jan01_2015_TO_May21_2015_amed_StateAxis_MassachusettsMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Pure">53</amed:NumberOfPatients>
  <amed:NumberOfPatients id="ID_314" decimals="0" contextRef="FROM_Jan01_2015_TO_Nov03_2015_amed_StateAxis_MorgantownWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Pure">66</amed:NumberOfPatients>
  <amed:NumberOfClaimsSubmittedBySubsidiary id="ID_315" decimals="0" contextRef="FROM_Jan01_2016_TO_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Claims">9</amed:NumberOfClaimsSubmittedBySubsidiary>
  <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary id="ID_316" decimals="-5" contextRef="AS_OF_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
  <amed:RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest id="ID_317" decimals="-5" contextRef="AS_OF_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5600000</amed:RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest>
  <us-gaap:LossContingencyNumberOfDefendants id="ID_318" decimals="0" contextRef="FROM_Aug02_2005_TO_Sep30_2011_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember" unitRef="Pure">7</us-gaap:LossContingencyNumberOfDefendants>
  <amed:EpisodeOfCareAsEpisodicBasedRevenue id="ID_319" decimals="0" contextRef="FROM_Aug02_2005_TO_Sep30_2011_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember" unitRef="Day">60</amed:EpisodeOfCareAsEpisodicBasedRevenue>
  <us-gaap:LossContingencyNumberOfDefendants id="ID_320" decimals="0" contextRef="FROM_Jan01_2016_TO_Aug19_2016_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableMember" unitRef="Pure">2</us-gaap:LossContingencyNumberOfDefendants>
  <us-gaap:LossContingencyNumberOfDefendants id="ID_321" decimals="0" contextRef="FROM_Jan01_2016_TO_Aug19_2016_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInPartMember" unitRef="Pure">3</us-gaap:LossContingencyNumberOfDefendants>
  <us-gaap:LossContingencyNumberOfDefendants id="ID_322" decimals="0" contextRef="FROM_Jan01_2016_TO_Aug19_2016_us-gaap_LitigationStatusAxis_SecuritiesClassActionLawsuitMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember" unitRef="Pure">4</us-gaap:LossContingencyNumberOfDefendants>
  <amed:NumberOfPatients id="ID_323" decimals="0" contextRef="FROM_Jan01_2016_TO_Jun27_2016_amed_StateAxis_ParkersburgWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Pure">68</amed:NumberOfPatients>
  <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld id="ID_324" decimals="-5" contextRef="AS_OF_Jun30_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
  <amed:HealthInsuranceRetentionLimit id="ID_325" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">900000</amed:HealthInsuranceRetentionLimit>
  <amed:WorkersCompensationInsuranceRetentionLimit id="ID_326" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">500000</amed:WorkersCompensationInsuranceRetentionLimit>
  <amed:ProfessionalLiabilityInsuranceRetentionLimit id="ID_327" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
  <us-gaap:SegmentReportingDisclosureTextBlock id="ID_328" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;"&gt;. Segment Information&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our operations involve servicing patients through our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; reportable business segments:  home health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and personal care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;completing important personal tasks&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Our hospice segment provides palliative care and comfort to terminally &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ill patients and their families. Our personal ca&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;re segment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which was established with the acquisition of Associated Home Care during the three-month period ended March 31, 2016, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;provides&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; patients with assistance with the esse&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ntial activities of daily living&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The &amp;#8220;other&amp;#8221; column in the following tables consist&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of costs relating to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;M&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;anagement&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;evaluates performance and allocates resources based on the operating income of the reportable segments, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;includes an allocation of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;corporate expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; directly attribu&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;table to the specific segment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and includes revenues and all other costs directly attributable to the specific segment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Segment assets are not reviewed by the company's chief operating decision maker and therefore are not disclosed below (amounts in millions).  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:9pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Three-Month Period Ended March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;271.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;85.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;370.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;163.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;215.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;68.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;29.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;118.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;235.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;63.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;345.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(32.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;25.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Three-Month Period Ended March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;272.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;73.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;348.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;160.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;201.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;71.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;127.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;236.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;56.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;41.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;337.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;36.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(41.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 5px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;(1) Acquired March 1, 2016.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:NumberOfReportableSegments id="ID_329" decimals="0" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="Segments">3</us-gaap:NumberOfReportableSegments>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock id="ID_330" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Three-Month Period Ended March 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;271.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;85.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;370.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;163.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;215.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;68.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;29.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;118.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;235.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;63.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;345.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(32.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;25.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Three-Month Period Ended March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;272.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;73.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;348.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;160.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;201.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;71.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;127.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;236.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;56.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;41.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;337.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;36.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(41.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 5px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;(1) Acquired March 1, 2016.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_331" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017" unitRef="USDollar">118800000</amed:GeneralAndAdministrativeExpenseSegment>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_332" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">271300000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_333" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">163000000</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_334" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">68000000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_335" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">3700000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_336" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">900000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_337" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">235600000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_338" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">35700000</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_339" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">85600000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_340" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">42400000</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_341" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">18000000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_342" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">2500000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_343" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">300000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_344" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">63200000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_345" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">22400000</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_346" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_347" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:CostOfServices>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_348" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">272700000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_349" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">160800000</us-gaap:CostOfServices>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_350" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">3200000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_351" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">1300000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_352" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">236500000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_353" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">36200000</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_354" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">73000000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_355" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">38800000</us-gaap:CostOfServices>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_356" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">700000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_357" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">300000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_358" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">56700000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_359" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">16300000</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_360" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_361" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:CostOfServices>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_362" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_363" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">2900000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_364" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">41900000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_365" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">-41900000</us-gaap:OperatingIncomeLoss>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_366" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">127500000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_367" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">71200000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_368" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">16900000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_369" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">39000000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_370" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">29500000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_371" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_372" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">3200000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_373" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">32700000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_374" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">-32700000</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_375" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">13600000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_376" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">10400000</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_377" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">3300000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_378" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">100000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_379" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_380" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">13800000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_381" decimals="-5" contextRef="FROM_Jan01_2017_TO_Mar31_2017_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">-200000</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_382" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">3100000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_383" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">2200000</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_384" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">400000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_385" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_386" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_387" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">2600000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_388" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">500000</us-gaap:OperatingIncomeLoss>
  <us-gaap:SubsequentEventsTextBlock id="ID_389" contextRef="FROM_Jan01_2017_TO_Mar31_2017">&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;7.&amp;#160; SUBSEQUENT EVENT&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;May 1, 2017, we acquired &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;certain&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; home health and hospice operations &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;from Tenet Healthcare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in Arizona, Illinois, Massachusetts, and Texas&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for a purchase price of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:8pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_390" decimals="-5" contextRef="FROM_Jan01_2017_TO_May01_2017_us-gaap_BusinessAcquisitionAxis_TenetHealthcareMember" unitRef="USDollar">20500000</us-gaap:BusinessCombinationConsiderationTransferred1>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>amed-20170331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.5.34 using Fujitsu Interstage XWand -->
<schema targetNamespace="http://www.amedisys.com/20170331" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:amed="http://www.amedisys.com/20170331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31">
    <annotation>
        <appinfo>
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:roleType roleURI="http://www.amedisys.com/role/DocumentAndEntityInformation" id="amed_ELRID_DocumentAndEntityInformation">
                <link:definition>000101 - Document - Document and Entity Information</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" id="amed_ELRID_CONSOLIDATEDBALANCESHEETS">
                <link:definition>000103 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" id="amed_ELRID_CONSOLIDATEDBALANCESHEETSParenthetical">
                <link:definition>000104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" id="amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
                <link:definition>000105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="amed_ELRID_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
                <link:definition>000108 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" id="amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
                <link:definition>010109 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
                <link:definition>010110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ACQUISITIONS" id="amed_ELRID_ACQUISITIONS">
                <link:definition>010111 - Disclosure - ACQUISITIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE" id="amed_ELRID_DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE">
                <link:definition>010112 - Disclosure - DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" id="amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNET">
                <link:definition>010113 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" id="amed_ELRID_LONGTERMOBLIGATIONS">
                <link:definition>010115 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" id="amed_ELRID_COMMITMENTSANDCONTINGENCIES">
                <link:definition>010118 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" id="amed_ELRID_SEGMENTINFORMATION">
                <link:definition>010122 - Disclosure - SEGMENT INFORMATION</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies" id="amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies">
                <link:definition>020010 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" id="amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
                <link:definition>030010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DISONTINUEDOPERATIONSANDASSETSHELDFORSALETables" id="amed_ELRID_DISONTINUEDOPERATIONSANDASSETSHELDFORSALETables">
                <link:definition>030020 - Disclosure - DISONTINUED OPERATIONS AND ASSETS HELD FOR SALE (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureGOODWILLANDOTHERINTANGIBLEASSETSNETTables" id="amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNETTables">
                <link:definition>030030 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" id="amed_ELRID_LONGTERMOBLIGATIONSTables">
                <link:definition>030050 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" id="amed_ELRID_SEGMENTINFORMATIONTables">
                <link:definition>030110 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" id="amed_ELRID_NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail">
                <link:definition>040010 - Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="amed_ELRID_SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
                <link:definition>040020 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" id="amed_ELRID_ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail">
                <link:definition>040023 - Disclosure - Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail" id="amed_ELRID_ScheduleOfWeightedAverageSharesOutstandingDetail">
                <link:definition>040024 - Disclosure - Schedule of Weighted Average Shares Outstanding (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" id="amed_ELRID_DiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail">
                <link:definition>040040 - Disclosure - Discontinued Operations and Assets Held For Sale - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ScheduleOfNetRevenuesAndOperatingResultsDetail" id="amed_ELRID_ScheduleOfNetRevenuesAndOperatingResultsDetail">
                <link:definition>040041 - Disclosure - Schedule of Net Revenues and Operating Results (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtDetail" id="amed_ELRID_LongTermDebtDetail">
                <link:definition>040070 - Disclosure - Long Term Debt (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail" id="amed_ELRID_LongTermDebtParentheticalDetail">
                <link:definition>040072 - Disclosure - Long Term Debt (Parenthetical) (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail" id="amed_ELRID_LongTermDebtAdditionalInformationDetail">
                <link:definition>040071 - Disclosure - Long Term Debt - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCommitmentsAndContingenciesDetail" id="amed_ELRID_CommitmentsAndContingenciesDetail">
                <link:definition>040100 - Disclosure - Commitments and Contingencies (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail" id="amed_ELRID_SegmentInformationAdditionalInformationDetail">
                <link:definition>040140 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" id="amed_ELRID_OperatingIncomeOfReportableSegmentsDetail">
                <link:definition>040141 - Disclosure - Operating Income of Reportable Segments (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EXITACTIVITIES" id="amed_ELRID_EXITACTIVITIES">
                <link:definition>010120 - Disclosure - EXIT ACTIVITIES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" id="amed_ELRID_SUBSEQUENTEVENT">
                <link:definition>010126 - Disclosure - SUBSEQUENT EVENT</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" id="amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTS">
                <link:definition>010114 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/INCOMETAXES" id="amed_ELRID_INCOMETAXES">
                <link:definition>010116 - Disclosure - INCOME TAXES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" id="amed_ELRID_EMPLOYEEBENEFITPLANS">
                <link:definition>010119 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS" id="amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTS">
                <link:definition>010121 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" id="amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION">
                <link:definition>010125 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" id="amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTSTables">
                <link:definition>030040 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/INCOMETAXESTables" id="amed_ELRID_INCOMETAXESTables">
                <link:definition>030060 - Disclosure - INCOME TAXES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables" id="amed_ELRID_COMMITMENTSANDCONTINGENCIESTables">
                <link:definition>030080 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EXITACTIVITIESTables" id="amed_ELRID_EXITACTIVITIESTables">
                <link:definition>030090 - Disclosure - EXIT ACTIVITIES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureVALUATIONANDQUALIFYINGACCOUNTSTables" id="amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTSTables">
                <link:definition>030100 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" id="amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables">
                <link:definition>030120 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsDetail" id="amed_ELRID_AcquisitionsDetail">
                <link:definition>040030 - Disclosure - Acquisitions (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail" id="amed_ELRID_GoodwillAndOtherIntangibleAssetsNetDetail">
                <link:definition>040050 - Disclosure - Goodwill and Other Intangible Assets, Net (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail" id="amed_ELRID_IncomeTaxesDetail">
                <link:definition>040080 - Disclosure - Income Taxes (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EmployeeBenefitPlansDetail" id="amed_ELRID_EmployeeBenefitPlansDetail">
                <link:definition>040110 - Disclosure - Employee Benefit Plans (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureFutureMinimumRentalCommitments" id="amed_ELRID_FutureMinimumRentalCommitments">
                <link:definition>040101 - Disclosure - Future Minimum Rental Commitments</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails" id="amed_ELRID_InsuranceProgramsDetails">
                <link:definition>040102 - Disclosure - Insurance Programs (Details)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ComponentsOfNetDeferredTaxAssetsDetail" id="amed_ELRID_ComponentsOfNetDeferredTaxAssetsDetail">
                <link:definition>040083 - Disclosure - Components of Net Deferred Tax Assets (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSourcesOfTaxEffectDetail" id="amed_ELRID_SourcesOfTaxEffectDetail">
                <link:definition>040082 - Disclosure - Sources of Tax Effect (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureReconciliationOfUnrecognizedTaxBenefitsDetail" id="amed_ELRID_ReconciliationOfUnrecognizedTaxBenefitsDetail">
                <link:definition>040085 - Disclosure - Reconciliation of Unrecognized Tax Benefits (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" id="amed_ELRID_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
                <link:definition>040021 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail" id="amed_ELRID_MaturitiesOfDebtDetail">
                <link:definition>040073 - Disclosure - Maturities of Debt (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail" id="amed_ELRID_CommitmentFeeUnderCreditFacilitiesDetail">
                <link:definition>040074 - Disclosure - Commitment Fee Under Credit Facilities (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail" id="amed_ELRID_ExitActivitiesReserveActivityDetail">
                <link:definition>040121 - Disclosure - Exit Activities - Reserve Activity (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" id="amed_ELRID_ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails">
                <link:definition>040022 - Disclosure - Schedule of Balances Related to Property and Equipment (Details)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSHAREREPURCHASEPROGRAM" id="amed_ELRID_SHAREREPURCHASEPROGRAM">
                <link:definition>010123 - Disclosure - SHARE REPURCHASE PROGRAM</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ShareRepurchaseProgramDetail" id="amed_ELRID_ShareRepurchaseProgramDetail">
                <link:definition>040150 - Disclosure - Share Repurchase Program (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" id="amed_ELRID_RELATEDPARTYTRANSACTIONS">
                <link:definition>010124 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/RelatedPartyTransactionDetail" id="amed_ELRID_RelatedPartyTransactionDetail">
                <link:definition>040160 - Disclosure - Related Party Transaction (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SubsequentEventDetail" id="amed_ELRID_SubsequentEventDetail">
                <link:definition>040170 - Statement - Subsequent Event (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
        </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
    <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
    <element name="CapYearAxis" id="amed_CapYearAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CapYearDomain" id="amed_CapYearDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CashDistributionToNoncontrollingInterest" id="amed_CashDistributionToNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="CmsTherapyAssessmentRequirementIntervalMinimum" id="amed_CmsTherapyAssessmentRequirementIntervalMinimum" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="CommimentsAndContingenciesTable" id="amed_CommimentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CommitmentsAndContingenciesDisclosureLineItems" id="amed_CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DepreciationAndAmortizationForContinuingOperations" id="amed_DepreciationAndAmortizationForContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" id="amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DocumentDocumentandEntityInformationAbstract" id="amed_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EpisodeOfCareAsEpisodicBasedRevenue" id="amed_EpisodeOfCareAsEpisodicBasedRevenue" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EpisodesInProgressThatBeginDuringReportingPeriod" id="amed_EpisodesInProgressThatBeginDuringReportingPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="FavorableMember" id="amed_FavorableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FinancialInstrumentDetailsTextBlock" id="amed_FinancialInstrumentDetailsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FirstThresholdOfTherapyServicesRequired" id="amed_FirstThresholdOfTherapyServicesRequired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FixedChargeCoverageRatio" id="amed_FixedChargeCoverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="GeneralAndAdministrativeExpenseSegment" id="amed_GeneralAndAdministrativeExpenseSegment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="HealthInsuranceRetentionLimit" id="amed_HealthInsuranceRetentionLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="HistoricalCollectionRateFromMedicare" id="amed_HistoricalCollectionRateFromMedicare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="HomeHealthMember" id="amed_HomeHealthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceMedicareRevenueRateAccountedForRoutineCare" id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceMember" id="amed_HospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InterestRateOnNotesPayableToBank" id="amed_InterestRateOnNotesPayableToBank" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="LowUtilizationPaymentAdjustmentNumberOfVisits" id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MassproAndHospiceMember" id="amed_MassproAndHospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumDaysToSubmitFinalBillFromStartOfEpisode" id="amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MaximusFederalServicesAndHospiceMember" id="amed_MaximusFederalServicesAndHospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximusFederalServicesMember" id="amed_MaximusFederalServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MedicareAdministrativeContractorMacMember" id="amed_MedicareAdministrativeContractorMacMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MinimumDaysAccountsReceivableOutstandingFullyReserved" id="amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MinimumPercentOwnershipForControllingInterestPercent" id="amed_MinimumPercentOwnershipForControllingInterestPercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="NonVestedStockAndStockUnits" id="amed_NonVestedStockAndStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersClosed" id="amed_NumberOfCareCentersClosed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersConsolidated" id="amed_NumberOfCareCentersConsolidated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersExited" id="amed_NumberOfCareCentersExited" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfClaimsSubmittedBySubsidiary" id="amed_NumberOfClaimsSubmittedBySubsidiary" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfRedeterminationDecisions" id="amed_NumberOfRedeterminationDecisions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfPatientReceivablesOutstanding" id="amed_PercentageOfPatientReceivablesOutstanding" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfTotalReimbursementOfOutlierPayment" id="amed_PercentageOfTotalReimbursementOfOutlierPayment" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PortionOfPatientAccountsReceivableDerivedFromMedicare" id="amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ProfessionalLiabilityInsuranceRetentionLimit" id="amed_ProfessionalLiabilityInsuranceRetentionLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="ProvisionForDoubtfulAccountsForContinuingOperations" id="amed_ProvisionForDoubtfulAccountsForContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="RecoveryAmountOfOverpaymentMadeToSubsidiary" id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="RelatedPartyMember" id="amed_RelatedPartyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RevenueAdjustmentToMedicareRevenue" id="amed_RevenueAdjustmentToMedicareRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="RevolvingCreditFacilitiesMember" id="amed_RevolvingCreditFacilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SecondThresholdOfServicesRequired" id="amed_SecondThresholdOfServicesRequired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="TermLoanMember" id="amed_TermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ThirdThresholdOfTherapyServicesRequired" id="amed_ThirdThresholdOfTherapyServicesRequired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="TotalLeverageRatio" id="amed_TotalLeverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="WorkersCompensationInsuranceRetentionLimit" id="amed_WorkersCompensationInsuranceRetentionLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="NumberOfEmployeesInWageHourLitigationMember" id="amed_NumberOfEmployeesInWageHourLitigationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximusFederalServicesAndHomeHealthMember" id="amed_MaximusFederalServicesAndHomeHealthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OperatingCareCenters" id="amed_OperatingCareCenters" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="OrganizationAndNatureOfOperationsTable" id="amed_OrganizationAndNatureOfOperationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceInpatientMember" id="amed_HospiceInpatientMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OrganizationAndNatureOfOperationsLineItems" id="amed_OrganizationAndNatureOfOperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="StateAxis" id="amed_StateAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="StateDomain" id="amed_StateDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IllinoisMember" id="amed_IllinoisMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ConnecticutMember" id="amed_ConnecticutMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OhioMember" id="amed_OhioMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SouthCarolinaMember" id="amed_SouthCarolinaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MassachusettsMember" id="amed_MassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfBeneficiaries" id="amed_NumberOfBeneficiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FinalLitigationSettlmentMember" id="amed_FinalLitigationSettlmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MedicareRevenue" id="amed_MedicareRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="ExtrapolatedMember" id="amed_ExtrapolatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumPercentOwnershipForEquityMethodPercent" id="amed_MaximumPercentOwnershipForEquityMethodPercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="MaximumPercentOwnershipForCostMethodPercent" id="amed_MaximumPercentOwnershipForCostMethodPercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="NumberOfCareCentersAvailableForSale" id="amed_NumberOfCareCentersAvailableForSale" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersSold" id="amed_NumberOfCareCentersSold" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersIncludedInDivestiturePlan" id="amed_NumberOfCareCentersIncludedInDivestiturePlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FederalDerivativeActionsMember" id="amed_FederalDerivativeActionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LineOfCreditFacilityEffectiveyBorrowingCapacity" id="amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="LineOfCreditFacilityDebtRestrictions" id="amed_LineOfCreditFacilityDebtRestrictions" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="DeferredDebtIssuanceCostsWrittenOff" id="amed_DeferredDebtIssuanceCostsWrittenOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="OtherRestructuringCostsAxis" id="amed_OtherRestructuringCostsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OtherRestructuringDomain" id="amed_OtherRestructuringDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="UnfavorableMember" id="amed_UnfavorableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumLeverageRatio" id="amed_MaximumLeverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="MinimumFixedChargeCoverageRatio" id="amed_MinimumFixedChargeCoverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="WeightedAverageInterestRate" id="amed_WeightedAverageInterestRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersRemovedFromAvailableForSale" id="amed_NumberOfCareCentersRemovedFromAvailableForSale" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" id="amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NetRevenueForCareCentersRemovedFromAvailableForSale" id="amed_NetRevenueForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" id="amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" id="amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" id="amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="InsuranceProceedsForReimbursementOfLegalFees" id="amed_InsuranceProceedsForReimbursementOfLegalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" id="amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="UsDepartmentOfJusticeSettlement" id="amed_UsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="UsDepartmentOfJusticeMember" id="amed_UsDepartmentOfJusticeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InterestRateOnUsDepartmentOfJusticeSettlement" id="amed_InterestRateOnUsDepartmentOfJusticeSettlement" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" id="amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="FinalPaymentOfUsDepartmentOfJusticeSettlement" id="amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" id="amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="OigSelfDisclosureMember" id="amed_OigSelfDisclosureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ErisaClassActionLawsuitMember" id="amed_ErisaClassActionLawsuitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" id="amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCenterStatusAxis" id="amed_CareCenterStatusAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCenterStatusDomain" id="amed_CareCenterStatusDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCentersRemovedFromAvailableForSaleMember" id="amed_CareCentersRemovedFromAvailableForSaleMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DetailsOfCertainBalanceSheetAccountsAbstract" id="amed_DetailsOfCertainBalanceSheetAccountsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" id="amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PensionAndOtherPostretirementBenefitsDisclosureAbstract" id="amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ProvisionForIncomeTaxesTextBlock" id="amed_ProvisionForIncomeTaxesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ReconciliationOfStatutoryTaxEffectsTextBlock" id="amed_ReconciliationOfStatutoryTaxEffectsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="InsuranceProgramsTableTextBlock" id="amed_InsuranceProgramsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ValuationAndQualifyingAccountsTableTextBlock" id="amed_ValuationAndQualifyingAccountsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" id="amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DefinedContributionPlanEmployerMatchingContribution" id="amed_DefinedContributionPlanEmployerMatchingContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" id="amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" id="amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" id="amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" id="amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="OperatingLeaseObligationsLineItems" id="amed_OperatingLeaseObligationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HealthInsurance" id="amed_HealthInsurance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="WokersCompensation" id="amed_WokersCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="ProfessionalLiability" id="amed_ProfessionalLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="EstimatedInsuranceTotal" id="amed_EstimatedInsuranceTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="EstimatedInsuranceLongTermPortion" id="amed_EstimatedInsuranceLongTermPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="EstimatedInsuranceExcludingLongTermPortion" id="amed_EstimatedInsuranceExcludingLongTermPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="IncomeTaxDisclosureLineItems" id="amed_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfIndividualStatesSubjectToIncomeTax" id="amed_NumberOfIndividualStatesSubjectToIncomeTax" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" id="amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" id="amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="DeferredTaxAssetsOtherCurrent" id="amed_DeferredTaxAssetsOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="GoodwillAndIntangibleAssetsLineItems" id="amed_GoodwillAndIntangibleAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCentersClosedOrConsolidatedMember" id="amed_CareCentersClosedOrConsolidatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoThousandAndElevenExitActivityMember" id="amed_TwoThousandAndElevenExitActivityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoThousandAndTwelveExitActivityMember" id="amed_TwoThousandAndTwelveExitActivityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoThousandAndThirteenExitActivityMember" id="amed_TwoThousandAndThirteenExitActivityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LeaseTerminationMember" id="amed_LeaseTerminationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" id="amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtIssuanceCostsPolicyTextBlock" id="amed_DebtIssuanceCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EquipmentAndFurnitureMember" id="amed_EquipmentAndFurnitureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ComputerSoftwareMember" id="amed_ComputerSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InternallyDevelopedComputerSoftwareAmortizationPeriod" id="amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="InternallyDevelopedComputerSoftware" id="amed_InternallyDevelopedComputerSoftware" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" id="amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" id="amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="AlabamaMember" id="amed_AlabamaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NorthCarolinaMember" id="amed_NorthCarolinaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="WestVirginiaMember" id="amed_WestVirginiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LouisianaMember" id="amed_LouisianaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FloridaMember" id="amed_FloridaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InHousePhysiciansPracticeMember" id="amed_InHousePhysiciansPracticeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RevolvingCreditFacilityTotal" id="amed_RevolvingCreditFacilityTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="LineOfCreditFacilityAdditionalBorrowingCapacity" id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="SwingLineLoanMember" id="amed_SwingLineLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentNumberOfPeriodicPayments" id="amed_DebtInstrumentNumberOfPeriodicPayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ApplicableMarginRateOnBaseRate" id="amed_ApplicableMarginRateOnBaseRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ApplicableMarginRateOnEurodollarRate" id="amed_ApplicableMarginRateOnEurodollarRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="AbrLoansMember" id="amed_AbrLoansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EurodollarLoansMember" id="amed_EurodollarLoansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OperatingLeaseCommitmentsForDiscontinuedOperations" id="amed_OperatingLeaseCommitmentsForDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="OperatingLeasesRentExpenseNetForContinuingOperations" id="amed_OperatingLeasesRentExpenseNetForContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="OperatingLeaseTermYears" id="amed_OperatingLeaseTermYears" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="OperatingLeasesAgreementExpirationYear" id="amed_OperatingLeasesAgreementExpirationYear" type="xbrli:dateItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PromissoryNotesMember" id="amed_PromissoryNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersIncludedInDiscontinuedOperations" id="amed_NumberOfCareCentersIncludedInDiscontinuedOperations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FutureRentalCommitmentsTable" id="amed_FutureRentalCommitmentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" id="amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedUsefulLifeOfIntangibleAssets" id="amed_EstimatedUsefulLifeOfIntangibleAssets" type="us-types:durationStringItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FavorableInFullMember" id="amed_FavorableInFullMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FavorableInPartMember" id="amed_FavorableInPartMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfClaimsAppealed" id="amed_NumberOfClaimsAppealed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" id="amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="GoodwillAndIntangibleAssetsImpairmentAxis" id="amed_GoodwillAndIntangibleAssetsImpairmentAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="GoodwillAndIntangibleAssetsDomain" id="amed_GoodwillAndIntangibleAssetsDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SecondLienCreditAgreementTermLoanMember" id="amed_SecondLienCreditAgreementTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SeniorSecuredLeverageRatio" id="amed_SeniorSecuredLeverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="SecondLienCreditAgreementRevolvingCreditFacilityMember" id="amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveABRRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestABRFlatRate" id="amed_DebtInstrumentInterestABRFlatRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EurodollarDepositsInterestPeriod" id="amed_EurodollarDepositsInterestPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestLiborFloor" id="amed_DebtInstrumentInterestLiborFloor" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="CreditAgreementMember" id="amed_CreditAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OtherLongTermObligationsMember" id="amed_OtherLongTermObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredIncomeTaxesMember" id="amed_DeferredIncomeTaxesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoThousandAndFourteenExitActivityMember" id="amed_TwoThousandAndFourteenExitActivityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CorporateIntegrityAgreementTerm" id="amed_CorporateIntegrityAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="TimePeriodAxis" id="amed_TimePeriodAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TimePeriodDomain" id="amed_TimePeriodDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OneMonthMember" id="amed_OneMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoMonthMember" id="amed_TwoMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ThreeMonthMember" id="amed_ThreeMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SixMonthMember" id="amed_SixMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OneYearMember" id="amed_OneYearMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoYearMember" id="amed_TwoYearMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AnnualImpairmentTestStepOneMember" id="amed_AnnualImpairmentTestStepOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="PrepaymentPenaltyPercentage" id="amed_PrepaymentPenaltyPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" id="amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" id="amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" id="amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="FeeTypeAxis" id="amed_FeeTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FeeTypeDomain" id="amed_FeeTypeDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ArrangerFeeMember" id="amed_ArrangerFeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ComputerInventoryAndDataSecurityReportingMember" id="amed_ComputerInventoryAndDataSecurityReportingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfIndividualsWithInformationOnMissingDevices" id="amed_NumberOfIndividualsWithInformationOnMissingDevices" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfMissingComputersAndLaptops" id="amed_NumberOfMissingComputersAndLaptops" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ThresholdOfIndividualsInDataBreach" id="amed_ThresholdOfIndividualsInDataBreach" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfCompanyDevicesUsed" id="amed_PercentageOfCompanyDevicesUsed" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="YearOfDeparture" id="amed_YearOfDeparture" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="AMS3writeoffcharge" id="amed_AMS3writeoffcharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="Buildingandleaseholdimprovements" id="amed_Buildingandleaseholdimprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="Equipmentandfurniture" id="amed_Equipmentandfurniture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="FrontierLitigationMember" id="amed_FrontierLitigationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" id="amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" id="amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" id="amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="HeritageHealthCareInnovationFundMemberMember" id="amed_HeritageHealthCareInnovationFundMemberMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="Goodwillisexpectedtobedeductibleforincometaxpurposesyears" id="amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PersonalCareMember" id="amed_PersonalCareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OneHundredMillionTermLoanMember" id="amed_OneHundredMillionTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoHundredMillionRevolvingCreditFacilityMember" id="amed_TwoHundredMillionRevolvingCreditFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfPatients" id="amed_NumberOfPatients" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest" id="amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="Percentageofpatientreceivablesoutstandingovertenpercent" id="amed_Percentageofpatientreceivablesoutstandingovertenpercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="AssetImpairmentAxis" id="amed_AssetImpairmentAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AssetImpairmentDomain" id="amed_AssetImpairmentDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="Ams3HomecareAndHospiceMember" id="amed_Ams3HomecareAndHospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HomeStaffLlcMember" id="amed_HomeStaffLlcMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" id="amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SuspensionOfMedicarePayments_days" id="amed_SuspensionOfMedicarePayments_days" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="SafeguardZoneProgramIntegrityContractorMember" id="amed_SafeguardZoneProgramIntegrityContractorMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MorgantownWestVirginiaMember" id="amed_MorgantownWestVirginiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SecuritiesClassActionLawsuitMember" id="amed_SecuritiesClassActionLawsuitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ParkersburgWestVirginiaMember" id="amed_ParkersburgWestVirginiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="AccountingStandardsUpdate201609Member" id="amed_AccountingStandardsUpdate201609Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MedicareRevenueMember" id="amed_MedicareRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TenetHealthcareMember" id="amed_TenetHealthcareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>amed-20170331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.5.34 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETS" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfWeightedAverageSharesOutstandingDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfNetRevenuesAndOperatingResultsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfNetRevenuesAndOperatingResultsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LongTermDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_OperatingIncomeOfReportableSegmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_InsuranceProgramsDetails" />
    <roleRef roleURI="http://www.amedisys.com/role/ComponentsOfNetDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ComponentsOfNetDeferredTaxAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_MaturitiesOfDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" />
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_158" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_157" xlink:to="Locator_us-gaap_AssetsCurrent_158" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_169" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_171" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="Locator_us-gaap_AccountsReceivableNetCurrent_172" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_171" xlink:to="Locator_us-gaap_AccountsReceivableNetCurrent_172" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_173" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="Locator_us-gaap_PrepaidExpenseCurrent_174" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_173" xlink:to="Locator_us-gaap_PrepaidExpenseCurrent_174" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_176" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_175" xlink:to="Locator_us-gaap_OtherAssetsCurrent_176" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_177" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_178" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_177" xlink:to="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_178" order="9.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_179" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetCurrent_180" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_179" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetCurrent_180" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_159" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_160" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_159" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentNet_160" order="11.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_161" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_162" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_161" xlink:to="Locator_us-gaap_Goodwill_162" order="12.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_163" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_164" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_163" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_164" order="13.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_165" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_166" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_165" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_166" order="14.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_167" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_168" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_167" xlink:to="Locator_us-gaap_OtherAssetsNoncurrent_168" order="15.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_181" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_182" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquity_181" xlink:to="Locator_us-gaap_Liabilities_182" order="28.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_185" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_186" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Liabilities_185" xlink:to="Locator_us-gaap_LiabilitiesCurrent_186" order="25.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_191" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="Locator_us-gaap_AccountsPayableCurrent_192" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_191" xlink:to="Locator_us-gaap_AccountsPayableCurrent_192" order="19.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_193" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_194" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_193" xlink:to="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_194" order="21.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_195" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_196" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_195" xlink:to="Locator_us-gaap_AccruedLiabilitiesCurrent_196" order="22.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_197" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_198" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_197" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_198" order="23.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_199" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_200" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_199" xlink:to="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_200" order="20.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_201" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_202" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_201" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_202" order="24.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_187" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_188" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Liabilities_187" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_188" order="26.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_189" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_190" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Liabilities_189" xlink:to="Locator_us-gaap_OtherLiabilitiesNoncurrent_190" order="27.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_183" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_184" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquity_183" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_184" order="39.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_204" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_203" xlink:to="Locator_us-gaap_StockholdersEquity_204" order="37.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="Locator_us-gaap_PreferredStockValueOutstanding_208" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_207" xlink:to="Locator_us-gaap_PreferredStockValueOutstanding_208" order="31.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="Locator_us-gaap_CommonStockValueOutstanding_210" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_209" xlink:to="Locator_us-gaap_CommonStockValueOutstanding_210" order="32.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_212" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_211" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_212" order="33.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="Locator_us-gaap_TreasuryStockValue_214" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_213" xlink:to="Locator_us-gaap_TreasuryStockValue_214" order="34.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_215" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_216" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_215" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_216" order="35.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_218" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_217" xlink:to="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_218" order="36.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="Locator_us-gaap_MinorityInterest_206" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_205" xlink:to="Locator_us-gaap_MinorityInterest_206" order="38.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_453" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_454" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ProfitLoss_453" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_454" order="22.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_457" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_458" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_457" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_458" order="20.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_502" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_501" xlink:to="Locator_us-gaap_OperatingIncomeLoss_502" order="13.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_462" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OperatingIncomeLoss_461" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_462" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_463" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_464" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OperatingIncomeLoss_463" xlink:to="Locator_us-gaap_CostsAndExpenses_464" order="12.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_465" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="Locator_us-gaap_LaborAndRelatedExpense_466" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_465" xlink:to="Locator_us-gaap_LaborAndRelatedExpense_466" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_467" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_468" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_467" xlink:to="Locator_us-gaap_ShareBasedCompensation_468" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_470" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_469" xlink:to="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_470" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_471" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_472" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_471" xlink:to="Locator_us-gaap_CostOfServices_472" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_473" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_474" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_473" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_474" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_475" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_476" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_475" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_476" order="9.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_477" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_478" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_477" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_478" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_479" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_480" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_479" xlink:to="Locator_us-gaap_AssetImpairmentCharges_480" order="11.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_504" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_503" xlink:to="Locator_us-gaap_NonoperatingIncomeExpense_504" order="19.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_481" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="Locator_us-gaap_InvestmentIncomeInterestAndDividend_482" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_481" xlink:to="Locator_us-gaap_InvestmentIncomeInterestAndDividend_482" order="15.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_483" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="Locator_us-gaap_InterestExpense_484" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_483" xlink:to="Locator_us-gaap_InterestExpense_484" order="16.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_485" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_486" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_485" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_486" order="17.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="Locator_us-gaap_OtherNonoperatingIncomeExpense_488" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_487" xlink:to="Locator_us-gaap_OtherNonoperatingIncomeExpense_488" order="18.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_460" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_459" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_460" order="21.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_455" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_456" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ProfitLoss_455" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_456" order="23.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_490" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareBasic_489" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_490" order="28.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_491" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_492" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareBasic_491" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_492" order="29.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_493" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_494" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareDiluted_493" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_494" order="33.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_495" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_496" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareDiluted_495" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_496" order="34.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_497" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_498" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetIncomeLoss_497" xlink:to="Locator_us-gaap_ProfitLoss_498" order="24.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_499" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_500" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetIncomeLoss_499" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_500" order="25.0" weight="-1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_705" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_706" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_705" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_706" order="24.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_749" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_750" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_749" xlink:to="Locator_us-gaap_ProfitLoss_750" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_751" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="Locator_us-gaap_DepreciationDepletionAndAmortization_752" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_751" xlink:to="Locator_us-gaap_DepreciationDepletionAndAmortization_752" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_753" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="Locator_us-gaap_ProvisionForDoubtfulAccounts_754" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_753" xlink:to="Locator_us-gaap_ProvisionForDoubtfulAccounts_754" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_756" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_755" xlink:to="Locator_us-gaap_ShareBasedCompensation_756" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_758" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_757" xlink:to="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_758" order="8.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_759" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_760" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_759" xlink:to="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_760" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_761" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_762" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_761" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_762" order="12.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_764" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_763" xlink:to="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_764" order="13.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_765" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_766" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_765" xlink:to="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_766" order="14.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_767" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_768" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_767" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_768" order="17.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_769" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_770" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_769" xlink:to="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_770" order="18.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_772" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_771" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_772" order="19.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_773" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_774" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_773" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_774" order="20.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_775" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_776" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_775" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_776" order="22.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_777" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_778" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_777" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_778" order="23.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_779" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_780" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_779" xlink:to="Locator_us-gaap_AssetImpairmentCharges_780" order="15.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_781" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_782" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_781" xlink:to="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_782" order="11.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_784" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_783" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_784" order="9.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_785" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_786" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_785" xlink:to="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_786" order="21.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionExpense" xlink:label="Locator_us-gaap_PensionExpense_788" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_787" xlink:to="Locator_us-gaap_PensionExpense_788" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_707" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_708" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_707" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_708" order="33.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_711" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_712" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_711" xlink:to="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_712" order="26.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_714" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_713" xlink:to="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_714" order="27.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_716" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_715" xlink:to="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_716" order="28.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_717" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_718" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_717" xlink:to="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_718" order="30.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_719" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_720" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_719" xlink:to="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_720" order="31.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="Locator_us-gaap_PaymentsForProceedsFromInvestments_722" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_721" xlink:to="Locator_us-gaap_PaymentsForProceedsFromInvestments_722" order="29.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_724" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_723" xlink:to="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_724" order="32.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_709" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_710" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_709" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_710" order="47.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="Locator_us-gaap_ProceedsFromStockOptionsExercised_726" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_725" xlink:to="Locator_us-gaap_ProceedsFromStockOptionsExercised_726" order="36.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="Locator_us-gaap_ProceedsFromStockPlans_728" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_727" xlink:to="Locator_us-gaap_ProceedsFromStockPlans_728" order="37.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_730" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_729" xlink:to="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_730" order="39.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_731" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfShortTermDebt_732" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_731" xlink:to="Locator_us-gaap_RepaymentsOfShortTermDebt_732" order="42.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfLongTermDebt_734" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_733" xlink:to="Locator_us-gaap_RepaymentsOfLongTermDebt_734" order="45.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="Locator_us-gaap_ProceedsFromShortTermDebt_736" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_735" xlink:to="Locator_us-gaap_ProceedsFromShortTermDebt_736" order="41.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_737" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="Locator_amed_CashDistributionToNoncontrollingInterest_738" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_737" xlink:to="Locator_amed_CashDistributionToNoncontrollingInterest_738" order="40.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_739" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_740" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_739" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_740" order="43.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_741" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="Locator_us-gaap_PaymentsOfFinancingCosts_742" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_741" xlink:to="Locator_us-gaap_PaymentsOfFinancingCosts_742" order="44.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:label="Locator_us-gaap_IncreaseDecreaseInBookOverdrafts_744" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_743" xlink:to="Locator_us-gaap_IncreaseDecreaseInBookOverdrafts_744" order="35.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_745" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_746" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_745" xlink:to="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_746" order="46.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_747" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="Locator_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_748" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_747" xlink:to="Locator_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_748" order="38.0" weight="-1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1251" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1252" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1251" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1252" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1253" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1254" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1253" xlink:to="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1254" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1255" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NonVestedStockAndStockUnits" xlink:label="Locator_amed_NonVestedStockAndStockUnits_1256" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1255" xlink:to="Locator_amed_NonVestedStockAndStockUnits_1256" order="3.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfNetRevenuesAndOperatingResultsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1350" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1349" xlink:to="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1350" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1352" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1351" xlink:to="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1352" order="3.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1353" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1354" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1353" xlink:to="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1354" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1355" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1356" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1355" xlink:to="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1356" order="8.0" weight="-1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1396" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LongTermDebt_1395" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1396" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="Locator_us-gaap_LongTermDebtNoncurrent_1398" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LongTermDebt_1397" xlink:to="Locator_us-gaap_LongTermDebtNoncurrent_1398" order="5.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2179" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_2180" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2179" xlink:to="Locator_us-gaap_CostOfServices_2180" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2181" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="Locator_amed_GeneralAndAdministrativeExpenseSegment_2182" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2181" xlink:to="Locator_amed_GeneralAndAdministrativeExpenseSegment_2182" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2183" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2184" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2183" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2184" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2185" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2186" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2185" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2186" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2187" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_2188" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2187" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_2188" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2189" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AMS3writeoffcharge" xlink:label="Locator_amed_AMS3writeoffcharge_2190" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2189" xlink:to="Locator_amed_AMS3writeoffcharge_2190" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2191" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_2192" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2191" xlink:to="Locator_us-gaap_AssetImpairmentCharges_2192" order="9.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails">
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_2695" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsurance" xlink:label="Locator_amed_HealthInsurance_2696" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_EstimatedInsuranceTotal_2695" xlink:to="Locator_amed_HealthInsurance_2696" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_2697" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WokersCompensation" xlink:label="Locator_amed_WokersCompensation_2698" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_EstimatedInsuranceTotal_2697" xlink:to="Locator_amed_WokersCompensation_2698" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_2699" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiability" xlink:label="Locator_amed_ProfessionalLiability_2700" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_EstimatedInsuranceTotal_2699" xlink:to="Locator_amed_ProfessionalLiability_2700" order="3.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ComponentsOfNetDeferredTaxAssetsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_2733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_2734" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_2733" xlink:to="Locator_us-gaap_DeferredTaxAssetsNet_2734" order="12.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_2737" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2738" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsNet_2737" xlink:to="Locator_us-gaap_DeferredTaxAssetsGross_2738" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2741" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2742" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2741" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2742" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2744" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2743" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2744" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2745" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_2746" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2745" xlink:to="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_2746" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2747" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_2748" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2747" xlink:to="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_2748" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2749" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2750" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2749" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2750" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2751" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_2752" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2751" xlink:to="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_2752" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2753" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="Locator_amed_DeferredTaxAssetsOtherCurrent_2754" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2753" xlink:to="Locator_amed_DeferredTaxAssetsOtherCurrent_2754" order="9.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2756" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2755" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2756" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2758" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_2757" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2758" order="5.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_2739" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_2740" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsNet_2739" xlink:to="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_2740" order="11.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_2735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_2736" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_2735" xlink:to="Locator_us-gaap_DeferredTaxLiabilities_2736" order="15.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_2759" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2760" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxLiabilities_2759" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2760" order="13.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_2761" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2762" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxLiabilities_2761" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2762" order="14.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2865" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2866" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2865" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2866" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2867" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2868" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2867" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2868" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2869" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2870" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2869" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2870" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2871" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2872" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2871" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2872" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2873" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2874" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2873" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2874" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2875" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2876" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2875" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2876" order="6.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_2989" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="Locator_us-gaap_CapitalizedComputerSoftwareGross_2990" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_2989" xlink:to="Locator_us-gaap_CapitalizedComputerSoftwareGross_2990" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_2991" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Equipmentandfurniture" xlink:label="Locator_amed_Equipmentandfurniture_2992" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_2991" xlink:to="Locator_amed_Equipmentandfurniture_2992" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_2993" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Buildingandleaseholdimprovements" xlink:label="Locator_amed_Buildingandleaseholdimprovements_2994" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_2993" xlink:to="Locator_amed_Buildingandleaseholdimprovements_2994" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_2995" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Land" xlink:label="Locator_us-gaap_Land_2996" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_2995" xlink:to="Locator_us-gaap_Land_2996" order="1.0" weight="1" />
    </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>amed-20170331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.5.34 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
    <roleRef roleURI="http://www.amedisys.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DocumentAndEntityInformation" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETS" />
    <roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETSParenthetical" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfNetRevenuesAndOperatingResultsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfNetRevenuesAndOperatingResultsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LongTermDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LongTermDebtParentheticalDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LongTermDebtAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentsAndContingenciesDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CommitmentsAndContingenciesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_OperatingIncomeOfReportableSegmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_AcquisitionsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_GoodwillAndOtherIntangibleAssetsNetDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_IncomeTaxesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureFutureMinimumRentalCommitments" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_FutureMinimumRentalCommitments" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CommitmentFeeUnderCreditFacilitiesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ExitActivitiesReserveActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SubsequentEventDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SubsequentEventDetail" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DocumentAndEntityInformation">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_37" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_38" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_37" xlink:to="Locator_dei_EntityDomain_38" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_31" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_32" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_dei_DocumentInformationLineItems_31" xlink:to="Locator_dei_EntitiesTable_32" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_35" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_36" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_dei_EntitiesTable_35" xlink:to="Locator_dei_LegalEntityAxis_36" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_39" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="Locator_dei_DocumentType_40" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_39" xlink:to="Locator_dei_DocumentType_40" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_41" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="Locator_dei_AmendmentFlag_42" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_41" xlink:to="Locator_dei_AmendmentFlag_42" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_43" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="Locator_dei_DocumentPeriodEndDate_44" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_43" xlink:to="Locator_dei_DocumentPeriodEndDate_44" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_45" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="Locator_dei_DocumentFiscalYearFocus_46" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_45" xlink:to="Locator_dei_DocumentFiscalYearFocus_46" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_47" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="Locator_dei_DocumentFiscalPeriodFocus_48" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_47" xlink:to="Locator_dei_DocumentFiscalPeriodFocus_48" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_49" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="Locator_dei_TradingSymbol_50" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_49" xlink:to="Locator_dei_TradingSymbol_50" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_51" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="Locator_dei_EntityRegistrantName_52" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_51" xlink:to="Locator_dei_EntityRegistrantName_52" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_53" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="Locator_dei_EntityCentralIndexKey_54" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_53" xlink:to="Locator_dei_EntityCentralIndexKey_54" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_55" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="Locator_dei_CurrentFiscalYearEndDate_56" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_55" xlink:to="Locator_dei_CurrentFiscalYearEndDate_56" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_57" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="Locator_dei_EntityFilerCategory_58" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_57" xlink:to="Locator_dei_EntityFilerCategory_58" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_59" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="Locator_dei_EntityCommonStockSharesOutstanding_60" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_59" xlink:to="Locator_dei_EntityCommonStockSharesOutstanding_60" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_61" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="Locator_dei_EntityPublicFloat_62" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_61" xlink:to="Locator_dei_EntityPublicFloat_62" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_63" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="Locator_dei_EntityVoluntaryFilers_64" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_63" xlink:to="Locator_dei_EntityVoluntaryFilers_64" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_65" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="Locator_dei_EntityCurrentReportingStatus_66" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_65" xlink:to="Locator_dei_EntityCurrentReportingStatus_66" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_67" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="Locator_dei_EntityWellKnownSeasonedIssuer_68" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_67" xlink:to="Locator_dei_EntityWellKnownSeasonedIssuer_68" order="15.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_223" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_224" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_223" xlink:to="Locator_us-gaap_AssetsAbstract_224" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_226" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_225" xlink:to="Locator_us-gaap_AssetsCurrentAbstract_226" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_228" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_227" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_228" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="Locator_us-gaap_AccountsReceivableNetCurrent_230" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_229" xlink:to="Locator_us-gaap_AccountsReceivableNetCurrent_230" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_231" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="Locator_us-gaap_PrepaidExpenseCurrent_232" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_231" xlink:to="Locator_us-gaap_PrepaidExpenseCurrent_232" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_233" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetCurrent_234" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_233" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetCurrent_234" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_235" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_236" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_235" xlink:to="Locator_us-gaap_OtherAssetsCurrent_236" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_238" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_237" xlink:to="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_238" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_240" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_239" xlink:to="Locator_us-gaap_AssetsCurrent_240" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_242" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_241" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentNet_242" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_243" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_244" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_243" xlink:to="Locator_us-gaap_Goodwill_244" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_245" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_246" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_245" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_246" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_247" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_248" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_247" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_248" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_250" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_249" xlink:to="Locator_us-gaap_OtherAssetsNoncurrent_250" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_251" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_252" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_251" xlink:to="Locator_us-gaap_Assets_252" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_253" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_254" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_253" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_254" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_255" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_256" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_255" xlink:to="Locator_us-gaap_LiabilitiesCurrentAbstract_256" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_257" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="Locator_us-gaap_AccountsPayableCurrent_258" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_257" xlink:to="Locator_us-gaap_AccountsPayableCurrent_258" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_259" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_260" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_259" xlink:to="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_260" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_261" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_262" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_261" xlink:to="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_262" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_263" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_264" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_263" xlink:to="Locator_us-gaap_AccruedLiabilitiesCurrent_264" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_266" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_265" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_266" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_267" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_268" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_267" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_268" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_269" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_270" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_269" xlink:to="Locator_us-gaap_LiabilitiesCurrent_270" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_272" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_271" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_272" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_273" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_274" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_273" xlink:to="Locator_us-gaap_OtherLiabilitiesNoncurrent_274" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_275" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_276" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_275" xlink:to="Locator_us-gaap_Liabilities_276" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_277" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="Locator_us-gaap_CommitmentsAndContingencies_278" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_277" xlink:to="Locator_us-gaap_CommitmentsAndContingencies_278" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_279" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_280" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_279" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_280" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_281" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="Locator_us-gaap_PreferredStockValueOutstanding_282" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_281" xlink:to="Locator_us-gaap_PreferredStockValueOutstanding_282" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_283" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="Locator_us-gaap_CommonStockValueOutstanding_284" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_283" xlink:to="Locator_us-gaap_CommonStockValueOutstanding_284" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_286" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_285" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_286" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_287" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="Locator_us-gaap_TreasuryStockValue_288" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_287" xlink:to="Locator_us-gaap_TreasuryStockValue_288" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_290" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_289" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_290" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_291" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_292" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_291" xlink:to="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_292" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_293" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_294" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_293" xlink:to="Locator_us-gaap_StockholdersEquity_294" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="Locator_us-gaap_MinorityInterest_296" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_295" xlink:to="Locator_us-gaap_MinorityInterest_296" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_297" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_298" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_297" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_298" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_300" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_299" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquity_300" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_79" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_80" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_StatementLineItems_79" xlink:to="Locator_us-gaap_StatementTable_80" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_220" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_StatementTable_219" xlink:to="Locator_dei_LegalEntityAxis_220" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_222" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_221" xlink:to="Locator_dei_EntityDomain_222" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_339" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_340" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_339" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_340" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_341" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_342" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_341" xlink:to="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_342" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_343" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_344" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_343" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_344" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_346" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_345" xlink:to="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_346" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="Locator_us-gaap_PreferredStockSharesAuthorized_348" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_347" xlink:to="Locator_us-gaap_PreferredStockSharesAuthorized_348" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="Locator_us-gaap_PreferredStockSharesIssued_350" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_349" xlink:to="Locator_us-gaap_PreferredStockSharesIssued_350" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="Locator_us-gaap_PreferredStockSharesOutstanding_352" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_351" xlink:to="Locator_us-gaap_PreferredStockSharesOutstanding_352" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_353" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_CommonStockParOrStatedValuePerShare_354" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_353" xlink:to="Locator_us-gaap_CommonStockParOrStatedValuePerShare_354" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_355" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="Locator_us-gaap_CommonStockSharesAuthorized_356" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_355" xlink:to="Locator_us-gaap_CommonStockSharesAuthorized_356" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_357" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="Locator_us-gaap_CommonStockSharesIssued_358" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_357" xlink:to="Locator_us-gaap_CommonStockSharesIssued_358" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="Locator_us-gaap_CommonStockSharesOutstanding_360" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_359" xlink:to="Locator_us-gaap_CommonStockSharesOutstanding_360" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_361" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="Locator_us-gaap_TreasuryStockShares_362" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_361" xlink:to="Locator_us-gaap_TreasuryStockShares_362" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_332" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_StatementLineItems_331" xlink:to="Locator_us-gaap_StatementTable_332" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_336" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_StatementTable_335" xlink:to="Locator_dei_LegalEntityAxis_336" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_337" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_338" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_337" xlink:to="Locator_dei_EntityDomain_338" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_363" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_364" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_dei_LegalEntityAxis_363" xlink:to="Locator_dei_EntityDomain_364" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_416" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_StatementLineItems_415" xlink:to="Locator_us-gaap_StatementTable_416" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_506" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_StatementTable_505" xlink:to="Locator_dei_LegalEntityAxis_506" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_507" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_508" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_507" xlink:to="Locator_dei_EntityDomain_508" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_510" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_509" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_510" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_511" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_512" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_511" xlink:to="Locator_us-gaap_CostOfServices_512" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_513" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_514" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_513" xlink:to="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_514" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_515" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="Locator_us-gaap_LaborAndRelatedExpense_516" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_515" xlink:to="Locator_us-gaap_LaborAndRelatedExpense_516" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_518" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_517" xlink:to="Locator_us-gaap_ShareBasedCompensation_518" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_520" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_519" xlink:to="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_520" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_521" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_522" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_521" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_522" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_523" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_524" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_523" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_524" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_525" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_526" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_525" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_526" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_527" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_528" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_527" xlink:to="Locator_us-gaap_AssetImpairmentCharges_528" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_529" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_530" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_529" xlink:to="Locator_us-gaap_CostsAndExpenses_530" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_531" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_532" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_531" xlink:to="Locator_us-gaap_OperatingIncomeLoss_532" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_533" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_534" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_533" xlink:to="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_534" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_535" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="Locator_us-gaap_InvestmentIncomeInterestAndDividend_536" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_535" xlink:to="Locator_us-gaap_InvestmentIncomeInterestAndDividend_536" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_537" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="Locator_us-gaap_InterestExpense_538" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_537" xlink:to="Locator_us-gaap_InterestExpense_538" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_540" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_539" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_540" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_541" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="Locator_us-gaap_OtherNonoperatingIncomeExpense_542" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_541" xlink:to="Locator_us-gaap_OtherNonoperatingIncomeExpense_542" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_543" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_544" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_543" xlink:to="Locator_us-gaap_NonoperatingIncomeExpense_544" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_545" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_546" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_545" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_546" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_548" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_547" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_548" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_549" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_550" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_549" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_550" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_552" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_551" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_552" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_553" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_554" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_553" xlink:to="Locator_us-gaap_ProfitLoss_554" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_556" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_555" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_556" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_558" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_557" xlink:to="Locator_us-gaap_EarningsPerShareBasicAbstract_558" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_560" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_559" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_560" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_561" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_562" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_561" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_562" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_564" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_563" xlink:to="Locator_us-gaap_EarningsPerShareBasic_564" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_565" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_566" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_565" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_566" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_568" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_567" xlink:to="Locator_us-gaap_EarningsPerShareDilutedAbstract_568" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_570" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_569" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_570" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_572" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_571" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_572" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_574" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_573" xlink:to="Locator_us-gaap_EarningsPerShareDiluted_574" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_575" xlink:to="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_577" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_578" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_577" xlink:to="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_578" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_579" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperations_580" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_579" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperations_580" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_581" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_582" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_581" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_582" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_583" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_584" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_583" xlink:to="Locator_us-gaap_NetIncomeLoss_584" order="3.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_897" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_898" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_897" xlink:to="Locator_us-gaap_SegmentDomain_898" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_949" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_950" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_949" xlink:to="Locator_us-gaap_SegmentDomain_950" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_903" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceInpatientMember" xlink:label="Locator_amed_HospiceInpatientMember_904" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_903" xlink:to="Locator_amed_HospiceInpatientMember_904" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_899" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_900" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_899" xlink:to="Locator_amed_HomeHealthMember_900" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_901" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_902" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_901" xlink:to="Locator_amed_HospiceMember_902" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_905" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_906" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_905" xlink:to="Locator_amed_PersonalCareMember_906" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_885" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_886" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_885" xlink:to="Locator_amed_OrganizationAndNatureOfOperationsTable_886" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_889" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_890" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_889" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_890" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_891" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_892" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_891" xlink:to="Locator_us-gaap_ConcentrationRiskByTypeAxis_892" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_907" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_908" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_ConcentrationRiskByTypeAxis_907" xlink:to="Locator_us-gaap_ConcentrationRiskTypeDomain_908" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_951" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_952" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_ConcentrationRiskByTypeAxis_951" xlink:to="Locator_us-gaap_ConcentrationRiskTypeDomain_952" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_909" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="Locator_us-gaap_CustomerConcentrationRiskMember_910" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_909" xlink:to="Locator_us-gaap_CustomerConcentrationRiskMember_910" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_911" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="Locator_us-gaap_SalesRevenueNetMember_912" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_911" xlink:to="Locator_us-gaap_SalesRevenueNetMember_912" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_913" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenueMember" xlink:label="Locator_amed_MedicareRevenueMember_914" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_913" xlink:to="Locator_amed_MedicareRevenueMember_914" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_893" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_894" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_893" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_894" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_915" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_916" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_915" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_916" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_917" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_918" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_917" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_918" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_895" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_896" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_895" xlink:to="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_896" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_919" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_920" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_919" xlink:to="Locator_us-gaap_EquityMethodInvesteeNameDomain_920" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_953" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_954" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_953" xlink:to="Locator_us-gaap_EquityMethodInvesteeNameDomain_954" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_921" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HeritageHealthCareInnovationFundMemberMember" xlink:label="Locator_amed_HeritageHealthCareInnovationFundMemberMember_922" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityMethodInvesteeNameDomain_921" xlink:to="Locator_amed_HeritageHealthCareInnovationFundMemberMember_922" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_923" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="Locator_us-gaap_ConcentrationRiskPercentage1_924" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_923" xlink:to="Locator_us-gaap_ConcentrationRiskPercentage1_924" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_925" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingCareCenters" xlink:label="Locator_amed_OperatingCareCenters_926" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_925" xlink:to="Locator_amed_OperatingCareCenters_926" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_927" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_928" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_927" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_928" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_929" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_930" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_929" xlink:to="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_930" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_931" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="Locator_us-gaap_EquityMethodInvestmentAggregateCost_932" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_931" xlink:to="Locator_us-gaap_EquityMethodInvestmentAggregateCost_932" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_933" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="Locator_us-gaap_CostMethodInvestments_934" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_933" xlink:to="Locator_us-gaap_CostMethodInvestments_934" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_935" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_936" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_935" xlink:to="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_936" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_937" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_938" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_937" xlink:to="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_938" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_939" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_940" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_939" xlink:to="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_940" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_941" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_942" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_941" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_942" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_943" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_944" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_943" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_944" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_945" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_946" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_945" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_946" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_947" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_948" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_947" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_948" order="13.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1077" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1078" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1077" xlink:to="Locator_us-gaap_SegmentDomain_1078" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1079" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1080" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1079" xlink:to="Locator_amed_HomeHealthMember_1080" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1081" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1082" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1081" xlink:to="Locator_amed_HospiceMember_1082" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1153" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="Locator_amed_InternallyDevelopedComputerSoftware_1154" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1153" xlink:to="Locator_amed_InternallyDevelopedComputerSoftware_1154" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1155" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1156" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1155" xlink:to="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1156" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="Locator_us-gaap_Depreciation_1158" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1157" xlink:to="Locator_us-gaap_Depreciation_1158" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1049" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1050" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1049" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1050" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1075" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1076" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1075" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1076" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1041" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1042" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1041" xlink:to="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1042" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1065" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1066" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1065" xlink:to="Locator_amed_CapYearAxis_1066" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1083" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1084" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_CapYearAxis_1083" xlink:to="Locator_amed_CapYearDomain_1084" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1159" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1160" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_CapYearAxis_1159" xlink:to="Locator_amed_CapYearDomain_1160" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1085" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" xlink:label="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember_1086" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CapYearDomain_1085" xlink:to="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember_1086" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1087" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" xlink:label="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember_1088" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CapYearDomain_1087" xlink:to="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember_1088" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1067" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1068" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1067" xlink:to="Locator_amed_AssetImpairmentAxis_1068" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1089" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1090" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_AssetImpairmentAxis_1089" xlink:to="Locator_amed_AssetImpairmentDomain_1090" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1161" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1162" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_AssetImpairmentAxis_1161" xlink:to="Locator_amed_AssetImpairmentDomain_1162" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1091" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="Locator_amed_Ams3HomecareAndHospiceMember_1092" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_AssetImpairmentDomain_1091" xlink:to="Locator_amed_Ams3HomecareAndHospiceMember_1092" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1069" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1070" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1069" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1070" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1071" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1072" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1071" xlink:to="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1072" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1101" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="Locator_us-gaap_TypeOfAdoptionMember_1102" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1101" xlink:to="Locator_us-gaap_TypeOfAdoptionMember_1102" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1165" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="Locator_us-gaap_TypeOfAdoptionMember_1166" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1165" xlink:to="Locator_us-gaap_TypeOfAdoptionMember_1166" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="Locator_us-gaap_TypeOfAdoptionMember_1093" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="Locator_us-gaap_NewAccountingPronouncementMember_1094" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_TypeOfAdoptionMember_1093" xlink:to="Locator_us-gaap_NewAccountingPronouncementMember_1094" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="Locator_us-gaap_NewAccountingPronouncementMember_1099" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccountingStandardsUpdate201609Member" xlink:label="Locator_amed_AccountingStandardsUpdate201609Member_1100" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NewAccountingPronouncementMember_1099" xlink:to="Locator_amed_AccountingStandardsUpdate201609Member_1100" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1073" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_1074" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1073" xlink:to="Locator_us-gaap_StatementEquityComponentsAxis_1074" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_1095" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_1096" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementEquityComponentsAxis_1095" xlink:to="Locator_us-gaap_EquityComponentDomain_1096" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_1163" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_1164" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_StatementEquityComponentsAxis_1163" xlink:to="Locator_us-gaap_EquityComponentDomain_1164" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_1097" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="Locator_us-gaap_RetainedEarningsMember_1098" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityComponentDomain_1097" xlink:to="Locator_us-gaap_RetainedEarningsMember_1098" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1103" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1104" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1103" xlink:to="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1104" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1105" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_1106" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1105" xlink:to="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_1106" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1107" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1108" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1107" xlink:to="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1108" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1109" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_FirstThresholdOfTherapyServicesRequired_1110" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1109" xlink:to="Locator_amed_FirstThresholdOfTherapyServicesRequired_1110" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1111" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="Locator_amed_SecondThresholdOfServicesRequired_1112" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1111" xlink:to="Locator_amed_SecondThresholdOfServicesRequired_1112" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1113" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1114" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1113" xlink:to="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1114" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1115" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1116" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1115" xlink:to="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1116" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1117" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="Locator_amed_HistoricalCollectionRateFromMedicare_1118" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1117" xlink:to="Locator_amed_HistoricalCollectionRateFromMedicare_1118" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1119" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1120" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1119" xlink:to="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1120" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1121" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1122" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1121" xlink:to="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1122" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1123" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1124" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1123" xlink:to="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1124" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1125" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="Locator_amed_PercentageOfPatientReceivablesOutstanding_1126" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1125" xlink:to="Locator_amed_PercentageOfPatientReceivablesOutstanding_1126" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1127" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1128" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1127" xlink:to="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1128" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1129" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1130" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1129" xlink:to="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1130" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1131" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="Locator_amed_RevenueAdjustmentToMedicareRevenue_1132" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1131" xlink:to="Locator_amed_RevenueAdjustmentToMedicareRevenue_1132" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1133" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1134" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1133" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1134" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1135" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1136" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1135" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1136" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1137" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1138" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1137" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1138" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1139" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1140" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1139" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1140" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1141" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1142" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1141" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1142" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1143" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Percentageofpatientreceivablesoutstandingovertenpercent" xlink:label="Locator_amed_Percentageofpatientreceivablesoutstandingovertenpercent_1144" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1143" xlink:to="Locator_amed_Percentageofpatientreceivablesoutstandingovertenpercent_1144" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_1146" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1145" xlink:to="Locator_us-gaap_AssetImpairmentCharges_1146" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1147" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1148" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1147" xlink:to="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1148" order="23.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1149" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1150" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1149" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1150" order="24.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1151" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1152" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1151" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1152" order="25.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1212" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1211" xlink:to="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1212" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1215" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1216" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1215" xlink:to="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1216" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1218" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1217" xlink:to="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1218" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1228" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1227" xlink:to="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1228" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="Locator_us-gaap_FairValueInputsLevel1Member_1220" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1219" xlink:to="Locator_us-gaap_FairValueInputsLevel1Member_1220" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="Locator_us-gaap_FairValueInputsLevel2Member_1222" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1221" xlink:to="Locator_us-gaap_FairValueInputsLevel2Member_1222" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1223" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="Locator_us-gaap_FairValueInputsLevel3Member_1224" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1223" xlink:to="Locator_us-gaap_FairValueInputsLevel3Member_1224" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="Locator_us-gaap_LiabilitiesFairValueDisclosure_1226" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1225" xlink:to="Locator_us-gaap_LiabilitiesFairValueDisclosure_1226" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1275" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1276" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1275" xlink:to="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1276" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1279" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1280" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1279" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1280" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1283" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1284" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1283" xlink:to="Locator_us-gaap_SegmentDomain_1284" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1285" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1286" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1285" xlink:to="Locator_amed_HomeHealthMember_1286" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1287" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1288" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1287" xlink:to="Locator_amed_HospiceMember_1288" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1281" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1282" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1281" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1282" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1290" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1289" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1290" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1312" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1311" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1312" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1291" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="Locator_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1292" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1291" xlink:to="Locator_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1292" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1293" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="Locator_amed_NumberOfCareCentersConsolidated_1294" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1293" xlink:to="Locator_amed_NumberOfCareCentersConsolidated_1294" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1295" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersClosed" xlink:label="Locator_amed_NumberOfCareCentersClosed_1296" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1295" xlink:to="Locator_amed_NumberOfCareCentersClosed_1296" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1297" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1298" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1297" xlink:to="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1298" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1299" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersExited" xlink:label="Locator_amed_NumberOfCareCentersExited_1300" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1299" xlink:to="Locator_amed_NumberOfCareCentersExited_1300" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1301" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersAvailableForSale_1302" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1301" xlink:to="Locator_amed_NumberOfCareCentersAvailableForSale_1302" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1303" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_1304" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1303" xlink:to="Locator_amed_NumberOfCareCentersSold_1304" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1305" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1306" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1305" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1306" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1307" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1308" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1307" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1308" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1309" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1310" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1309" xlink:to="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1310" order="9.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfNetRevenuesAndOperatingResultsDetail">
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1347" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1348" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1347" xlink:to="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1348" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1357" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1358" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1357" xlink:to="Locator_amed_CareCenterStatusAxis_1358" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1359" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1360" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_CareCenterStatusAxis_1359" xlink:to="Locator_amed_CareCenterStatusDomain_1360" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1371" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1372" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_CareCenterStatusAxis_1371" xlink:to="Locator_amed_CareCenterStatusDomain_1372" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1361" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1362" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CareCenterStatusDomain_1361" xlink:to="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1362" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1363" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1364" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1363" xlink:to="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1364" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1365" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1366" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1365" xlink:to="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1366" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1367" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1368" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1367" xlink:to="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1368" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1369" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1370" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1369" xlink:to="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1370" order="4.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1421" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1422" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1421" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1422" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="Locator_us-gaap_LongTermDebtNoncurrent_1424" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1423" xlink:to="Locator_us-gaap_LongTermDebtNoncurrent_1424" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1426" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1425" xlink:to="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1426" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1391" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1392" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1391" xlink:to="Locator_us-gaap_DebtInstrumentTable_1392" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1400" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1399" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1400" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1402" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1401" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1402" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1403" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1404" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1403" xlink:to="Locator_amed_TermLoanMember_1404" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1405" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1406" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1405" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1406" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1407" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1408" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1407" xlink:to="Locator_amed_SwingLineLoanMember_1408" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1410" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1409" xlink:to="Locator_us-gaap_LetterOfCreditMember_1410" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1413" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1414" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1413" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1414" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1415" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1416" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1415" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1416" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1411" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1412" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1411" xlink:to="Locator_amed_PromissoryNotesMember_1412" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1420" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1419" xlink:to="Locator_us-gaap_LongTermDebt_1420" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1418" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1417" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1418" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1495" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1496" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1495" xlink:to="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1496" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1499" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="Locator_amed_InterestRateOnNotesPayableToBank_1500" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1499" xlink:to="Locator_amed_InterestRateOnNotesPayableToBank_1500" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1504" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1503" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1504" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1462" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1461" xlink:to="Locator_us-gaap_DebtInstrumentTable_1462" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1465" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1466" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1465" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1466" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1470" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1469" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1470" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1507" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1508" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1507" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1508" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1481" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1482" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1481" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1482" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1471" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1472" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1471" xlink:to="Locator_amed_TermLoanMember_1472" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1473" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1474" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1473" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1474" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1475" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1476" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1475" xlink:to="Locator_amed_SwingLineLoanMember_1476" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1477" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1478" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1477" xlink:to="Locator_us-gaap_LetterOfCreditMember_1478" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1483" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1484" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1483" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1484" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1485" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1486" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1485" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1486" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1479" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1480" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1479" xlink:to="Locator_amed_PromissoryNotesMember_1480" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1467" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1468" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1467" xlink:to="Locator_us-gaap_RangeAxis_1468" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1488" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_1487" xlink:to="Locator_us-gaap_RangeMember_1488" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1510" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_RangeAxis_1509" xlink:to="Locator_us-gaap_RangeMember_1510" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1491" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1492" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1491" xlink:to="Locator_us-gaap_MinimumMember_1492" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1490" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1489" xlink:to="Locator_us-gaap_MaximumMember_1490" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1493" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1494" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1493" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1494" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1502" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1501" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1502" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1506" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1505" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1506" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1497" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1498" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1497" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1498" order="3.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1618" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1617" xlink:to="Locator_us-gaap_DebtInstrumentTable_1618" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1621" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1622" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1621" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1622" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1630" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1629" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1630" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1631" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1632" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1631" xlink:to="Locator_amed_TermLoanMember_1632" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1633" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1634" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1633" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1634" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1635" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1636" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1635" xlink:to="Locator_amed_SwingLineLoanMember_1636" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1637" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1638" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1637" xlink:to="Locator_us-gaap_LetterOfCreditMember_1638" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1641" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CreditAgreementMember" xlink:label="Locator_amed_CreditAgreementMember_1642" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1641" xlink:to="Locator_amed_CreditAgreementMember_1642" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1643" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1644" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1643" xlink:to="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1644" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1645" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1646" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1645" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1646" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1647" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1648" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1647" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1648" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1639" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1640" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1639" xlink:to="Locator_amed_PromissoryNotesMember_1640" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1624" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1623" xlink:to="Locator_us-gaap_RangeAxis_1624" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1649" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1650" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_1649" xlink:to="Locator_us-gaap_RangeMember_1650" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1672" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1671" xlink:to="Locator_us-gaap_MinimumMember_1672" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1670" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1669" xlink:to="Locator_us-gaap_MaximumMember_1670" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1625" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1626" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1625" xlink:to="Locator_amed_TimePeriodAxis_1626" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1651" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1652" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_TimePeriodAxis_1651" xlink:to="Locator_amed_TimePeriodDomain_1652" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1749" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1750" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_TimePeriodAxis_1749" xlink:to="Locator_amed_TimePeriodDomain_1750" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1653" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneMonthMember" xlink:label="Locator_amed_OneMonthMember_1654" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1653" xlink:to="Locator_amed_OneMonthMember_1654" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1655" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoMonthMember" xlink:label="Locator_amed_TwoMonthMember_1656" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1655" xlink:to="Locator_amed_TwoMonthMember_1656" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1657" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThreeMonthMember" xlink:label="Locator_amed_ThreeMonthMember_1658" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1657" xlink:to="Locator_amed_ThreeMonthMember_1658" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1659" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SixMonthMember" xlink:label="Locator_amed_SixMonthMember_1660" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1659" xlink:to="Locator_amed_SixMonthMember_1660" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1661" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneYearMember" xlink:label="Locator_amed_OneYearMember_1662" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1661" xlink:to="Locator_amed_OneYearMember_1662" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1663" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoYearMember" xlink:label="Locator_amed_TwoYearMember_1664" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1663" xlink:to="Locator_amed_TwoYearMember_1664" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1627" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1628" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1627" xlink:to="Locator_amed_FeeTypeAxis_1628" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1665" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1666" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_FeeTypeAxis_1665" xlink:to="Locator_amed_FeeTypeDomain_1666" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1751" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1752" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_FeeTypeAxis_1751" xlink:to="Locator_amed_FeeTypeDomain_1752" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1667" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ArrangerFeeMember" xlink:label="Locator_amed_ArrangerFeeMember_1668" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_FeeTypeDomain_1667" xlink:to="Locator_amed_ArrangerFeeMember_1668" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="Locator_us-gaap_DebtInstrumentTerm_1674" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1673" xlink:to="Locator_us-gaap_DebtInstrumentTerm_1674" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1675" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WeightedAverageInterestRate" xlink:label="Locator_amed_WeightedAverageInterestRate_1676" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1675" xlink:to="Locator_amed_WeightedAverageInterestRate_1676" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1677" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TotalLeverageRatio" xlink:label="Locator_amed_TotalLeverageRatio_1678" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1677" xlink:to="Locator_amed_TotalLeverageRatio_1678" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1679" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FixedChargeCoverageRatio" xlink:label="Locator_amed_FixedChargeCoverageRatio_1680" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1679" xlink:to="Locator_amed_FixedChargeCoverageRatio_1680" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1681" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1682" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1681" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1682" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1684" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1683" xlink:to="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1684" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1685" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="Locator_us-gaap_LettersOfCreditOutstandingAmount_1686" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1685" xlink:to="Locator_us-gaap_LettersOfCreditOutstandingAmount_1686" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1687" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1688" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1687" xlink:to="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1688" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1689" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="Locator_amed_LineOfCreditFacilityDebtRestrictions_1690" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1689" xlink:to="Locator_amed_LineOfCreditFacilityDebtRestrictions_1690" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1691" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumLeverageRatio" xlink:label="Locator_amed_MaximumLeverageRatio_1692" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1691" xlink:to="Locator_amed_MaximumLeverageRatio_1692" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1693" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="Locator_amed_MinimumFixedChargeCoverageRatio_1694" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1693" xlink:to="Locator_amed_MinimumFixedChargeCoverageRatio_1694" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1695" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1696" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1695" xlink:to="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1696" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1697" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="Locator_amed_RevolvingCreditFacilityTotal_1698" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1697" xlink:to="Locator_amed_RevolvingCreditFacilityTotal_1698" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1699" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1700" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1699" xlink:to="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1700" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1702" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1701" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1702" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1703" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1704" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1703" xlink:to="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1704" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1705" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1706" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1705" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1706" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1707" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="Locator_us-gaap_DeferredFinanceCostsNet_1708" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1707" xlink:to="Locator_us-gaap_DeferredFinanceCostsNet_1708" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1709" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1710" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1709" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1710" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1711" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1712" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1711" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1712" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1713" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1714" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1713" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1714" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1715" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="Locator_amed_DebtInstrumentInterestABRFlatRate_1716" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1715" xlink:to="Locator_amed_DebtInstrumentInterestABRFlatRate_1716" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1717" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1718" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1717" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1718" order="23.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1719" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="Locator_amed_ApplicableMarginRateOnBaseRate_1720" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1719" xlink:to="Locator_amed_ApplicableMarginRateOnBaseRate_1720" order="24.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1721" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="Locator_amed_ApplicableMarginRateOnEurodollarRate_1722" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1721" xlink:to="Locator_amed_ApplicableMarginRateOnEurodollarRate_1722" order="25.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1723" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="Locator_amed_EurodollarDepositsInterestPeriod_1724" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1723" xlink:to="Locator_amed_EurodollarDepositsInterestPeriod_1724" order="26.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1725" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="Locator_amed_DebtInstrumentInterestLiborFloor_1726" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1725" xlink:to="Locator_amed_DebtInstrumentInterestLiborFloor_1726" order="27.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1727" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="Locator_amed_PrepaymentPenaltyPercentage_1728" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1727" xlink:to="Locator_amed_PrepaymentPenaltyPercentage_1728" order="28.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1729" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1730" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1729" xlink:to="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1730" order="29.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1731" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1732" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1731" xlink:to="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1732" order="30.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1734" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1733" xlink:to="Locator_us-gaap_LongTermDebt_1734" order="31.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="Locator_us-gaap_OtherNotesPayable_1736" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1735" xlink:to="Locator_us-gaap_OtherNotesPayable_1736" order="32.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1737" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1738" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1737" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1738" order="33.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1739" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="Locator_us-gaap_RepaymentsOfLinesOfCredit_1740" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1739" xlink:to="Locator_us-gaap_RepaymentsOfLinesOfCredit_1740" order="34.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1741" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1742" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1741" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1742" order="35.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="Locator_us-gaap_DebtWeightedAverageInterestRate_1744" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1743" xlink:to="Locator_us-gaap_DebtWeightedAverageInterestRate_1744" order="36.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1745" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="Locator_amed_SeniorSecuredLeverageRatio_1746" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1745" xlink:to="Locator_amed_SeniorSecuredLeverageRatio_1746" order="37.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1747" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1748" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1747" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1748" order="38.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentsAndContingenciesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1895" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1896" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_1895" xlink:to="Locator_us-gaap_RangeMember_1896" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1973" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1974" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1973" xlink:to="Locator_us-gaap_MinimumMember_1974" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1975" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1976" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1975" xlink:to="Locator_us-gaap_MaximumMember_1976" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1897" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1898" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1897" xlink:to="Locator_us-gaap_SegmentDomain_1898" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1901" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesMember" xlink:label="Locator_amed_MaximusFederalServicesMember_1902" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1901" xlink:to="Locator_amed_MaximusFederalServicesMember_1902" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1905" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="Locator_amed_MaximusFederalServicesAndHospiceMember_1906" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1905" xlink:to="Locator_amed_MaximusFederalServicesAndHospiceMember_1906" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1907" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassproAndHospiceMember" xlink:label="Locator_amed_MassproAndHospiceMember_1908" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1907" xlink:to="Locator_amed_MassproAndHospiceMember_1908" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1909" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfEmployeesInWageHourLitigationMember" xlink:label="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_1910" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1909" xlink:to="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_1910" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1911" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="Locator_amed_MaximusFederalServicesAndHomeHealthMember_1912" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1911" xlink:to="Locator_amed_MaximusFederalServicesAndHomeHealthMember_1912" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1899" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1900" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1899" xlink:to="Locator_amed_HomeHealthMember_1900" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1903" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1904" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1903" xlink:to="Locator_amed_HospiceMember_1904" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_1913" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_1914" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_1913" xlink:to="Locator_dei_EntityDomain_1914" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_1915" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="Locator_amed_MedicareAdministrativeContractorMacMember_1916" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_EntityDomain_1915" xlink:to="Locator_amed_MedicareAdministrativeContractorMacMember_1916" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1877" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1878" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1877" xlink:to="Locator_amed_CommimentsAndContingenciesTable_1878" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1881" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1882" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_1881" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1882" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1883" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_1884" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_1883" xlink:to="Locator_dei_LegalEntityAxis_1884" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1885" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_1886" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_1885" xlink:to="Locator_us-gaap_LitigationStatusAxis_1886" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_1917" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1918" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LitigationStatusAxis_1917" xlink:to="Locator_us-gaap_LitigationStatusDomain_1918" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2047" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2048" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LitigationStatusAxis_2047" xlink:to="Locator_us-gaap_LitigationStatusDomain_2048" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1919" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="Locator_us-gaap_PendingLitigationMember_1920" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1919" xlink:to="Locator_us-gaap_PendingLitigationMember_1920" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1921" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalLitigationSettlmentMember" xlink:label="Locator_amed_FinalLitigationSettlmentMember_1922" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1921" xlink:to="Locator_amed_FinalLitigationSettlmentMember_1922" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1923" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FederalDerivativeActionsMember" xlink:label="Locator_amed_FederalDerivativeActionsMember_1924" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1923" xlink:to="Locator_amed_FederalDerivativeActionsMember_1924" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1925" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OigSelfDisclosureMember" xlink:label="Locator_amed_OigSelfDisclosureMember_1926" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1925" xlink:to="Locator_amed_OigSelfDisclosureMember_1926" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1927" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="Locator_amed_ErisaClassActionLawsuitMember_1928" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1927" xlink:to="Locator_amed_ErisaClassActionLawsuitMember_1928" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1929" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_1930" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1929" xlink:to="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_1930" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1931" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FrontierLitigationMember" xlink:label="Locator_amed_FrontierLitigationMember_1932" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1931" xlink:to="Locator_amed_FrontierLitigationMember_1932" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1933" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="Locator_amed_UsDepartmentOfJusticeMember_1934" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1933" xlink:to="Locator_amed_UsDepartmentOfJusticeMember_1934" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1935" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember" xlink:label="Locator_amed_SafeguardZoneProgramIntegrityContractorMember_1936" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1935" xlink:to="Locator_amed_SafeguardZoneProgramIntegrityContractorMember_1936" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_1937" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="Locator_amed_SecuritiesClassActionLawsuitMember_1938" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_1937" xlink:to="Locator_amed_SecuritiesClassActionLawsuitMember_1938" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1887" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_1888" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_1887" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_1888" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_1939" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_1940" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_1939" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_1940" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2049" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2050" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2049" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2050" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_1941" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RelatedPartyMember" xlink:label="Locator_amed_RelatedPartyMember_1942" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_1941" xlink:to="Locator_amed_RelatedPartyMember_1942" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1889" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_1890" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_1889" xlink:to="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_1890" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_1943" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_1944" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_1943" xlink:to="Locator_us-gaap_LossContingencyNatureDomain_1944" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2052" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2051" xlink:to="Locator_us-gaap_LossContingencyNatureDomain_2052" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_1945" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ExtrapolatedMember" xlink:label="Locator_amed_ExtrapolatedMember_1946" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_1945" xlink:to="Locator_amed_ExtrapolatedMember_1946" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_1947" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableMember" xlink:label="Locator_amed_FavorableMember_1948" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_1947" xlink:to="Locator_amed_FavorableMember_1948" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_1949" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UnfavorableMember" xlink:label="Locator_amed_UnfavorableMember_1950" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_1949" xlink:to="Locator_amed_UnfavorableMember_1950" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_1951" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInFullMember" xlink:label="Locator_amed_FavorableInFullMember_1952" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_1951" xlink:to="Locator_amed_FavorableInFullMember_1952" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_1953" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInPartMember" xlink:label="Locator_amed_FavorableInPartMember_1954" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_1953" xlink:to="Locator_amed_FavorableInPartMember_1954" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1891" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_1892" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_1891" xlink:to="Locator_amed_StateAxis_1892" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_1955" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1956" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_StateAxis_1955" xlink:to="Locator_amed_StateDomain_1956" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2053" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2054" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_StateAxis_2053" xlink:to="Locator_amed_StateDomain_2054" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1957" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IllinoisMember" xlink:label="Locator_amed_IllinoisMember_1958" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1957" xlink:to="Locator_amed_IllinoisMember_1958" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1959" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ConnecticutMember" xlink:label="Locator_amed_ConnecticutMember_1960" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1959" xlink:to="Locator_amed_ConnecticutMember_1960" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1961" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OhioMember" xlink:label="Locator_amed_OhioMember_1962" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1961" xlink:to="Locator_amed_OhioMember_1962" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1963" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SouthCarolinaMember" xlink:label="Locator_amed_SouthCarolinaMember_1964" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1963" xlink:to="Locator_amed_SouthCarolinaMember_1964" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1969" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MorgantownWestVirginiaMember" xlink:label="Locator_amed_MorgantownWestVirginiaMember_1970" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1969" xlink:to="Locator_amed_MorgantownWestVirginiaMember_1970" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1971" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="Locator_amed_ParkersburgWestVirginiaMember_1972" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1971" xlink:to="Locator_amed_ParkersburgWestVirginiaMember_1972" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1967" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_1968" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1967" xlink:to="Locator_amed_WestVirginiaMember_1968" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_1965" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_1966" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_1965" xlink:to="Locator_amed_MassachusettsMember_1966" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1893" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1894" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_1893" xlink:to="Locator_us-gaap_RangeAxis_1894" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1977" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenue" xlink:label="Locator_amed_MedicareRevenue_1978" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1977" xlink:to="Locator_amed_MedicareRevenue_1978" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1979" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_1980" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1979" xlink:to="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_1980" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1981" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_1982" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1981" xlink:to="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_1982" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1983" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_1984" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1983" xlink:to="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_1984" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1985" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_1986" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1985" xlink:to="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_1986" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1987" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsAppealed" xlink:label="Locator_amed_NumberOfClaimsAppealed_1988" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1987" xlink:to="Locator_amed_NumberOfClaimsAppealed_1988" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1989" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="Locator_amed_NumberOfRedeterminationDecisions_1990" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1989" xlink:to="Locator_amed_NumberOfRedeterminationDecisions_1990" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1991" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="Locator_amed_HealthInsuranceRetentionLimit_1992" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1991" xlink:to="Locator_amed_HealthInsuranceRetentionLimit_1992" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1993" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="Locator_amed_WorkersCompensationInsuranceRetentionLimit_1994" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1993" xlink:to="Locator_amed_WorkersCompensationInsuranceRetentionLimit_1994" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1995" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_1996" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1995" xlink:to="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_1996" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1997" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfBeneficiaries" xlink:label="Locator_amed_NumberOfBeneficiaries_1998" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1997" xlink:to="Locator_amed_NumberOfBeneficiaries_1998" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1999" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="Locator_us-gaap_LitigationSettlementAmount_2000" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1999" xlink:to="Locator_us-gaap_LitigationSettlementAmount_2000" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2001" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_2002" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2001" xlink:to="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_2002" order="13.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2003" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_2004" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2003" xlink:to="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_2004" order="14.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2005" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_2006" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2005" xlink:to="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_2006" order="15.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2007" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_2008" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2007" xlink:to="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_2008" order="16.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2009" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_2010" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2009" xlink:to="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_2010" order="17.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2011" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_2012" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2011" xlink:to="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_2012" order="18.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2013" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_2014" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2013" xlink:to="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_2014" order="19.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2015" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="Locator_us-gaap_LossContingencyAccrualProvision_2016" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2015" xlink:to="Locator_us-gaap_LossContingencyAccrualProvision_2016" order="20.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2017" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="Locator_amed_CorporateIntegrityAgreementTerm_2018" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2017" xlink:to="Locator_amed_CorporateIntegrityAgreementTerm_2018" order="21.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2019" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_2020" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2019" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_2020" order="22.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2021" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_2022" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2021" xlink:to="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_2022" order="23.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2023" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="Locator_amed_NumberOfMissingComputersAndLaptops_2024" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2023" xlink:to="Locator_amed_NumberOfMissingComputersAndLaptops_2024" order="24.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2025" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="Locator_amed_ThresholdOfIndividualsInDataBreach_2026" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2025" xlink:to="Locator_amed_ThresholdOfIndividualsInDataBreach_2026" order="25.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2027" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="Locator_amed_PercentageOfCompanyDevicesUsed_2028" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2027" xlink:to="Locator_amed_PercentageOfCompanyDevicesUsed_2028" order="26.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2029" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_YearOfDeparture" xlink:label="Locator_amed_YearOfDeparture_2030" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2029" xlink:to="Locator_amed_YearOfDeparture_2030" order="27.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2031" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_2032" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2031" xlink:to="Locator_amed_NumberOfCareCentersSold_2032" order="28.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2033" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfPatients" xlink:label="Locator_amed_NumberOfPatients_2034" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2033" xlink:to="Locator_amed_NumberOfPatients_2034" order="29.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2035" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest" xlink:label="Locator_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest_2036" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2035" xlink:to="Locator_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest_2036" order="30.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2037" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingCareCenters" xlink:label="Locator_amed_OperatingCareCenters_2038" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2037" xlink:to="Locator_amed_OperatingCareCenters_2038" order="31.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2039" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SuspensionOfMedicarePayments_days" xlink:label="Locator_amed_SuspensionOfMedicarePayments_days_2040" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2039" xlink:to="Locator_amed_SuspensionOfMedicarePayments_days_2040" order="32.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2041" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="Locator_us-gaap_LossContingencyNumberOfDefendants_2042" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2041" xlink:to="Locator_us-gaap_LossContingencyNumberOfDefendants_2042" order="33.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2043" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_2044" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2043" xlink:to="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_2044" order="34.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2045" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_2046" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2045" xlink:to="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_2046" order="35.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2195" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2196" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2195" xlink:to="Locator_us-gaap_SegmentDomain_2196" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="Locator_us-gaap_AllOtherSegmentsMember_2204" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2203" xlink:to="Locator_us-gaap_AllOtherSegmentsMember_2204" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2197" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2198" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2197" xlink:to="Locator_amed_HomeHealthMember_2198" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2199" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2200" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2199" xlink:to="Locator_amed_HospiceMember_2200" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2201" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2202" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2201" xlink:to="Locator_amed_PersonalCareMember_2202" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2176" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2175" xlink:to="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2176" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2193" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2194" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2193" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2194" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2206" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2205" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2206" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_2208" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2207" xlink:to="Locator_us-gaap_CostOfServices_2208" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2209" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="Locator_amed_GeneralAndAdministrativeExpenseSegment_2210" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2209" xlink:to="Locator_amed_GeneralAndAdministrativeExpenseSegment_2210" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2211" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2212" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2211" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2212" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2213" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2214" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2213" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2214" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2215" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_2216" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2215" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_2216" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2217" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AMS3writeoffcharge" xlink:label="Locator_amed_AMS3writeoffcharge_2218" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2217" xlink:to="Locator_amed_AMS3writeoffcharge_2218" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_2220" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2219" xlink:to="Locator_us-gaap_AssetImpairmentCharges_2220" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2222" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2221" xlink:to="Locator_us-gaap_CostsAndExpenses_2222" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2223" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_2224" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2223" xlink:to="Locator_us-gaap_OperatingIncomeLoss_2224" order="10.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureAcquisitionsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2322" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_2321" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_2322" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2323" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_2324" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_2323" xlink:to="Locator_amed_PromissoryNotesMember_2324" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2326" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2325" xlink:to="Locator_us-gaap_SegmentDomain_2326" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2327" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2328" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2327" xlink:to="Locator_amed_HomeHealthMember_2328" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2329" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2330" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2329" xlink:to="Locator_amed_HospiceMember_2330" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2331" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2332" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2331" xlink:to="Locator_amed_PersonalCareMember_2332" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2348" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2347" xlink:to="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2348" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2388" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2387" xlink:to="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2388" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2353" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="Locator_amed_InHousePhysiciansPracticeMember_2354" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2353" xlink:to="Locator_amed_InHousePhysiciansPracticeMember_2354" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2355" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_2356" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2355" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_2356" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2357" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeStaffLlcMember" xlink:label="Locator_amed_HomeStaffLlcMember_2358" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2357" xlink:to="Locator_amed_HomeStaffLlcMember_2358" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2333" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2334" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_StateAxis_2333" xlink:to="Locator_amed_StateDomain_2334" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2335" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AlabamaMember" xlink:label="Locator_amed_AlabamaMember_2336" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2335" xlink:to="Locator_amed_AlabamaMember_2336" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2337" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NorthCarolinaMember" xlink:label="Locator_amed_NorthCarolinaMember_2338" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2337" xlink:to="Locator_amed_NorthCarolinaMember_2338" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2339" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_2340" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2339" xlink:to="Locator_amed_WestVirginiaMember_2340" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2341" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LouisianaMember" xlink:label="Locator_amed_LouisianaMember_2342" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2341" xlink:to="Locator_amed_LouisianaMember_2342" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2343" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FloridaMember" xlink:label="Locator_amed_FloridaMember_2344" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2343" xlink:to="Locator_amed_FloridaMember_2344" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2345" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_2346" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2345" xlink:to="Locator_amed_MassachusettsMember_2346" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2307" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2308" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2307" xlink:to="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2308" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2312" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311" xlink:to="Locator_amed_StateAxis_2312" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2314" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2313" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_2314" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2316" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2315" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2316" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2318" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2317" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2318" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2350" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2349" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2350" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2386" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2385" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2386" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_2352" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2351" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_2352" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2320" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2319" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_2320" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2360" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2359" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2360" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2361" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="Locator_us-gaap_NumberOfBusinessesAcquired_2362" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2361" xlink:to="Locator_us-gaap_NumberOfBusinessesAcquired_2362" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2363" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2364" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2363" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2364" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2365" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2366" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2365" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2366" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2367" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2368" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2367" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2368" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2369" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2370" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2369" xlink:to="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2370" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2371" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2372" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2371" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2372" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2374" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2373" xlink:to="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2374" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2375" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2376" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2375" xlink:to="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2376" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2377" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="Locator_us-gaap_EscrowDeposit_2378" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2377" xlink:to="Locator_us-gaap_EscrowDeposit_2378" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2379" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2380" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2379" xlink:to="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2380" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2381" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_2382" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2381" xlink:to="Locator_us-gaap_LongTermDebt_2382" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2384" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2383" xlink:to="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2384" order="13.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2453" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2454" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2453" xlink:to="Locator_us-gaap_SegmentDomain_2454" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2455" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2456" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2455" xlink:to="Locator_amed_HomeHealthMember_2456" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2457" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2458" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2457" xlink:to="Locator_amed_HospiceMember_2458" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2459" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2460" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2459" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_2460" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2473" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2474" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2473" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_2474" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_2462" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2461" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_2462" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2463" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="Locator_amed_CareCentersClosedOrConsolidatedMember_2464" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2463" xlink:to="Locator_amed_CareCentersClosedOrConsolidatedMember_2464" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2465" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="Locator_amed_AnnualImpairmentTestStepOneMember_2466" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2465" xlink:to="Locator_amed_AnnualImpairmentTestStepOneMember_2466" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2446" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2445" xlink:to="Locator_us-gaap_ScheduleOfGoodwillTable_2446" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2449" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2450" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2449" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2450" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2452" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2451" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2452" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2467" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2468" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2467" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2468" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_2470" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2469" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_2470" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2471" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2472" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2471" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2472" order="3.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2529" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2530" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_2529" xlink:to="Locator_us-gaap_RangeMember_2530" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2545" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2546" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2545" xlink:to="Locator_us-gaap_MinimumMember_2546" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2548" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2547" xlink:to="Locator_us-gaap_MaximumMember_2548" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2520" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2519" xlink:to="Locator_us-gaap_IncomeTaxExaminationTable_2520" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2523" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_2524" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_2523" xlink:to="Locator_us-gaap_IncomeTaxAuthorityAxis_2524" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_2531" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2532" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_IncomeTaxAuthorityAxis_2531" xlink:to="Locator_us-gaap_IncomeTaxAuthorityDomain_2532" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_2571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2572" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_IncomeTaxAuthorityAxis_2571" xlink:to="Locator_us-gaap_IncomeTaxAuthorityDomain_2572" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2533" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="Locator_us-gaap_StateAndLocalJurisdictionMember_2534" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_2533" xlink:to="Locator_us-gaap_StateAndLocalJurisdictionMember_2534" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2535" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="Locator_us-gaap_DomesticCountryMember_2536" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_2535" xlink:to="Locator_us-gaap_DomesticCountryMember_2536" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2537" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="Locator_us-gaap_ForeignCountryMember_2538" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_2537" xlink:to="Locator_us-gaap_ForeignCountryMember_2538" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2525" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2526" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_2525" xlink:to="Locator_us-gaap_RangeAxis_2526" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2527" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_2528" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_2527" xlink:to="Locator_us-gaap_BalanceSheetLocationAxis_2528" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_2539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_2540" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_BalanceSheetLocationAxis_2539" xlink:to="Locator_us-gaap_BalanceSheetLocationDomain_2540" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_2573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_2574" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_BalanceSheetLocationAxis_2573" xlink:to="Locator_us-gaap_BalanceSheetLocationDomain_2574" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_2541" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherLongTermObligationsMember" xlink:label="Locator_amed_OtherLongTermObligationsMember_2542" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_2541" xlink:to="Locator_amed_OtherLongTermObligationsMember_2542" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_2543" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredIncomeTaxesMember" xlink:label="Locator_amed_DeferredIncomeTaxesMember_2544" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_2543" xlink:to="Locator_amed_DeferredIncomeTaxesMember_2544" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2549" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="Locator_us-gaap_IncomeTaxesReceivable_2550" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2549" xlink:to="Locator_us-gaap_IncomeTaxesReceivable_2550" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="Locator_us-gaap_OperatingLossCarryforwards_2552" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2551" xlink:to="Locator_us-gaap_OperatingLossCarryforwards_2552" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2553" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_2554" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2553" xlink:to="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_2554" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_2556" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2555" xlink:to="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_2556" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_2558" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2557" xlink:to="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_2558" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2560" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2559" xlink:to="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2560" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2561" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_2562" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2561" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_2562" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2564" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2563" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2564" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2565" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_2566" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2565" xlink:to="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_2566" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="Locator_us-gaap_OpenTaxYear_2568" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2567" xlink:to="Locator_us-gaap_OpenTaxYear_2568" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_2570" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2569" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_2570" order="12.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureFutureMinimumRentalCommitments">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2646" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_2645" xlink:to="Locator_us-gaap_RangeMember_2646" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2647" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2648" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2647" xlink:to="Locator_us-gaap_MinimumMember_2648" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2649" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2650" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2649" xlink:to="Locator_us-gaap_MaximumMember_2650" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2639" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_2640" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2639" xlink:to="Locator_amed_FutureRentalCommitmentsTable_2640" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_2643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2644" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_FutureRentalCommitmentsTable_2643" xlink:to="Locator_us-gaap_RangeAxis_2644" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2651" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2652" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2651" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2652" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2653" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2654" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2653" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2654" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2656" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2655" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2656" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2658" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2657" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2658" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2660" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2659" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2660" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2662" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2661" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2662" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2663" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2664" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2663" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2664" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2665" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_2666" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2665" xlink:to="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_2666" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2667" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_2668" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2667" xlink:to="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_2668" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2669" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseTermYears" xlink:label="Locator_amed_OperatingLeaseTermYears_2670" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2669" xlink:to="Locator_amed_OperatingLeaseTermYears_2670" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2671" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="Locator_amed_OperatingLeasesAgreementExpirationYear_2672" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2671" xlink:to="Locator_amed_OperatingLeasesAgreementExpirationYear_2672" order="11.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2804" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_2803" xlink:to="Locator_us-gaap_RangeMember_2804" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2807" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2808" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2807" xlink:to="Locator_us-gaap_MinimumMember_2808" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2810" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2809" xlink:to="Locator_us-gaap_MaximumMember_2810" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2795" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2796" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2795" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2796" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2799" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2800" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2799" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2800" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2806" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2805" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2806" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2825" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2826" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2825" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2826" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2811" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="Locator_us-gaap_BuildingMember_2812" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2811" xlink:to="Locator_us-gaap_BuildingMember_2812" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2813" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="Locator_us-gaap_LeaseholdImprovementsMember_2814" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2813" xlink:to="Locator_us-gaap_LeaseholdImprovementsMember_2814" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2815" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquipmentAndFurnitureMember" xlink:label="Locator_amed_EquipmentAndFurnitureMember_2816" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2815" xlink:to="Locator_amed_EquipmentAndFurnitureMember_2816" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2817" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VehiclesMember" xlink:label="Locator_us-gaap_VehiclesMember_2818" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2817" xlink:to="Locator_us-gaap_VehiclesMember_2818" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2819" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerSoftwareMember" xlink:label="Locator_amed_ComputerSoftwareMember_2820" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2819" xlink:to="Locator_amed_ComputerSoftwareMember_2820" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2801" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2802" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2801" xlink:to="Locator_us-gaap_RangeAxis_2802" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2821" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_2822" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2821" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_2822" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2823" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2824" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2823" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2824" order="2.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2889" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2890" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_2889" xlink:to="Locator_us-gaap_RangeMember_2890" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_2881" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_2882" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_2881" xlink:to="Locator_us-gaap_LineOfCreditFacilityTable_2882" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_2885" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2886" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_2885" xlink:to="Locator_us-gaap_RangeAxis_2886" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_2887" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="Locator_us-gaap_CreditFacilityAxis_2888" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_2887" xlink:to="Locator_us-gaap_CreditFacilityAxis_2888" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="Locator_us-gaap_CreditFacilityAxis_2895" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="Locator_us-gaap_CreditFacilityDomain_2896" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_CreditFacilityAxis_2895" xlink:to="Locator_us-gaap_CreditFacilityDomain_2896" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="Locator_us-gaap_CreditFacilityAxis_2901" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="Locator_us-gaap_CreditFacilityDomain_2902" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_CreditFacilityAxis_2901" xlink:to="Locator_us-gaap_CreditFacilityDomain_2902" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="Locator_us-gaap_CreditFacilityDomain_2891" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AbrLoansMember" xlink:label="Locator_amed_AbrLoansMember_2892" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_CreditFacilityDomain_2891" xlink:to="Locator_amed_AbrLoansMember_2892" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="Locator_us-gaap_CreditFacilityDomain_2893" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarLoansMember" xlink:label="Locator_amed_EurodollarLoansMember_2894" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_CreditFacilityDomain_2893" xlink:to="Locator_amed_EurodollarLoansMember_2894" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_2897" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_2898" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_2897" xlink:to="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_2898" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_2899" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2900" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_2899" xlink:to="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2900" order="2.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2923" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2924" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2923" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2924" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2927" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2928" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2927" xlink:to="Locator_amed_OtherRestructuringCostsAxis_2928" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2931" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2932" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_OtherRestructuringCostsAxis_2931" xlink:to="Locator_amed_OtherRestructuringDomain_2932" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2953" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2954" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_OtherRestructuringCostsAxis_2953" xlink:to="Locator_amed_OtherRestructuringDomain_2954" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2933" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndElevenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndElevenExitActivityMember_2934" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_2933" xlink:to="Locator_amed_TwoThousandAndElevenExitActivityMember_2934" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2935" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndTwelveExitActivityMember" xlink:label="Locator_amed_TwoThousandAndTwelveExitActivityMember_2936" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_2935" xlink:to="Locator_amed_TwoThousandAndTwelveExitActivityMember_2936" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2937" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndThirteenExitActivityMember_2938" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_2937" xlink:to="Locator_amed_TwoThousandAndThirteenExitActivityMember_2938" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2939" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndFourteenExitActivityMember_2940" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_2939" xlink:to="Locator_amed_TwoThousandAndFourteenExitActivityMember_2940" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2929" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2930" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2929" xlink:to="Locator_us-gaap_RestructuringCostAndReserveAxis_2930" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2941" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="Locator_us-gaap_TypeOfRestructuringDomain_2942" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_2941" xlink:to="Locator_us-gaap_TypeOfRestructuringDomain_2942" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2955" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="Locator_us-gaap_TypeOfRestructuringDomain_2956" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_2955" xlink:to="Locator_us-gaap_TypeOfRestructuringDomain_2956" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="Locator_us-gaap_TypeOfRestructuringDomain_2943" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LeaseTerminationMember" xlink:label="Locator_amed_LeaseTerminationMember_2944" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_TypeOfRestructuringDomain_2943" xlink:to="Locator_amed_LeaseTerminationMember_2944" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="Locator_us-gaap_TypeOfRestructuringDomain_2945" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="Locator_us-gaap_EmployeeSeveranceMember_2946" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_TypeOfRestructuringDomain_2945" xlink:to="Locator_us-gaap_EmployeeSeveranceMember_2946" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2947" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="Locator_us-gaap_RestructuringReserve_2948" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2947" xlink:to="Locator_us-gaap_RestructuringReserve_2948" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2949" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="Locator_us-gaap_RestructuringCharges_2950" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2949" xlink:to="Locator_us-gaap_RestructuringCharges_2950" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2951" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="Locator_us-gaap_PaymentsForRestructuring_2952" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2951" xlink:to="Locator_us-gaap_PaymentsForRestructuring_2952" order="3.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SubsequentEventDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_3023" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3024" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_3023" xlink:to="Locator_us-gaap_SegmentDomain_3024" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3025" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_3026" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_3025" xlink:to="Locator_amed_HomeHealthMember_3026" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3027" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_3028" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_3027" xlink:to="Locator_amed_HospiceMember_3028" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3029" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_3030" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_3029" xlink:to="Locator_amed_PersonalCareMember_3030" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_3017" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="Locator_us-gaap_SubsequentEventTable_3018" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_SubsequentEventLineItems_3017" xlink:to="Locator_us-gaap_SubsequentEventTable_3018" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="Locator_us-gaap_SubsequentEventTable_3019" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_3020" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_SubsequentEventTable_3019" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_3020" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="Locator_us-gaap_SubsequentEventTable_3021" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_3022" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_SubsequentEventTable_3021" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_3022" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_3031" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3032" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_3031" xlink:to="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3032" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3033" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TenetHealthcareMember" xlink:label="Locator_amed_TenetHealthcareMember_3034" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3033" xlink:to="Locator_amed_TenetHealthcareMember_3034" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_3035" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_3036" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SubsequentEventLineItems_3035" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_3036" order="1.0" />
    </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>amed-20170331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.5.34 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
    <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
    <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
    <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="element1" />
        <label xlink:type="resource" xlink:label="label1" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccountingPoliciesAbstract_en-US">Accounting Policies [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1" xlink:to="label1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="element2" />
        <label xlink:type="resource" xlink:label="label2" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccountsPayableCurrent_en-US">Accounts Payable Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element2" xlink:to="label2" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="element3" />
        <label xlink:type="resource" xlink:label="label3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccountsPayableCurrent_en-US">Accounts payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element3" xlink:to="label3" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="element4" />
        <label xlink:type="resource" xlink:label="label4" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent_en-US">Accounts Receivable Net Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element4" xlink:to="label4" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="element5" />
        <label xlink:type="resource" xlink:label="label5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccountsReceivableNetCurrent_en-US">Patient accounts receivable, net of allowance for doubtful accounts of $19,249, and $17,716</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element5" xlink:to="label5" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="element6" />
        <label xlink:type="resource" xlink:label="label6" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent_en-US">Accrued Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element6" xlink:to="label6" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="element7" />
        <label xlink:type="resource" xlink:label="label7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccruedLiabilitiesCurrent_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element7" xlink:to="label7" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="element8" />
        <label xlink:type="resource" xlink:label="label8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_AccruedLiabilitiesCurrent_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element8" xlink:to="label8" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="element9" />
        <label xlink:type="resource" xlink:label="label9" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_en-US">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element9" xlink:to="label9" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="element10" />
        <label xlink:type="resource" xlink:label="label10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_en-US">Property and equipment, accumulated depreciation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element10" xlink:to="label10" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="element11" />
        <label xlink:type="resource" xlink:label="label11" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_en-US">Less accumulated depreciation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element11" xlink:to="label11" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="element12" />
        <label xlink:type="resource" xlink:label="label12" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_en-US">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element12" xlink:to="label12" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="element13" />
        <label xlink:type="resource" xlink:label="label13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_en-US">Accumulated other comprehensive income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element13" xlink:to="label13" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="element14" />
        <label xlink:type="resource" xlink:label="label14" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_en-US">Acquired Finite Lived Intangible Assets Weighted Average</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element14" xlink:to="label14" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="element15" />
        <label xlink:type="resource" xlink:label="label15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_en-US">Weighted-average amortization period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element15" xlink:to="label15" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="element16" />
        <label xlink:type="resource" xlink:label="label16" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock_en-US">Additional Paid In Capital Common Stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element16" xlink:to="label16" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="element17" />
        <label xlink:type="resource" xlink:label="label17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdditionalPaidInCapitalCommonStock_en-US">Additional paid-in capital</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element17" xlink:to="label17" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element18" />
        <label xlink:type="resource" xlink:label="label18" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element18" xlink:to="label18" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element19" />
        <label xlink:type="resource" xlink:label="label19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Adjustments to reconcile net income to net cash provided by operating activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element19" xlink:to="label19" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="element20" />
        <label xlink:type="resource" xlink:label="label20" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element20" xlink:to="label20" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="element21" />
        <label xlink:type="resource" xlink:label="label21" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdvertisingExpense_en-US">Advertising Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element21" xlink:to="label21" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="element22" />
        <label xlink:type="resource" xlink:label="label22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdvertisingExpense_en-US">Advertising expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element22" xlink:to="label22" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="element23" />
        <label xlink:type="resource" xlink:label="label23" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdvertisingCostsPolicyTextBlock_en-US">Advertising Costs Policy Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element23" xlink:to="label23" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="element24" />
        <label xlink:type="resource" xlink:label="label24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdvertisingCostsPolicyTextBlock_en-US">Advertising Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element24" xlink:to="label24" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="element25" />
        <label xlink:type="resource" xlink:label="label25" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AllOtherSegmentsMember_en-US">All Other Segments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element25" xlink:to="label25" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="element26" />
        <label xlink:type="resource" xlink:label="label26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AllOtherSegmentsMember_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element26" xlink:to="label26" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="element27" />
        <label xlink:type="resource" xlink:label="label27" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_en-US">Allowance For Doubtful Accounts Receivable Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element27" xlink:to="label27" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="element28" />
        <label xlink:type="resource" xlink:label="label28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_en-US">Patient accounts receivable, allowance for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element28" xlink:to="label28" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="element29" />
        <label xlink:type="resource" xlink:label="label29" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts_en-US">Amortization Of Financing Costs And Discounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element29" xlink:to="label29" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="element30" />
        <label xlink:type="resource" xlink:label="label30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AmortizationOfFinancingCostsAndDiscounts_en-US">Amortization of deferred debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element30" xlink:to="label30" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="element31" />
        <label xlink:type="resource" xlink:label="label31" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element31" xlink:to="label31" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="element32" />
        <label xlink:type="resource" xlink:label="label32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_en-US">Anti-dilutive securities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element32" xlink:to="label32" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="element33" />
        <label xlink:type="resource" xlink:label="label33" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges_en-US">Asset Impairment Charges</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element33" xlink:to="label33" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="element34" />
        <label xlink:type="resource" xlink:label="label34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetImpairmentCharges_en-US">Asset impairment charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element34" xlink:to="label34" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="element35" />
        <label xlink:type="resource" xlink:label="label35" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Assets_en-US">Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element35" xlink:to="label35" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="element36" />
        <label xlink:type="resource" xlink:label="label36" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_Assets_en-US">Total assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element36" xlink:to="label36" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="element37" />
        <label xlink:type="resource" xlink:label="label37" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsAbstract_en-US">Assets [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element37" xlink:to="label37" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="element38" />
        <label xlink:type="resource" xlink:label="label38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetsAbstract_en-US">ASSETS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element38" xlink:to="label38" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="element39" />
        <label xlink:type="resource" xlink:label="label39" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_en-US">Assets Of Disposal Group Including Discontinued Operation Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element39" xlink:to="label39" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="element40" />
        <label xlink:type="resource" xlink:label="label40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_en-US">Assets held for sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element40" xlink:to="label40" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="element41" />
        <label xlink:type="resource" xlink:label="label41" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract_en-US">Assets Current [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element41" xlink:to="label41" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="element42" />
        <label xlink:type="resource" xlink:label="label42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetsCurrentAbstract_en-US">Current assets:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element42" xlink:to="label42" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="element43" />
        <label xlink:type="resource" xlink:label="label43" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsCurrent_en-US">Assets Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element43" xlink:to="label43" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="element44" />
        <label xlink:type="resource" xlink:label="label44" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_AssetsCurrent_en-US">Total current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element44" xlink:to="label44" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="element45" />
        <label xlink:type="resource" xlink:label="label45" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BalanceSheetLocationAxis_en-US">Balance Sheet [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element45" xlink:to="label45" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="element46" />
        <label xlink:type="resource" xlink:label="label46" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BalanceSheetLocationDomain_en-US">Balance Sheet [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element46" xlink:to="label46" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="element47" />
        <label xlink:type="resource" xlink:label="label47" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_en-US">Basis Of Accounting Policy Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element47" xlink:to="label47" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="element48" />
        <label xlink:type="resource" xlink:label="label48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_en-US">Basis of Presentation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element48" xlink:to="label48" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="element49" />
        <label xlink:type="resource" xlink:label="label49" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BuildingMember_en-US">Building [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element49" xlink:to="label49" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="element50" />
        <label xlink:type="resource" xlink:label="label50" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionAxis_en-US">Business Acquisition [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element50" xlink:to="label50" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="element51" />
        <label xlink:type="resource" xlink:label="label51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionAxis_en-US">Business Acquisition [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element51" xlink:to="label51" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="element52" />
        <label xlink:type="resource" xlink:label="label52" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_en-US">Business Acquisition Purchase Price Allocation Intangible Assets Other Than Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element52" xlink:to="label52" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="element53" />
        <label xlink:type="resource" xlink:label="label53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_en-US">Acquisition, other intangibles recorded</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element53" xlink:to="label53" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="element54" />
        <label xlink:type="resource" xlink:label="label54" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_en-US">Business Acquisition Purchase Price Allocation Current Assets Cash And Cash Equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element54" xlink:to="label54" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="element55" />
        <label xlink:type="resource" xlink:label="label55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_en-US">Acquisition, cash recorded</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element55" xlink:to="label55" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="element56" />
        <label xlink:type="resource" xlink:label="label56" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionAcquireeDomain_en-US">Business Acquisition, Acquiree [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element56" xlink:to="label56" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="element57" />
        <label xlink:type="resource" xlink:label="label57" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationConsiderationTransferred1_en-US">Business Acquisition Cost Of Acquired Entity Purchase Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element57" xlink:to="label57" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="element58" />
        <label xlink:type="resource" xlink:label="label58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationConsiderationTransferred1_en-US">Acquisition, total purchase price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element58" xlink:to="label58" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="element59" />
        <label xlink:type="resource" xlink:label="label59" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationsAbstract_en-US">Business Combinations [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element59" xlink:to="label59" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="element60" />
        <label xlink:type="resource" xlink:label="label60" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_en-US">Business Acquisition Contingent Consideration Potential Cash Payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element60" xlink:to="label60" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="element61" />
        <label xlink:type="resource" xlink:label="label61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_en-US">Accrued liability resulting from acquisition</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element61" xlink:to="label61" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="element62" />
        <label xlink:type="resource" xlink:label="label62" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_en-US">Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element62" xlink:to="label62" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="element63" />
        <label xlink:type="resource" xlink:label="label63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_en-US">Goodwill deductible for income tax purposes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element63" xlink:to="label63" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="element64" />
        <label xlink:type="resource" xlink:label="label64" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_en-US">Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element64" xlink:to="label64" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="element65" />
        <label xlink:type="resource" xlink:label="label65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_en-US">Acquisition, recorded other assets and liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element65" xlink:to="label65" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="element66" />
        <label xlink:type="resource" xlink:label="label66" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationDisclosureTextBlock_en-US">Business Combination Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element66" xlink:to="label66" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="element67" />
        <label xlink:type="resource" xlink:label="label67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationDisclosureTextBlock_en-US">ACQUISITIONS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element67" xlink:to="label67" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="element68" />
        <label xlink:type="resource" xlink:label="label68" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CapitalizedComputerSoftwareGross_en-US">Capitalized Computer Software, Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element68" xlink:to="label68" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="element69" />
        <label xlink:type="resource" xlink:label="label69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CapitalizedComputerSoftwareGross_en-US">Computer software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element69" xlink:to="label69" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element70" />
        <label xlink:type="resource" xlink:label="label70" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash And Cash Equivalents At Carrying Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element70" xlink:to="label70" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element71" />
        <label xlink:type="resource" xlink:label="label71" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash and cash equivalents at end of period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element71" xlink:to="label71" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element72" />
        <label xlink:type="resource" xlink:label="label72" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash and cash equivalents at beginning of period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element72" xlink:to="label72" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element73" />
        <label xlink:type="resource" xlink:label="label73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash and cash equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element73" xlink:to="label73" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="element74" />
        <label xlink:type="resource" xlink:label="label74" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_en-US">Cash And Cash Equivalents Policy Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element74" xlink:to="label74" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="element75" />
        <label xlink:type="resource" xlink:label="label75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CashAndCashEquivalentsPolicyTextBlock_en-US">Cash and Cash Equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element75" xlink:to="label75" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="element76" />
        <label xlink:type="resource" xlink:label="label76" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_en-US">Cash And Cash Equivalents Period Increase Decrease</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element76" xlink:to="label76" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="element77" />
        <label xlink:type="resource" xlink:label="label77" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_en-US">Net increase (decrease) in cash and cash equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element77" xlink:to="label77" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="element78" />
        <label xlink:type="resource" xlink:label="label78" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_en-US">CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element78" xlink:to="label78" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="element79" />
        <label xlink:type="resource" xlink:label="label79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_en-US">Supplemental Disclosures of Non-Cash Financing and Investing Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element79" xlink:to="label79" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="element80" />
        <label xlink:type="resource" xlink:label="label80" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_en-US">Commitments And Contingencies Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element80" xlink:to="label80" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="element81" />
        <label xlink:type="resource" xlink:label="label81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_en-US">COMMITMENTS AND CONTINGENCIES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element81" xlink:to="label81" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="element82" />
        <label xlink:type="resource" xlink:label="label82" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies_en-US">Commitments And Contingencies</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element82" xlink:to="label82" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="element83" />
        <label xlink:type="resource" xlink:label="label83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommitmentsAndContingencies_en-US">Commitments and Contingencies - Note 5</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element83" xlink:to="label83" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="element84" />
        <label xlink:type="resource" xlink:label="label84" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_en-US">Commitments and Contingencies Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element84" xlink:to="label84" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="element85" />
        <label xlink:type="resource" xlink:label="label85" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_en-US">Common Stock Shares Issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element85" xlink:to="label85" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="element86" />
        <label xlink:type="resource" xlink:label="label86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockSharesIssued_en-US">Common Stock, shares issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element86" xlink:to="label86" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="element87" />
        <label xlink:type="resource" xlink:label="label87" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockValueOutstanding_en-US">Common Stock Value Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element87" xlink:to="label87" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="element88" />
        <label xlink:type="resource" xlink:label="label88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockValueOutstanding_en-US">Common Stock, $0.001 par value, 60,000,000 shares authorized; 35,364,752, and 35,253,577 shares issued; and 33,693,027 and 33,597,215 shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element88" xlink:to="label88" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="element89" />
        <label xlink:type="resource" xlink:label="label89" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized_en-US">Common Stock Shares Authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element89" xlink:to="label89" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="element90" />
        <label xlink:type="resource" xlink:label="label90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockSharesAuthorized_en-US">Common Stock, shares authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element90" xlink:to="label90" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="element91" />
        <label xlink:type="resource" xlink:label="label91" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_en-US">Common Stock Par Or Stated Value Per Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element91" xlink:to="label91" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="element92" />
        <label xlink:type="resource" xlink:label="label92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockParOrStatedValuePerShare_en-US">Common Stock, par value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element92" xlink:to="label92" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="element93" />
        <label xlink:type="resource" xlink:label="label93" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding_en-US">Common Stock Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element93" xlink:to="label93" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="element94" />
        <label xlink:type="resource" xlink:label="label94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockSharesOutstanding_en-US">Common Stock, shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element94" xlink:to="label94" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComparabilityOfPriorYearFinancialData" xlink:label="element95" />
        <label xlink:type="resource" xlink:label="label95" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ComparabilityOfPriorYearFinancialData_en-US">Comparability Of Prior Year Financial Data</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element95" xlink:to="label95" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComparabilityOfPriorYearFinancialData" xlink:label="element96" />
        <label xlink:type="resource" xlink:label="label96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ComparabilityOfPriorYearFinancialData_en-US">Reclassifications and Comparability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element96" xlink:to="label96" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="element97" />
        <label xlink:type="resource" xlink:label="label97" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskByTypeAxis_en-US">Concentration Risk Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element97" xlink:to="label97" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="element98" />
        <label xlink:type="resource" xlink:label="label98" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskTypeDomain_en-US">Concentration Risk Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element98" xlink:to="label98" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="element99" />
        <label xlink:type="resource" xlink:label="label99" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskPercentage1_en-US">Percent Of Net Services Revenue Provided By Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element99" xlink:to="label99" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="element100" />
        <label xlink:type="resource" xlink:label="label100" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConsolidationPolicyTextBlock_en-US">Consolidation Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element100" xlink:to="label100" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="element101" />
        <label xlink:type="resource" xlink:label="label101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ConsolidationPolicyTextBlock_en-US">Principles of Consolidation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element101" xlink:to="label101" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="element102" />
        <label xlink:type="resource" xlink:label="label102" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CostOfServices_en-US">Cost Of Services</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element102" xlink:to="label102" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="element103" />
        <label xlink:type="resource" xlink:label="label103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CostOfServices_en-US">Cost of service, excluding depreciation and amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element103" xlink:to="label103" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="element104" />
        <label xlink:type="resource" xlink:label="label104" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CostMethodInvestments_en-US">Cost Method Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element104" xlink:to="label104" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="element105" />
        <label xlink:type="resource" xlink:label="label105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CostMethodInvestments_en-US">Cost method investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element105" xlink:to="label105" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="element106" />
        <label xlink:type="resource" xlink:label="label106" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CostsAndExpenses_en-US">Costs And Expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element106" xlink:to="label106" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="element107" />
        <label xlink:type="resource" xlink:label="label107" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_CostsAndExpenses_en-US">Operating expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element107" xlink:to="label107" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="element108" />
        <label xlink:type="resource" xlink:label="label108" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CreditFacilityAxis_en-US">Credit Facility [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element108" xlink:to="label108" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="element109" />
        <label xlink:type="resource" xlink:label="label109" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CreditFacilityDomain_en-US">Line Of Credit Facility [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element109" xlink:to="label109" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="element110" />
        <label xlink:type="resource" xlink:label="label110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CreditFacilityDomain_en-US">Line Of Credit Facility [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element110" xlink:to="label110" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="element111" />
        <label xlink:type="resource" xlink:label="label111" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CustomerConcentrationRiskMember_en-US">Customer Concentration Risk [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element111" xlink:to="label111" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="element112" />
        <label xlink:type="resource" xlink:label="label112" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentLineItems_en-US">Debt Instrument [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element112" xlink:to="label112" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="element113" />
        <label xlink:type="resource" xlink:label="label113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentLineItems_en-US">Debt Instrument [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element113" xlink:to="label113" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="element114" />
        <label xlink:type="resource" xlink:label="label114" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock_en-US">Debt Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element114" xlink:to="label114" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="element115" />
        <label xlink:type="resource" xlink:label="label115" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtDisclosureTextBlock_en-US">LONG-TERM OBLIGATIONS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element115" xlink:to="label115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="element116" />
        <label xlink:type="resource" xlink:label="label116" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtWeightedAverageInterestRate_en-US">Debt Weighted Average Interest Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element116" xlink:to="label116" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="element117" />
        <label xlink:type="resource" xlink:label="label117" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtDisclosureAbstract_en-US">Debt Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element117" xlink:to="label117" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="element118" />
        <label xlink:type="resource" xlink:label="label118" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentTerm_en-US">Debt Instrument Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element118" xlink:to="label118" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="element119" />
        <label xlink:type="resource" xlink:label="label119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentTerm_en-US">Term loan, period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element119" xlink:to="label119" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="element120" />
        <label xlink:type="resource" xlink:label="label120" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentTable_en-US">Debt Instrument [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element120" xlink:to="label120" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="element121" />
        <label xlink:type="resource" xlink:label="label121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentTable_en-US">Schedule of Long-term Debt Instruments [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element121" xlink:to="label121" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="element122" />
        <label xlink:type="resource" xlink:label="label122" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtLongtermAndShorttermCombinedAmount_en-US">Debt Longterm And Shortterm Combined Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element122" xlink:to="label122" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="element123" />
        <label xlink:type="resource" xlink:label="label123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtLongtermAndShorttermCombinedAmount_en-US">Total longterm and shortterm debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element123" xlink:to="label123" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="element124" />
        <label xlink:type="resource" xlink:label="label124" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DebtLongtermAndShorttermCombinedAmount_en-US">Total longterm and shortterm debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element124" xlink:to="label124" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="element125" />
        <label xlink:type="resource" xlink:label="label125" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_en-US">Debt Instrument Basis Spread On Variable Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element125" xlink:to="label125" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="element126" />
        <label xlink:type="resource" xlink:label="label126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_en-US">Margin on Loans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element126" xlink:to="label126" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="element127" />
        <label xlink:type="resource" xlink:label="label127" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFaceAmount_en-US">Debt Instrument Face Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element127" xlink:to="label127" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="element128" />
        <label xlink:type="resource" xlink:label="label128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentFaceAmount_en-US">Principal amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element128" xlink:to="label128" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="element129" />
        <label xlink:type="resource" xlink:label="label129" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_en-US">Debt Instrument Periodic Payment Principal</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element129" xlink:to="label129" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="element130" />
        <label xlink:type="resource" xlink:label="label130" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentUnamortizedDiscount_en-US">Debt Instrument Unamortized Discount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element130" xlink:to="label130" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="element131" />
        <label xlink:type="resource" xlink:label="label131" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentUnamortizedDiscount_en-US">Discount on long-term debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element131" xlink:to="label131" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="element132" />
        <label xlink:type="resource" xlink:label="label132" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPeriodicPaymentInterest_en-US">Debt Instrument Periodic Payment Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element132" xlink:to="label132" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="element133" />
        <label xlink:type="resource" xlink:label="label133" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_en-US">Debt Instrument, Frequency of Periodic Payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element133" xlink:to="label133" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="element134" />
        <label xlink:type="resource" xlink:label="label134" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_en-US">Debt Instrument Interest Rate Stated Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element134" xlink:to="label134" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="element135" />
        <label xlink:type="resource" xlink:label="label135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentInterestRateStatedPercentage_en-US">Senior long-term notes, interest rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element135" xlink:to="label135" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="element136" />
        <label xlink:type="resource" xlink:label="label136" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DebtInstrumentInterestRateStatedPercentage_en-US">Promissory notes, interest rate percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element136" xlink:to="label136" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="element137" />
        <label xlink:type="resource" xlink:label="label137" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate_en-US">Debt Instrument Maturity Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element137" xlink:to="label137" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="element138" />
        <label xlink:type="resource" xlink:label="label138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentMaturityDate_en-US">Maturity date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element138" xlink:to="label138" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="element139" />
        <label xlink:type="resource" xlink:label="label139" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredFinanceCostsNet_en-US">Debt Issuance Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element139" xlink:to="label139" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="element140" />
        <label xlink:type="resource" xlink:label="label140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredFinanceCostsNet_en-US">Deferred debt issuance cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element140" xlink:to="label140" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="element141" />
        <label xlink:type="resource" xlink:label="label141" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredIncomeTaxExpenseBenefit_en-US">Deferred Income Tax Expense Benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element141" xlink:to="label141" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="element142" />
        <label xlink:type="resource" xlink:label="label142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredIncomeTaxExpenseBenefit_en-US">Deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element142" xlink:to="label142" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="element143" />
        <label xlink:type="resource" xlink:label="label143" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNet_en-US">Deferred Tax Assets Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element143" xlink:to="label143" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="element144" />
        <label xlink:type="resource" xlink:label="label144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsNet_en-US">Net deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element144" xlink:to="label144" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="element145" />
        <label xlink:type="resource" xlink:label="label145" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxAssetsNet_en-US">Net deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element145" xlink:to="label145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="element146" />
        <label xlink:type="resource" xlink:label="label146" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_en-US">Deferred Tax Assets Liabilities Net Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element146" xlink:to="label146" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="element147" />
        <label xlink:type="resource" xlink:label="label147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_en-US">Noncurrent portion of deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element147" xlink:to="label147" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="element148" />
        <label xlink:type="resource" xlink:label="label148" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsGross_en-US">Deferred Tax Assets Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element148" xlink:to="label148" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="element149" />
        <label xlink:type="resource" xlink:label="label149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsGross_en-US">Gross deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element149" xlink:to="label149" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="element150" />
        <label xlink:type="resource" xlink:label="label150" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxAssetsGross_en-US">Gross deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element150" xlink:to="label150" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="element151" />
        <label xlink:type="resource" xlink:label="label151" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNet_en-US">Deferred Tax Assets Liabilities Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element151" xlink:to="label151" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="element152" />
        <label xlink:type="resource" xlink:label="label152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsLiabilitiesNet_en-US">Net deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element152" xlink:to="label152" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="element153" />
        <label xlink:type="resource" xlink:label="label153" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxAssetsLiabilitiesNet_en-US">Net deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element153" xlink:to="label153" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="element154" />
        <label xlink:type="resource" xlink:label="label154" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNetNoncurrent_en-US">Deferred Tax Assets Net Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element154" xlink:to="label154" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="element155" />
        <label xlink:type="resource" xlink:label="label155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsNetNoncurrent_en-US">Deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element155" xlink:to="label155" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="element156" />
        <label xlink:type="resource" xlink:label="label156" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DeferredTaxAssetsNetNoncurrent_en-US">Noncurrent deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element156" xlink:to="label156" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="element157" />
        <label xlink:type="resource" xlink:label="label157" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNetCurrent_en-US">Deferred Tax Assets, Net of Valuation Allowance, Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element157" xlink:to="label157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="element158" />
        <label xlink:type="resource" xlink:label="label158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsNetCurrent_en-US">Deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element158" xlink:to="label158" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="element159" />
        <label xlink:type="resource" xlink:label="label159" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DeferredTaxAssetsNetCurrent_en-US">Current deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element159" xlink:to="label159" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="element160" />
        <label xlink:type="resource" xlink:label="label160" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_en-US">Deferred Tax Assets Liabilities Net Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element160" xlink:to="label160" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="element161" />
        <label xlink:type="resource" xlink:label="label161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_en-US">Current portion of deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element161" xlink:to="label161" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="element162" />
        <label xlink:type="resource" xlink:label="label162" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_en-US">DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element162" xlink:to="label162" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="element163" />
        <label xlink:type="resource" xlink:label="label163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_en-US">Deferred tax benefit as result of impairment charges</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element163" xlink:to="label163" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="element164" />
        <label xlink:type="resource" xlink:label="label164" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_en-US">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element164" xlink:to="label164" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="element165" />
        <label xlink:type="resource" xlink:label="label165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_en-US">Allowance for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element165" xlink:to="label165" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="element166" />
        <label xlink:type="resource" xlink:label="label166" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element166" xlink:to="label166" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="element167" />
        <label xlink:type="resource" xlink:label="label167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_en-US">Share-based compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element167" xlink:to="label167" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="element168" />
        <label xlink:type="resource" xlink:label="label168" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_en-US">Deferred Tax Assets Tax Credit Carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element168" xlink:to="label168" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="element169" />
        <label xlink:type="resource" xlink:label="label169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_en-US">Tax credit carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element169" xlink:to="label169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="element170" />
        <label xlink:type="resource" xlink:label="label170" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_en-US">Deferred Tax Assets Other Loss Carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element170" xlink:to="label170" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="element171" />
        <label xlink:type="resource" xlink:label="label171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_en-US">Net operating loss carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element171" xlink:to="label171" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="element172" />
        <label xlink:type="resource" xlink:label="label172" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_en-US">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element172" xlink:to="label172" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="element173" />
        <label xlink:type="resource" xlink:label="label173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element173" xlink:to="label173" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="element174" />
        <label xlink:type="resource" xlink:label="label174" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilities_en-US">Deferred Tax Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element174" xlink:to="label174" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="element175" />
        <label xlink:type="resource" xlink:label="label175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilities_en-US">Gross deferred tax (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element175" xlink:to="label175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="element176" />
        <label xlink:type="resource" xlink:label="label176" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxLiabilities_en-US">Gross deferred tax (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element176" xlink:to="label176" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="element177" />
        <label xlink:type="resource" xlink:label="label177" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_en-US">Deferred Tax Liabilities Tax Deferred Income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element177" xlink:to="label177" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="element178" />
        <label xlink:type="resource" xlink:label="label178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_en-US">Deferred revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element178" xlink:to="label178" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="element179" />
        <label xlink:type="resource" xlink:label="label179" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_en-US">Deferred revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element179" xlink:to="label179" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="element180" />
        <label xlink:type="resource" xlink:label="label180" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesCurrent_en-US">Deferred Tax Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element180" xlink:to="label180" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="element181" />
        <label xlink:type="resource" xlink:label="label181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesCurrent_en-US">Current portion of deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element181" xlink:to="label181" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="element182" />
        <label xlink:type="resource" xlink:label="label182" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DeferredTaxLiabilitiesCurrent_en-US">Current deferred tax liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element182" xlink:to="label182" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="element183" />
        <label xlink:type="resource" xlink:label="label183" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_en-US">Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element183" xlink:to="label183" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="element184" />
        <label xlink:type="resource" xlink:label="label184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_en-US">Amortization of intangible assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element184" xlink:to="label184" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="element185" />
        <label xlink:type="resource" xlink:label="label185" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_en-US">Deferred Tax Liabilities Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element185" xlink:to="label185" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="element186" />
        <label xlink:type="resource" xlink:label="label186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_en-US">Property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element186" xlink:to="label186" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="element187" />
        <label xlink:type="resource" xlink:label="label187" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance_en-US">Deferred Tax Assets Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element187" xlink:to="label187" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="element188" />
        <label xlink:type="resource" xlink:label="label188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsValuationAllowance_en-US">Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element188" xlink:to="label188" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="element189" />
        <label xlink:type="resource" xlink:label="label189" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanCostRecognized_en-US">DefinedContributionPlanCostRecognized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element189" xlink:to="label189" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="element190" />
        <label xlink:type="resource" xlink:label="label190" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DefinedContributionPlanCostRecognized_en-US">401 (k) Expense Recognized by Company</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element190" xlink:to="label190" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="element191" />
        <label xlink:type="resource" xlink:label="label191" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DepreciationDepletionAndAmortization_en-US">Depreciation Depletion And Amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element191" xlink:to="label191" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="element192" />
        <label xlink:type="resource" xlink:label="label192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DepreciationDepletionAndAmortization_en-US">Depreciation and amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element192" xlink:to="label192" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="element193" />
        <label xlink:type="resource" xlink:label="label193" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Depreciation_en-US">Depreciation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element193" xlink:to="label193" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="element194" />
        <label xlink:type="resource" xlink:label="label194" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_en-US">Discontinued Operation Tax Effect Of Discontinued Operation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element194" xlink:to="label194" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="element195" />
        <label xlink:type="resource" xlink:label="label195" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_en-US">Income tax benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element195" xlink:to="label195" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="element196" />
        <label xlink:type="resource" xlink:label="label196" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_en-US">Discontinued Operation Income Loss From Discontinued Operation Before Income Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element196" xlink:to="label196" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="element197" />
        <label xlink:type="resource" xlink:label="label197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_en-US">(Loss) before income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element197" xlink:to="label197" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="element198" />
        <label xlink:type="resource" xlink:label="label198" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_en-US">Discontinued Operation, Additional Disclosures [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element198" xlink:to="label198" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="element199" />
        <label xlink:type="resource" xlink:label="label199" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_en-US">Disposal Group Including Discontinued Operation Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element199" xlink:to="label199" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="element200" />
        <label xlink:type="resource" xlink:label="label200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_en-US">Net revenues</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element200" xlink:to="label200" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="element201" />
        <label xlink:type="resource" xlink:label="label201" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_en-US">Assets Held-for-sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element201" xlink:to="label201" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="element202" />
        <label xlink:type="resource" xlink:label="label202" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_en-US">Disposal Groups Including Discontinued Operations Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element202" xlink:to="label202" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="element203" />
        <label xlink:type="resource" xlink:label="label203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_en-US">DISCONTINUED OPERATIONS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element203" xlink:to="label203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="element204" />
        <label xlink:type="resource" xlink:label="label204" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DomesticCountryMember_en-US">Domestic [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element204" xlink:to="label204" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="element205" />
        <label xlink:type="resource" xlink:label="label205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DomesticCountryMember_en-US">Federal [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element205" xlink:to="label205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="element206" />
        <label xlink:type="resource" xlink:label="label206" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAbstract_en-US">Earnings Per Share Basic [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element206" xlink:to="label206" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="element207" />
        <label xlink:type="resource" xlink:label="label207" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EarningsPerShareBasicAbstract_en-US">Basic earnings per common share:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element207" xlink:to="label207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="element208" />
        <label xlink:type="resource" xlink:label="label208" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDilutedAbstract_en-US">Earnings Per Share Diluted [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element208" xlink:to="label208" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="element209" />
        <label xlink:type="resource" xlink:label="label209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EarningsPerShareDilutedAbstract_en-US">Diluted earnings per common share:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element209" xlink:to="label209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="element210" />
        <label xlink:type="resource" xlink:label="label210" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock_en-US">Earnings Per Share Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element210" xlink:to="label210" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="element211" />
        <label xlink:type="resource" xlink:label="label211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EarningsPerSharePolicyTextBlock_en-US">Weighted-Average Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element211" xlink:to="label211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="element212" />
        <label xlink:type="resource" xlink:label="label212" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasic_en-US">Earnings Per Share Basic</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element212" xlink:to="label212" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="element213" />
        <label xlink:type="resource" xlink:label="label213" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_EarningsPerShareBasic_en-US">Net income attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element213" xlink:to="label213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="element214" />
        <label xlink:type="resource" xlink:label="label214" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDiluted_en-US">Earnings Per Share Diluted</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element214" xlink:to="label214" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="element215" />
        <label xlink:type="resource" xlink:label="label215" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_EarningsPerShareDiluted_en-US">Net income attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element215" xlink:to="label215" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="element216" />
        <label xlink:type="resource" xlink:label="label216" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_en-US">EffectiveIncomeTaxRateReconciliationNondeductibleExpense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element216" xlink:to="label216" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="element217" />
        <label xlink:type="resource" xlink:label="label217" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_en-US">Nondeductible expenses and other, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element217" xlink:to="label217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="element218" />
        <label xlink:type="resource" xlink:label="label218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_en-US">Statutory Tax Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element218" xlink:to="label218" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="element219" />
        <label xlink:type="resource" xlink:label="label219" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element219" xlink:to="label219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="element220" />
        <label xlink:type="resource" xlink:label="label220" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_en-US">EffectiveIncomeTaxRateReconciliationTaxCredits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element220" xlink:to="label220" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="element221" />
        <label xlink:type="resource" xlink:label="label221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_en-US">Tax credits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element221" xlink:to="label221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="element222" />
        <label xlink:type="resource" xlink:label="label222" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_en-US">EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element222" xlink:to="label222" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="element223" />
        <label xlink:type="resource" xlink:label="label223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_en-US">Goodwill impairment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element223" xlink:to="label223" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="element224" />
        <label xlink:type="resource" xlink:label="label224" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_en-US">EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element224" xlink:to="label224" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="element225" />
        <label xlink:type="resource" xlink:label="label225" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_en-US">State and local income taxes and other, net of federal income tax benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element225" xlink:to="label225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="element226" />
        <label xlink:type="resource" xlink:label="label226" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_en-US">EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element226" xlink:to="label226" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="element227" />
        <label xlink:type="resource" xlink:label="label227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_en-US">Valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element227" xlink:to="label227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="element228" />
        <label xlink:type="resource" xlink:label="label228" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_en-US">EffectiveIncomeTaxRateContinuingOperations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element228" xlink:to="label228" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="element229" />
        <label xlink:type="resource" xlink:label="label229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateContinuingOperations_en-US">Continuing operations effective income tax rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element229" xlink:to="label229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="element230" />
        <label xlink:type="resource" xlink:label="label230" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_en-US">Employee Related Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element230" xlink:to="label230" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="element231" />
        <label xlink:type="resource" xlink:label="label231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeRelatedLiabilitiesCurrent_en-US">Payroll and employee benefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element231" xlink:to="label231" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="element232" />
        <label xlink:type="resource" xlink:label="label232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeSeveranceMember_en-US">Severance [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element232" xlink:to="label232" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="element233" />
        <label xlink:type="resource" xlink:label="label233" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeSeveranceMember_en-US">Severance [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element233" xlink:to="label233" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="element234" />
        <label xlink:type="resource" xlink:label="label234" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_en-US">Employee Service Share Based Compensation Tax Benefit From Compensation Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element234" xlink:to="label234" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="element235" />
        <label xlink:type="resource" xlink:label="label235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_en-US">Share-based compensation, tax benefit recognized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element235" xlink:to="label235" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="element236" />
        <label xlink:type="resource" xlink:label="label236" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvesteeNameDomain_en-US">Equity Method Name</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element236" xlink:to="label236" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="element237" />
        <label xlink:type="resource" xlink:label="label237" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityAbstract_en-US">Equity Abstract</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element237" xlink:to="label237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="element238" />
        <label xlink:type="resource" xlink:label="label238" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityComponentDomain_en-US">Equity Component Domain</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element238" xlink:to="label238" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="element239" />
        <label xlink:type="resource" xlink:label="label239" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentAggregateCost_en-US">Equity Method Investment Aggregate Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element239" xlink:to="label239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="element240" />
        <label xlink:type="resource" xlink:label="label240" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentDividendsOrDistributions_en-US">Equity Method Investment Dividends Or Distributions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element240" xlink:to="label240" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="element241" />
        <label xlink:type="resource" xlink:label="label241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentDividendsOrDistributions_en-US">Return on equity investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element241" xlink:to="label241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="element242" />
        <label xlink:type="resource" xlink:label="label242" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentsMember_en-US">Equity Method Investments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element242" xlink:to="label242" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="element243" />
        <label xlink:type="resource" xlink:label="label243" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentsPolicy_en-US">Equity Method Investments Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element243" xlink:to="label243" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="element244" />
        <label xlink:type="resource" xlink:label="label244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentsPolicy_en-US">Equity Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element244" xlink:to="label244" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="element245" />
        <label xlink:type="resource" xlink:label="label245" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EscrowDeposit_en-US">Escrow Deposit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element245" xlink:to="label245" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="element246" />
        <label xlink:type="resource" xlink:label="label246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EscrowDeposit_en-US">Escrow depost for indemnification purposes and working capital price adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element246" xlink:to="label246" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="element247" />
        <label xlink:type="resource" xlink:label="label247" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_en-US">Excess Tax Benefit From Share Based Compensation Financing Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element247" xlink:to="label247" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="element248" />
        <label xlink:type="resource" xlink:label="label248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_en-US">Tax benefit from stock options exercised and restricted stock vesting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element248" xlink:to="label248" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="element249" />
        <label xlink:type="resource" xlink:label="label249" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueByFairValueHierarchyLevelAxis_en-US">Fair Value By Fair Value Hierarchy Level [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element249" xlink:to="label249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="element250" />
        <label xlink:type="resource" xlink:label="label250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueByFairValueHierarchyLevelAxis_en-US">Fair Value, Hierarchy [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element250" xlink:to="label250" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="element251" />
        <label xlink:type="resource" xlink:label="label251" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element251" xlink:to="label251" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="element252" />
        <label xlink:type="resource" xlink:label="label252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element252" xlink:to="label252" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="element253" />
        <label xlink:type="resource" xlink:label="label253" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element253" xlink:to="label253" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="element254" />
        <label xlink:type="resource" xlink:label="label254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element254" xlink:to="label254" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="element255" />
        <label xlink:type="resource" xlink:label="label255" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element255" xlink:to="label255" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="element256" />
        <label xlink:type="resource" xlink:label="label256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element256" xlink:to="label256" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="element257" />
        <label xlink:type="resource" xlink:label="label257" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_en-US">Fair Value Of Financial Instruments Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element257" xlink:to="label257" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="element258" />
        <label xlink:type="resource" xlink:label="label258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueOfFinancialInstrumentsPolicy_en-US">Fair Value of Financial Instruments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element258" xlink:to="label258" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="element259" />
        <label xlink:type="resource" xlink:label="label259" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel3Member_en-US">Fair Value, Inputs, Level 3 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element259" xlink:to="label259" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="element260" />
        <label xlink:type="resource" xlink:label="label260" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel1Member_en-US">Fair Value, Inputs, Level 1 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element260" xlink:to="label260" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="element261" />
        <label xlink:type="resource" xlink:label="label261" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel2Member_en-US">Fair Value Inputs Level 2 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element261" xlink:to="label261" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="element262" />
        <label xlink:type="resource" xlink:label="label262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueInputsLevel2Member_en-US">Significant Other Observable Inputs (Level 2)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element262" xlink:to="label262" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="element263" />
        <label xlink:type="resource" xlink:label="label263" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_en-US">Finite Lived Intangible Assets By Major Class [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element263" xlink:to="label263" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="element264" />
        <label xlink:type="resource" xlink:label="label264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_en-US">Finite Lived Intangible Assets By Major Class [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element264" xlink:to="label264" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="element265" />
        <label xlink:type="resource" xlink:label="label265" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_en-US">Finite Lived Intangible Assets Accumulated Amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element265" xlink:to="label265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="element266" />
        <label xlink:type="resource" xlink:label="label266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_en-US">Intangible assets, accumulated amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element266" xlink:to="label266" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="element267" />
        <label xlink:type="resource" xlink:label="label267" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_en-US">Finite Lived Intangible Assets Major Class Name [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element267" xlink:to="label267" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="element268" />
        <label xlink:type="resource" xlink:label="label268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_en-US">Finite Lived Intangible Assets Major Class Name [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element268" xlink:to="label268" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="element269" />
        <label xlink:type="resource" xlink:label="label269" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ForeignCountryMember_en-US">Foreign [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element269" xlink:to="label269" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="element270" />
        <label xlink:type="resource" xlink:label="label270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ForeignCountryMember_en-US">Puerto Rico [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element270" xlink:to="label270" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="element271" />
        <label xlink:type="resource" xlink:label="label271" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_en-US">Gain Loss On Sale Of Property Plant Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element271" xlink:to="label271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="element272" />
        <label xlink:type="resource" xlink:label="label272" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_en-US">(Gain) loss on disposal of property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element272" xlink:to="label272" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="element273" />
        <label xlink:type="resource" xlink:label="label273" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GainsLossesOnSalesOfAssets_en-US">Gains (Losses) on Sales of Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element273" xlink:to="label273" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="element274" />
        <label xlink:type="resource" xlink:label="label274" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_GainsLossesOnSalesOfAssets_en-US">Gain on sale of care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element274" xlink:to="label274" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="element275" />
        <label xlink:type="resource" xlink:label="label275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GainsLossesOnSalesOfAssets_en-US">Gain (loss) on sale of care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element275" xlink:to="label275" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="element276" />
        <label xlink:type="resource" xlink:label="label276" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpenseAbstract_en-US">General And Administrative Expense [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element276" xlink:to="label276" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="element277" />
        <label xlink:type="resource" xlink:label="label277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GeneralAndAdministrativeExpenseAbstract_en-US">General and administrative expenses:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element277" xlink:to="label277" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="element278" />
        <label xlink:type="resource" xlink:label="label278" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_en-US">Goodwill And Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element278" xlink:to="label278" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="element279" />
        <label xlink:type="resource" xlink:label="label279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_en-US">Goodwill And Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element279" xlink:to="label279" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="element280" />
        <label xlink:type="resource" xlink:label="label280" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillImpairmentLoss_en-US">Goodwill, Impairment Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element280" xlink:to="label280" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="element281" />
        <label xlink:type="resource" xlink:label="label281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillImpairmentLoss_en-US">Goodwill impairment loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element281" xlink:to="label281" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="element282" />
        <label xlink:type="resource" xlink:label="label282" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Goodwill_en-US">Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element282" xlink:to="label282" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="element283" />
        <label xlink:type="resource" xlink:label="label283" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_Goodwill_en-US">Ending balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element283" xlink:to="label283" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="element284" />
        <label xlink:type="resource" xlink:label="label284" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_Goodwill_en-US">Beginning balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element284" xlink:to="label284" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="element285" />
        <label xlink:type="resource" xlink:label="label285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_Goodwill_en-US">Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element285" xlink:to="label285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="element286" />
        <label xlink:type="resource" xlink:label="label286" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_en-US">Goodwill And Intangible Assets Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element286" xlink:to="label286" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="element287" />
        <label xlink:type="resource" xlink:label="label287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_en-US">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element287" xlink:to="label287" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="element288" />
        <label xlink:type="resource" xlink:label="label288" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAcquiredDuringPeriod_en-US">GoodwillAcquiredDuringPeriod</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element288" xlink:to="label288" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="element289" />
        <label xlink:type="resource" xlink:label="label289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillAcquiredDuringPeriod_en-US">Additions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element289" xlink:to="label289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="element290" />
        <label xlink:type="resource" xlink:label="label290" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element290" xlink:to="label290" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="element291" />
        <label xlink:type="resource" xlink:label="label291" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_HealthCareOrganizationPatientServiceRevenue_en-US">Health Care Organization Patient Service Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element291" xlink:to="label291" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="element292" />
        <label xlink:type="resource" xlink:label="label292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_HealthCareOrganizationPatientServiceRevenue_en-US">Net service revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element292" xlink:to="label292" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="element293" />
        <label xlink:type="resource" xlink:label="label293" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_HealthCareOrganizationRevenueSourcesDomain_en-US">Health Care Organization Revenue Sources [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element293" xlink:to="label293" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="element294" />
        <label xlink:type="resource" xlink:label="label294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_HealthCareOrganizationRevenueSourcesDomain_en-US">Health Care Organization, Revenue Sources [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element294" xlink:to="label294" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="element295" />
        <label xlink:type="resource" xlink:label="label295" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_HealthCareOrganizationRevenueSourcesAxis_en-US">Health Care Organization Revenue Sources [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element295" xlink:to="label295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="element296" />
        <label xlink:type="resource" xlink:label="label296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_HealthCareOrganizationRevenueSourcesAxis_en-US">Health Care Organization, Revenue Sources [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element296" xlink:to="label296" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="element297" />
        <label xlink:type="resource" xlink:label="label297" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_en-US">ImpairmentOfIntangibleAssetsExcludingGoodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element297" xlink:to="label297" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="element298" />
        <label xlink:type="resource" xlink:label="label298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_en-US">Other intangibles impairment charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element298" xlink:to="label298" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="element299" />
        <label xlink:type="resource" xlink:label="label299" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureAbstract_en-US">Income Tax Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element299" xlink:to="label299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="element300" />
        <label xlink:type="resource" xlink:label="label300" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperations_en-US">Income Loss From Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element300" xlink:to="label300" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="element301" />
        <label xlink:type="resource" xlink:label="label301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromContinuingOperations_en-US">Loss from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element301" xlink:to="label301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="element302" />
        <label xlink:type="resource" xlink:label="label302" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_en-US">Income Loss From Discontinued Operations Net Of Tax Per Diluted Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element302" xlink:to="label302" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="element303" />
        <label xlink:type="resource" xlink:label="label303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element303" xlink:to="label303" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="element304" />
        <label xlink:type="resource" xlink:label="label304" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_en-US">Income Loss From Continuing Operations Per Basic Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element304" xlink:to="label304" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="element305" />
        <label xlink:type="resource" xlink:label="label305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_en-US">Loss from continuing operations attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element305" xlink:to="label305" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="element306" />
        <label xlink:type="resource" xlink:label="label306" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromEquityMethodInvestments_en-US">Income Loss From Equity Method Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element306" xlink:to="label306" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="element307" />
        <label xlink:type="resource" xlink:label="label307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromEquityMethodInvestments_en-US">Equity in loss from equity method investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element307" xlink:to="label307" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="element308" />
        <label xlink:type="resource" xlink:label="label308" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncomeLossFromEquityMethodInvestments_en-US">Equity in loss of equity method investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element308" xlink:to="label308" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="element309" />
        <label xlink:type="resource" xlink:label="label309" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_en-US">Income Loss From Discontinued Operations Net Of Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element309" xlink:to="label309" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="element310" />
        <label xlink:type="resource" xlink:label="label310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element310" xlink:to="label310" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="element311" />
        <label xlink:type="resource" xlink:label="label311" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element311" xlink:to="label311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="element312" />
        <label xlink:type="resource" xlink:label="label312" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityAxis_en-US">Income Tax Authority [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element312" xlink:to="label312" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="element313" />
        <label xlink:type="resource" xlink:label="label313" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_en-US">Income Loss From Discontinued Operations Net Of Tax Per Basic Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element313" xlink:to="label313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="element314" />
        <label xlink:type="resource" xlink:label="label314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element314" xlink:to="label314" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="element315" />
        <label xlink:type="resource" xlink:label="label315" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element315" xlink:to="label315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="element316" />
        <label xlink:type="resource" xlink:label="label316" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_en-US">Income before income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element316" xlink:to="label316" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="element317" />
        <label xlink:type="resource" xlink:label="label317" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_en-US">Income Loss From Continuing Operations Per Diluted Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element317" xlink:to="label317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="element318" />
        <label xlink:type="resource" xlink:label="label318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_en-US">Loss from continuing operations attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element318" xlink:to="label318" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="element319" />
        <label xlink:type="resource" xlink:label="label319" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityDomain_en-US">Income Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element319" xlink:to="label319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="element320" />
        <label xlink:type="resource" xlink:label="label320" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxExaminationTable_en-US">Income Tax Examination [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element320" xlink:to="label320" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="element321" />
        <label xlink:type="resource" xlink:label="label321" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock_en-US">Income Tax Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element321" xlink:to="label321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="element322" />
        <label xlink:type="resource" xlink:label="label322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxDisclosureTextBlock_en-US">INCOME TAXES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element322" xlink:to="label322" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="element323" />
        <label xlink:type="resource" xlink:label="label323" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxCreditsAndAdjustments_en-US">Income Tax Credits And Adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element323" xlink:to="label323" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="element324" />
        <label xlink:type="resource" xlink:label="label324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxCreditsAndAdjustments_en-US">Tax credits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element324" xlink:to="label324" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="element325" />
        <label xlink:type="resource" xlink:label="label325" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit_en-US">Income Tax Expense Benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element325" xlink:to="label325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="element326" />
        <label xlink:type="resource" xlink:label="label326" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncomeTaxExpenseBenefit_en-US">Income tax expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element326" xlink:to="label326" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="element327" />
        <label xlink:type="resource" xlink:label="label327" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_IncomeTaxExpenseBenefit_en-US">Income tax expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element327" xlink:to="label327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="element328" />
        <label xlink:type="resource" xlink:label="label328" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeStatementAbstract_en-US">Income Statement [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element328" xlink:to="label328" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="element329" />
        <label xlink:type="resource" xlink:label="label329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeStatementAbstract_en-US">Income Statement [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element329" xlink:to="label329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="element330" />
        <label xlink:type="resource" xlink:label="label330" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element330" xlink:to="label330" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="element331" />
        <label xlink:type="resource" xlink:label="label331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element331" xlink:to="label331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="element332" />
        <label xlink:type="resource" xlink:label="label332" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element332" xlink:to="label332" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="element333" />
        <label xlink:type="resource" xlink:label="label333" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element333" xlink:to="label333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="element334" />
        <label xlink:type="resource" xlink:label="label334" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_en-US">Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element334" xlink:to="label334" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="element335" />
        <label xlink:type="resource" xlink:label="label335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element335" xlink:to="label335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="element336" />
        <label xlink:type="resource" xlink:label="label336" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxesReceivable_en-US">IncomeTaxesReceivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element336" xlink:to="label336" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="element337" />
        <label xlink:type="resource" xlink:label="label337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxesReceivable_en-US">Income tax receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element337" xlink:to="label337" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="element338" />
        <label xlink:type="resource" xlink:label="label338" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxesPaidNet_en-US">Income Taxes Paid Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element338" xlink:to="label338" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="element339" />
        <label xlink:type="resource" xlink:label="label339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxesPaidNet_en-US">Cash paid for income taxes, net of refunds received</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element339" xlink:to="label339" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="element340" />
        <label xlink:type="resource" xlink:label="label340" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxPolicyTextBlock_en-US">Income Taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element340" xlink:to="label340" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="element341" />
        <label xlink:type="resource" xlink:label="label341" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock_en-US">Income Tax, Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element341" xlink:to="label341" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="element342" />
        <label xlink:type="resource" xlink:label="label342" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_en-US">Income Amounts Attributable To Reporting Entity Disclosures [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element342" xlink:to="label342" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="element343" />
        <label xlink:type="resource" xlink:label="label343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_en-US">Amounts attributable to Amedisys, Inc. common stockholders:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element343" xlink:to="label343" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element344" />
        <label xlink:type="resource" xlink:label="label344" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_en-US">Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element344" xlink:to="label344" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element345" />
        <label xlink:type="resource" xlink:label="label345" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_en-US">Loss from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element345" xlink:to="label345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="element346" />
        <label xlink:type="resource" xlink:label="label346" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_en-US">IncreaseDecreaseinOtherCurrentLiabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element346" xlink:to="label346" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="element347" />
        <label xlink:type="resource" xlink:label="label347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_en-US">Settlement of the Estimated Federal Cap</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element347" xlink:to="label347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="element348" />
        <label xlink:type="resource" xlink:label="label348" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayable_en-US">Increase Decrease In Accounts Payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element348" xlink:to="label348" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="element349" />
        <label xlink:type="resource" xlink:label="label349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInAccountsPayable_en-US">Accounts payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element349" xlink:to="label349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="element350" />
        <label xlink:type="resource" xlink:label="label350" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_en-US">Increase Decrease In Accounts Receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element350" xlink:to="label350" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="element351" />
        <label xlink:type="resource" xlink:label="label351" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncreaseDecreaseInAccountsReceivable_en-US">Patient accounts receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element351" xlink:to="label351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="element352" />
        <label xlink:type="resource" xlink:label="label352" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccruedLiabilities_en-US">Increase Decrease In Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element352" xlink:to="label352" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="element353" />
        <label xlink:type="resource" xlink:label="label353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInAccruedLiabilities_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element353" xlink:to="label353" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:label="element354" />
        <label xlink:type="resource" xlink:label="label354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInBookOverdrafts_en-US">Outstanding checks in excess of bank balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element354" xlink:to="label354" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:label="element355" />
        <label xlink:type="resource" xlink:label="label355" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInBookOverdrafts_en-US">Increase Decrease In Book Overdrafts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element355" xlink:to="label355" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:label="element356" />
        <label xlink:type="resource" xlink:label="label356" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncreaseDecreaseInBookOverdrafts_en-US">Outstanding checks in excess of bank balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element356" xlink:to="label356" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="element357" />
        <label xlink:type="resource" xlink:label="label357" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_en-US">Other long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element357" xlink:to="label357" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="element358" />
        <label xlink:type="resource" xlink:label="label358" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_en-US">Increase Decrease In Operating Capital [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element358" xlink:to="label358" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="element359" />
        <label xlink:type="resource" xlink:label="label359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element359" xlink:to="label359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="element360" />
        <label xlink:type="resource" xlink:label="label360" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOtherOperatingAssets_en-US">Increase Decrease In Other Operating Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element360" xlink:to="label360" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="element361" />
        <label xlink:type="resource" xlink:label="label361" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncreaseDecreaseInOtherOperatingAssets_en-US">Other assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element361" xlink:to="label361" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="element362" />
        <label xlink:type="resource" xlink:label="label362" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_en-US">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element362" xlink:to="label362" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="element363" />
        <label xlink:type="resource" xlink:label="label363" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_en-US">Other current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element363" xlink:to="label363" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="element364" />
        <label xlink:type="resource" xlink:label="label364" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_en-US">Incremental Common Shares Attributable To Share Based Payment Arrangements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element364" xlink:to="label364" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="element365" />
        <label xlink:type="resource" xlink:label="label365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_en-US">Stock options</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element365" xlink:to="label365" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element366" />
        <label xlink:type="resource" xlink:label="label366" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Intangible Assets Net Excluding Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element366" xlink:to="label366" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element367" />
        <label xlink:type="resource" xlink:label="label367" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Ending balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element367" xlink:to="label367" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element368" />
        <label xlink:type="resource" xlink:label="label368" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Beginning balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element368" xlink:to="label368" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element369" />
        <label xlink:type="resource" xlink:label="label369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Intangible assets, net of accumulated amortization of $28,557 and $27,864</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element369" xlink:to="label369" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="element370" />
        <label xlink:type="resource" xlink:label="label370" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_InterestExpense_en-US">Interest Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element370" xlink:to="label370" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="element371" />
        <label xlink:type="resource" xlink:label="label371" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_InterestExpense_en-US">Interest expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element371" xlink:to="label371" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="element372" />
        <label xlink:type="resource" xlink:label="label372" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_InterestPaid_en-US">Interest Paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element372" xlink:to="label372" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="element373" />
        <label xlink:type="resource" xlink:label="label373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_InterestPaid_en-US">Cash paid for interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element373" xlink:to="label373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="element374" />
        <label xlink:type="resource" xlink:label="label374" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_InvestmentIncomeInterestAndDividend_en-US">Investment Income Interest And Dividend</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element374" xlink:to="label374" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="element375" />
        <label xlink:type="resource" xlink:label="label375" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_InvestmentIncomeInterestAndDividend_en-US">Interest income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element375" xlink:to="label375" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="element376" />
        <label xlink:type="resource" xlink:label="label376" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LettersOfCreditOutstandingAmount_en-US">Letters Of Credit Outstanding Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element376" xlink:to="label376" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="element377" />
        <label xlink:type="resource" xlink:label="label377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LettersOfCreditOutstandingAmount_en-US">Outstanding letters of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element377" xlink:to="label377" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="element378" />
        <label xlink:type="resource" xlink:label="label378" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongtermDebtTypeAxis_en-US">Longterm Debt Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element378" xlink:to="label378" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="element379" />
        <label xlink:type="resource" xlink:label="label379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongtermDebtTypeAxis_en-US">Long-term Debt, Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element379" xlink:to="label379" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="element380" />
        <label xlink:type="resource" xlink:label="label380" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongtermDebtTypeDomain_en-US">Longterm Debt Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element380" xlink:to="label380" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="element381" />
        <label xlink:type="resource" xlink:label="label381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongtermDebtTypeDomain_en-US">Long-term Debt, Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element381" xlink:to="label381" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="element382" />
        <label xlink:type="resource" xlink:label="label382" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LaborAndRelatedExpense_en-US">Labor And Related Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element382" xlink:to="label382" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="element383" />
        <label xlink:type="resource" xlink:label="label383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LaborAndRelatedExpense_en-US">Salaries and benefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element383" xlink:to="label383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Land" xlink:label="element384" />
        <label xlink:type="resource" xlink:label="label384" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Land_en-US">Land</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element384" xlink:to="label384" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="element385" />
        <label xlink:type="resource" xlink:label="label385" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LeaseholdImprovementsMember_en-US">Leasehold Improvements [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element385" xlink:to="label385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="element386" />
        <label xlink:type="resource" xlink:label="label386" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LetterOfCreditMember_en-US">Letter Of Credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element386" xlink:to="label386" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="element387" />
        <label xlink:type="resource" xlink:label="label387" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Liabilities_en-US">Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element387" xlink:to="label387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="element388" />
        <label xlink:type="resource" xlink:label="label388" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_Liabilities_en-US">Total liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element388" xlink:to="label388" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="element389" />
        <label xlink:type="resource" xlink:label="label389" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity_en-US">Liabilities And Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element389" xlink:to="label389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="element390" />
        <label xlink:type="resource" xlink:label="label390" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_LiabilitiesAndStockholdersEquity_en-US">Total liabilities and equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element390" xlink:to="label390" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="element391" />
        <label xlink:type="resource" xlink:label="label391" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_en-US">Liabilities And Stockholders Equity [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element391" xlink:to="label391" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="element392" />
        <label xlink:type="resource" xlink:label="label392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LiabilitiesAndStockholdersEquityAbstract_en-US">LIABILITIES AND EQUITY</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element392" xlink:to="label392" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="element393" />
        <label xlink:type="resource" xlink:label="label393" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesFairValueDisclosure_en-US">Liabilities Fair Value Disclosure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element393" xlink:to="label393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="element394" />
        <label xlink:type="resource" xlink:label="label394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LiabilitiesFairValueDisclosure_en-US">Long-term obligations, excluding capital leases</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element394" xlink:to="label394" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="element395" />
        <label xlink:type="resource" xlink:label="label395" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_en-US">Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element395" xlink:to="label395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="element396" />
        <label xlink:type="resource" xlink:label="label396" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_LiabilitiesCurrent_en-US">Total current liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element396" xlink:to="label396" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="element397" />
        <label xlink:type="resource" xlink:label="label397" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract_en-US">Liabilities Current [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element397" xlink:to="label397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="element398" />
        <label xlink:type="resource" xlink:label="label398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LiabilitiesCurrentAbstract_en-US">Current liabilities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element398" xlink:to="label398" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="element399" />
        <label xlink:type="resource" xlink:label="label399" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityTable_en-US">Line of Credit Facility [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element399" xlink:to="label399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="element400" />
        <label xlink:type="resource" xlink:label="label400" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityLineItems_en-US">Line of Credit Facility [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element400" xlink:to="label400" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="element401" />
        <label xlink:type="resource" xlink:label="label401" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_en-US">Line Of Credit Facility Commitment Fee Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element401" xlink:to="label401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="element402" />
        <label xlink:type="resource" xlink:label="label402" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_en-US">Commitment Fee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element402" xlink:to="label402" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="element403" />
        <label xlink:type="resource" xlink:label="label403" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_en-US">Line Of Credit Facility Maximum Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element403" xlink:to="label403" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="element404" />
        <label xlink:type="resource" xlink:label="label404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_en-US">Credit facility, maximum borrowing capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element404" xlink:to="label404" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="element405" />
        <label xlink:type="resource" xlink:label="label405" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_en-US">Line Of Credit Facility Remaining Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element405" xlink:to="label405" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="element406" />
        <label xlink:type="resource" xlink:label="label406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_en-US">Availability under the revolving credit facility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element406" xlink:to="label406" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="element407" />
        <label xlink:type="resource" xlink:label="label407" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LitigationSettlementAmount_en-US">Loss Contingency, Settlement Agreement, Consideration</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element407" xlink:to="label407" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="element408" />
        <label xlink:type="resource" xlink:label="label408" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LitigationStatusAxis_en-US">Litigation Status [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element408" xlink:to="label408" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="element409" />
        <label xlink:type="resource" xlink:label="label409" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LitigationStatusDomain_en-US">Litigation Status [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element409" xlink:to="label409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="element410" />
        <label xlink:type="resource" xlink:label="label410" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_en-US">Long Lived Assets Held-for-sale by Asset Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element410" xlink:to="label410" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="element411" />
        <label xlink:type="resource" xlink:label="label411" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongLivedAssetsHeldForSaleNameDomain_en-US">Long Lived Assets Held-for-sale, Name [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element411" xlink:to="label411" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="element412" />
        <label xlink:type="resource" xlink:label="label412" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebt_en-US">Long Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element412" xlink:to="label412" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="element413" />
        <label xlink:type="resource" xlink:label="label413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebt_en-US">Long-term debt including current portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element413" xlink:to="label413" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="element414" />
        <label xlink:type="resource" xlink:label="label414" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_LongTermDebt_en-US">Long-term debt including current portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element414" xlink:to="label414" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="element415" />
        <label xlink:type="resource" xlink:label="label415" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtAbstract_en-US">Long-term Debt [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element415" xlink:to="label415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="element416" />
        <label xlink:type="resource" xlink:label="label416" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtAndCapitalLeaseObligations_en-US">Long Term Debt And Capital Lease Obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element416" xlink:to="label416" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="element417" />
        <label xlink:type="resource" xlink:label="label417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtAndCapitalLeaseObligations_en-US">Long-term obligations, less current portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element417" xlink:to="label417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="element418" />
        <label xlink:type="resource" xlink:label="label418" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_en-US">Long Term Debt And Capital Lease Obligations Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element418" xlink:to="label418" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="element419" />
        <label xlink:type="resource" xlink:label="label419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_en-US">Current portion of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element419" xlink:to="label419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="element420" />
        <label xlink:type="resource" xlink:label="label420" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_en-US">Current portion of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element420" xlink:to="label420" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="element421" />
        <label xlink:type="resource" xlink:label="label421" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_en-US">Long Term Debt Maturities Repayments Of Principal In Year Three</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element421" xlink:to="label421" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="element422" />
        <label xlink:type="resource" xlink:label="label422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_en-US">2017</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element422" xlink:to="label422" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="element423" />
        <label xlink:type="resource" xlink:label="label423" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_en-US">Long Term Debt Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element423" xlink:to="label423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="element424" />
        <label xlink:type="resource" xlink:label="label424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtNoncurrent_en-US">Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element424" xlink:to="label424" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="element425" />
        <label xlink:type="resource" xlink:label="label425" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_en-US">Long Term Debt Maturities Repayments Of Principal After Year Five</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element425" xlink:to="label425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="element426" />
        <label xlink:type="resource" xlink:label="label426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_en-US">Future Years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element426" xlink:to="label426" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="element427" />
        <label xlink:type="resource" xlink:label="label427" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_en-US">Long Term Debt Maturities Repayments Of Principal In Year Two</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element427" xlink:to="label427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="element428" />
        <label xlink:type="resource" xlink:label="label428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_en-US">2016</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element428" xlink:to="label428" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="element429" />
        <label xlink:type="resource" xlink:label="label429" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_en-US">Long Term Debt Maturities Repayments Of Principal In Year Four</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element429" xlink:to="label429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="element430" />
        <label xlink:type="resource" xlink:label="label430" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_en-US">2018</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element430" xlink:to="label430" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="element431" />
        <label xlink:type="resource" xlink:label="label431" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_en-US">Long Term Debt Maturities Repayments Of Principal In Year Five</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element431" xlink:to="label431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="element432" />
        <label xlink:type="resource" xlink:label="label432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_en-US">2019</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element432" xlink:to="label432" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="element433" />
        <label xlink:type="resource" xlink:label="label433" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_en-US">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element433" xlink:to="label433" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="element434" />
        <label xlink:type="resource" xlink:label="label434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_en-US">2015</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element434" xlink:to="label434" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="element435" />
        <label xlink:type="resource" xlink:label="label435" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyNumberOfDefendants_en-US">Loss Contingency Number Of Defendants</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element435" xlink:to="label435" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="element436" />
        <label xlink:type="resource" xlink:label="label436" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyAccrualAtCarryingValue_en-US">Loss Contingency Accrual, at Carrying Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element436" xlink:to="label436" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="element437" />
        <label xlink:type="resource" xlink:label="label437" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyAccrualProvision_en-US">LossContingencyAccrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element437" xlink:to="label437" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="element438" />
        <label xlink:type="resource" xlink:label="label438" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyAccrualProvision_en-US">Loss Contingency Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element438" xlink:to="label438" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="element439" />
        <label xlink:type="resource" xlink:label="label439" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyNumberOfPlaintiffs_en-US">Loss Contingency Number Of Plaintiffs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element439" xlink:to="label439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="element440" />
        <label xlink:type="resource" xlink:label="label440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyNumberOfPlaintiffs_en-US">Number of former employees who filled a putative collective and class action complaint</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element440" xlink:to="label440" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="element441" />
        <label xlink:type="resource" xlink:label="label441" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyActionsTakenByPlaintiff_en-US">Loss Contingency Actions Taken By Plaintiff</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element441" xlink:to="label441" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="element442" />
        <label xlink:type="resource" xlink:label="label442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyActionsTakenByPlaintiff_en-US">Description of plaintiffs class certification request</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element442" xlink:to="label442" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="element443" />
        <label xlink:type="resource" xlink:label="label443" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingenciesByNatureOfContingencyAxis_en-US">Loss Contingencies By Nature Of Contingency [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element443" xlink:to="label443" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="element444" />
        <label xlink:type="resource" xlink:label="label444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingenciesByNatureOfContingencyAxis_en-US">Loss Contingency Nature [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element444" xlink:to="label444" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="element445" />
        <label xlink:type="resource" xlink:label="label445" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyNatureDomain_en-US">Loss Contingency Nature [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element445" xlink:to="label445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="element446" />
        <label xlink:type="resource" xlink:label="label446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyNatureDomain_en-US">Loss Contingency, Nature [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element446" xlink:to="label446" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="element447" />
        <label xlink:type="resource" xlink:label="label447" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyEstimateOfPossibleLoss_en-US">Loss Contingency, Estimate of Possible Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element447" xlink:to="label447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="element448" />
        <label xlink:type="resource" xlink:label="label448" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MaturitiesOfLongTermDebtAbstract_en-US">Maturities of Long-term Debt [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element448" xlink:to="label448" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="element449" />
        <label xlink:type="resource" xlink:label="label449" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MaximumMember_en-US">Maximum [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element449" xlink:to="label449" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="element450" />
        <label xlink:type="resource" xlink:label="label450" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinimumMember_en-US">Minimum [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element450" xlink:to="label450" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="element451" />
        <label xlink:type="resource" xlink:label="label451" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element451" xlink:to="label451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="element452" />
        <label xlink:type="resource" xlink:label="label452" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinorityInterest_en-US">Minority Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element452" xlink:to="label452" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="element453" />
        <label xlink:type="resource" xlink:label="label453" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_MinorityInterest_en-US">Noncontrolling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element453" xlink:to="label453" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="element454" />
        <label xlink:type="resource" xlink:label="label454" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element454" xlink:to="label454" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="element455" />
        <label xlink:type="resource" xlink:label="label455" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_en-US">Net cash used in investing activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element455" xlink:to="label455" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="element456" />
        <label xlink:type="resource" xlink:label="label456" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element456" xlink:to="label456" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="element457" />
        <label xlink:type="resource" xlink:label="label457" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_en-US">Net cash (used in) provided by financing activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element457" xlink:to="label457" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="element458" />
        <label xlink:type="resource" xlink:label="label458" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element458" xlink:to="label458" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="element459" />
        <label xlink:type="resource" xlink:label="label459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_en-US">Cash Flows from Financing Activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element459" xlink:to="label459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="element460" />
        <label xlink:type="resource" xlink:label="label460" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element460" xlink:to="label460" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="element461" />
        <label xlink:type="resource" xlink:label="label461" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_en-US">Net cash provided by operating activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element461" xlink:to="label461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="element462" />
        <label xlink:type="resource" xlink:label="label462" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element462" xlink:to="label462" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="element463" />
        <label xlink:type="resource" xlink:label="label463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_en-US">Cash Flows from Investing Activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element463" xlink:to="label463" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element464" />
        <label xlink:type="resource" xlink:label="label464" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element464" xlink:to="label464" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element465" />
        <label xlink:type="resource" xlink:label="label465" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Cash Flows from Operating Activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element465" xlink:to="label465" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="element466" />
        <label xlink:type="resource" xlink:label="label466" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_en-US">Net Income Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element466" xlink:to="label466" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="element467" />
        <label xlink:type="resource" xlink:label="label467" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetIncomeLoss_en-US">Net income attributable to Amedisys, Inc.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element467" xlink:to="label467" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="element468" />
        <label xlink:type="resource" xlink:label="label468" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_en-US">Net Income Loss Attributable To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element468" xlink:to="label468" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="element469" />
        <label xlink:type="resource" xlink:label="label469" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_en-US">Net loss (income) attributable to noncontrolling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element469" xlink:to="label469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="element470" />
        <label xlink:type="resource" xlink:label="label470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_en-US">Comprehensive income attributable to non-controlling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element470" xlink:to="label470" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="element471" />
        <label xlink:type="resource" xlink:label="label471" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xml:lang="en-US" id="NegatedTerse_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_en-US">Net income attributable to noncontrolling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element471" xlink:to="label471" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="element472" />
        <label xlink:type="resource" xlink:label="label472" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_en-US">Accounting Pronouncements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element472" xlink:to="label472" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="element473" />
        <label xlink:type="resource" xlink:label="label473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_en-US">Recently Issued Accounting Pronouncements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element473" xlink:to="label473" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="element474" />
        <label xlink:type="resource" xlink:label="label474" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementMember_en-US">New Accounting Pronouncement [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element474" xlink:to="label474" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="element475" />
        <label xlink:type="resource" xlink:label="label475" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_en-US">NoncashOrPartNoncashAcquisitionDebtAssumed1</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element475" xlink:to="label475" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="element476" />
        <label xlink:type="resource" xlink:label="label476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_en-US">Notes payable issued for/assumed in acquisitions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element476" xlink:to="label476" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="element477" />
        <label xlink:type="resource" xlink:label="label477" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NoncompeteAgreementsMember_en-US">Noncompete Agreements [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element477" xlink:to="label477" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="element478" />
        <label xlink:type="resource" xlink:label="label478" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_en-US">Nonoperating Income Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element478" xlink:to="label478" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="element479" />
        <label xlink:type="resource" xlink:label="label479" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NonoperatingIncomeExpense_en-US">Total other expense, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element479" xlink:to="label479" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="element480" />
        <label xlink:type="resource" xlink:label="label480" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpenseAbstract_en-US">Nonoperating Income Expense [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element480" xlink:to="label480" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="element481" />
        <label xlink:type="resource" xlink:label="label481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NonoperatingIncomeExpenseAbstract_en-US">Other expense:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element481" xlink:to="label481" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesIssued1" xlink:label="element482" />
        <label xlink:type="resource" xlink:label="label482" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NotesIssued1_en-US">NotesIssued1</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element482" xlink:to="label482" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesIssued1" xlink:label="element483" />
        <label xlink:type="resource" xlink:label="label483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NotesIssued1_en-US">Notes payable issued for software licenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element483" xlink:to="label483" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="element484" />
        <label xlink:type="resource" xlink:label="label484" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NumberOfReportableSegments_en-US">Number Of Reportable Segments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element484" xlink:to="label484" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="element485" />
        <label xlink:type="resource" xlink:label="label485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NumberOfReportableSegments_en-US">Number of reportable business segments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element485" xlink:to="label485" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="element486" />
        <label xlink:type="resource" xlink:label="label486" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NumberOfBusinessesAcquired_en-US">Number Of Businesses Acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element486" xlink:to="label486" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="element487" />
        <label xlink:type="resource" xlink:label="label487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NumberOfBusinessesAcquired_en-US">Acquisition, number of care centers acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element487" xlink:to="label487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="element488" />
        <label xlink:type="resource" xlink:label="label488" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NumberOfStatesInWhichEntityOperates_en-US">Number Of States With Facilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element488" xlink:to="label488" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="element489" />
        <label xlink:type="resource" xlink:label="label489" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OpenTaxYear_en-US">OpenTaxYear</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element489" xlink:to="label489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="element490" />
        <label xlink:type="resource" xlink:label="label490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OpenTaxYear_en-US">Tax years open to examination</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element490" xlink:to="label490" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="element491" />
        <label xlink:type="resource" xlink:label="label491" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_en-US">OperatingLeasesFutureMinimumPaymentsDue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element491" xlink:to="label491" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="element492" />
        <label xlink:type="resource" xlink:label="label492" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_en-US">Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element492" xlink:to="label492" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="element493" />
        <label xlink:type="resource" xlink:label="label493" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInTwoYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element493" xlink:to="label493" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="element494" />
        <label xlink:type="resource" xlink:label="label494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_en-US">2016</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element494" xlink:to="label494" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="element495" />
        <label xlink:type="resource" xlink:label="label495" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_en-US">OperatingLeasesFutureMinimumPaymentsDueCurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element495" xlink:to="label495" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="element496" />
        <label xlink:type="resource" xlink:label="label496" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_en-US">2015</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element496" xlink:to="label496" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="element497" />
        <label xlink:type="resource" xlink:label="label497" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwardsValuationAllowance_en-US">Operating Loss Carryforwards Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element497" xlink:to="label497" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="element498" />
        <label xlink:type="resource" xlink:label="label498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLossCarryforwardsValuationAllowance_en-US">Net operating loss carryforwards valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element498" xlink:to="label498" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="element499" />
        <label xlink:type="resource" xlink:label="label499" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_en-US">OperatingLeasesFutureMinimumPaymentsDueThereafter</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element499" xlink:to="label499" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="element500" />
        <label xlink:type="resource" xlink:label="label500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_en-US">Future years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element500" xlink:to="label500" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="element501" />
        <label xlink:type="resource" xlink:label="label501" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards_en-US">Operating Loss Carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element501" xlink:to="label501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="element502" />
        <label xlink:type="resource" xlink:label="label502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLossCarryforwards_en-US">Net operating loss carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element502" xlink:to="label502" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="element503" />
        <label xlink:type="resource" xlink:label="label503" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInThreeYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element503" xlink:to="label503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="element504" />
        <label xlink:type="resource" xlink:label="label504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_en-US">2017</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element504" xlink:to="label504" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element505" />
        <label xlink:type="resource" xlink:label="label505" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_en-US">Operating Income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element505" xlink:to="label505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element506" />
        <label xlink:type="resource" xlink:label="label506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingIncomeLoss_en-US">Operating income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element506" xlink:to="label506" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element507" />
        <label xlink:type="resource" xlink:label="label507" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OperatingIncomeLoss_en-US">Operating income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element507" xlink:to="label507" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element508" />
        <label xlink:type="resource" xlink:label="label508" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_OperatingIncomeLoss_en-US">Operating income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element508" xlink:to="label508" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="element509" />
        <label xlink:type="resource" xlink:label="label509" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInFourYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element509" xlink:to="label509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="element510" />
        <label xlink:type="resource" xlink:label="label510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_en-US">2018</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element510" xlink:to="label510" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="element511" />
        <label xlink:type="resource" xlink:label="label511" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInFiveYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element511" xlink:to="label511" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="element512" />
        <label xlink:type="resource" xlink:label="label512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_en-US">2019</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element512" xlink:to="label512" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="element513" />
        <label xlink:type="resource" xlink:label="label513" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element513" xlink:to="label513" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="element514" />
        <label xlink:type="resource" xlink:label="label514" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element514" xlink:to="label514" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="element515" />
        <label xlink:type="resource" xlink:label="label515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element515" xlink:to="label515" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="element516" />
        <label xlink:type="resource" xlink:label="label516" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherAssetsCurrent_en-US">Other Assets Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element516" xlink:to="label516" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="element517" />
        <label xlink:type="resource" xlink:label="label517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherAssetsCurrent_en-US">Other current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element517" xlink:to="label517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="element518" />
        <label xlink:type="resource" xlink:label="label518" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OtherAssetsCurrent_en-US">Other current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element518" xlink:to="label518" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="element519" />
        <label xlink:type="resource" xlink:label="label519" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherAssetsNoncurrent_en-US">Other Assets Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element519" xlink:to="label519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="element520" />
        <label xlink:type="resource" xlink:label="label520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherAssetsNoncurrent_en-US">Other assets, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element520" xlink:to="label520" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="element521" />
        <label xlink:type="resource" xlink:label="label521" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OtherAssetsNoncurrent_en-US">Other assets, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element521" xlink:to="label521" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="element522" />
        <label xlink:type="resource" xlink:label="label522" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherGeneralAndAdministrativeExpense_en-US">Other General And Administrative Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element522" xlink:to="label522" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="element523" />
        <label xlink:type="resource" xlink:label="label523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherGeneralAndAdministrativeExpense_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element523" xlink:to="label523" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="element524" />
        <label xlink:type="resource" xlink:label="label524" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncomeExpense_en-US">Other Nonoperating Income Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element524" xlink:to="label524" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="element525" />
        <label xlink:type="resource" xlink:label="label525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherNonoperatingIncomeExpense_en-US">Miscellaneous, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element525" xlink:to="label525" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="element526" />
        <label xlink:type="resource" xlink:label="label526" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherLiabilitiesNoncurrent_en-US">Other Liabilities Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element526" xlink:to="label526" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="element527" />
        <label xlink:type="resource" xlink:label="label527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherLiabilitiesNoncurrent_en-US">Other long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element527" xlink:to="label527" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="element528" />
        <label xlink:type="resource" xlink:label="label528" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OtherLiabilitiesNoncurrent_en-US">Other long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element528" xlink:to="label528" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="element529" />
        <label xlink:type="resource" xlink:label="label529" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherNotesPayable_en-US">Other Notes Payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element529" xlink:to="label529" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="element530" />
        <label xlink:type="resource" xlink:label="label530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherNotesPayable_en-US">Promissory notes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element530" xlink:to="label530" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="element531" />
        <label xlink:type="resource" xlink:label="label531" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_en-US">Payments Related To Tax Withholding For Share Based Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element531" xlink:to="label531" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="element532" />
        <label xlink:type="resource" xlink:label="label532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_en-US">Shares withheld upon stock vesting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element532" xlink:to="label532" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="element533" />
        <label xlink:type="resource" xlink:label="label533" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_en-US">Shares withheld upon stock vesting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element533" xlink:to="label533" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="element534" />
        <label xlink:type="resource" xlink:label="label534" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromInvestments_en-US">PaymentsForProceedsFromInvestments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element534" xlink:to="label534" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="element535" />
        <label xlink:type="resource" xlink:label="label535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsForProceedsFromInvestments_en-US">Purchase of investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element535" xlink:to="label535" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="element536" />
        <label xlink:type="resource" xlink:label="label536" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsForProceedsFromInvestments_en-US">Purchase of investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element536" xlink:to="label536" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="element537" />
        <label xlink:type="resource" xlink:label="label537" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsForRestructuring_en-US">RestructuringReserveSettledWithCash</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element537" xlink:to="label537" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="element538" />
        <label xlink:type="resource" xlink:label="label538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsForRestructuring_en-US">Cash Expenditure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element538" xlink:to="label538" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="element539" />
        <label xlink:type="resource" xlink:label="label539" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsOfFinancingCosts_en-US">Payment of deferred financing fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element539" xlink:to="label539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="element540" />
        <label xlink:type="resource" xlink:label="label540" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsOfFinancingCosts_en-US">Debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element540" xlink:to="label540" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="element541" />
        <label xlink:type="resource" xlink:label="label541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsOfFinancingCosts_en-US">Debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element541" xlink:to="label541" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="element542" />
        <label xlink:type="resource" xlink:label="label542" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_en-US">Payments To Acquire Businesses Net Of Cash Acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element542" xlink:to="label542" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="element543" />
        <label xlink:type="resource" xlink:label="label543" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_en-US">Acquisitions of businesses, net of cash acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element543" xlink:to="label543" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="element544" />
        <label xlink:type="resource" xlink:label="label544" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsForRepurchaseOfCommonStock_en-US">Payments For Repurchase Of Common Stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element544" xlink:to="label544" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="element545" />
        <label xlink:type="resource" xlink:label="label545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsForRepurchaseOfCommonStock_en-US">Purchase of company stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element545" xlink:to="label545" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="element546" />
        <label xlink:type="resource" xlink:label="label546" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsForRepurchaseOfCommonStock_en-US">Purchase of company stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element546" xlink:to="label546" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="element547" />
        <label xlink:type="resource" xlink:label="label547" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireRestrictedInvestments_en-US">Payments To Acquire Restricted Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element547" xlink:to="label547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="element548" />
        <label xlink:type="resource" xlink:label="label548" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsToAcquireRestrictedInvestments_en-US">Purchases of deferred compensation plan assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element548" xlink:to="label548" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="element549" />
        <label xlink:type="resource" xlink:label="label549" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_en-US">Payments To Acquire Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element549" xlink:to="label549" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="element550" />
        <label xlink:type="resource" xlink:label="label550" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_en-US">Purchases of property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element550" xlink:to="label550" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="element551" />
        <label xlink:type="resource" xlink:label="label551" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PendingLitigationMember_en-US">Pending Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element551" xlink:to="label551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="element552" />
        <label xlink:type="resource" xlink:label="label552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PendingLitigationMember_en-US">Wage and Hour Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element552" xlink:to="label552" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionExpense" xlink:label="element553" />
        <label xlink:type="resource" xlink:label="label553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PensionExpense_en-US">401(k) employer match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element553" xlink:to="label553" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionExpense" xlink:label="element554" />
        <label xlink:type="resource" xlink:label="label554" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PensionExpense_en-US">Pension Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element554" xlink:to="label554" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="element555" />
        <label xlink:type="resource" xlink:label="label555" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_en-US">Pension And Other Postretirement Benefits DisclosureText Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element555" xlink:to="label555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="element556" />
        <label xlink:type="resource" xlink:label="label556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_en-US">EMPLOYEE BENEFIT PLANS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element556" xlink:to="label556" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="element557" />
        <label xlink:type="resource" xlink:label="label557" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockSharesIssued_en-US">Preferred Stock Shares Issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element557" xlink:to="label557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="element558" />
        <label xlink:type="resource" xlink:label="label558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockSharesIssued_en-US">Preferred stock, issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element558" xlink:to="label558" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="element559" />
        <label xlink:type="resource" xlink:label="label559" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockSharesAuthorized_en-US">Preferred Stock Shares Authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element559" xlink:to="label559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="element560" />
        <label xlink:type="resource" xlink:label="label560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockSharesAuthorized_en-US">Preferred stock, shares authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element560" xlink:to="label560" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="element561" />
        <label xlink:type="resource" xlink:label="label561" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockParOrStatedValuePerShare_en-US">Preferred Stock Par Or Stated Value Per Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element561" xlink:to="label561" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="element562" />
        <label xlink:type="resource" xlink:label="label562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockParOrStatedValuePerShare_en-US">Preferred stock, par value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element562" xlink:to="label562" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="element563" />
        <label xlink:type="resource" xlink:label="label563" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockSharesOutstanding_en-US">Preferred Stock Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element563" xlink:to="label563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="element564" />
        <label xlink:type="resource" xlink:label="label564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockSharesOutstanding_en-US">Preferred stock, outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element564" xlink:to="label564" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="element565" />
        <label xlink:type="resource" xlink:label="label565" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockValueOutstanding_en-US">Preferred Stock Value Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element565" xlink:to="label565" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="element566" />
        <label xlink:type="resource" xlink:label="label566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockValueOutstanding_en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element566" xlink:to="label566" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="element567" />
        <label xlink:type="resource" xlink:label="label567" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseCurrent_en-US">Prepaid Expense Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element567" xlink:to="label567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="element568" />
        <label xlink:type="resource" xlink:label="label568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PrepaidExpenseCurrent_en-US">Prepaid expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element568" xlink:to="label568" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="element569" />
        <label xlink:type="resource" xlink:label="label569" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfDebt_en-US">Proceeds From Issuance Of Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element569" xlink:to="label569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="element570" />
        <label xlink:type="resource" xlink:label="label570" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfLongTermDebt_en-US">Proceeds from issuance of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element570" xlink:to="label570" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="element571" />
        <label xlink:type="resource" xlink:label="label571" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromDivestitureOfBusinesses_en-US">Proceeds from Divestiture of Business</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element571" xlink:to="label571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="element572" />
        <label xlink:type="resource" xlink:label="label572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromDivestitureOfBusinesses_en-US">Proceeds from dispositions of care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element572" xlink:to="label572" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="element573" />
        <label xlink:type="resource" xlink:label="label573" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_en-US">Proceeds From Sale Of Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element573" xlink:to="label573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="element574" />
        <label xlink:type="resource" xlink:label="label574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_en-US">Proceeds from the sale of property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element574" xlink:to="label574" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="element575" />
        <label xlink:type="resource" xlink:label="label575" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfRestrictedInvestments_en-US">Proceeds From Sale Of Restricted Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element575" xlink:to="label575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="element576" />
        <label xlink:type="resource" xlink:label="label576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromSaleOfRestrictedInvestments_en-US">Proceeds from sale of deferred compensation plan assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element576" xlink:to="label576" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="element577" />
        <label xlink:type="resource" xlink:label="label577" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromShortTermDebt_en-US">Proceeds from revolving line of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element577" xlink:to="label577" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="element578" />
        <label xlink:type="resource" xlink:label="label578" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_en-US">Proceeds From Stock Options Exercised</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element578" xlink:to="label578" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="element579" />
        <label xlink:type="resource" xlink:label="label579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromStockOptionsExercised_en-US">Proceeds from issuance of stock upon exercise of stock options and warrants</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element579" xlink:to="label579" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="element580" />
        <label xlink:type="resource" xlink:label="label580" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockPlans_en-US">Proceeds From Stock Plans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element580" xlink:to="label580" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="element581" />
        <label xlink:type="resource" xlink:label="label581" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromStockPlans_en-US">Proceeds from issuance of stock to employee stock purchase plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element581" xlink:to="label581" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element582" />
        <label xlink:type="resource" xlink:label="label582" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProfitLoss_en-US">Profit Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element582" xlink:to="label582" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element583" />
        <label xlink:type="resource" xlink:label="label583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProfitLoss_en-US">Net income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element583" xlink:to="label583" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element584" />
        <label xlink:type="resource" xlink:label="label584" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_ProfitLoss_en-US">Net income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element584" xlink:to="label584" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element585" />
        <label xlink:type="resource" xlink:label="label585" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_ProfitLoss_en-US">Net income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element585" xlink:to="label585" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="element586" />
        <label xlink:type="resource" xlink:label="label586" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_en-US">Property Plant And Equipment Useful Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element586" xlink:to="label586" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="element587" />
        <label xlink:type="resource" xlink:label="label587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentUsefulLife_en-US">Useful Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element587" xlink:to="label587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="element588" />
        <label xlink:type="resource" xlink:label="label588" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTypeDomain_en-US">Property Plant And Equipment By Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element588" xlink:to="label588" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="element589" />
        <label xlink:type="resource" xlink:label="label589" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_en-US">Property Plant And Equipment Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element589" xlink:to="label589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="element590" />
        <label xlink:type="resource" xlink:label="label590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_en-US">Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element590" xlink:to="label590" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="element591" />
        <label xlink:type="resource" xlink:label="label591" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentAbstract_en-US">Property Plant And Equipment [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element591" xlink:to="label591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="element592" />
        <label xlink:type="resource" xlink:label="label592" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_en-US">Property Plant And Equipment Estimated Useful Lives</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element592" xlink:to="label592" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="element593" />
        <label xlink:type="resource" xlink:label="label593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_en-US">Estimated Useful Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element593" xlink:to="label593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="element594" />
        <label xlink:type="resource" xlink:label="label594" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock_en-US">Property Plant And Equipment Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element594" xlink:to="label594" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="element595" />
        <label xlink:type="resource" xlink:label="label595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentTextBlock_en-US">Property Plant and Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element595" xlink:to="label595" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="element596" />
        <label xlink:type="resource" xlink:label="label596" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_en-US">Property Plant And Equipment Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element596" xlink:to="label596" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="element597" />
        <label xlink:type="resource" xlink:label="label597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentNet_en-US">Property and equipment, net of accumulated depreciation of $142,185 and $138,650</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element597" xlink:to="label597" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="element598" />
        <label xlink:type="resource" xlink:label="label598" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_PropertyPlantAndEquipmentNet_en-US">Property and equipment, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element598" xlink:to="label598" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="element599" />
        <label xlink:type="resource" xlink:label="label599" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentLineItems_en-US">Property Plant And Equipment [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element599" xlink:to="label599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="element600" />
        <label xlink:type="resource" xlink:label="label600" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentGross_en-US">Property Plant And Equipment Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element600" xlink:to="label600" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="element601" />
        <label xlink:type="resource" xlink:label="label601" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_PropertyPlantAndEquipmentGross_en-US">Property and Equipment, Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element601" xlink:to="label601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="element602" />
        <label xlink:type="resource" xlink:label="label602" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis_en-US">Property Plant And Equipment By Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element602" xlink:to="label602" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="element603" />
        <label xlink:type="resource" xlink:label="label603" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProvisionForDoubtfulAccounts_en-US">Provision For Doubtful Accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element603" xlink:to="label603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="element604" />
        <label xlink:type="resource" xlink:label="label604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProvisionForDoubtfulAccounts_en-US">Provision for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element604" xlink:to="label604" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="element605" />
        <label xlink:type="resource" xlink:label="label605" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_QuarterlyFinancialInformationTextBlock_en-US">Quarterly Financial Information [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element605" xlink:to="label605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="element606" />
        <label xlink:type="resource" xlink:label="label606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_QuarterlyFinancialInformationTextBlock_en-US">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element606" xlink:to="label606" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="element607" />
        <label xlink:type="resource" xlink:label="label607" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_en-US">Quarterly Financial Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element607" xlink:to="label607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="element608" />
        <label xlink:type="resource" xlink:label="label608" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RangeAxis_en-US">Range [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element608" xlink:to="label608" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="element609" />
        <label xlink:type="resource" xlink:label="label609" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RangeMember_en-US">Range [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element609" xlink:to="label609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="element610" />
        <label xlink:type="resource" xlink:label="label610" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_en-US">RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element610" xlink:to="label610" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="element611" />
        <label xlink:type="resource" xlink:label="label611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_en-US">Related party transaction expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element611" xlink:to="label611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="element612" />
        <label xlink:type="resource" xlink:label="label612" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_en-US">Related Party Transactions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element612" xlink:to="label612" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="element613" />
        <label xlink:type="resource" xlink:label="label613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_en-US">RELATED PARTY TRANSACTION</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element613" xlink:to="label613" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="element614" />
        <label xlink:type="resource" xlink:label="label614" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction_en-US">Related Party Transaction Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element614" xlink:to="label614" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="element615" />
        <label xlink:type="resource" xlink:label="label615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RelatedPartyTransactionAmountsOfTransaction_en-US">Related party transaction amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element615" xlink:to="label615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="element616" />
        <label xlink:type="resource" xlink:label="label616" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsAbstract_en-US">Related Party Transaction</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element616" xlink:to="label616" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="element617" />
        <label xlink:type="resource" xlink:label="label617" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RepaymentsOfLongTermDebt_en-US">Repayments Of Long Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element617" xlink:to="label617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="element618" />
        <label xlink:type="resource" xlink:label="label618" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_RepaymentsOfLongTermDebt_en-US">Principal payments of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element618" xlink:to="label618" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="element619" />
        <label xlink:type="resource" xlink:label="label619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RepaymentsOfLongTermDebt_en-US">Principal amount of existing term loan paid off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element619" xlink:to="label619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="element620" />
        <label xlink:type="resource" xlink:label="label620" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RepaymentsOfShortTermDebt_en-US">Repayments Of Short Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element620" xlink:to="label620" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="element621" />
        <label xlink:type="resource" xlink:label="label621" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_RepaymentsOfShortTermDebt_en-US">Repayments of revolving line of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element621" xlink:to="label621" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="element622" />
        <label xlink:type="resource" xlink:label="label622" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RepaymentsOfLinesOfCredit_en-US">Line Of Credit Facility Decrease Repayments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element622" xlink:to="label622" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="element623" />
        <label xlink:type="resource" xlink:label="label623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RepaymentsOfLinesOfCredit_en-US">Repayments of lines of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element623" xlink:to="label623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="element624" />
        <label xlink:type="resource" xlink:label="label624" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringCharges_en-US">Restructuring Charges</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element624" xlink:to="label624" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="element625" />
        <label xlink:type="resource" xlink:label="label625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RestructuringCharges_en-US">Charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element625" xlink:to="label625" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="element626" />
        <label xlink:type="resource" xlink:label="label626" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_RestructuringCharges_en-US">Exit activity costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element626" xlink:to="label626" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="element627" />
        <label xlink:type="resource" xlink:label="label627" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringReserve_en-US">Restructuring Reserve</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element627" xlink:to="label627" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="element628" />
        <label xlink:type="resource" xlink:label="label628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RestructuringReserve_en-US">Reserve Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element628" xlink:to="label628" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="element629" />
        <label xlink:type="resource" xlink:label="label629" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringAndRelatedActivitiesAbstract_en-US">Restructuring and Related Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element629" xlink:to="label629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="element630" />
        <label xlink:type="resource" xlink:label="label630" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringCostAndReserveAxis_en-US">Restructuring Cost And Reserve [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element630" xlink:to="label630" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="element631" />
        <label xlink:type="resource" xlink:label="label631" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringCostAndReserveLineItems_en-US">Restructuring Cost and Reserve [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element631" xlink:to="label631" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="element632" />
        <label xlink:type="resource" xlink:label="label632" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_en-US">Restructuring and Related Activities Disclosure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element632" xlink:to="label632" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="element633" />
        <label xlink:type="resource" xlink:label="label633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_en-US">EXIT ACTIVITIES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element633" xlink:to="label633" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="element634" />
        <label xlink:type="resource" xlink:label="label634" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember_en-US">Retained Earnings [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element634" xlink:to="label634" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="element635" />
        <label xlink:type="resource" xlink:label="label635" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit_en-US">Retained Earnings Accumulated Deficit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element635" xlink:to="label635" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="element636" />
        <label xlink:type="resource" xlink:label="label636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RetainedEarningsAccumulatedDeficit_en-US">Retained earnings</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element636" xlink:to="label636" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="element637" />
        <label xlink:type="resource" xlink:label="label637" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_en-US">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element637" xlink:to="label637" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="element638" />
        <label xlink:type="resource" xlink:label="label638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element638" xlink:to="label638" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="element639" />
        <label xlink:type="resource" xlink:label="label639" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_en-US">Revenue Recognition Multiple Deliverable Arrangements [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element639" xlink:to="label639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="element640" />
        <label xlink:type="resource" xlink:label="label640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element640" xlink:to="label640" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="element641" />
        <label xlink:type="resource" xlink:label="label641" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock_en-US">Revenue Recognition Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element641" xlink:to="label641" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="element642" />
        <label xlink:type="resource" xlink:label="label642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RevenueRecognitionPolicyTextBlock_en-US">Revenue Recognition</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element642" xlink:to="label642" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="element643" />
        <label xlink:type="resource" xlink:label="label643" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SalesRevenueNetMember_en-US">Sales Revenue Net [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element643" xlink:to="label643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="element644" />
        <label xlink:type="resource" xlink:label="label644" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfOtherAssetsTableTextBlock_en-US">Schedule of Other Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element644" xlink:to="label644" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="element645" />
        <label xlink:type="resource" xlink:label="label645" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfOtherAssetsTableTextBlock_en-US">Other Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element645" xlink:to="label645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="element646" />
        <label xlink:type="resource" xlink:label="label646" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_en-US">Components of Net Deferred Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element646" xlink:to="label646" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="element647" />
        <label xlink:type="resource" xlink:label="label647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_en-US">Net Deferred Tax Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element647" xlink:to="label647" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="element648" />
        <label xlink:type="resource" xlink:label="label648" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_en-US">Schedule of Other Current Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element648" xlink:to="label648" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="element649" />
        <label xlink:type="resource" xlink:label="label649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_en-US">Other Current Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element649" xlink:to="label649" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="element650" />
        <label xlink:type="resource" xlink:label="label650" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_en-US">Schedule of Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element650" xlink:to="label650" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="element651" />
        <label xlink:type="resource" xlink:label="label651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_en-US">Accrued Expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element651" xlink:to="label651" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="element652" />
        <label xlink:type="resource" xlink:label="label652" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_en-US">Schedule Of Intangible Assets And Goodwill Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element652" xlink:to="label652" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="element653" />
        <label xlink:type="resource" xlink:label="label653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_en-US">Summary of Activity Related to Goodwill and Other Intangible Assets Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element653" xlink:to="label653" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="element654" />
        <label xlink:type="resource" xlink:label="label654" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_en-US">Unrecognized Tax Benefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element654" xlink:to="label654" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="element655" />
        <label xlink:type="resource" xlink:label="label655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_en-US">Uncertain Tax Positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element655" xlink:to="label655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="element656" />
        <label xlink:type="resource" xlink:label="label656" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_en-US">OtherLiabilitiesTableTextBlock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element656" xlink:to="label656" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="element657" />
        <label xlink:type="resource" xlink:label="label657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_en-US">Other Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element657" xlink:to="label657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="element658" />
        <label xlink:type="resource" xlink:label="label658" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_en-US">Schedule Of Weighted Average Number Of Shares Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element658" xlink:to="label658" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="element659" />
        <label xlink:type="resource" xlink:label="label659" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_en-US">Weighted-Average Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element659" xlink:to="label659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="element660" />
        <label xlink:type="resource" xlink:label="label660" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_en-US">Schedule of Quarterly Financial Information</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element660" xlink:to="label660" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="element661" />
        <label xlink:type="resource" xlink:label="label661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_en-US">Unaudited Summarized Quarterly Financial Information</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element661" xlink:to="label661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="element662" />
        <label xlink:type="resource" xlink:label="label662" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_en-US">Schedule of Future Minimum Rental Payments for Operating Leases</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element662" xlink:to="label662" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="element663" />
        <label xlink:type="resource" xlink:label="label663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_en-US">Future Minimum Rental Commitments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element663" xlink:to="label663" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="element664" />
        <label xlink:type="resource" xlink:label="label664" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_en-US">Schedule of Maturities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element664" xlink:to="label664" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="element665" />
        <label xlink:type="resource" xlink:label="label665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_en-US">Maturities of Long-Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element665" xlink:to="label665" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="element666" />
        <label xlink:type="resource" xlink:label="label666" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_en-US">Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element666" xlink:to="label666" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="element667" />
        <label xlink:type="resource" xlink:label="label667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_en-US">Net Revenues and Operating Results</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element667" xlink:to="label667" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="element668" />
        <label xlink:type="resource" xlink:label="label668" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfDebtInstrumentsTextBlock_en-US">Schedule Of Debt Instruments [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element668" xlink:to="label668" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="element669" />
        <label xlink:type="resource" xlink:label="label669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfDebtInstrumentsTextBlock_en-US">Long-Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element669" xlink:to="label669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="element670" />
        <label xlink:type="resource" xlink:label="label670" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element670" xlink:to="label670" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="element671" />
        <label xlink:type="resource" xlink:label="label671" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_en-US">Equity Method Investee Name [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element671" xlink:to="label671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="element672" />
        <label xlink:type="resource" xlink:label="label672" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfGoodwillTable_en-US">Schedule of Goodwill [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element672" xlink:to="label672" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="element673" />
        <label xlink:type="resource" xlink:label="label673" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_en-US">Schedule Of Property Plant And Equipment [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element673" xlink:to="label673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="element674" />
        <label xlink:type="resource" xlink:label="label674" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_en-US">Schedule of Line of Credit Facilities [Table Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element674" xlink:to="label674" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="element675" />
        <label xlink:type="resource" xlink:label="label675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_en-US">Commitment Fee Under Credit Facilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element675" xlink:to="label675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="element676" />
        <label xlink:type="resource" xlink:label="label676" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_en-US">Schedule Of Segment Reporting Information By Segment [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element676" xlink:to="label676" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="element677" />
        <label xlink:type="resource" xlink:label="label677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_en-US">Operating Income of Reportable Segments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element677" xlink:to="label677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="element678" />
        <label xlink:type="resource" xlink:label="label678" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_en-US">Restructuring Costs [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element678" xlink:to="label678" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="element679" />
        <label xlink:type="resource" xlink:label="label679" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_en-US">Schedule Of Segment Reporting Information By Segment [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element679" xlink:to="label679" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="element680" />
        <label xlink:type="resource" xlink:label="label680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element680" xlink:to="label680" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="element681" />
        <label xlink:type="resource" xlink:label="label681" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_en-US">Schedule of Restructuring and Related Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element681" xlink:to="label681" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="element682" />
        <label xlink:type="resource" xlink:label="label682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_en-US">Exit Activity Reserves</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element682" xlink:to="label682" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="element683" />
        <label xlink:type="resource" xlink:label="label683" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_en-US">Schedule Of Valuation And Qualifying Accounts Disclosure Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element683" xlink:to="label683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="element684" />
        <label xlink:type="resource" xlink:label="label684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_en-US">VALUATION AND QUALIFYING ACCOUNTS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element684" xlink:to="label684" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="element685" />
        <label xlink:type="resource" xlink:label="label685" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentReportingDisclosureTextBlock_en-US">Segment Reporting Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element685" xlink:to="label685" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="element686" />
        <label xlink:type="resource" xlink:label="label686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SegmentReportingDisclosureTextBlock_en-US">SEGMENT INFORMATION</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element686" xlink:to="label686" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="element687" />
        <label xlink:type="resource" xlink:label="label687" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentDomain_en-US">Segment [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element687" xlink:to="label687" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="element688" />
        <label xlink:type="resource" xlink:label="label688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SegmentDomain_en-US">Segment [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element688" xlink:to="label688" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="element689" />
        <label xlink:type="resource" xlink:label="label689" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentReportingAbstract_en-US">Segment Reporting [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element689" xlink:to="label689" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="element690" />
        <label xlink:type="resource" xlink:label="label690" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentReportingInformationLineItems_en-US">Segment Reporting Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element690" xlink:to="label690" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="element691" />
        <label xlink:type="resource" xlink:label="label691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SegmentReportingInformationLineItems_en-US">Segment Reporting Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element691" xlink:to="label691" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="element692" />
        <label xlink:type="resource" xlink:label="label692" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation_en-US">Share Based Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element692" xlink:to="label692" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="element693" />
        <label xlink:type="resource" xlink:label="label693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensation_en-US">Non-cash compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element693" xlink:to="label693" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="element694" />
        <label xlink:type="resource" xlink:label="label694" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_en-US">Share Based Compensation Option And Incentive Plans Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element694" xlink:to="label694" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="element695" />
        <label xlink:type="resource" xlink:label="label695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_en-US">Share-Based Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element695" xlink:to="label695" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="element696" />
        <label xlink:type="resource" xlink:label="label696" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SignificantAccountingPoliciesTextBlock_en-US">Significant Accounting Policies [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element696" xlink:to="label696" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="element697" />
        <label xlink:type="resource" xlink:label="label697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SignificantAccountingPoliciesTextBlock_en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element697" xlink:to="label697" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="element698" />
        <label xlink:type="resource" xlink:label="label698" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StateAndLocalJurisdictionMember_en-US">State and Local Jurisdiction [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element698" xlink:to="label698" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="element699" />
        <label xlink:type="resource" xlink:label="label699" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementLineItems_en-US">Statement [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element699" xlink:to="label699" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="element700" />
        <label xlink:type="resource" xlink:label="label700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementLineItems_en-US">Statement [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element700" xlink:to="label700" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="element701" />
        <label xlink:type="resource" xlink:label="label701" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementEquityComponentsAxis_en-US">Statement Equity Components [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element701" xlink:to="label701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="element702" />
        <label xlink:type="resource" xlink:label="label702" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementOfCashFlowsAbstract_en-US">Statement Of Cash Flows [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element702" xlink:to="label702" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="element703" />
        <label xlink:type="resource" xlink:label="label703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementOfCashFlowsAbstract_en-US">Statement of Cash Flows [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element703" xlink:to="label703" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="element704" />
        <label xlink:type="resource" xlink:label="label704" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementTable_en-US">Statement [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element704" xlink:to="label704" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="element705" />
        <label xlink:type="resource" xlink:label="label705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementTable_en-US">Statement [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element705" xlink:to="label705" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="element706" />
        <label xlink:type="resource" xlink:label="label706" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementOfFinancialPositionAbstract_en-US">Statement Of Financial Position [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element706" xlink:to="label706" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="element707" />
        <label xlink:type="resource" xlink:label="label707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementOfFinancialPositionAbstract_en-US">Statement of Financial Position [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element707" xlink:to="label707" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="element708" />
        <label xlink:type="resource" xlink:label="label708" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementBusinessSegmentsAxis_en-US">Statement Business Segments [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element708" xlink:to="label708" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="element709" />
        <label xlink:type="resource" xlink:label="label709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementBusinessSegmentsAxis_en-US">Business Segments [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element709" xlink:to="label709" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="element710" />
        <label xlink:type="resource" xlink:label="label710" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockRepurchaseProgramAuthorizedAmount1_en-US">StockRepurchaseProgramAuthorizedAmount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element710" xlink:to="label710" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="element711" />
        <label xlink:type="resource" xlink:label="label711" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockRepurchaseProgramAuthorizedAmount1_en-US">Share Repurchase Program authorized amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element711" xlink:to="label711" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="element712" />
        <label xlink:type="resource" xlink:label="label712" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_en-US">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element712" xlink:to="label712" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="element713" />
        <label xlink:type="resource" xlink:label="label713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_en-US">Equity:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element713" xlink:to="label713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element714" />
        <label xlink:type="resource" xlink:label="label714" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element714" xlink:to="label714" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element715" />
        <label xlink:type="resource" xlink:label="label715" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Total equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element715" xlink:to="label715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element716" />
        <label xlink:type="resource" xlink:label="label716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Balance, Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element716" xlink:to="label716" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="element717" />
        <label xlink:type="resource" xlink:label="label717" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_en-US">Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element717" xlink:to="label717" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="element718" />
        <label xlink:type="resource" xlink:label="label718" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_StockholdersEquity_en-US">Total Amedisys, Inc. stockholders' equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element718" xlink:to="label718" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="element719" />
        <label xlink:type="resource" xlink:label="label719" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SubsequentEventsAbstract_en-US">Subsequent Event [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element719" xlink:to="label719" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="element720" />
        <label xlink:type="resource" xlink:label="label720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SubsequentEventsTextBlock_en-US">SUBSEQUENT EVENT</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element720" xlink:to="label720" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="element721" />
        <label xlink:type="resource" xlink:label="label721" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock_en-US">Subsequent Events [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element721" xlink:to="label721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="element722" />
        <label xlink:type="resource" xlink:label="label722" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SubsequentEventLineItems_en-US">Subsequent Event [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element722" xlink:to="label722" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="element723" />
        <label xlink:type="resource" xlink:label="label723" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SubsequentEventTable_en-US">Subsequent Event Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element723" xlink:to="label723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="element724" />
        <label xlink:type="resource" xlink:label="label724" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract_en-US">Supplemental Cash Flow Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element724" xlink:to="label724" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="element725" />
        <label xlink:type="resource" xlink:label="label725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SupplementalCashFlowInformationAbstract_en-US">Supplemental Disclosures of Cash Flow Information:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element725" xlink:to="label725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="element726" />
        <label xlink:type="resource" xlink:label="label726" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TaxCreditCarryforwardValuationAllowance_en-US">Tax Credit Carryforward Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element726" xlink:to="label726" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="element727" />
        <label xlink:type="resource" xlink:label="label727" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TaxCreditCarryforwardValuationAllowance_en-US">Tax credit carryforwards valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element727" xlink:to="label727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="element728" />
        <label xlink:type="resource" xlink:label="label728" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TradeAndOtherAccountsReceivablePolicy_en-US">Trade And Other Accounts Receivable Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element728" xlink:to="label728" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="element729" />
        <label xlink:type="resource" xlink:label="label729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TradeAndOtherAccountsReceivablePolicy_en-US">Patient Accounts Receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element729" xlink:to="label729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="element730" />
        <label xlink:type="resource" xlink:label="label730" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockAcquiredAverageCostPerShare_en-US">Treasury Stock Acquired Average Cost Per Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element730" xlink:to="label730" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="element731" />
        <label xlink:type="resource" xlink:label="label731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockAcquiredAverageCostPerShare_en-US">Treasury Stock Weighted Average Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element731" xlink:to="label731" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="element732" />
        <label xlink:type="resource" xlink:label="label732" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockShares_en-US">Treasury Stock Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element732" xlink:to="label732" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="element733" />
        <label xlink:type="resource" xlink:label="label733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockShares_en-US">Treasury Stock at cost, shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element733" xlink:to="label733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="element734" />
        <label xlink:type="resource" xlink:label="label734" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockTextBlock_en-US">TreasuryStockTextBlock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element734" xlink:to="label734" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="element735" />
        <label xlink:type="resource" xlink:label="label735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockTextBlock_en-US">SHARE REPURCHASE PROGRAM</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element735" xlink:to="label735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="element736" />
        <label xlink:type="resource" xlink:label="label736" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockValueAcquiredCostMethod_en-US">Treasury Stock Value Acquired Cost Method</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element736" xlink:to="label736" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="element737" />
        <label xlink:type="resource" xlink:label="label737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockValueAcquiredCostMethod_en-US">Shares repurchased</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element737" xlink:to="label737" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="element738" />
        <label xlink:type="resource" xlink:label="label738" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockSharesAcquired_en-US">Treasury Stock Shares Acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element738" xlink:to="label738" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="element739" />
        <label xlink:type="resource" xlink:label="label739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockSharesAcquired_en-US">Treasury Stock Shares Repurchased</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element739" xlink:to="label739" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="element740" />
        <label xlink:type="resource" xlink:label="label740" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockValue_en-US">Treasury Stock Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element740" xlink:to="label740" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="element741" />
        <label xlink:type="resource" xlink:label="label741" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_TreasuryStockValue_en-US">Treasury Stock at cost 1,671,725 and 1,656,362 shares of common stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element741" xlink:to="label741" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="element742" />
        <label xlink:type="resource" xlink:label="label742" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TypeOfRestructuringDomain_en-US">Type of Restructuring [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element742" xlink:to="label742" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="element743" />
        <label xlink:type="resource" xlink:label="label743" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TypeOfAdoptionMember_en-US">Type of Adoption [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element743" xlink:to="label743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="element744" />
        <label xlink:type="resource" xlink:label="label744" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnamortizedDebtIssuanceExpense_en-US">Unamortized Debt Issuance Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element744" xlink:to="label744" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="element745" />
        <label xlink:type="resource" xlink:label="label745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnamortizedDebtIssuanceExpense_en-US">Unamortized debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element745" xlink:to="label745" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="element746" />
        <label xlink:type="resource" xlink:label="label746" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_UnamortizedDebtIssuanceExpense_en-US">Deferred debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element746" xlink:to="label746" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="element747" />
        <label xlink:type="resource" xlink:label="label747" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_en-US">nrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element747" xlink:to="label747" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="element748" />
        <label xlink:type="resource" xlink:label="label748" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_en-US">Additions for tax positions of prior years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element748" xlink:to="label748" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="element749" />
        <label xlink:type="resource" xlink:label="label749" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_en-US">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element749" xlink:to="label749" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="element750" />
        <label xlink:type="resource" xlink:label="label750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_en-US">Additions for tax positions related to current year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element750" xlink:to="label750" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="element751" />
        <label xlink:type="resource" xlink:label="label751" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_en-US">Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element751" xlink:to="label751" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="element752" />
        <label xlink:type="resource" xlink:label="label752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_en-US">Lapse of statute of limitations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element752" xlink:to="label752" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="element753" />
        <label xlink:type="resource" xlink:label="label753" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_en-US">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element753" xlink:to="label753" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="element754" />
        <label xlink:type="resource" xlink:label="label754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_en-US">Interest and penalties recognized related to uncertain income tax positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element754" xlink:to="label754" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="element755" />
        <label xlink:type="resource" xlink:label="label755" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_en-US">UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element755" xlink:to="label755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="element756" />
        <label xlink:type="resource" xlink:label="label756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_en-US">Interest and penalties accrued related to uncertain income tax positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element756" xlink:to="label756" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="element757" />
        <label xlink:type="resource" xlink:label="label757" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_en-US">Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element757" xlink:to="label757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="element758" />
        <label xlink:type="resource" xlink:label="label758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_en-US">Settlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element758" xlink:to="label758" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element759" />
        <label xlink:type="resource" xlink:label="label759" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefits_en-US">UnrecognizedTaxBenefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element759" xlink:to="label759" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element760" />
        <label xlink:type="resource" xlink:label="label760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefits_en-US">Uncertain tax benefits accrued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element760" xlink:to="label760" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element761" />
        <label xlink:type="resource" xlink:label="label761" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_UnrecognizedTaxBenefits_en-US">Uncertain tax benefits accrued, beginning balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element761" xlink:to="label761" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element762" />
        <label xlink:type="resource" xlink:label="label762" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_UnrecognizedTaxBenefits_en-US">Uncertain tax benefits accrued, ending balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element762" xlink:to="label762" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="element763" />
        <label xlink:type="resource" xlink:label="label763" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_en-US">UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element763" xlink:to="label763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="element764" />
        <label xlink:type="resource" xlink:label="label764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_en-US">Reductions for tax positions of prior years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element764" xlink:to="label764" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="element765" />
        <label xlink:type="resource" xlink:label="label765" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UseOfEstimates_en-US">Use Of Estimates</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element765" xlink:to="label765" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="element766" />
        <label xlink:type="resource" xlink:label="label766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UseOfEstimates_en-US">Use of Estimates</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element766" xlink:to="label766" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="element767" />
        <label xlink:type="resource" xlink:label="label767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_en-US">Net change in total valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element767" xlink:to="label767" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="element768" />
        <label xlink:type="resource" xlink:label="label768" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_en-US">ValuationAllowanceDeferredTaxAssetChangeInAmount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element768" xlink:to="label768" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="element769" />
        <label xlink:type="resource" xlink:label="label769" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAndQualifyingAccountsAbstract_en-US">Valuation And Qualifying Accounts [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element769" xlink:to="label769" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VehiclesMember" xlink:label="element770" />
        <label xlink:type="resource" xlink:label="label770" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_VehiclesMember_en-US">Vehicles [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element770" xlink:to="label770" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="element771" />
        <label xlink:type="resource" xlink:label="label771" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_en-US">Weighted Average Number Of Diluted Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element771" xlink:to="label771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="element772" />
        <label xlink:type="resource" xlink:label="label772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_en-US">Weighted average shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element772" xlink:to="label772" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="element773" />
        <label xlink:type="resource" xlink:label="label773" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_en-US">Weighted average number of shares outstanding - diluted</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element773" xlink:to="label773" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="element774" />
        <label xlink:type="resource" xlink:label="label774" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_en-US">Weighted Average Number Of Shares Outstanding Basic</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element774" xlink:to="label774" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="element775" />
        <label xlink:type="resource" xlink:label="label775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_en-US">Weighted average number of shares outstanding - basic</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element775" xlink:to="label775" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="element776" />
        <label xlink:type="resource" xlink:label="label776" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_en-US">Weighted average shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element776" xlink:to="label776" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="element777" />
        <label xlink:type="resource" xlink:label="label777" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_AmendmentFlag_en-US">Amendment Flag</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element777" xlink:to="label777" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="element778" />
        <label xlink:type="resource" xlink:label="label778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_AmendmentFlag_en-US">Amendment Flag</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element778" xlink:to="label778" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="element779" />
        <label xlink:type="resource" xlink:label="label779" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate_en-US">Current Fiscal Year End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element779" xlink:to="label779" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="element780" />
        <label xlink:type="resource" xlink:label="label780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_CurrentFiscalYearEndDate_en-US">Current Fiscal Year End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element780" xlink:to="label780" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="element781" />
        <label xlink:type="resource" xlink:label="label781" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentInformationLineItems_en-US">Document Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element781" xlink:to="label781" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="element782" />
        <label xlink:type="resource" xlink:label="label782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentInformationLineItems_en-US">Document Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element782" xlink:to="label782" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="element783" />
        <label xlink:type="resource" xlink:label="label783" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate_en-US">Document Period End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element783" xlink:to="label783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="element784" />
        <label xlink:type="resource" xlink:label="label784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentPeriodEndDate_en-US">Document Period End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element784" xlink:to="label784" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="element785" />
        <label xlink:type="resource" xlink:label="label785" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntitiesTable_en-US">Entities [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element785" xlink:to="label785" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="element786" />
        <label xlink:type="resource" xlink:label="label786" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntitiesTable_en-US">Entities [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element786" xlink:to="label786" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="element787" />
        <label xlink:type="resource" xlink:label="label787" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityDomain_en-US">Entity [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element787" xlink:to="label787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="element788" />
        <label xlink:type="resource" xlink:label="label788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityDomain_en-US">Entity [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element788" xlink:to="label788" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="element789" />
        <label xlink:type="resource" xlink:label="label789" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_TradingSymbol_en-US">Trading Symbol</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element789" xlink:to="label789" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="element790" />
        <label xlink:type="resource" xlink:label="label790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_TradingSymbol_en-US">Trading Symbol</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element790" xlink:to="label790" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="element791" />
        <label xlink:type="resource" xlink:label="label791" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityWellKnownSeasonedIssuer_en-US">Entity Well-known Seasoned Issuer</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element791" xlink:to="label791" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="element792" />
        <label xlink:type="resource" xlink:label="label792" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityVoluntaryFilers_en-US">Entity Voluntary Filers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element792" xlink:to="label792" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="element793" />
        <label xlink:type="resource" xlink:label="label793" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityCurrentReportingStatus_en-US">Entity Current Reporting Status</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element793" xlink:to="label793" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="element794" />
        <label xlink:type="resource" xlink:label="label794" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityFilerCategory_en-US">Entity Filer Category</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element794" xlink:to="label794" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="element795" />
        <label xlink:type="resource" xlink:label="label795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityFilerCategory_en-US">Entity Filer Category</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element795" xlink:to="label795" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="element796" />
        <label xlink:type="resource" xlink:label="label796" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityPublicFloat_en-US">Entity Public Float</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element796" xlink:to="label796" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="element797" />
        <label xlink:type="resource" xlink:label="label797" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityRegistrantName_en-US">Entity Registrant Name</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element797" xlink:to="label797" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="element798" />
        <label xlink:type="resource" xlink:label="label798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityRegistrantName_en-US">Entity Registrant Name</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element798" xlink:to="label798" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="element799" />
        <label xlink:type="resource" xlink:label="label799" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityCentralIndexKey_en-US">Entity Central Index Key</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element799" xlink:to="label799" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="element800" />
        <label xlink:type="resource" xlink:label="label800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityCentralIndexKey_en-US">Entity Central Index Key</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element800" xlink:to="label800" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="element801" />
        <label xlink:type="resource" xlink:label="label801" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding_en-US">Entity Common Stock Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element801" xlink:to="label801" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="element802" />
        <label xlink:type="resource" xlink:label="label802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityCommonStockSharesOutstanding_en-US">Entity Common Stock, Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element802" xlink:to="label802" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="element803" />
        <label xlink:type="resource" xlink:label="label803" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus_en-US">Document Fiscal Year Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element803" xlink:to="label803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="element804" />
        <label xlink:type="resource" xlink:label="label804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentFiscalYearFocus_en-US">Document Fiscal Year Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element804" xlink:to="label804" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="element805" />
        <label xlink:type="resource" xlink:label="label805" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus_en-US">Document Fiscal Period Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element805" xlink:to="label805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="element806" />
        <label xlink:type="resource" xlink:label="label806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentFiscalPeriodFocus_en-US">Document Fiscal Period Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element806" xlink:to="label806" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="element807" />
        <label xlink:type="resource" xlink:label="label807" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_LegalEntityAxis_en-US">Legal Entity [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element807" xlink:to="label807" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="element808" />
        <label xlink:type="resource" xlink:label="label808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_LegalEntityAxis_en-US">Legal Entity [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element808" xlink:to="label808" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="element809" />
        <label xlink:type="resource" xlink:label="label809" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentType_en-US">Document Type</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element809" xlink:to="label809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="element810" />
        <label xlink:type="resource" xlink:label="label810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentType_en-US">Document Type</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element810" xlink:to="label810" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="element811" />
        <label xlink:type="resource" xlink:label="label811" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearAxis_en-US">Cap Year [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element811" xlink:to="label811" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="element812" />
        <label xlink:type="resource" xlink:label="label812" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearAxis_en-US">Cap Year [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element812" xlink:to="label812" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="element813" />
        <label xlink:type="resource" xlink:label="label813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearAxis_en-US">Cap Year [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element813" xlink:to="label813" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="element814" />
        <label xlink:type="resource" xlink:label="label814" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearDomain_en-US">Cap Year [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element814" xlink:to="label814" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="element815" />
        <label xlink:type="resource" xlink:label="label815" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearDomain_en-US">Cap Year [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element815" xlink:to="label815" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="element816" />
        <label xlink:type="resource" xlink:label="label816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearDomain_en-US">Cap Year [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element816" xlink:to="label816" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="element817" />
        <label xlink:type="resource" xlink:label="label817" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CashDistributionToNoncontrollingInterest_en-US">Payment of dividends or other distributions to noncontrolling interest holders.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element817" xlink:to="label817" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="element818" />
        <label xlink:type="resource" xlink:label="label818" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CashDistributionToNoncontrollingInterest_en-US">Cash Distribution To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element818" xlink:to="label818" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="element819" />
        <label xlink:type="resource" xlink:label="label819" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_amed_CashDistributionToNoncontrollingInterest_en-US">Non-controlling interest distribution</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element819" xlink:to="label819" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="element820" />
        <label xlink:type="resource" xlink:label="label820" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CmsTherapyAssessmentRequirementIntervalMinimum_en-US">Description of the number of days in which a therapy assessment is required during a therapy patient's course of treatment.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element820" xlink:to="label820" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="element821" />
        <label xlink:type="resource" xlink:label="label821" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CmsTherapyAssessmentRequirementIntervalMinimum_en-US">Cms Therapy Assessment Requirement Interval Minimum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element821" xlink:to="label821" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="element822" />
        <label xlink:type="resource" xlink:label="label822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CmsTherapyAssessmentRequirementIntervalMinimum_en-US">CMS therapy assessment requirement interval minimum, days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element822" xlink:to="label822" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="element823" />
        <label xlink:type="resource" xlink:label="label823" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CommimentsAndContingenciesTable_en-US">Commiments And Contingencies [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element823" xlink:to="label823" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="element824" />
        <label xlink:type="resource" xlink:label="label824" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CommimentsAndContingenciesTable_en-US">Commiments And Contingencies [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element824" xlink:to="label824" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="element825" />
        <label xlink:type="resource" xlink:label="label825" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CommimentsAndContingenciesTable_en-US">Commiments And Contingencies [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element825" xlink:to="label825" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="element826" />
        <label xlink:type="resource" xlink:label="label826" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CommitmentsAndContingenciesDisclosureLineItems_en-US">Commitments and Contingencies Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element826" xlink:to="label826" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="element827" />
        <label xlink:type="resource" xlink:label="label827" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CommitmentsAndContingenciesDisclosureLineItems_en-US">Commitments And Contingencies Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element827" xlink:to="label827" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="element828" />
        <label xlink:type="resource" xlink:label="label828" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CommitmentsAndContingenciesDisclosureLineItems_en-US">Commitments and Contingencies Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element828" xlink:to="label828" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="element829" />
        <label xlink:type="resource" xlink:label="label829" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DepreciationAndAmortizationForContinuingOperations_en-US">Depreciation And Amortization For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element829" xlink:to="label829" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="element830" />
        <label xlink:type="resource" xlink:label="label830" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DepreciationAndAmortizationForContinuingOperations_en-US">Depreciation And Amortization For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element830" xlink:to="label830" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="element831" />
        <label xlink:type="resource" xlink:label="label831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DepreciationAndAmortizationForContinuingOperations_en-US">Depreciation and amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element831" xlink:to="label831" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="element832" />
        <label xlink:type="resource" xlink:label="label832" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_en-US">Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element832" xlink:to="label832" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="element833" />
        <label xlink:type="resource" xlink:label="label833" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_en-US">Disclosure Nature Of Operations Consolidation And Presentation Of Financial Statements Additional Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element833" xlink:to="label833" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="element834" />
        <label xlink:type="resource" xlink:label="label834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_en-US">Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element834" xlink:to="label834" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="element835" />
        <label xlink:type="resource" xlink:label="label835" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DocumentDocumentandEntityInformationAbstract_en-US">Document - Document and Entity Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element835" xlink:to="label835" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="element836" />
        <label xlink:type="resource" xlink:label="label836" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DocumentDocumentandEntityInformationAbstract_en-US">Document Documentand Entity Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element836" xlink:to="label836" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="element837" />
        <label xlink:type="resource" xlink:label="label837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DocumentDocumentandEntityInformationAbstract_en-US">Document - Document and Entity Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element837" xlink:to="label837" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="element838" />
        <label xlink:type="resource" xlink:label="label838" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EpisodeOfCareAsEpisodicBasedRevenue_en-US">Description containing the number of days in a home health episode of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element838" xlink:to="label838" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="element839" />
        <label xlink:type="resource" xlink:label="label839" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EpisodeOfCareAsEpisodicBasedRevenue_en-US">Episode Of Care As Episodic Based Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element839" xlink:to="label839" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="element840" />
        <label xlink:type="resource" xlink:label="label840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EpisodeOfCareAsEpisodicBasedRevenue_en-US">Episode of care as episodic-based revenue, days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element840" xlink:to="label840" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="element841" />
        <label xlink:type="resource" xlink:label="label841" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EpisodesInProgressThatBeginDuringReportingPeriod_en-US">Description containing the number of days in an episode of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element841" xlink:to="label841" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="element842" />
        <label xlink:type="resource" xlink:label="label842" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EpisodesInProgressThatBeginDuringReportingPeriod_en-US">Episodes In Progress That Begin During Reporting Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element842" xlink:to="label842" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="element843" />
        <label xlink:type="resource" xlink:label="label843" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EpisodesInProgressThatBeginDuringReportingPeriod_en-US">Episodes in progress that begin during reporting period, days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element843" xlink:to="label843" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="element844" />
        <label xlink:type="resource" xlink:label="label844" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element844" xlink:to="label844" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="element845" />
        <label xlink:type="resource" xlink:label="label845" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element845" xlink:to="label845" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="element846" />
        <label xlink:type="resource" xlink:label="label846" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_en-US">Estimated amounts due back to Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element846" xlink:to="label846" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableMember" xlink:label="element847" />
        <label xlink:type="resource" xlink:label="label847" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FavorableMember_en-US">Favorable [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element847" xlink:to="label847" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableMember" xlink:label="element848" />
        <label xlink:type="resource" xlink:label="label848" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FavorableMember_en-US">Favorable [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element848" xlink:to="label848" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableMember" xlink:label="element849" />
        <label xlink:type="resource" xlink:label="label849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FavorableMember_en-US">Favorable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element849" xlink:to="label849" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="element850" />
        <label xlink:type="resource" xlink:label="label850" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FinancialInstrumentDetailsTextBlock_en-US">Financial instrument details, table.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element850" xlink:to="label850" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="element851" />
        <label xlink:type="resource" xlink:label="label851" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FinancialInstrumentDetailsTextBlock_en-US">Financial Instrument Details [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element851" xlink:to="label851" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="element852" />
        <label xlink:type="resource" xlink:label="label852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FinancialInstrumentDetailsTextBlock_en-US">Financial Instruments Where Carrying Value and Fair Value Differ</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element852" xlink:to="label852" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="element853" />
        <label xlink:type="resource" xlink:label="label853" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FirstThresholdOfTherapyServicesRequired_en-US">Description containing the number of visits related to the first threshold of therapy services required.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element853" xlink:to="label853" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="element854" />
        <label xlink:type="resource" xlink:label="label854" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FirstThresholdOfTherapyServicesRequired_en-US">First Threshold Of Therapy Services Required</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element854" xlink:to="label854" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="element855" />
        <label xlink:type="resource" xlink:label="label855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FirstThresholdOfTherapyServicesRequired_en-US">First threshold of therapy services required, visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element855" xlink:to="label855" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FixedChargeCoverageRatio" xlink:label="element856" />
        <label xlink:type="resource" xlink:label="label856" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FixedChargeCoverageRatio_en-US">Ratio of adjusted earnings before interest, taxes , depreciation and amortization plus rent expense to certain fixed charges (interest expense, required principal payments and capital expenditures).</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element856" xlink:to="label856" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FixedChargeCoverageRatio" xlink:label="element857" />
        <label xlink:type="resource" xlink:label="label857" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FixedChargeCoverageRatio_en-US">Fixed Charge Coverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element857" xlink:to="label857" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FixedChargeCoverageRatio" xlink:label="element858" />
        <label xlink:type="resource" xlink:label="label858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FixedChargeCoverageRatio_en-US">Fixed charge coverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element858" xlink:to="label858" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="element859" />
        <label xlink:type="resource" xlink:label="label859" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_GeneralAndAdministrativeExpenseSegment_en-US">The aggregate total of expenses of managing and administering the affairs of each segment of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element859" xlink:to="label859" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="element860" />
        <label xlink:type="resource" xlink:label="label860" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GeneralAndAdministrativeExpenseSegment_en-US">General And Administrative Expense Segment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element860" xlink:to="label860" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="element861" />
        <label xlink:type="resource" xlink:label="label861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_GeneralAndAdministrativeExpenseSegment_en-US">General and administrative expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element861" xlink:to="label861" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="element862" />
        <label xlink:type="resource" xlink:label="label862" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HealthInsuranceRetentionLimit_en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element862" xlink:to="label862" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="element863" />
        <label xlink:type="resource" xlink:label="label863" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HealthInsuranceRetentionLimit_en-US">Health Insurance Retention Limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element863" xlink:to="label863" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="element864" />
        <label xlink:type="resource" xlink:label="label864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HealthInsuranceRetentionLimit_en-US">Health insurance retention limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element864" xlink:to="label864" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="element865" />
        <label xlink:type="resource" xlink:label="label865" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HistoricalCollectionRateFromMedicare_en-US">Historical collection rate from Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element865" xlink:to="label865" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="element866" />
        <label xlink:type="resource" xlink:label="label866" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HistoricalCollectionRateFromMedicare_en-US">Historical Collection Rate From Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element866" xlink:to="label866" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="element867" />
        <label xlink:type="resource" xlink:label="label867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HistoricalCollectionRateFromMedicare_en-US">Historical collection rate from Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element867" xlink:to="label867" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="element868" />
        <label xlink:type="resource" xlink:label="label868" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HomeHealthMember_en-US">Home Health [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element868" xlink:to="label868" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="element869" />
        <label xlink:type="resource" xlink:label="label869" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HomeHealthMember_en-US">Home Health [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element869" xlink:to="label869" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="element870" />
        <label xlink:type="resource" xlink:label="label870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HomeHealthMember_en-US">Home Health</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element870" xlink:to="label870" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="element871" />
        <label xlink:type="resource" xlink:label="label871" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element871" xlink:to="label871" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="element872" />
        <label xlink:type="resource" xlink:label="label872" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element872" xlink:to="label872" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="element873" />
        <label xlink:type="resource" xlink:label="label873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_en-US">Hospice Medicare revenue rate accounted for routine care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element873" xlink:to="label873" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="element874" />
        <label xlink:type="resource" xlink:label="label874" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HospiceMember_en-US">Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element874" xlink:to="label874" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="element875" />
        <label xlink:type="resource" xlink:label="label875" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceMember_en-US">Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element875" xlink:to="label875" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="element876" />
        <label xlink:type="resource" xlink:label="label876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HospiceMember_en-US">Hospice care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element876" xlink:to="label876" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="element877" />
        <label xlink:type="resource" xlink:label="label877" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InterestRateOnNotesPayableToBank_en-US">Interest rate for the amounts borrowed under the Term Loan, including the terms and method for determining the interest rate at the balance sheet date.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element877" xlink:to="label877" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="element878" />
        <label xlink:type="resource" xlink:label="label878" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InterestRateOnNotesPayableToBank_en-US">Interest Rate On Notes Payable To Bank</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element878" xlink:to="label878" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="element879" />
        <label xlink:type="resource" xlink:label="label879" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InterestRateOnNotesPayableToBank_en-US">Eurodollar Rate plus the applicable percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element879" xlink:to="label879" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="element880" />
        <label xlink:type="resource" xlink:label="label880" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_en-US">Description containing the visit threshold for a low utilization payment adjustment.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element880" xlink:to="label880" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="element881" />
        <label xlink:type="resource" xlink:label="label881" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_en-US">Low Utilization Payment Adjustment Number Of Visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element881" xlink:to="label881" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="element882" />
        <label xlink:type="resource" xlink:label="label882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_en-US">Low utilization payment adjustment, maximum number of visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element882" xlink:to="label882" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassproAndHospiceMember" xlink:label="element883" />
        <label xlink:type="resource" xlink:label="label883" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MassproAndHospiceMember_en-US">MassPro and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element883" xlink:to="label883" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassproAndHospiceMember" xlink:label="element884" />
        <label xlink:type="resource" xlink:label="label884" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MassproAndHospiceMember_en-US">Masspro And Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element884" xlink:to="label884" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassproAndHospiceMember" xlink:label="element885" />
        <label xlink:type="resource" xlink:label="label885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MassproAndHospiceMember_en-US">Masspro and Hospice</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element885" xlink:to="label885" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="element886" />
        <label xlink:type="resource" xlink:label="label886" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element886" xlink:to="label886" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="element887" />
        <label xlink:type="resource" xlink:label="label887" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element887" xlink:to="label887" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="element888" />
        <label xlink:type="resource" xlink:label="label888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element888" xlink:to="label888" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="element889" />
        <label xlink:type="resource" xlink:label="label889" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_en-US">Description containing the number of days from the start of the episode in which the final bill must be submitted to Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element889" xlink:to="label889" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="element890" />
        <label xlink:type="resource" xlink:label="label890" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_en-US">Maximum Days To Submit Final Bill From Start Of Episode</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element890" xlink:to="label890" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="element891" />
        <label xlink:type="resource" xlink:label="label891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_en-US">Maximum days to submit final bill from the start of episode</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element891" xlink:to="label891" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="element892" />
        <label xlink:type="resource" xlink:label="label892" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximusFederalServicesAndHospiceMember_en-US">MAXIMUS Federal Services and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element892" xlink:to="label892" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="element893" />
        <label xlink:type="resource" xlink:label="label893" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximusFederalServicesAndHospiceMember_en-US">Maximus Federal Services And Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element893" xlink:to="label893" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="element894" />
        <label xlink:type="resource" xlink:label="label894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximusFederalServicesAndHospiceMember_en-US">Maximus Federal Services And Hospice</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element894" xlink:to="label894" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesMember" xlink:label="element895" />
        <label xlink:type="resource" xlink:label="label895" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximusFederalServicesMember_en-US">MAXIMUS Federal Services [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element895" xlink:to="label895" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesMember" xlink:label="element896" />
        <label xlink:type="resource" xlink:label="label896" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximusFederalServicesMember_en-US">Maximus Federal Services [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element896" xlink:to="label896" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesMember" xlink:label="element897" />
        <label xlink:type="resource" xlink:label="label897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximusFederalServicesMember_en-US">Maximus Federal Services</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element897" xlink:to="label897" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="element898" />
        <label xlink:type="resource" xlink:label="label898" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MedicareAdministrativeContractorMacMember_en-US">Medicare Administrative Contractor (MAC) [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element898" xlink:to="label898" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="element899" />
        <label xlink:type="resource" xlink:label="label899" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MedicareAdministrativeContractorMacMember_en-US">Medicare Administrative Contractor Mac [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element899" xlink:to="label899" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="element900" />
        <label xlink:type="resource" xlink:label="label900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MedicareAdministrativeContractorMacMember_en-US">Medicare Administrative Contractor (MAC)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element900" xlink:to="label900" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="element901" />
        <label xlink:type="resource" xlink:label="label901" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_en-US">The number of days required before a patient accounts receivable must be outstanding to be fully reserved.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element901" xlink:to="label901" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="element902" />
        <label xlink:type="resource" xlink:label="label902" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_en-US">Minimum Days Accounts Receivable Outstanding Fully Reserved</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element902" xlink:to="label902" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="element903" />
        <label xlink:type="resource" xlink:label="label903" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_en-US">Minimum days for accounts receivable outstanding to be fully reserved</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element903" xlink:to="label903" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="element904" />
        <label xlink:type="resource" xlink:label="label904" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumPercentOwnershipForControllingInterestPercent_en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element904" xlink:to="label904" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="element905" />
        <label xlink:type="resource" xlink:label="label905" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumPercentOwnershipForControllingInterestPercent_en-US">Minimum Percent Ownership For Controlling Interest Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element905" xlink:to="label905" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="element906" />
        <label xlink:type="resource" xlink:label="label906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MinimumPercentOwnershipForControllingInterestPercent_en-US">Minimum percent ownership for controlling interest percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element906" xlink:to="label906" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NonVestedStockAndStockUnits" xlink:label="element907" />
        <label xlink:type="resource" xlink:label="label907" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NonVestedStockAndStockUnits_en-US">Non vested stock and stock units.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element907" xlink:to="label907" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NonVestedStockAndStockUnits" xlink:label="element908" />
        <label xlink:type="resource" xlink:label="label908" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NonVestedStockAndStockUnits_en-US">Non Vested Stock And Stock Units</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element908" xlink:to="label908" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NonVestedStockAndStockUnits" xlink:label="element909" />
        <label xlink:type="resource" xlink:label="label909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NonVestedStockAndStockUnits_en-US">Non-vested stock and stock units</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element909" xlink:to="label909" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersClosed" xlink:label="element910" />
        <label xlink:type="resource" xlink:label="label910" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersClosed_en-US">Number of operating care centers that were closed during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element910" xlink:to="label910" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersClosed" xlink:label="element911" />
        <label xlink:type="resource" xlink:label="label911" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersClosed_en-US">Number Of Care Centers Closed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element911" xlink:to="label911" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersClosed" xlink:label="element912" />
        <label xlink:type="resource" xlink:label="label912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersClosed_en-US">Number of care centers closed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element912" xlink:to="label912" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="element913" />
        <label xlink:type="resource" xlink:label="label913" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersConsolidated_en-US">Number of operating care centers that were consolidated with care centers servicing the same market during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element913" xlink:to="label913" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="element914" />
        <label xlink:type="resource" xlink:label="label914" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersConsolidated_en-US">Number Of Care Centers Consolidated</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element914" xlink:to="label914" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="element915" />
        <label xlink:type="resource" xlink:label="label915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersConsolidated_en-US">Number of care centers consolidated</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element915" xlink:to="label915" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersExited" xlink:label="element916" />
        <label xlink:type="resource" xlink:label="label916" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersExited_en-US">Number of Care Centers that were exited during the period though closure, consolidation or discontinued start-up process.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element916" xlink:to="label916" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersExited" xlink:label="element917" />
        <label xlink:type="resource" xlink:label="label917" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersExited_en-US">Number Of Care Centers Exited</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element917" xlink:to="label917" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersExited" xlink:label="element918" />
        <label xlink:type="resource" xlink:label="label918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersExited_en-US">Number of care centers exited</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element918" xlink:to="label918" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="element919" />
        <label xlink:type="resource" xlink:label="label919" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfClaimsSubmittedBySubsidiary_en-US">Number of claims submitted by subsidiary.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element919" xlink:to="label919" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="element920" />
        <label xlink:type="resource" xlink:label="label920" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfClaimsSubmittedBySubsidiary_en-US">Number Of Claims Submitted By Subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element920" xlink:to="label920" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="element921" />
        <label xlink:type="resource" xlink:label="label921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfClaimsSubmittedBySubsidiary_en-US">Number of claims submitted by subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element921" xlink:to="label921" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="element922" />
        <label xlink:type="resource" xlink:label="label922" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfRedeterminationDecisions_en-US">Number of redetermination decisions.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element922" xlink:to="label922" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="element923" />
        <label xlink:type="resource" xlink:label="label923" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfRedeterminationDecisions_en-US">Number Of Redetermination Decisions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element923" xlink:to="label923" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="element924" />
        <label xlink:type="resource" xlink:label="label924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfRedeterminationDecisions_en-US">Number of redetermination decisions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element924" xlink:to="label924" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="element925" />
        <label xlink:type="resource" xlink:label="label925" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfPatientReceivablesOutstanding_en-US">Percentage of patient receivables outstanding.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element925" xlink:to="label925" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="element926" />
        <label xlink:type="resource" xlink:label="label926" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfPatientReceivablesOutstanding_en-US">Percentage Of Patient Receivables Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element926" xlink:to="label926" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="element927" />
        <label xlink:type="resource" xlink:label="label927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfPatientReceivablesOutstanding_en-US">Percentage of patient receivables outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element927" xlink:to="label927" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="element928" />
        <label xlink:type="resource" xlink:label="label928" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfTotalReimbursementOfOutlierPayment_en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element928" xlink:to="label928" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="element929" />
        <label xlink:type="resource" xlink:label="label929" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfTotalReimbursementOfOutlierPayment_en-US">Percentage Of Total Reimbursement Of Outlier Payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element929" xlink:to="label929" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="element930" />
        <label xlink:type="resource" xlink:label="label930" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfTotalReimbursementOfOutlierPayment_en-US">Percentage of total reimbursement of outlier payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element930" xlink:to="label930" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="element931" />
        <label xlink:type="resource" xlink:label="label931" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_en-US">Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element931" xlink:to="label931" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="element932" />
        <label xlink:type="resource" xlink:label="label932" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_en-US">Portion Of Patient Accounts Receivable Derived From Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element932" xlink:to="label932" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="element933" />
        <label xlink:type="resource" xlink:label="label933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_en-US">Portion of accounts receivable derived from Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element933" xlink:to="label933" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="element934" />
        <label xlink:type="resource" xlink:label="label934" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProfessionalLiabilityInsuranceRetentionLimit_en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element934" xlink:to="label934" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="element935" />
        <label xlink:type="resource" xlink:label="label935" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProfessionalLiabilityInsuranceRetentionLimit_en-US">Professional Liability Insurance Retention Limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element935" xlink:to="label935" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="element936" />
        <label xlink:type="resource" xlink:label="label936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProfessionalLiabilityInsuranceRetentionLimit_en-US">Professional liability insurance retention limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element936" xlink:to="label936" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="element937" />
        <label xlink:type="resource" xlink:label="label937" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProvisionForDoubtfulAccountsForContinuingOperations_en-US">Provision For Doubtful Accounts For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element937" xlink:to="label937" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="element938" />
        <label xlink:type="resource" xlink:label="label938" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProvisionForDoubtfulAccountsForContinuingOperations_en-US">Provision For Doubtful Accounts For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element938" xlink:to="label938" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="element939" />
        <label xlink:type="resource" xlink:label="label939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProvisionForDoubtfulAccountsForContinuingOperations_en-US">Provision for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element939" xlink:to="label939" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="element940" />
        <label xlink:type="resource" xlink:label="label940" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial episode of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element940" xlink:to="label940" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="element941" />
        <label xlink:type="resource" xlink:label="label941" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_en-US">Rate Of Request For Anticipated Payment Submitted For Initial Episode Of Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element941" xlink:to="label941" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="element942" />
        <label xlink:type="resource" xlink:label="label942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_en-US">Rate of request for anticipated payment submitted for the initial episode of care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element942" xlink:to="label942" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="element943" />
        <label xlink:type="resource" xlink:label="label943" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element943" xlink:to="label943" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="element944" />
        <label xlink:type="resource" xlink:label="label944" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element944" xlink:to="label944" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="element945" />
        <label xlink:type="resource" xlink:label="label945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element945" xlink:to="label945" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="element946" />
        <label xlink:type="resource" xlink:label="label946" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_en-US">Recovery amount of the overpayment made to the subsidiary.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element946" xlink:to="label946" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="element947" />
        <label xlink:type="resource" xlink:label="label947" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_en-US">Recovery Amount Of Overpayment Made To Subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element947" xlink:to="label947" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="element948" />
        <label xlink:type="resource" xlink:label="label948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_en-US">Recovery amount of the overpayment made to the subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element948" xlink:to="label948" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RelatedPartyMember" xlink:label="element949" />
        <label xlink:type="resource" xlink:label="label949" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RelatedPartyMember_en-US">Related Party [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element949" xlink:to="label949" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RelatedPartyMember" xlink:label="element950" />
        <label xlink:type="resource" xlink:label="label950" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RelatedPartyMember_en-US">Related Party [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element950" xlink:to="label950" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RelatedPartyMember" xlink:label="element951" />
        <label xlink:type="resource" xlink:label="label951" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RelatedPartyMember_en-US">Large physician group</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element951" xlink:to="label951" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="element952" />
        <label xlink:type="resource" xlink:label="label952" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RevenueAdjustmentToMedicareRevenue_en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element952" xlink:to="label952" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="element953" />
        <label xlink:type="resource" xlink:label="label953" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RevenueAdjustmentToMedicareRevenue_en-US">Revenue Adjustment To Medicare Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element953" xlink:to="label953" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="element954" />
        <label xlink:type="resource" xlink:label="label954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RevenueAdjustmentToMedicareRevenue_en-US">Revenue adjustment to Medicare revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element954" xlink:to="label954" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="element955" />
        <label xlink:type="resource" xlink:label="label955" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RevolvingCreditFacilitiesMember_en-US">Revolving Credit Facilities [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element955" xlink:to="label955" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="element956" />
        <label xlink:type="resource" xlink:label="label956" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RevolvingCreditFacilitiesMember_en-US">Revolving Credit Facilities [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element956" xlink:to="label956" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="element957" />
        <label xlink:type="resource" xlink:label="label957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RevolvingCreditFacilitiesMember_en-US">Revolving Credit Facilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element957" xlink:to="label957" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="element958" />
        <label xlink:type="resource" xlink:label="label958" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecondThresholdOfServicesRequired_en-US">Description containing the number of visits related to the second threshold of therapy services required.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element958" xlink:to="label958" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="element959" />
        <label xlink:type="resource" xlink:label="label959" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecondThresholdOfServicesRequired_en-US">Second Threshold Of Services Required</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element959" xlink:to="label959" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="element960" />
        <label xlink:type="resource" xlink:label="label960" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SecondThresholdOfServicesRequired_en-US">Second threshold of services required, visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element960" xlink:to="label960" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="element961" />
        <label xlink:type="resource" xlink:label="label961" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TermLoanMember_en-US">Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element961" xlink:to="label961" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="element962" />
        <label xlink:type="resource" xlink:label="label962" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TermLoanMember_en-US">Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element962" xlink:to="label962" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="element963" />
        <label xlink:type="resource" xlink:label="label963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TermLoanMember_en-US">Term Loan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element963" xlink:to="label963" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="element964" />
        <label xlink:type="resource" xlink:label="label964" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ThirdThresholdOfTherapyServicesRequired_en-US">Description containing the number of visits related to the third threshold of therapy services required.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element964" xlink:to="label964" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="element965" />
        <label xlink:type="resource" xlink:label="label965" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ThirdThresholdOfTherapyServicesRequired_en-US">Third Threshold Of Therapy Services Required</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element965" xlink:to="label965" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="element966" />
        <label xlink:type="resource" xlink:label="label966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ThirdThresholdOfTherapyServicesRequired_en-US">Third threshold of therapy services required, visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element966" xlink:to="label966" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TotalLeverageRatio" xlink:label="element967" />
        <label xlink:type="resource" xlink:label="label967" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TotalLeverageRatio_en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element967" xlink:to="label967" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TotalLeverageRatio" xlink:label="element968" />
        <label xlink:type="resource" xlink:label="label968" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TotalLeverageRatio_en-US">Total Leverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element968" xlink:to="label968" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TotalLeverageRatio" xlink:label="element969" />
        <label xlink:type="resource" xlink:label="label969" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TotalLeverageRatio_en-US">Total leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element969" xlink:to="label969" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="element970" />
        <label xlink:type="resource" xlink:label="label970" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WorkersCompensationInsuranceRetentionLimit_en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element970" xlink:to="label970" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="element971" />
        <label xlink:type="resource" xlink:label="label971" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WorkersCompensationInsuranceRetentionLimit_en-US">Workers Compensation Insurance Retention Limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element971" xlink:to="label971" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="element972" />
        <label xlink:type="resource" xlink:label="label972" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WorkersCompensationInsuranceRetentionLimit_en-US">Workers' compensation insurance retention limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element972" xlink:to="label972" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfEmployeesInWageHourLitigationMember" xlink:label="element973" />
        <label xlink:type="resource" xlink:label="label973" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfEmployeesInWageHourLitigationMember_en-US">Number Of Employees In Wage Hour Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element973" xlink:to="label973" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="element974" />
        <label xlink:type="resource" xlink:label="label974" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximusFederalServicesAndHomeHealthMember_en-US">Maximus Federal Services And Home Health [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element974" xlink:to="label974" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="element975" />
        <label xlink:type="resource" xlink:label="label975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximusFederalServicesAndHomeHealthMember_en-US">Maximus Federal Services And Home Health</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element975" xlink:to="label975" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="element976" />
        <label xlink:type="resource" xlink:label="label976" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximusFederalServicesAndHomeHealthMember_en-US">Maximus Federal Services And Home Health</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element976" xlink:to="label976" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingCareCenters" xlink:label="element977" />
        <label xlink:type="resource" xlink:label="label977" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingCareCenters_en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element977" xlink:to="label977" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingCareCenters" xlink:label="element978" />
        <label xlink:type="resource" xlink:label="label978" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingCareCenters_en-US">Operating Care Centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element978" xlink:to="label978" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingCareCenters" xlink:label="element979" />
        <label xlink:type="resource" xlink:label="label979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingCareCenters_en-US">Operating Care Centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element979" xlink:to="label979" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="element980" />
        <label xlink:type="resource" xlink:label="label980" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OrganizationAndNatureOfOperationsTable_en-US">Organization And Nature Of Operations [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element980" xlink:to="label980" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceInpatientMember" xlink:label="element981" />
        <label xlink:type="resource" xlink:label="label981" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceInpatientMember_en-US">Hospice Inpatient [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element981" xlink:to="label981" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="element982" />
        <label xlink:type="resource" xlink:label="label982" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OrganizationAndNatureOfOperationsLineItems_en-US">Organization And Nature Of Operations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element982" xlink:to="label982" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="element983" />
        <label xlink:type="resource" xlink:label="label983" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StateAxis_en-US">State [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element983" xlink:to="label983" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="element984" />
        <label xlink:type="resource" xlink:label="label984" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StateDomain_en-US">State [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element984" xlink:to="label984" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IllinoisMember" xlink:label="element985" />
        <label xlink:type="resource" xlink:label="label985" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IllinoisMember_en-US">Illinois [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element985" xlink:to="label985" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ConnecticutMember" xlink:label="element986" />
        <label xlink:type="resource" xlink:label="label986" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ConnecticutMember_en-US">Connecticut [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element986" xlink:to="label986" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OhioMember" xlink:label="element987" />
        <label xlink:type="resource" xlink:label="label987" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OhioMember_en-US">Ohio [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element987" xlink:to="label987" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SouthCarolinaMember" xlink:label="element988" />
        <label xlink:type="resource" xlink:label="label988" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SouthCarolinaMember_en-US">South Carolina [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element988" xlink:to="label988" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassachusettsMember" xlink:label="element989" />
        <label xlink:type="resource" xlink:label="label989" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MassachusettsMember_en-US">Massachusetts [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element989" xlink:to="label989" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfBeneficiaries" xlink:label="element990" />
        <label xlink:type="resource" xlink:label="label990" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfBeneficiaries_en-US">Number of beneficiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element990" xlink:to="label990" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfBeneficiaries" xlink:label="element991" />
        <label xlink:type="resource" xlink:label="label991" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfBeneficiaries_en-US">Number of beneficiaries who received services</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element991" xlink:to="label991" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalLitigationSettlmentMember" xlink:label="element992" />
        <label xlink:type="resource" xlink:label="label992" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FinalLitigationSettlmentMember_en-US">Final Litigation Settlment [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element992" xlink:to="label992" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalLitigationSettlmentMember" xlink:label="element993" />
        <label xlink:type="resource" xlink:label="label993" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FinalLitigationSettlmentMember_en-US">Amount of litigation settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element993" xlink:to="label993" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenue" xlink:label="element994" />
        <label xlink:type="resource" xlink:label="label994" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MedicareRevenue_en-US">Medicare Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element994" xlink:to="label994" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenue" xlink:label="element995" />
        <label xlink:type="resource" xlink:label="label995" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MedicareRevenue_en-US">Amount of net service revenue derived from Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element995" xlink:to="label995" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ExtrapolatedMember" xlink:label="element996" />
        <label xlink:type="resource" xlink:label="label996" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ExtrapolatedMember_en-US">Extrapolated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element996" xlink:to="label996" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ExtrapolatedMember" xlink:label="element997" />
        <label xlink:type="resource" xlink:label="label997" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ExtrapolatedMember_en-US">Extrapolated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element997" xlink:to="label997" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ExtrapolatedMember" xlink:label="element998" />
        <label xlink:type="resource" xlink:label="label998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ExtrapolatedMember_en-US">Extrapolated</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element998" xlink:to="label998" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="element999" />
        <label xlink:type="resource" xlink:label="label999" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumPercentOwnershipForEquityMethodPercent_en-US">Maximum Percent Ownership For Equity Method Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element999" xlink:to="label999" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="element1000" />
        <label xlink:type="resource" xlink:label="label1000" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumPercentOwnershipForEquityMethodPercent_en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1000" xlink:to="label1000" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="element1001" />
        <label xlink:type="resource" xlink:label="label1001" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumPercentOwnershipForCostMethodPercent_en-US">Maximum Percent Ownership For Cost Method Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1001" xlink:to="label1001" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="element1002" />
        <label xlink:type="resource" xlink:label="label1002" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumPercentOwnershipForCostMethodPercent_en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1002" xlink:to="label1002" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="element1003" />
        <label xlink:type="resource" xlink:label="label1003" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersAvailableForSale_en-US">Number Of Care Centers Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1003" xlink:to="label1003" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="element1004" />
        <label xlink:type="resource" xlink:label="label1004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersAvailableForSale_en-US">Number of care centers available for sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1004" xlink:to="label1004" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="element1005" />
        <label xlink:type="resource" xlink:label="label1005" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersAvailableForSale_en-US">Number of care centers that were classified as available for sale during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1005" xlink:to="label1005" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersSold" xlink:label="element1006" />
        <label xlink:type="resource" xlink:label="label1006" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersSold_en-US">Number Of Care Centers Sold</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1006" xlink:to="label1006" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersSold" xlink:label="element1007" />
        <label xlink:type="resource" xlink:label="label1007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersSold_en-US">Number of care centers sold</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1007" xlink:to="label1007" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersSold" xlink:label="element1008" />
        <label xlink:type="resource" xlink:label="label1008" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersSold_en-US">Number of care centers sold during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1008" xlink:to="label1008" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="element1009" />
        <label xlink:type="resource" xlink:label="label1009" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersIncludedInDivestiturePlan_en-US">Number of Care Centers Included in Divestiture Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1009" xlink:to="label1009" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="element1010" />
        <label xlink:type="resource" xlink:label="label1010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersIncludedInDivestiturePlan_en-US">Number of care centers included in divestiture plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1010" xlink:to="label1010" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="element1011" />
        <label xlink:type="resource" xlink:label="label1011" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersIncludedInDivestiturePlan_en-US">The number of care centers that were included in the divestiture plan during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1011" xlink:to="label1011" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FederalDerivativeActionsMember" xlink:label="element1012" />
        <label xlink:type="resource" xlink:label="label1012" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FederalDerivativeActionsMember_en-US">Federal Derivative Actions [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1012" xlink:to="label1012" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FederalDerivativeActionsMember" xlink:label="element1013" />
        <label xlink:type="resource" xlink:label="label1013" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FederalDerivativeActionsMember_en-US">Federal Derivative Actions [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1013" xlink:to="label1013" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FederalDerivativeActionsMember" xlink:label="element1014" />
        <label xlink:type="resource" xlink:label="label1014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FederalDerivativeActionsMember_en-US">Federal Derivative Actions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1014" xlink:to="label1014" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="element1015" />
        <label xlink:type="resource" xlink:label="label1015" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_en-US">Line Of Credit Facility Effectivey Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1015" xlink:to="label1015" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="element1016" />
        <label xlink:type="resource" xlink:label="label1016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_en-US">Effective availability under the revolving credit facility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1016" xlink:to="label1016" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="element1017" />
        <label xlink:type="resource" xlink:label="label1017" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_en-US">Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed less the amount of borrowings outstanding.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1017" xlink:to="label1017" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="element1018" />
        <label xlink:type="resource" xlink:label="label1018" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityDebtRestrictions_en-US">Line of Credit Facility Debt Restrictions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1018" xlink:to="label1018" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="element1019" />
        <label xlink:type="resource" xlink:label="label1019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityDebtRestrictions_en-US">Line of Credit Facility Debt Restrictions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1019" xlink:to="label1019" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="element1020" />
        <label xlink:type="resource" xlink:label="label1020" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LineOfCreditFacilityDebtRestrictions_en-US">The amount by which overall debt must be less than earnings before interest, taxes, depreciation and amortization.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1020" xlink:to="label1020" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="element1021" />
        <label xlink:type="resource" xlink:label="label1021" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredDebtIssuanceCostsWrittenOff_en-US">Deferred Debt Issuance Costs Written Off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1021" xlink:to="label1021" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="element1022" />
        <label xlink:type="resource" xlink:label="label1022" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredDebtIssuanceCostsWrittenOff_en-US">The amount of deferred debt issuance costs written off during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1022" xlink:to="label1022" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="element1023" />
        <label xlink:type="resource" xlink:label="label1023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredDebtIssuanceCostsWrittenOff_en-US">Write off deferred debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1023" xlink:to="label1023" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringCostsAxis" xlink:label="element1024" />
        <label xlink:type="resource" xlink:label="label1024" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherRestructuringCostsAxis_en-US">Other Restructuring Costs [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1024" xlink:to="label1024" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="element1025" />
        <label xlink:type="resource" xlink:label="label1025" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherRestructuringDomain_en-US">Other Restructuring [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1025" xlink:to="label1025" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="element1026" />
        <label xlink:type="resource" xlink:label="label1026" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OtherRestructuringDomain_en-US">Other Restructuring [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1026" xlink:to="label1026" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UnfavorableMember" xlink:label="element1027" />
        <label xlink:type="resource" xlink:label="label1027" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UnfavorableMember_en-US">Unfavorable [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1027" xlink:to="label1027" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumLeverageRatio" xlink:label="element1028" />
        <label xlink:type="resource" xlink:label="label1028" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumLeverageRatio_en-US">Maximum Leverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1028" xlink:to="label1028" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumLeverageRatio" xlink:label="element1029" />
        <label xlink:type="resource" xlink:label="label1029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximumLeverageRatio_en-US">Maximum leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1029" xlink:to="label1029" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumLeverageRatio" xlink:label="element1030" />
        <label xlink:type="resource" xlink:label="label1030" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumLeverageRatio_en-US">The maximum total leverage ratio allowed as defined by the Company's Credit Agreement.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1030" xlink:to="label1030" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="element1031" />
        <label xlink:type="resource" xlink:label="label1031" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumFixedChargeCoverageRatio_en-US">Minimum Fixed Charge Coverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1031" xlink:to="label1031" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="element1032" />
        <label xlink:type="resource" xlink:label="label1032" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumFixedChargeCoverageRatio_en-US">The minumum fixed charge ratio allowed as defined by the Company's Credit Agreement.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1032" xlink:to="label1032" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="element1033" />
        <label xlink:type="resource" xlink:label="label1033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MinimumFixedChargeCoverageRatio_en-US">Minimum fixed charge coverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1033" xlink:to="label1033" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WeightedAverageInterestRate" xlink:label="element1034" />
        <label xlink:type="resource" xlink:label="label1034" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WeightedAverageInterestRate_en-US">Weighted Average Interest Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1034" xlink:to="label1034" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WeightedAverageInterestRate" xlink:label="element1035" />
        <label xlink:type="resource" xlink:label="label1035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WeightedAverageInterestRate_en-US">Weighted-average interest rate for five year Term Loan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1035" xlink:to="label1035" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="element1036" />
        <label xlink:type="resource" xlink:label="label1036" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersRemovedFromAvailableForSale_en-US">Number Of Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1036" xlink:to="label1036" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="element1037" />
        <label xlink:type="resource" xlink:label="label1037" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersRemovedFromAvailableForSale_en-US">Number of care centers removed from available for sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1037" xlink:to="label1037" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="element1038" />
        <label xlink:type="resource" xlink:label="label1038" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersRemovedFromAvailableForSale_en-US">Number of care centers that were removed from available for sale classification during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1038" xlink:to="label1038" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="element1039" />
        <label xlink:type="resource" xlink:label="label1039" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1039" xlink:to="label1039" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="element1040" />
        <label xlink:type="resource" xlink:label="label1040" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1040" xlink:to="label1040" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="element1041" />
        <label xlink:type="resource" xlink:label="label1041" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_en-US">Net Revenue For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1041" xlink:to="label1041" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="element1042" />
        <label xlink:type="resource" xlink:label="label1042" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_en-US">Net Revenue For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1042" xlink:to="label1042" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="element1043" />
        <label xlink:type="resource" xlink:label="label1043" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_en-US">Net revenues</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1043" xlink:to="label1043" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="element1044" />
        <label xlink:type="resource" xlink:label="label1044" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_en-US">Income (Loss) Before Income Taxes For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1044" xlink:to="label1044" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="element1045" />
        <label xlink:type="resource" xlink:label="label1045" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_en-US">Income (Loss) Before Income Taxes For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1045" xlink:to="label1045" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="element1046" />
        <label xlink:type="resource" xlink:label="label1046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_en-US">Income before income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1046" xlink:to="label1046" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="element1047" />
        <label xlink:type="resource" xlink:label="label1047" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_en-US">Income Tax Benefit (Expense) For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1047" xlink:to="label1047" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="element1048" />
        <label xlink:type="resource" xlink:label="label1048" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_en-US">Income Tax Benefit (Expense) For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1048" xlink:to="label1048" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="element1049" />
        <label xlink:type="resource" xlink:label="label1049" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_en-US">Income tax expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1049" xlink:to="label1049" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1050" />
        <label xlink:type="resource" xlink:label="label1050" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income From Continuing Operations For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1050" xlink:to="label1050" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1051" />
        <label xlink:type="resource" xlink:label="label1051" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income From Continuing Operations For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1051" xlink:to="label1051" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1052" />
        <label xlink:type="resource" xlink:label="label1052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1052" xlink:to="label1052" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1053" />
        <label xlink:type="resource" xlink:label="label1053" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1053" xlink:to="label1053" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="element1054" />
        <label xlink:type="resource" xlink:label="label1054" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InsuranceProceedsForReimbursementOfLegalFees_en-US">Insurance Proceeds For Reimbursement Of Legal Fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1054" xlink:to="label1054" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="element1055" />
        <label xlink:type="resource" xlink:label="label1055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InsuranceProceedsForReimbursementOfLegalFees_en-US">Insurance proceeds for reimbursement of legal fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1055" xlink:to="label1055" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="element1056" />
        <label xlink:type="resource" xlink:label="label1056" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InsuranceProceedsForReimbursementOfLegalFees_en-US">Proceeds received for insurance carrier for the reimbursement of legal fees related to current litigation activities.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1056" xlink:to="label1056" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="element1057" />
        <label xlink:type="resource" xlink:label="label1057" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_en-US">Accrued Charge Related To U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1057" xlink:to="label1057" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="element1058" />
        <label xlink:type="resource" xlink:label="label1058" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_en-US">Accrued charge related to U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1058" xlink:to="label1058" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="element1059" />
        <label xlink:type="resource" xlink:label="label1059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_en-US">Accrued charge related to U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1059" xlink:to="label1059" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="element1060" />
        <label xlink:type="resource" xlink:label="label1060" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UsDepartmentOfJusticeSettlement_en-US">U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1060" xlink:to="label1060" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="element1061" />
        <label xlink:type="resource" xlink:label="label1061" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UsDepartmentOfJusticeSettlement_en-US">Charge related to U.S. Department of Justice setlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1061" xlink:to="label1061" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="element1062" />
        <label xlink:type="resource" xlink:label="label1062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_UsDepartmentOfJusticeSettlement_en-US">U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1062" xlink:to="label1062" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="element1063" />
        <label xlink:type="resource" xlink:label="label1063" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UsDepartmentOfJusticeMember_en-US">U.S. Department of Justice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1063" xlink:to="label1063" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="element1064" />
        <label xlink:type="resource" xlink:label="label1064" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UsDepartmentOfJusticeMember_en-US">U.S. Department of Justice</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1064" xlink:to="label1064" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="element1065" />
        <label xlink:type="resource" xlink:label="label1065" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InterestRateOnUsDepartmentOfJusticeSettlement_en-US">Interest Rate On U.S. Department of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1065" xlink:to="label1065" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="element1066" />
        <label xlink:type="resource" xlink:label="label1066" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InterestRateOnUsDepartmentOfJusticeSettlement_en-US">Interest rate on U.S. Department of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1066" xlink:to="label1066" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="element1067" />
        <label xlink:type="resource" xlink:label="label1067" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_en-US">Payment Upon Execution Of U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1067" xlink:to="label1067" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="element1068" />
        <label xlink:type="resource" xlink:label="label1068" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_en-US">Payment upon execution of U.S. Department of Justice settlement documents.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1068" xlink:to="label1068" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1069" />
        <label xlink:type="resource" xlink:label="label1069" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Final Payment Of U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1069" xlink:to="label1069" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1070" />
        <label xlink:type="resource" xlink:label="label1070" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Final payment of U.S. Department of Justice settlement.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1070" xlink:to="label1070" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1071" />
        <label xlink:type="resource" xlink:label="label1071" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Period Of Time For Final Payment Of U.S. Department of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1071" xlink:to="label1071" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1072" />
        <label xlink:type="resource" xlink:label="label1072" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Period of time final payment of U.S. Department of Justice payment is due after initial payment.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1072" xlink:to="label1072" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OigSelfDisclosureMember" xlink:label="element1073" />
        <label xlink:type="resource" xlink:label="label1073" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OigSelfDisclosureMember_en-US">OIG Self-Disclosure [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1073" xlink:to="label1073" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OigSelfDisclosureMember" xlink:label="element1074" />
        <label xlink:type="resource" xlink:label="label1074" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OigSelfDisclosureMember_en-US">OIG Self-Disclosure matters</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1074" xlink:to="label1074" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="element1075" />
        <label xlink:type="resource" xlink:label="label1075" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ErisaClassActionLawsuitMember_en-US">ERISA Class Action Lawsuit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1075" xlink:to="label1075" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="element1076" />
        <label xlink:type="resource" xlink:label="label1076" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ErisaClassActionLawsuitMember_en-US">ERISA Class Action Lawsuit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1076" xlink:to="label1076" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="element1077" />
        <label xlink:type="resource" xlink:label="label1077" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1077" xlink:to="label1077" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="element1078" />
        <label xlink:type="resource" xlink:label="label1078" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1078" xlink:to="label1078" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusAxis" xlink:label="element1079" />
        <label xlink:type="resource" xlink:label="label1079" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCenterStatusAxis_en-US">Care Center Status [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1079" xlink:to="label1079" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusAxis" xlink:label="element1080" />
        <label xlink:type="resource" xlink:label="label1080" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCenterStatusAxis_en-US">Care Center Status [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1080" xlink:to="label1080" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusDomain" xlink:label="element1081" />
        <label xlink:type="resource" xlink:label="label1081" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCenterStatusDomain_en-US">Care Center Status [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1081" xlink:to="label1081" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusDomain" xlink:label="element1082" />
        <label xlink:type="resource" xlink:label="label1082" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCenterStatusDomain_en-US">Care Center Status [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1082" xlink:to="label1082" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="element1083" />
        <label xlink:type="resource" xlink:label="label1083" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCentersRemovedFromAvailableForSaleMember_en-US">Care Centers Removed From Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1083" xlink:to="label1083" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="element1084" />
        <label xlink:type="resource" xlink:label="label1084" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCentersRemovedFromAvailableForSaleMember_en-US">Care Centers Removed From Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1084" xlink:to="label1084" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="element1085" />
        <label xlink:type="resource" xlink:label="label1085" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DetailsOfCertainBalanceSheetAccountsAbstract_en-US">Details Of Certain Balance Sheet Accounts [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1085" xlink:to="label1085" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:label="element1086" />
        <label xlink:type="resource" xlink:label="label1086" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_en-US">Details of Certain Balance Sheet Accounts Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1086" xlink:to="label1086" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:label="element1087" />
        <label xlink:type="resource" xlink:label="label1087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_en-US">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1087" xlink:to="label1087" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="element1088" />
        <label xlink:type="resource" xlink:label="label1088" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_en-US">Pension and Other Postretirement Benefits Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1088" xlink:to="label1088" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="element1089" />
        <label xlink:type="resource" xlink:label="label1089" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProvisionForIncomeTaxesTextBlock_en-US">Provision for Income Taxes [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1089" xlink:to="label1089" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="element1090" />
        <label xlink:type="resource" xlink:label="label1090" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProvisionForIncomeTaxesTextBlock_en-US">Provision for Income Taxes Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1090" xlink:to="label1090" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="element1091" />
        <label xlink:type="resource" xlink:label="label1091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProvisionForIncomeTaxesTextBlock_en-US">Income Tax Provision</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1091" xlink:to="label1091" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="element1092" />
        <label xlink:type="resource" xlink:label="label1092" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_en-US">Reconciliation of Statutory Tax Effects [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1092" xlink:to="label1092" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="element1093" />
        <label xlink:type="resource" xlink:label="label1093" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_en-US">Reconciliation of Statutory Tax Effects Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1093" xlink:to="label1093" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="element1094" />
        <label xlink:type="resource" xlink:label="label1094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_en-US">Sources of Tax Effects</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1094" xlink:to="label1094" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="element1095" />
        <label xlink:type="resource" xlink:label="label1095" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InsuranceProgramsTableTextBlock_en-US">Insurance Programs Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1095" xlink:to="label1095" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="element1096" />
        <label xlink:type="resource" xlink:label="label1096" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InsuranceProgramsTableTextBlock_en-US">Insurance Programs Details, Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1096" xlink:to="label1096" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="element1097" />
        <label xlink:type="resource" xlink:label="label1097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InsuranceProgramsTableTextBlock_en-US">Insurance Programs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1097" xlink:to="label1097" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="element1098" />
        <label xlink:type="resource" xlink:label="label1098" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ValuationAndQualifyingAccountsTableTextBlock_en-US">Valuation and Qualifying Accounts Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1098" xlink:to="label1098" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="element1099" />
        <label xlink:type="resource" xlink:label="label1099" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ValuationAndQualifyingAccountsTableTextBlock_en-US">A schedule of allowance and reserve accounts including their beginning and ending balances, as well as a reconciliation by type of activity during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1099" xlink:to="label1099" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="element1100" />
        <label xlink:type="resource" xlink:label="label1100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ValuationAndQualifyingAccountsTableTextBlock_en-US">Valuation and Qualifying Accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1100" xlink:to="label1100" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" xlink:label="element1101" />
        <label xlink:type="resource" xlink:label="label1101" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_en-US">Minimum Eligible Age For Employees To Contribute To Benefit Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1101" xlink:to="label1101" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" xlink:label="element1102" />
        <label xlink:type="resource" xlink:label="label1102" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_en-US">Minimum eligible age for employees to contribute to benefit plan, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1102" xlink:to="label1102" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="element1103" />
        <label xlink:type="resource" xlink:label="label1103" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DefinedContributionPlanEmployerMatchingContribution_en-US">Defined Contribution Plan Employer Matching Contribution</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1103" xlink:to="label1103" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="element1104" />
        <label xlink:type="resource" xlink:label="label1104" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DefinedContributionPlanEmployerMatchingContribution_en-US">Defined contribution plan employer matching contribution.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1104" xlink:to="label1104" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="element1105" />
        <label xlink:type="resource" xlink:label="label1105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DefinedContributionPlanEmployerMatchingContribution_en-US">Employer Match Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1105" xlink:to="label1105" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="element1106" />
        <label xlink:type="resource" xlink:label="label1106" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_en-US">Defined Contribution Plan Employee Contribution For Employee Matching Program</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1106" xlink:to="label1106" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="element1107" />
        <label xlink:type="resource" xlink:label="label1107" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_en-US">Defined Contribution Plan Employee Contribution For Employer Matching Program</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1107" xlink:to="label1107" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="element1108" />
        <label xlink:type="resource" xlink:label="label1108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_en-US">Employee Contribution Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1108" xlink:to="label1108" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="element1109" />
        <label xlink:type="resource" xlink:label="label1109" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_en-US">Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1109" xlink:to="label1109" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="element1110" />
        <label xlink:type="resource" xlink:label="label1110" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_en-US">Maximum Percentage of Employee Salary Eligible for Employer Match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1110" xlink:to="label1110" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="element1111" />
        <label xlink:type="resource" xlink:label="label1111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_en-US">Maximum Percentage of Employee Salary Eligible for Employer Match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1111" xlink:to="label1111" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="element1112" />
        <label xlink:type="resource" xlink:label="label1112" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_en-US">Deferred Compensation Arrangement Maximum Percentage Of Salary Deferment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1112" xlink:to="label1112" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="element1113" />
        <label xlink:type="resource" xlink:label="label1113" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_en-US">Maximum percentage of annual salary that participant is allowed to defer per terms of the Company's Deferred Compensation Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1113" xlink:to="label1113" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="element1114" />
        <label xlink:type="resource" xlink:label="label1114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_en-US">Permitted deferment of annual salary, percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1114" xlink:to="label1114" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="element1115" />
        <label xlink:type="resource" xlink:label="label1115" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_en-US">Deferred Compensation Arrangement Maximum Percentage Of Annual Bonus Deferment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1115" xlink:to="label1115" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="element1116" />
        <label xlink:type="resource" xlink:label="label1116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_en-US">Permitted deferment of annual bonus, percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1116" xlink:to="label1116" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="element1117" />
        <label xlink:type="resource" xlink:label="label1117" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_en-US">Maximum percentage of annual bonus that participant is allowed to defer per terms of the Company's Deferred Compensation Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1117" xlink:to="label1117" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="element1118" />
        <label xlink:type="resource" xlink:label="label1118" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeaseObligationsLineItems_en-US">Operating Lease Obligations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1118" xlink:to="label1118" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="element1119" />
        <label xlink:type="resource" xlink:label="label1119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeaseObligationsLineItems_en-US">Operating Lease Obligations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1119" xlink:to="label1119" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsurance" xlink:label="element1120" />
        <label xlink:type="resource" xlink:label="label1120" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HealthInsurance_en-US">Health Insurance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1120" xlink:to="label1120" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsurance" xlink:label="element1121" />
        <label xlink:type="resource" xlink:label="label1121" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HealthInsurance_en-US">Health insurance, estimated liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1121" xlink:to="label1121" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsurance" xlink:label="element1122" />
        <label xlink:type="resource" xlink:label="label1122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HealthInsurance_en-US">Health Insurance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1122" xlink:to="label1122" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WokersCompensation" xlink:label="element1123" />
        <label xlink:type="resource" xlink:label="label1123" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WokersCompensation_en-US">Wokers Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1123" xlink:to="label1123" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WokersCompensation" xlink:label="element1124" />
        <label xlink:type="resource" xlink:label="label1124" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WokersCompensation_en-US">Workers' Compensation insurance, estimated liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1124" xlink:to="label1124" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WokersCompensation" xlink:label="element1125" />
        <label xlink:type="resource" xlink:label="label1125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WokersCompensation_en-US">Wokers Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1125" xlink:to="label1125" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiability" xlink:label="element1126" />
        <label xlink:type="resource" xlink:label="label1126" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProfessionalLiability_en-US">Professional Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1126" xlink:to="label1126" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiability" xlink:label="element1127" />
        <label xlink:type="resource" xlink:label="label1127" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProfessionalLiability_en-US">Professional liability insurance, estimated liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1127" xlink:to="label1127" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiability" xlink:label="element1128" />
        <label xlink:type="resource" xlink:label="label1128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProfessionalLiability_en-US">Professional Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1128" xlink:to="label1128" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceTotal" xlink:label="element1129" />
        <label xlink:type="resource" xlink:label="label1129" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedInsuranceTotal_en-US">Estimated Insurance Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1129" xlink:to="label1129" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceTotal" xlink:label="element1130" />
        <label xlink:type="resource" xlink:label="label1130" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedInsuranceTotal_en-US">Estimated insurance, total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1130" xlink:to="label1130" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceTotal" xlink:label="element1131" />
        <label xlink:type="resource" xlink:label="label1131" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_amed_EstimatedInsuranceTotal_en-US">Estimated Insurance Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1131" xlink:to="label1131" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="element1132" />
        <label xlink:type="resource" xlink:label="label1132" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedInsuranceLongTermPortion_en-US">Estimated Insurance Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1132" xlink:to="label1132" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="element1133" />
        <label xlink:type="resource" xlink:label="label1133" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedInsuranceLongTermPortion_en-US">Long term portion of estimated insurance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1133" xlink:to="label1133" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="element1134" />
        <label xlink:type="resource" xlink:label="label1134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedInsuranceLongTermPortion_en-US">Estimated Insurance Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1134" xlink:to="label1134" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="element1135" />
        <label xlink:type="resource" xlink:label="label1135" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedInsuranceExcludingLongTermPortion_en-US">Estimated Insurance Excluding Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1135" xlink:to="label1135" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="element1136" />
        <label xlink:type="resource" xlink:label="label1136" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedInsuranceExcludingLongTermPortion_en-US">Estimated insurance liability, excluding long-term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1136" xlink:to="label1136" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="element1137" />
        <label xlink:type="resource" xlink:label="label1137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedInsuranceExcludingLongTermPortion_en-US">Estimated Insurance Excluding Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1137" xlink:to="label1137" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="element1138" />
        <label xlink:type="resource" xlink:label="label1138" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxDisclosureLineItems_en-US">Income Tax Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1138" xlink:to="label1138" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="element1139" />
        <label xlink:type="resource" xlink:label="label1139" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeTaxDisclosureLineItems_en-US">Income Tax Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1139" xlink:to="label1139" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="element1140" />
        <label xlink:type="resource" xlink:label="label1140" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfIndividualStatesSubjectToIncomeTax_en-US">Number of Individual States Subject To Income Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1140" xlink:to="label1140" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="element1141" />
        <label xlink:type="resource" xlink:label="label1141" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfIndividualStatesSubjectToIncomeTax_en-US">Number of individual states subject to income tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1141" xlink:to="label1141" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="element1142" />
        <label xlink:type="resource" xlink:label="label1142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfIndividualStatesSubjectToIncomeTax_en-US">Number of individual states subject to income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1142" xlink:to="label1142" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1143" />
        <label xlink:type="resource" xlink:label="label1143" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_en-US">Deferred Tax Assets Deferred Expense US Department Of Justice Settlement Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1143" xlink:to="label1143" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1144" />
        <label xlink:type="resource" xlink:label="label1144" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from U.S. Department of Justice settlement accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1144" xlink:to="label1144" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1145" />
        <label xlink:type="resource" xlink:label="label1145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_en-US">Settlement accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1145" xlink:to="label1145" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="element1146" />
        <label xlink:type="resource" xlink:label="label1146" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1146" xlink:to="label1146" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="element1147" />
        <label xlink:type="resource" xlink:label="label1147" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_en-US">Deferred tax assets tax deferred expense compensation and benefits workers compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1147" xlink:to="label1147" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="element1148" />
        <label xlink:type="resource" xlink:label="label1148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_en-US">Workers' compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1148" xlink:to="label1148" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="element1149" />
        <label xlink:type="resource" xlink:label="label1149" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredTaxAssetsOtherCurrent_en-US">Deferred Tax Assets Other Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1149" xlink:to="label1149" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="element1150" />
        <label xlink:type="resource" xlink:label="label1150" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredTaxAssetsOtherCurrent_en-US">Amount before allocation of valuation allowances of current deferred tax asset attributable to deductible temporary differences not separately disclosed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1150" xlink:to="label1150" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="element1151" />
        <label xlink:type="resource" xlink:label="label1151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredTaxAssetsOtherCurrent_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1151" xlink:to="label1151" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="element1152" />
        <label xlink:type="resource" xlink:label="label1152" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GoodwillAndIntangibleAssetsLineItems_en-US">Goodwill and Intangible Assets [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1152" xlink:to="label1152" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="element1153" />
        <label xlink:type="resource" xlink:label="label1153" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_GoodwillAndIntangibleAssetsLineItems_en-US">Goodwill and Intangible Assets [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1153" xlink:to="label1153" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="element1154" />
        <label xlink:type="resource" xlink:label="label1154" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCentersClosedOrConsolidatedMember_en-US">Care Centers Closed Or Consolidated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1154" xlink:to="label1154" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="element1155" />
        <label xlink:type="resource" xlink:label="label1155" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCentersClosedOrConsolidatedMember_en-US">Care Centers Closed Or Consolidated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1155" xlink:to="label1155" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndElevenExitActivityMember" xlink:label="element1156" />
        <label xlink:type="resource" xlink:label="label1156" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoThousandAndElevenExitActivityMember_en-US">Two Thousand And Eleven Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1156" xlink:to="label1156" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndElevenExitActivityMember" xlink:label="element1157" />
        <label xlink:type="resource" xlink:label="label1157" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoThousandAndElevenExitActivityMember_en-US">Two Thousand And Eleven Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1157" xlink:to="label1157" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndElevenExitActivityMember" xlink:label="element1158" />
        <label xlink:type="resource" xlink:label="label1158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TwoThousandAndElevenExitActivityMember_en-US">2011 Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1158" xlink:to="label1158" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndTwelveExitActivityMember" xlink:label="element1159" />
        <label xlink:type="resource" xlink:label="label1159" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoThousandAndTwelveExitActivityMember_en-US">Two Thousand And Twelve Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1159" xlink:to="label1159" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndTwelveExitActivityMember" xlink:label="element1160" />
        <label xlink:type="resource" xlink:label="label1160" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoThousandAndTwelveExitActivityMember_en-US">Two Thousand And Twelve Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1160" xlink:to="label1160" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndTwelveExitActivityMember" xlink:label="element1161" />
        <label xlink:type="resource" xlink:label="label1161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TwoThousandAndTwelveExitActivityMember_en-US">2012 Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1161" xlink:to="label1161" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="element1162" />
        <label xlink:type="resource" xlink:label="label1162" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoThousandAndThirteenExitActivityMember_en-US">Two Thousand And Thirteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1162" xlink:to="label1162" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="element1163" />
        <label xlink:type="resource" xlink:label="label1163" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoThousandAndThirteenExitActivityMember_en-US">Two Thousand And Thirteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1163" xlink:to="label1163" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="element1164" />
        <label xlink:type="resource" xlink:label="label1164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TwoThousandAndThirteenExitActivityMember_en-US">2013 Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1164" xlink:to="label1164" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LeaseTerminationMember" xlink:label="element1165" />
        <label xlink:type="resource" xlink:label="label1165" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LeaseTerminationMember_en-US">Lease Termination [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1165" xlink:to="label1165" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LeaseTerminationMember" xlink:label="element1166" />
        <label xlink:type="resource" xlink:label="label1166" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LeaseTerminationMember_en-US">Lease Termination [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1166" xlink:to="label1166" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="element1167" />
        <label xlink:type="resource" xlink:label="label1167" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_en-US">Estimated Useful Lives Of Property And Equipment [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1167" xlink:to="label1167" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="element1168" />
        <label xlink:type="resource" xlink:label="label1168" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_en-US">stimated Useful Lives Of Property And Equipment, table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1168" xlink:to="label1168" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="element1169" />
        <label xlink:type="resource" xlink:label="label1169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_en-US">Estimated Useful Lives Of Property And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1169" xlink:to="label1169" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="element1170" />
        <label xlink:type="resource" xlink:label="label1170" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtIssuanceCostsPolicyTextBlock_en-US">Debt Issuance Costs Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1170" xlink:to="label1170" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="element1171" />
        <label xlink:type="resource" xlink:label="label1171" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtIssuanceCostsPolicyTextBlock_en-US">Disclosure of accounting policy for debt issuance costs.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1171" xlink:to="label1171" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="element1172" />
        <label xlink:type="resource" xlink:label="label1172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtIssuanceCostsPolicyTextBlock_en-US">Debt Issuance Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1172" xlink:to="label1172" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquipmentAndFurnitureMember" xlink:label="element1173" />
        <label xlink:type="resource" xlink:label="label1173" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquipmentAndFurnitureMember_en-US">Equipment And Furniture [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1173" xlink:to="label1173" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquipmentAndFurnitureMember" xlink:label="element1174" />
        <label xlink:type="resource" xlink:label="label1174" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquipmentAndFurnitureMember_en-US">Equipment And Furniture [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1174" xlink:to="label1174" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerSoftwareMember" xlink:label="element1175" />
        <label xlink:type="resource" xlink:label="label1175" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ComputerSoftwareMember_en-US">Computer Software [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1175" xlink:to="label1175" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerSoftwareMember" xlink:label="element1176" />
        <label xlink:type="resource" xlink:label="label1176" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ComputerSoftwareMember_en-US">Computer Software [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1176" xlink:to="label1176" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="element1177" />
        <label xlink:type="resource" xlink:label="label1177" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_en-US">Internally Developed Computer Software Amortization Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1177" xlink:to="label1177" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="element1178" />
        <label xlink:type="resource" xlink:label="label1178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_en-US">Internally developed computer software amortization period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1178" xlink:to="label1178" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="element1179" />
        <label xlink:type="resource" xlink:label="label1179" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_en-US">Expected amortization period of internally developed AMS3 software once placed in service</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1179" xlink:to="label1179" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="element1180" />
        <label xlink:type="resource" xlink:label="label1180" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InternallyDevelopedComputerSoftware_en-US">Internally Developed Computer Software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1180" xlink:to="label1180" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="element1181" />
        <label xlink:type="resource" xlink:label="label1181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InternallyDevelopedComputerSoftware_en-US">Internally developed computer software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1181" xlink:to="label1181" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="element1182" />
        <label xlink:type="resource" xlink:label="label1182" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InternallyDevelopedComputerSoftware_en-US">Internally developed AMS3 computer software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1182" xlink:to="label1182" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="element1183" />
        <label xlink:type="resource" xlink:label="label1183" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_en-US">Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1183" xlink:to="label1183" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="element1184" />
        <label xlink:type="resource" xlink:label="label1184" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_en-US">Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1184" xlink:to="label1184" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="element1185" />
        <label xlink:type="resource" xlink:label="label1185" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_en-US">Business Acquisition Cost Of Acquired Entity Liabilities Paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1185" xlink:to="label1185" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="element1186" />
        <label xlink:type="resource" xlink:label="label1186" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_en-US">Accrued liability paid to seller</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1186" xlink:to="label1186" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="element1187" />
        <label xlink:type="resource" xlink:label="label1187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_en-US">Accrued liability paid to seller</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1187" xlink:to="label1187" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AlabamaMember" xlink:label="element1188" />
        <label xlink:type="resource" xlink:label="label1188" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AlabamaMember_en-US">Alabama [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1188" xlink:to="label1188" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AlabamaMember" xlink:label="element1189" />
        <label xlink:type="resource" xlink:label="label1189" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AlabamaMember_en-US">Alabama [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1189" xlink:to="label1189" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NorthCarolinaMember" xlink:label="element1190" />
        <label xlink:type="resource" xlink:label="label1190" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NorthCarolinaMember_en-US">North Carolina [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1190" xlink:to="label1190" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NorthCarolinaMember" xlink:label="element1191" />
        <label xlink:type="resource" xlink:label="label1191" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NorthCarolinaMember_en-US">North Carolina [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1191" xlink:to="label1191" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WestVirginiaMember" xlink:label="element1192" />
        <label xlink:type="resource" xlink:label="label1192" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WestVirginiaMember_en-US">West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1192" xlink:to="label1192" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WestVirginiaMember" xlink:label="element1193" />
        <label xlink:type="resource" xlink:label="label1193" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WestVirginiaMember_en-US">West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1193" xlink:to="label1193" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LouisianaMember" xlink:label="element1194" />
        <label xlink:type="resource" xlink:label="label1194" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LouisianaMember_en-US">Louisiana [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1194" xlink:to="label1194" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LouisianaMember" xlink:label="element1195" />
        <label xlink:type="resource" xlink:label="label1195" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LouisianaMember_en-US">Louisiana [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1195" xlink:to="label1195" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FloridaMember" xlink:label="element1196" />
        <label xlink:type="resource" xlink:label="label1196" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FloridaMember_en-US">Florida [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1196" xlink:to="label1196" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FloridaMember" xlink:label="element1197" />
        <label xlink:type="resource" xlink:label="label1197" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FloridaMember_en-US">Florida [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1197" xlink:to="label1197" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="element1198" />
        <label xlink:type="resource" xlink:label="label1198" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InHousePhysiciansPracticeMember_en-US">In House Physicians Practice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1198" xlink:to="label1198" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="element1199" />
        <label xlink:type="resource" xlink:label="label1199" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InHousePhysiciansPracticeMember_en-US">In House Physicians Practice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1199" xlink:to="label1199" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="element1200" />
        <label xlink:type="resource" xlink:label="label1200" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RevolvingCreditFacilityTotal_en-US">Revolving Credit Facility Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1200" xlink:to="label1200" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="element1201" />
        <label xlink:type="resource" xlink:label="label1201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RevolvingCreditFacilityTotal_en-US">Amount of Revolving Credit Facility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1201" xlink:to="label1201" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="element1202" />
        <label xlink:type="resource" xlink:label="label1202" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_en-US">Line Of Credit Facility Additional Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1202" xlink:to="label1202" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="element1203" />
        <label xlink:type="resource" xlink:label="label1203" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_en-US">Line Of Credit Facility Additional Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1203" xlink:to="label1203" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="element1204" />
        <label xlink:type="resource" xlink:label="label1204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_en-US">Credit facility, maximum additional borrowing capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1204" xlink:to="label1204" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="element1205" />
        <label xlink:type="resource" xlink:label="label1205" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SwingLineLoanMember_en-US">Swing Line Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1205" xlink:to="label1205" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="element1206" />
        <label xlink:type="resource" xlink:label="label1206" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SwingLineLoanMember_en-US">Swing Line Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1206" xlink:to="label1206" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="element1207" />
        <label xlink:type="resource" xlink:label="label1207" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentNumberOfPeriodicPayments_en-US">Debt Instrument Number Of Periodic Payments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1207" xlink:to="label1207" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="element1208" />
        <label xlink:type="resource" xlink:label="label1208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentNumberOfPeriodicPayments_en-US">Debt instrument, number of quarterly installments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1208" xlink:to="label1208" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="element1209" />
        <label xlink:type="resource" xlink:label="label1209" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentNumberOfPeriodicPayments_en-US">Debt instrument, number of quarterly installments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1209" xlink:to="label1209" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="element1210" />
        <label xlink:type="resource" xlink:label="label1210" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1210" xlink:to="label1210" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="element1211" />
        <label xlink:type="resource" xlink:label="label1211" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1211" xlink:to="label1211" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="element1212" />
        <label xlink:type="resource" xlink:label="label1212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_en-US">Credit facility, additional interest rate over Federal Funds rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1212" xlink:to="label1212" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="element1213" />
        <label xlink:type="resource" xlink:label="label1213" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1213" xlink:to="label1213" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="element1214" />
        <label xlink:type="resource" xlink:label="label1214" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1214" xlink:to="label1214" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="element1215" />
        <label xlink:type="resource" xlink:label="label1215" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_en-US">Credit Facility, additional interest rate over Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1215" xlink:to="label1215" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="element1216" />
        <label xlink:type="resource" xlink:label="label1216" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ApplicableMarginRateOnBaseRate_en-US">Applicable Margin Rate On Base Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1216" xlink:to="label1216" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="element1217" />
        <label xlink:type="resource" xlink:label="label1217" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ApplicableMarginRateOnBaseRate_en-US">Applicable Margin Rate On Base Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1217" xlink:to="label1217" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="element1218" />
        <label xlink:type="resource" xlink:label="label1218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ApplicableMarginRateOnBaseRate_en-US">Credit Facility, applicable margin on Base Rate Advances</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1218" xlink:to="label1218" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="element1219" />
        <label xlink:type="resource" xlink:label="label1219" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ApplicableMarginRateOnEurodollarRate_en-US">Applicable Margin Rate On Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1219" xlink:to="label1219" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="element1220" />
        <label xlink:type="resource" xlink:label="label1220" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ApplicableMarginRateOnEurodollarRate_en-US">Applicable Margin Rate On Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1220" xlink:to="label1220" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="element1221" />
        <label xlink:type="resource" xlink:label="label1221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ApplicableMarginRateOnEurodollarRate_en-US">Credit Facility, applicable margin on Eurodollar Rate Advances</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1221" xlink:to="label1221" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AbrLoansMember" xlink:label="element1222" />
        <label xlink:type="resource" xlink:label="label1222" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AbrLoansMember_en-US">Abr Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1222" xlink:to="label1222" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AbrLoansMember" xlink:label="element1223" />
        <label xlink:type="resource" xlink:label="label1223" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AbrLoansMember_en-US">Abr Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1223" xlink:to="label1223" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarLoansMember" xlink:label="element1224" />
        <label xlink:type="resource" xlink:label="label1224" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EurodollarLoansMember_en-US">Eurodollar Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1224" xlink:to="label1224" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarLoansMember" xlink:label="element1225" />
        <label xlink:type="resource" xlink:label="label1225" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EurodollarLoansMember_en-US">Eurodollar Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1225" xlink:to="label1225" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="element1226" />
        <label xlink:type="resource" xlink:label="label1226" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_en-US">Operating Lease Commitments For Discontinued Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1226" xlink:to="label1226" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="element1227" />
        <label xlink:type="resource" xlink:label="label1227" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_en-US">Operating Lease Commitments For Discontinued Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1227" xlink:to="label1227" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="element1228" />
        <label xlink:type="resource" xlink:label="label1228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_en-US">Future rental commitments for discontinued operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1228" xlink:to="label1228" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="element1229" />
        <label xlink:type="resource" xlink:label="label1229" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeasesRentExpenseNetForContinuingOperations_en-US">Operating Leases Rent Expense Net For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1229" xlink:to="label1229" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="element1230" />
        <label xlink:type="resource" xlink:label="label1230" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeasesRentExpenseNetForContinuingOperations_en-US">Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income for continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1230" xlink:to="label1230" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="element1231" />
        <label xlink:type="resource" xlink:label="label1231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeasesRentExpenseNetForContinuingOperations_en-US">Rent expense for non-cancelable operating leases</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1231" xlink:to="label1231" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseTermYears" xlink:label="element1232" />
        <label xlink:type="resource" xlink:label="label1232" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeaseTermYears_en-US">Operating Lease Term Years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1232" xlink:to="label1232" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseTermYears" xlink:label="element1233" />
        <label xlink:type="resource" xlink:label="label1233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeaseTermYears_en-US">Operating lease term, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1233" xlink:to="label1233" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseTermYears" xlink:label="element1234" />
        <label xlink:type="resource" xlink:label="label1234" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeaseTermYears_en-US">Operating lease term, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1234" xlink:to="label1234" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="element1235" />
        <label xlink:type="resource" xlink:label="label1235" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeasesAgreementExpirationYear_en-US">Operating Leases Agreement Expiration Year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1235" xlink:to="label1235" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="element1236" />
        <label xlink:type="resource" xlink:label="label1236" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeasesAgreementExpirationYear_en-US">Operating lease agreement year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1236" xlink:to="label1236" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="element1237" />
        <label xlink:type="resource" xlink:label="label1237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeasesAgreementExpirationYear_en-US">Operating lease agreement year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1237" xlink:to="label1237" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="element1238" />
        <label xlink:type="resource" xlink:label="label1238" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1238" xlink:to="label1238" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="element1239" />
        <label xlink:type="resource" xlink:label="label1239" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1239" xlink:to="label1239" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="element1240" />
        <label xlink:type="resource" xlink:label="label1240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1240" xlink:to="label1240" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="element1241" />
        <label xlink:type="resource" xlink:label="label1241" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PromissoryNotesMember_en-US">Promissory Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1241" xlink:to="label1241" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="element1242" />
        <label xlink:type="resource" xlink:label="label1242" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PromissoryNotesMember_en-US">Promissory Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1242" xlink:to="label1242" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="element1243" />
        <label xlink:type="resource" xlink:label="label1243" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_en-US">Number Of Care Centers Included In Discontinued Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1243" xlink:to="label1243" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="element1244" />
        <label xlink:type="resource" xlink:label="label1244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_en-US">Number of care centers included in discontinued operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1244" xlink:to="label1244" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="element1245" />
        <label xlink:type="resource" xlink:label="label1245" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_en-US">The number of care centers included in discontinued operations during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1245" xlink:to="label1245" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FutureRentalCommitmentsTable" xlink:label="element1246" />
        <label xlink:type="resource" xlink:label="label1246" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FutureRentalCommitmentsTable_en-US">Future Rental Commitments [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1246" xlink:to="label1246" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="element1247" />
        <label xlink:type="resource" xlink:label="label1247" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1247" xlink:to="label1247" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="element1248" />
        <label xlink:type="resource" xlink:label="label1248" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1248" xlink:to="label1248" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="element1249" />
        <label xlink:type="resource" xlink:label="label1249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1249" xlink:to="label1249" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" xlink:label="element1250" />
        <label xlink:type="resource" xlink:label="label1250" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Sixteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1250" xlink:to="label1250" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" xlink:label="element1251" />
        <label xlink:type="resource" xlink:label="label1251" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Sixteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1251" xlink:to="label1251" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" xlink:label="element1252" />
        <label xlink:type="resource" xlink:label="label1252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember_en-US">2013 - 2016</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1252" xlink:to="label1252" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="element1253" />
        <label xlink:type="resource" xlink:label="label1253" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedUsefulLifeOfIntangibleAssets_en-US">Estimated Useful Life of Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1253" xlink:to="label1253" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="element1254" />
        <label xlink:type="resource" xlink:label="label1254" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedUsefulLifeOfIntangibleAssets_en-US">The estimated useful life of the company's intangible assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1254" xlink:to="label1254" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="element1255" />
        <label xlink:type="resource" xlink:label="label1255" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedUsefulLifeOfIntangibleAssets_en-US">Estimated useful life of intangible assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1255" xlink:to="label1255" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInFullMember" xlink:label="element1256" />
        <label xlink:type="resource" xlink:label="label1256" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FavorableInFullMember_en-US">Favorable In Full [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1256" xlink:to="label1256" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInFullMember" xlink:label="element1257" />
        <label xlink:type="resource" xlink:label="label1257" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FavorableInFullMember_en-US">Favorable In Full [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1257" xlink:to="label1257" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInPartMember" xlink:label="element1258" />
        <label xlink:type="resource" xlink:label="label1258" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FavorableInPartMember_en-US">Favorable In Part [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1258" xlink:to="label1258" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInPartMember" xlink:label="element1259" />
        <label xlink:type="resource" xlink:label="label1259" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FavorableInPartMember_en-US">Favorable In Part [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1259" xlink:to="label1259" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsAppealed" xlink:label="element1260" />
        <label xlink:type="resource" xlink:label="label1260" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfClaimsAppealed_en-US">Number Of Claims Appealed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1260" xlink:to="label1260" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsAppealed" xlink:label="element1261" />
        <label xlink:type="resource" xlink:label="label1261" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfClaimsAppealed_en-US">Number of claims appealed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1261" xlink:to="label1261" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsAppealed" xlink:label="element1262" />
        <label xlink:type="resource" xlink:label="label1262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfClaimsAppealed_en-US">Number of claims appealed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1262" xlink:to="label1262" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="element1263" />
        <label xlink:type="resource" xlink:label="label1263" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_en-US">Number Of Prospective Unopened Care Centers Start Up Process Discontinued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1263" xlink:to="label1263" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="element1264" />
        <label xlink:type="resource" xlink:label="label1264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_en-US">Number of care centers start-up process discontinued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1264" xlink:to="label1264" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="element1265" />
        <label xlink:type="resource" xlink:label="label1265" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_en-US">The number of prospective unopened care centers for which the start-up process was discontinued during the period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1265" xlink:to="label1265" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="element1266" />
        <label xlink:type="resource" xlink:label="label1266" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GoodwillAndIntangibleAssetsImpairmentAxis_en-US">Goodwill And Intangible Assets Impairment [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1266" xlink:to="label1266" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="element1267" />
        <label xlink:type="resource" xlink:label="label1267" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GoodwillAndIntangibleAssetsDomain_en-US">Goodwill And Intangible Assets [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1267" xlink:to="label1267" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="element1268" />
        <label xlink:type="resource" xlink:label="label1268" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecondLienCreditAgreementTermLoanMember_en-US">Second Lien Credit Agreement Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1268" xlink:to="label1268" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="element1269" />
        <label xlink:type="resource" xlink:label="label1269" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecondLienCreditAgreementTermLoanMember_en-US">Second Lien Credit Agreement Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1269" xlink:to="label1269" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="element1270" />
        <label xlink:type="resource" xlink:label="label1270" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SeniorSecuredLeverageRatio_en-US">Senior Secured Leverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1270" xlink:to="label1270" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="element1271" />
        <label xlink:type="resource" xlink:label="label1271" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SeniorSecuredLeverageRatio_en-US">Senior secured leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1271" xlink:to="label1271" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="element1272" />
        <label xlink:type="resource" xlink:label="label1272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SeniorSecuredLeverageRatio_en-US">Senior secured leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1272" xlink:to="label1272" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="element1273" />
        <label xlink:type="resource" xlink:label="label1273" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_en-US">Second Lien Credit Agreement Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1273" xlink:to="label1273" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="element1274" />
        <label xlink:type="resource" xlink:label="label1274" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_en-US">Second Lien Credit Agreement Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1274" xlink:to="label1274" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="element1275" />
        <label xlink:type="resource" xlink:label="label1275" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_en-US">Debt Instrument Interest Additional Interest Above ABR Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1275" xlink:to="label1275" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="element1276" />
        <label xlink:type="resource" xlink:label="label1276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_en-US">Credit Facility, additional interest rate over ABR Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1276" xlink:to="label1276" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="element1277" />
        <label xlink:type="resource" xlink:label="label1277" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_en-US">Debt Instrument Interest Additional Interest Above ABR Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1277" xlink:to="label1277" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="element1278" />
        <label xlink:type="resource" xlink:label="label1278" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above One Month Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1278" xlink:to="label1278" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="element1279" />
        <label xlink:type="resource" xlink:label="label1279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_en-US">Credit Facility, additional interest rate over One Month Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1279" xlink:to="label1279" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="element1280" />
        <label xlink:type="resource" xlink:label="label1280" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above One Month Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1280" xlink:to="label1280" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="element1281" />
        <label xlink:type="resource" xlink:label="label1281" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestABRFlatRate_en-US">Debt Instrument Interest ABR Flat Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1281" xlink:to="label1281" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="element1282" />
        <label xlink:type="resource" xlink:label="label1282" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestABRFlatRate_en-US">Debt Instrument Interest ABR Flat Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1282" xlink:to="label1282" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="element1283" />
        <label xlink:type="resource" xlink:label="label1283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestABRFlatRate_en-US">Credit Facility, ABR Flat Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1283" xlink:to="label1283" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="element1284" />
        <label xlink:type="resource" xlink:label="label1284" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EurodollarDepositsInterestPeriod_en-US">Eurodollar Deposits Interest Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1284" xlink:to="label1284" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="element1285" />
        <label xlink:type="resource" xlink:label="label1285" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EurodollarDepositsInterestPeriod_en-US">Eurodollar Deposits Interest Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1285" xlink:to="label1285" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="element1286" />
        <label xlink:type="resource" xlink:label="label1286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EurodollarDepositsInterestPeriod_en-US">Eurodollar deposits interest period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1286" xlink:to="label1286" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="element1287" />
        <label xlink:type="resource" xlink:label="label1287" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestLiborFloor_en-US">Debt Instrument Interest LIBOR Floor</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1287" xlink:to="label1287" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="element1288" />
        <label xlink:type="resource" xlink:label="label1288" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestLiborFloor_en-US">Debt Instrument Interest LIBOR Floor</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1288" xlink:to="label1288" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="element1289" />
        <label xlink:type="resource" xlink:label="label1289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestLiborFloor_en-US">Credit Facility, LIBOR floor</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1289" xlink:to="label1289" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CreditAgreementMember" xlink:label="element1290" />
        <label xlink:type="resource" xlink:label="label1290" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CreditAgreementMember_en-US">Credit Agreement [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1290" xlink:to="label1290" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CreditAgreementMember" xlink:label="element1291" />
        <label xlink:type="resource" xlink:label="label1291" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CreditAgreementMember_en-US">Credit Agreement [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1291" xlink:to="label1291" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherLongTermObligationsMember" xlink:label="element1292" />
        <label xlink:type="resource" xlink:label="label1292" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherLongTermObligationsMember_en-US">Other Long Term Obligations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1292" xlink:to="label1292" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherLongTermObligationsMember" xlink:label="element1293" />
        <label xlink:type="resource" xlink:label="label1293" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OtherLongTermObligationsMember_en-US">Other Long Term Obligations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1293" xlink:to="label1293" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredIncomeTaxesMember" xlink:label="element1294" />
        <label xlink:type="resource" xlink:label="label1294" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredIncomeTaxesMember_en-US">Deferred Income Taxes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1294" xlink:to="label1294" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredIncomeTaxesMember" xlink:label="element1295" />
        <label xlink:type="resource" xlink:label="label1295" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredIncomeTaxesMember_en-US">Deferred Income Taxes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1295" xlink:to="label1295" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="element1296" />
        <label xlink:type="resource" xlink:label="label1296" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoThousandAndFourteenExitActivityMember_en-US">Two Thousand And Fourteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1296" xlink:to="label1296" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="element1297" />
        <label xlink:type="resource" xlink:label="label1297" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoThousandAndFourteenExitActivityMember_en-US">Two Thousand And Fourteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1297" xlink:to="label1297" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="element1298" />
        <label xlink:type="resource" xlink:label="label1298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TwoThousandAndFourteenExitActivityMember_en-US">2014 Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1298" xlink:to="label1298" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="element1299" />
        <label xlink:type="resource" xlink:label="label1299" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CorporateIntegrityAgreementTerm_en-US">Corporate Integrity Agreement Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1299" xlink:to="label1299" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="element1300" />
        <label xlink:type="resource" xlink:label="label1300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CorporateIntegrityAgreementTerm_en-US">Corporate Integrity Agreement Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1300" xlink:to="label1300" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="element1301" />
        <label xlink:type="resource" xlink:label="label1301" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CorporateIntegrityAgreementTerm_en-US">Corporate Integrity Agreement Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1301" xlink:to="label1301" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodAxis" xlink:label="element1302" />
        <label xlink:type="resource" xlink:label="label1302" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TimePeriodAxis_en-US">Time Period [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1302" xlink:to="label1302" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="element1303" />
        <label xlink:type="resource" xlink:label="label1303" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TimePeriodDomain_en-US">Time Period [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1303" xlink:to="label1303" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneMonthMember" xlink:label="element1304" />
        <label xlink:type="resource" xlink:label="label1304" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OneMonthMember_en-US">One Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1304" xlink:to="label1304" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneMonthMember" xlink:label="element1305" />
        <label xlink:type="resource" xlink:label="label1305" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OneMonthMember_en-US">One Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1305" xlink:to="label1305" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoMonthMember" xlink:label="element1306" />
        <label xlink:type="resource" xlink:label="label1306" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoMonthMember_en-US">Two Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1306" xlink:to="label1306" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoMonthMember" xlink:label="element1307" />
        <label xlink:type="resource" xlink:label="label1307" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoMonthMember_en-US">Two Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1307" xlink:to="label1307" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThreeMonthMember" xlink:label="element1308" />
        <label xlink:type="resource" xlink:label="label1308" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ThreeMonthMember_en-US">Three Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1308" xlink:to="label1308" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThreeMonthMember" xlink:label="element1309" />
        <label xlink:type="resource" xlink:label="label1309" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ThreeMonthMember_en-US">Three Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1309" xlink:to="label1309" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SixMonthMember" xlink:label="element1310" />
        <label xlink:type="resource" xlink:label="label1310" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SixMonthMember_en-US">Six Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1310" xlink:to="label1310" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SixMonthMember" xlink:label="element1311" />
        <label xlink:type="resource" xlink:label="label1311" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SixMonthMember_en-US">Six Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1311" xlink:to="label1311" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneYearMember" xlink:label="element1312" />
        <label xlink:type="resource" xlink:label="label1312" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OneYearMember_en-US">One Year [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1312" xlink:to="label1312" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoYearMember" xlink:label="element1313" />
        <label xlink:type="resource" xlink:label="label1313" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoYearMember_en-US">Two Year [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1313" xlink:to="label1313" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="element1314" />
        <label xlink:type="resource" xlink:label="label1314" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AnnualImpairmentTestStepOneMember_en-US">Annual Impairment Test Step One [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1314" xlink:to="label1314" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="element1315" />
        <label xlink:type="resource" xlink:label="label1315" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AnnualImpairmentTestStepOneMember_en-US">Annual Impairment Test Step One [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1315" xlink:to="label1315" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="element1316" />
        <label xlink:type="resource" xlink:label="label1316" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PrepaymentPenaltyPercentage_en-US">Prepayment Penalty Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1316" xlink:to="label1316" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="element1317" />
        <label xlink:type="resource" xlink:label="label1317" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PrepaymentPenaltyPercentage_en-US">Prepayment Penalty Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1317" xlink:to="label1317" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="element1318" />
        <label xlink:type="resource" xlink:label="label1318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PrepaymentPenaltyPercentage_en-US">Prepayment penalty percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1318" xlink:to="label1318" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1319" />
        <label xlink:type="resource" xlink:label="label1319" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_en-US">Increase Decrease In U.S. Department of Justice Settlement Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1319" xlink:to="label1319" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1320" />
        <label xlink:type="resource" xlink:label="label1320" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_en-US">Increase Decrease In U.S. Department of Justice Settlement Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1320" xlink:to="label1320" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1321" />
        <label xlink:type="resource" xlink:label="label1321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_en-US">U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1321" xlink:to="label1321" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="element1322" />
        <label xlink:type="resource" xlink:label="label1322" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_en-US">Classification Of Deferred Tax Assets Liabilities [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1322" xlink:to="label1322" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="element1323" />
        <label xlink:type="resource" xlink:label="label1323" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_en-US">Classification Of Deferred Tax Assets Liabilities Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1323" xlink:to="label1323" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="element1324" />
        <label xlink:type="resource" xlink:label="label1324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_en-US">Classification of Deferred Tax Assets and Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1324" xlink:to="label1324" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="element1325" />
        <label xlink:type="resource" xlink:label="label1325" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_en-US">Noncash Or Part Noncash Sale Acquisition Of Noncontrolling Interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1325" xlink:to="label1325" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="element1326" />
        <label xlink:type="resource" xlink:label="label1326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_en-US">(Sale) acquistion of noncontrolling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1326" xlink:to="label1326" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="element1327" />
        <label xlink:type="resource" xlink:label="label1327" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_en-US">Noncash Or Part Noncash Sale Acquisition Of Noncontrolling Interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1327" xlink:to="label1327" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeAxis" xlink:label="element1328" />
        <label xlink:type="resource" xlink:label="label1328" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FeeTypeAxis_en-US">Fee Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1328" xlink:to="label1328" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeAxis" xlink:label="element1329" />
        <label xlink:type="resource" xlink:label="label1329" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FeeTypeAxis_en-US">Fee Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1329" xlink:to="label1329" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeDomain" xlink:label="element1330" />
        <label xlink:type="resource" xlink:label="label1330" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FeeTypeDomain_en-US">Fee Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1330" xlink:to="label1330" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ArrangerFeeMember" xlink:label="element1331" />
        <label xlink:type="resource" xlink:label="label1331" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ArrangerFeeMember_en-US">Arranger Fee [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1331" xlink:to="label1331" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ArrangerFeeMember" xlink:label="element1332" />
        <label xlink:type="resource" xlink:label="label1332" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ArrangerFeeMember_en-US">Arranger Fee [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1332" xlink:to="label1332" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="element1333" />
        <label xlink:type="resource" xlink:label="label1333" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ComputerInventoryAndDataSecurityReportingMember_en-US">Computer Inventory And Data Security Reporting [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1333" xlink:to="label1333" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="element1334" />
        <label xlink:type="resource" xlink:label="label1334" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ComputerInventoryAndDataSecurityReportingMember_en-US">Computer Inventory And Data Security Reporting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1334" xlink:to="label1334" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="element1335" />
        <label xlink:type="resource" xlink:label="label1335" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfIndividualsWithInformationOnMissingDevices_en-US">Number of Individuals With Information on Missing Devices</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1335" xlink:to="label1335" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="element1336" />
        <label xlink:type="resource" xlink:label="label1336" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfIndividualsWithInformationOnMissingDevices_en-US">Number of individuals whose information was on reported missing devices</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1336" xlink:to="label1336" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="element1337" />
        <label xlink:type="resource" xlink:label="label1337" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfMissingComputersAndLaptops_en-US">Number of Missing Computers and Laptops</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1337" xlink:to="label1337" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="element1338" />
        <label xlink:type="resource" xlink:label="label1338" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfMissingComputersAndLaptops_en-US">Number of missing computers and laptops</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1338" xlink:to="label1338" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="element1339" />
        <label xlink:type="resource" xlink:label="label1339" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ThresholdOfIndividualsInDataBreach_en-US">Threshold of Individuals in Data Breach</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1339" xlink:to="label1339" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="element1340" />
        <label xlink:type="resource" xlink:label="label1340" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ThresholdOfIndividualsInDataBreach_en-US">Threshold of number of individuals involved in a data breach</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1340" xlink:to="label1340" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="element1341" />
        <label xlink:type="resource" xlink:label="label1341" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfCompanyDevicesUsed_en-US">Percentage Of Company Devices Used</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1341" xlink:to="label1341" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="element1342" />
        <label xlink:type="resource" xlink:label="label1342" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfCompanyDevicesUsed_en-US">Percentage of devices used by the Company</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1342" xlink:to="label1342" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_YearOfDeparture" xlink:label="element1343" />
        <label xlink:type="resource" xlink:label="label1343" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_YearOfDeparture_en-US">Year of Departure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1343" xlink:to="label1343" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_YearOfDeparture" xlink:label="element1344" />
        <label xlink:type="resource" xlink:label="label1344" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_YearOfDeparture_en-US">Year of departure from the company</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1344" xlink:to="label1344" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AMS3writeoffcharge" xlink:label="element1345" />
        <label xlink:type="resource" xlink:label="label1345" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AMS3writeoffcharge_en-US">AMS3 Writeoff Charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1345" xlink:to="label1345" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AMS3writeoffcharge" xlink:label="element1346" />
        <label xlink:type="resource" xlink:label="label1346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_AMS3writeoffcharge_en-US">AMS3 writeoff charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1346" xlink:to="label1346" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AMS3writeoffcharge" xlink:label="element1347" />
        <label xlink:type="resource" xlink:label="label1347" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AMS3writeoffcharge_en-US">AMS3 Writeoff Charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1347" xlink:to="label1347" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Buildingandleaseholdimprovements" xlink:label="element1348" />
        <label xlink:type="resource" xlink:label="label1348" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Buildingandleaseholdimprovements_en-US">Building And Leasehold Improvements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1348" xlink:to="label1348" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Buildingandleaseholdimprovements" xlink:label="element1349" />
        <label xlink:type="resource" xlink:label="label1349" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Buildingandleaseholdimprovements_en-US">Building And Leasehold Improvements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1349" xlink:to="label1349" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Buildingandleaseholdimprovements" xlink:label="element1350" />
        <label xlink:type="resource" xlink:label="label1350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Buildingandleaseholdimprovements_en-US">Building and leasehold improvements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1350" xlink:to="label1350" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Equipmentandfurniture" xlink:label="element1351" />
        <label xlink:type="resource" xlink:label="label1351" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Equipmentandfurniture_en-US">Equipment And Furniture</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1351" xlink:to="label1351" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Equipmentandfurniture" xlink:label="element1352" />
        <label xlink:type="resource" xlink:label="label1352" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Equipmentandfurniture_en-US">Equipment And Furniture</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1352" xlink:to="label1352" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Equipmentandfurniture" xlink:label="element1353" />
        <label xlink:type="resource" xlink:label="label1353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Equipmentandfurniture_en-US">Equipment and furniture</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1353" xlink:to="label1353" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FrontierLitigationMember" xlink:label="element1354" />
        <label xlink:type="resource" xlink:label="label1354" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FrontierLitigationMember_en-US">Frontier Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1354" xlink:to="label1354" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FrontierLitigationMember" xlink:label="element1355" />
        <label xlink:type="resource" xlink:label="label1355" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FrontierLitigationMember_en-US">Frontier Litigation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1355" xlink:to="label1355" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="element1356" />
        <label xlink:type="resource" xlink:label="label1356" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_en-US">Equity Method Investment Summarized Financial Information Total Investment Income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1356" xlink:to="label1356" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="element1357" />
        <label xlink:type="resource" xlink:label="label1357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_en-US">Equity method investment total investment income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1357" xlink:to="label1357" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="element1358" />
        <label xlink:type="resource" xlink:label="label1358" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_en-US">Investment income (loss) of equity method investee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1358" xlink:to="label1358" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="element1359" />
        <label xlink:type="resource" xlink:label="label1359" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_en-US">Equity Method Investment Summarized Financial Information Total Expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1359" xlink:to="label1359" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="element1360" />
        <label xlink:type="resource" xlink:label="label1360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_en-US">Equity method investment summarized financial information total expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1360" xlink:to="label1360" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="element1361" />
        <label xlink:type="resource" xlink:label="label1361" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_en-US">Total expenses of equity method investee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1361" xlink:to="label1361" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="element1362" />
        <label xlink:type="resource" xlink:label="label1362" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_en-US">Equity Method Investment Summarized Financial Information Net Increase In Partners Capital From Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1362" xlink:to="label1362" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="element1363" />
        <label xlink:type="resource" xlink:label="label1363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_en-US">Equity method investment summarized financial information net increase (decrease) in partners capital from operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1363" xlink:to="label1363" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="element1364" />
        <label xlink:type="resource" xlink:label="label1364" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_en-US">Net increase (decrease) in partner's capital from operations of equity method investee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1364" xlink:to="label1364" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HeritageHealthCareInnovationFundMemberMember" xlink:label="element1365" />
        <label xlink:type="resource" xlink:label="label1365" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HeritageHealthCareInnovationFundMemberMember_en-US">Heritage Healthcare Innovation Fund [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1365" xlink:to="label1365" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="element1366" />
        <label xlink:type="resource" xlink:label="label1366" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_en-US">Goodwill Is Expected To Be Deductible For Income Tax Purposes Years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1366" xlink:to="label1366" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="element1367" />
        <label xlink:type="resource" xlink:label="label1367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_en-US">Period in which goodwill is expected to be deductible for income tax purposes, in years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1367" xlink:to="label1367" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="element1368" />
        <label xlink:type="resource" xlink:label="label1368" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_en-US">Period in which goodwill is expected to be deductible for income tax purposes, in years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1368" xlink:to="label1368" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="element1369" />
        <label xlink:type="resource" xlink:label="label1369" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PersonalCareMember_en-US">Personal Care [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1369" xlink:to="label1369" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="element1370" />
        <label xlink:type="resource" xlink:label="label1370" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PersonalCareMember_en-US">Personal Care [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1370" xlink:to="label1370" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="element1371" />
        <label xlink:type="resource" xlink:label="label1371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PersonalCareMember_en-US">Personal Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1371" xlink:to="label1371" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="element1372" />
        <label xlink:type="resource" xlink:label="label1372" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OneHundredMillionTermLoanMember_en-US">One Hundred Million Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1372" xlink:to="label1372" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="element1373" />
        <label xlink:type="resource" xlink:label="label1373" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OneHundredMillionTermLoanMember_en-US">100 Million Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1373" xlink:to="label1373" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="element1374" />
        <label xlink:type="resource" xlink:label="label1374" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoHundredMillionRevolvingCreditFacilityMember_en-US">Two Hundred Million Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1374" xlink:to="label1374" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="element1375" />
        <label xlink:type="resource" xlink:label="label1375" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoHundredMillionRevolvingCreditFacilityMember_en-US">Two Hundred Million Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1375" xlink:to="label1375" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfPatients" xlink:label="element1376" />
        <label xlink:type="resource" xlink:label="label1376" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfPatients_en-US">Number of patients</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1376" xlink:to="label1376" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfPatients" xlink:label="element1377" />
        <label xlink:type="resource" xlink:label="label1377" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfPatients_en-US">Number of patients</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1377" xlink:to="label1377" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest" xlink:label="element1378" />
        <label xlink:type="resource" xlink:label="label1378" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest_en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1378" xlink:to="label1378" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest" xlink:label="element1379" />
        <label xlink:type="resource" xlink:label="label1379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest_en-US">Recovery amount of over payment made to subsidiary including interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1379" xlink:to="label1379" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest" xlink:label="element1380" />
        <label xlink:type="resource" xlink:label="label1380" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest_en-US">Recovery amount of over payment made to subsidiary including interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1380" xlink:to="label1380" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Percentageofpatientreceivablesoutstandingovertenpercent" xlink:label="element1381" />
        <label xlink:type="resource" xlink:label="label1381" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Percentageofpatientreceivablesoutstandingovertenpercent_en-US">Percentage Of Patient Receivables Outstanding Over Ten Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1381" xlink:to="label1381" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Percentageofpatientreceivablesoutstandingovertenpercent" xlink:label="element1382" />
        <label xlink:type="resource" xlink:label="label1382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Percentageofpatientreceivablesoutstandingovertenpercent_en-US">Percentage Of Patient Receivables Outstanding Over Ten Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1382" xlink:to="label1382" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Percentageofpatientreceivablesoutstandingovertenpercent" xlink:label="element1383" />
        <label xlink:type="resource" xlink:label="label1383" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Percentageofpatientreceivablesoutstandingovertenpercent_en-US">Percentage of patient receivables outstanding over ten percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1383" xlink:to="label1383" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentAxis" xlink:label="element1384" />
        <label xlink:type="resource" xlink:label="label1384" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AssetImpairmentAxis_en-US">Asset Impairment [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1384" xlink:to="label1384" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentAxis" xlink:label="element1385" />
        <label xlink:type="resource" xlink:label="label1385" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AssetImpairmentAxis_en-US">Asset Impairment [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1385" xlink:to="label1385" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentDomain" xlink:label="element1386" />
        <label xlink:type="resource" xlink:label="label1386" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AssetImpairmentDomain_en-US">Asset Impairment [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1386" xlink:to="label1386" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentDomain" xlink:label="element1387" />
        <label xlink:type="resource" xlink:label="label1387" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AssetImpairmentDomain_en-US">Asset Impairment [Domian]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1387" xlink:to="label1387" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="element1388" />
        <label xlink:type="resource" xlink:label="label1388" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Ams3HomecareAndHospiceMember_en-US">AMS3 Homecare and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1388" xlink:to="label1388" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="element1389" />
        <label xlink:type="resource" xlink:label="label1389" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Ams3HomecareAndHospiceMember_en-US">AMS3 Homecare and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1389" xlink:to="label1389" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeStaffLlcMember" xlink:label="element1390" />
        <label xlink:type="resource" xlink:label="label1390" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HomeStaffLlcMember_en-US">Home Staff, L.L.C. [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1390" xlink:to="label1390" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeStaffLlcMember" xlink:label="element1391" />
        <label xlink:type="resource" xlink:label="label1391" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HomeStaffLlcMember_en-US">Home Staff, L.L.C. [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1391" xlink:to="label1391" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" xlink:label="element1392" />
        <label xlink:type="resource" xlink:label="label1392" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Seventeen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1392" xlink:to="label1392" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" xlink:label="element1393" />
        <label xlink:type="resource" xlink:label="label1393" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Seventeen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1393" xlink:to="label1393" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" xlink:label="element1394" />
        <label xlink:type="resource" xlink:label="label1394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember_en-US">2013 - 2017</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1394" xlink:to="label1394" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SuspensionOfMedicarePayments_days" xlink:label="element1395" />
        <label xlink:type="resource" xlink:label="label1395" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SuspensionOfMedicarePayments_days_en-US">Suspension of Medicare Payments_Days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1395" xlink:to="label1395" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SuspensionOfMedicarePayments_days" xlink:label="element1396" />
        <label xlink:type="resource" xlink:label="label1396" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SuspensionOfMedicarePayments_days_en-US">Description containing the number of days regarding the receipt of a Notice of Suspension of Medicare Payments.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1396" xlink:to="label1396" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SuspensionOfMedicarePayments_days" xlink:label="element1397" />
        <label xlink:type="resource" xlink:label="label1397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SuspensionOfMedicarePayments_days_en-US">Suspension of Medicare Payments, Days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1397" xlink:to="label1397" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember" xlink:label="element1398" />
        <label xlink:type="resource" xlink:label="label1398" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SafeguardZoneProgramIntegrityContractorMember_en-US">SafeGuard Zone Program Integrity Contractor [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1398" xlink:to="label1398" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember" xlink:label="element1399" />
        <label xlink:type="resource" xlink:label="label1399" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SafeguardZoneProgramIntegrityContractorMember_en-US">SafeGuard Zone Program Integrity Contractor [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1399" xlink:to="label1399" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MorgantownWestVirginiaMember" xlink:label="element1400" />
        <label xlink:type="resource" xlink:label="label1400" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MorgantownWestVirginiaMember_en-US">Morgantown, West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1400" xlink:to="label1400" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MorgantownWestVirginiaMember" xlink:label="element1401" />
        <label xlink:type="resource" xlink:label="label1401" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MorgantownWestVirginiaMember_en-US">Morgantown, West Virginia [Member</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1401" xlink:to="label1401" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="element1402" />
        <label xlink:type="resource" xlink:label="label1402" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecuritiesClassActionLawsuitMember_en-US">Securities Class Action Lawsuit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1402" xlink:to="label1402" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="element1403" />
        <label xlink:type="resource" xlink:label="label1403" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SecuritiesClassActionLawsuitMember_en-US">Securities Class Action Lawsuit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1403" xlink:to="label1403" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="element1404" />
        <label xlink:type="resource" xlink:label="label1404" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecuritiesClassActionLawsuitMember_en-US">Securities Class Action Lawsuit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1404" xlink:to="label1404" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="element1405" />
        <label xlink:type="resource" xlink:label="label1405" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ParkersburgWestVirginiaMember_en-US">Parkersburg, West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1405" xlink:to="label1405" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="element1406" />
        <label xlink:type="resource" xlink:label="label1406" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ParkersburgWestVirginiaMember_en-US">Parkersburg, West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1406" xlink:to="label1406" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="element1407" />
        <label xlink:type="resource" xlink:label="label1407" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_en-US">Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1407" xlink:to="label1407" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="element1408" />
        <label xlink:type="resource" xlink:label="label1408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_en-US">Recovery amount of over payment made to subsidiary including interest withheld</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1408" xlink:to="label1408" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="element1409" />
        <label xlink:type="resource" xlink:label="label1409" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_en-US">Recovery amount of over payment made to subsidiary including interest withheld</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1409" xlink:to="label1409" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccountingStandardsUpdate201609Member" xlink:label="element1410" />
        <label xlink:type="resource" xlink:label="label1410" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AccountingStandardsUpdate201609Member_en-US">Accounting Standards Update 2016-09 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1410" xlink:to="label1410" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccountingStandardsUpdate201609Member" xlink:label="element1411" />
        <label xlink:type="resource" xlink:label="label1411" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AccountingStandardsUpdate201609Member_en-US">Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1411" xlink:to="label1411" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenueMember" xlink:label="element1412" />
        <label xlink:type="resource" xlink:label="label1412" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MedicareRevenueMember_en-US">Medicare Revenue [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1412" xlink:to="label1412" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenueMember" xlink:label="element1413" />
        <label xlink:type="resource" xlink:label="label1413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MedicareRevenueMember_en-US">Medicare Revenue [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1413" xlink:to="label1413" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenueMember" xlink:label="element1414" />
        <label xlink:type="resource" xlink:label="label1414" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MedicareRevenueMember_en-US">Revenue from sale of goods and services rendered, in relation to Medicare, during the normal course of business, when it serves as a benchmark in a concentration of risk calculation.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1414" xlink:to="label1414" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TenetHealthcareMember" xlink:label="element1415" />
        <label xlink:type="resource" xlink:label="label1415" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TenetHealthcareMember_en-US">Tenet Healthcare [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1415" xlink:to="label1415" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TenetHealthcareMember" xlink:label="element1416" />
        <label xlink:type="resource" xlink:label="label1416" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TenetHealthcareMember_en-US">Tenet Healthcare [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1416" xlink:to="label1416" />
    </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>amed-20170331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.5.34 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
    <roleRef roleURI="http://www.amedisys.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DocumentAndEntityInformation" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETS" />
    <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
    <roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETSParenthetical" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS" />
    <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" />
    <roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" />
    <roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" />
    <roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ACQUISITIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE" />
    <roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNET" />
    <roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LONGTERMOBLIGATIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_COMMITMENTSANDCONTINGENCIES" />
    <roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SEGMENTINFORMATION" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DISONTINUEDOPERATIONSANDASSETSHELDFORSALETables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DISONTINUEDOPERATIONSANDASSETSHELDFORSALETables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureGOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNETTables" />
    <roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LONGTERMOBLIGATIONSTables" />
    <roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SEGMENTINFORMATIONTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfWeightedAverageSharesOutstandingDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfNetRevenuesAndOperatingResultsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfNetRevenuesAndOperatingResultsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LongTermDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LongTermDebtParentheticalDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_LongTermDebtAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentsAndContingenciesDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CommitmentsAndContingenciesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SegmentInformationAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_OperatingIncomeOfReportableSegmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/EXITACTIVITIES" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_EXITACTIVITIES" />
    <roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SUBSEQUENTEVENT" />
    <roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTS" />
    <roleRef roleURI="http://www.amedisys.com/role/INCOMETAXES" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_INCOMETAXES" />
    <roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_EMPLOYEEBENEFITPLANS" />
    <roleRef roleURI="http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTS" />
    <roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" />
    <roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" />
    <roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_INCOMETAXESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_COMMITMENTSANDCONTINGENCIESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/EXITACTIVITIESTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_EXITACTIVITIESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureVALUATIONANDQUALIFYINGACCOUNTSTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTSTables" />
    <roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_AcquisitionsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_GoodwillAndOtherIntangibleAssetsNetDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_IncomeTaxesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/EmployeeBenefitPlansDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_EmployeeBenefitPlansDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureFutureMinimumRentalCommitments" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_FutureMinimumRentalCommitments" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_InsuranceProgramsDetails" />
    <roleRef roleURI="http://www.amedisys.com/role/ComponentsOfNetDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ComponentsOfNetDeferredTaxAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSourcesOfTaxEffectDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SourcesOfTaxEffectDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ReconciliationOfUnrecognizedTaxBenefitsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_MaturitiesOfDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_CommitmentFeeUnderCreditFacilitiesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ExitActivitiesReserveActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSHAREREPURCHASEPROGRAM" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SHAREREPURCHASEPROGRAM" />
    <roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseProgramDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_ShareRepurchaseProgramDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_RELATEDPARTYTRANSACTIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_RelatedPartyTransactionDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SubsequentEventDetail" xlink:type="simple" xlink:href="amed-20170331.xsd#amed_ELRID_SubsequentEventDetail" />
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DocumentAndEntityInformation">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_73" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_74" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_73" xlink:to="Locator_dei_EntityDomain_74" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="Locator_amed_DocumentDocumentandEntityInformationAbstract_33" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_34" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DocumentDocumentandEntityInformationAbstract_33" xlink:to="Locator_dei_EntitiesTable_34" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_69" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_70" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_EntitiesTable_69" xlink:to="Locator_dei_DocumentInformationLineItems_70" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="Locator_dei_DocumentType_2" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_1" xlink:to="Locator_dei_DocumentType_2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_3" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="Locator_dei_AmendmentFlag_4" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_3" xlink:to="Locator_dei_AmendmentFlag_4" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_5" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="Locator_dei_DocumentPeriodEndDate_6" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_5" xlink:to="Locator_dei_DocumentPeriodEndDate_6" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_7" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="Locator_dei_DocumentFiscalYearFocus_8" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_7" xlink:to="Locator_dei_DocumentFiscalYearFocus_8" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_9" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="Locator_dei_DocumentFiscalPeriodFocus_10" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_9" xlink:to="Locator_dei_DocumentFiscalPeriodFocus_10" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_11" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="Locator_dei_TradingSymbol_12" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_11" xlink:to="Locator_dei_TradingSymbol_12" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_13" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="Locator_dei_EntityRegistrantName_14" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_13" xlink:to="Locator_dei_EntityRegistrantName_14" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_15" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="Locator_dei_EntityCentralIndexKey_16" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_15" xlink:to="Locator_dei_EntityCentralIndexKey_16" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_17" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="Locator_dei_CurrentFiscalYearEndDate_18" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_17" xlink:to="Locator_dei_CurrentFiscalYearEndDate_18" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_19" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="Locator_dei_EntityFilerCategory_20" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_19" xlink:to="Locator_dei_EntityFilerCategory_20" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_21" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="Locator_dei_EntityCommonStockSharesOutstanding_22" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_21" xlink:to="Locator_dei_EntityCommonStockSharesOutstanding_22" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_23" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="Locator_dei_EntityPublicFloat_24" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_23" xlink:to="Locator_dei_EntityPublicFloat_24" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_25" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="Locator_dei_EntityVoluntaryFilers_26" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_25" xlink:to="Locator_dei_EntityVoluntaryFilers_26" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_27" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="Locator_dei_EntityCurrentReportingStatus_28" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_27" xlink:to="Locator_dei_EntityCurrentReportingStatus_28" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_29" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="Locator_dei_EntityWellKnownSeasonedIssuer_30" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_29" xlink:to="Locator_dei_EntityWellKnownSeasonedIssuer_30" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_71" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_72" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_EntitiesTable_71" xlink:to="Locator_dei_LegalEntityAxis_72" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_305" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_306" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_305" xlink:to="Locator_dei_EntityDomain_306" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_302" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_301" xlink:to="Locator_us-gaap_StatementLineItems_302" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_75" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_76" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_75" xlink:to="Locator_us-gaap_AssetsAbstract_76" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_81" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_82" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_81" xlink:to="Locator_us-gaap_AssetsCurrentAbstract_82" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_95" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_96" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_95" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_96" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_97" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="Locator_us-gaap_AccountsReceivableNetCurrent_98" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_97" xlink:to="Locator_us-gaap_AccountsReceivableNetCurrent_98" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_99" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="Locator_us-gaap_PrepaidExpenseCurrent_100" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_99" xlink:to="Locator_us-gaap_PrepaidExpenseCurrent_100" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_101" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetCurrent_102" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_101" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetCurrent_102" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_103" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_104" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_103" xlink:to="Locator_us-gaap_OtherAssetsCurrent_104" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_105" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_106" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_105" xlink:to="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_106" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_107" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_108" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_107" xlink:to="Locator_us-gaap_AssetsCurrent_108" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_83" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_84" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_83" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentNet_84" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_85" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_86" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_85" xlink:to="Locator_us-gaap_Goodwill_86" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_87" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_88" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_87" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_88" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_89" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_90" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_89" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_90" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_91" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_92" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_91" xlink:to="Locator_us-gaap_OtherAssetsNoncurrent_92" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_93" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_94" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_93" xlink:to="Locator_us-gaap_Assets_94" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_77" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_78" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_77" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_78" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_109" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_110" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_109" xlink:to="Locator_us-gaap_LiabilitiesCurrentAbstract_110" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_123" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="Locator_us-gaap_AccountsPayableCurrent_124" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_123" xlink:to="Locator_us-gaap_AccountsPayableCurrent_124" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_125" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_126" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_125" xlink:to="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_126" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_127" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_128" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_127" xlink:to="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_128" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_129" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_130" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_129" xlink:to="Locator_us-gaap_AccruedLiabilitiesCurrent_130" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_131" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_132" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_131" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_132" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_133" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_134" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_133" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_134" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_135" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_136" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_135" xlink:to="Locator_us-gaap_LiabilitiesCurrent_136" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_111" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_112" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_111" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_112" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_113" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_114" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_113" xlink:to="Locator_us-gaap_OtherLiabilitiesNoncurrent_114" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_116" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="Locator_us-gaap_Liabilities_116" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_117" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="Locator_us-gaap_CommitmentsAndContingencies_118" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_117" xlink:to="Locator_us-gaap_CommitmentsAndContingencies_118" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_119" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_120" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_119" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_120" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_137" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="Locator_us-gaap_PreferredStockValueOutstanding_138" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_137" xlink:to="Locator_us-gaap_PreferredStockValueOutstanding_138" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_139" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="Locator_us-gaap_CommonStockValueOutstanding_140" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_139" xlink:to="Locator_us-gaap_CommonStockValueOutstanding_140" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_141" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_142" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_141" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_142" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_143" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="Locator_us-gaap_TreasuryStockValue_144" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_143" xlink:to="Locator_us-gaap_TreasuryStockValue_144" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_146" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_145" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_146" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_147" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_148" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_147" xlink:to="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_148" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_149" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_150" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_149" xlink:to="Locator_us-gaap_StockholdersEquity_150" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_151" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="Locator_us-gaap_MinorityInterest_152" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_151" xlink:to="Locator_us-gaap_MinorityInterest_152" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_153" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_154" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_153" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_154" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_122" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquity_122" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_303" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_304" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_303" xlink:to="Locator_dei_LegalEntityAxis_304" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="Locator_us-gaap_StatementOfFinancialPositionAbstract_155" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_156" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfFinancialPositionAbstract_155" xlink:to="Locator_us-gaap_StatementTable_156" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_369" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_370" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_369" xlink:to="Locator_dei_EntityDomain_370" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_365" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_366" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_365" xlink:to="Locator_us-gaap_StatementLineItems_366" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_307" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_308" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_307" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_308" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_309" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_310" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_309" xlink:to="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_310" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_311" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_314" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_313" xlink:to="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_314" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="Locator_us-gaap_PreferredStockSharesAuthorized_316" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_315" xlink:to="Locator_us-gaap_PreferredStockSharesAuthorized_316" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="Locator_us-gaap_PreferredStockSharesIssued_318" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_317" xlink:to="Locator_us-gaap_PreferredStockSharesIssued_318" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="Locator_us-gaap_PreferredStockSharesOutstanding_320" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_319" xlink:to="Locator_us-gaap_PreferredStockSharesOutstanding_320" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_CommonStockParOrStatedValuePerShare_322" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_321" xlink:to="Locator_us-gaap_CommonStockParOrStatedValuePerShare_322" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_323" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="Locator_us-gaap_CommonStockSharesAuthorized_324" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_323" xlink:to="Locator_us-gaap_CommonStockSharesAuthorized_324" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="Locator_us-gaap_CommonStockSharesIssued_326" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_325" xlink:to="Locator_us-gaap_CommonStockSharesIssued_326" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="Locator_us-gaap_CommonStockSharesOutstanding_328" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_327" xlink:to="Locator_us-gaap_CommonStockSharesOutstanding_328" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="Locator_us-gaap_TreasuryStockShares_330" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_329" xlink:to="Locator_us-gaap_TreasuryStockShares_330" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_367" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_368" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_367" xlink:to="Locator_dei_LegalEntityAxis_368" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="Locator_us-gaap_StatementOfFinancialPositionAbstract_333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_334" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfFinancialPositionAbstract_333" xlink:to="Locator_us-gaap_StatementTable_334" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_590" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_589" xlink:to="Locator_dei_EntityDomain_590" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="Locator_us-gaap_IncomeStatementAbstract_451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_452" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementAbstract_451" xlink:to="Locator_us-gaap_StatementTable_452" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_585" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_586" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_585" xlink:to="Locator_us-gaap_StatementLineItems_586" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_371" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_372" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_371" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_372" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_374" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_373" xlink:to="Locator_us-gaap_CostOfServices_374" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_375" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_376" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_375" xlink:to="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_376" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="Locator_us-gaap_LaborAndRelatedExpense_418" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_417" xlink:to="Locator_us-gaap_LaborAndRelatedExpense_418" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_420" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_419" xlink:to="Locator_us-gaap_ShareBasedCompensation_420" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_421" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_422" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_421" xlink:to="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_422" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_377" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_378" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_377" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_378" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_379" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_380" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_379" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_380" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_381" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_382" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_381" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_382" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_384" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_383" xlink:to="Locator_us-gaap_AssetImpairmentCharges_384" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_386" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_385" xlink:to="Locator_us-gaap_CostsAndExpenses_386" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_388" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_387" xlink:to="Locator_us-gaap_OperatingIncomeLoss_388" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_390" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_389" xlink:to="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_390" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="Locator_us-gaap_InvestmentIncomeInterestAndDividend_424" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_423" xlink:to="Locator_us-gaap_InvestmentIncomeInterestAndDividend_424" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="Locator_us-gaap_InterestExpense_426" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="Locator_us-gaap_InterestExpense_426" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_428" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_427" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_428" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="Locator_us-gaap_OtherNonoperatingIncomeExpense_430" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_429" xlink:to="Locator_us-gaap_OtherNonoperatingIncomeExpense_430" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_432" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_431" xlink:to="Locator_us-gaap_NonoperatingIncomeExpense_432" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_391" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_392" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_391" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_392" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_394" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_393" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_394" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_396" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_395" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_396" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_398" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_397" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_398" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_400" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_399" xlink:to="Locator_us-gaap_ProfitLoss_400" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_402" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_401" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_402" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_403" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_404" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_403" xlink:to="Locator_us-gaap_NetIncomeLoss_404" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_405" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_406" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_405" xlink:to="Locator_us-gaap_EarningsPerShareBasicAbstract_406" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_433" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_434" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_433" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_434" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_435" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_436" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_435" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_436" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_437" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_438" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_437" xlink:to="Locator_us-gaap_EarningsPerShareBasic_438" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_407" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_408" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_407" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_408" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_410" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_409" xlink:to="Locator_us-gaap_EarningsPerShareDilutedAbstract_410" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_440" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_439" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_440" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_441" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_442" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_441" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_442" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_443" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_444" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_443" xlink:to="Locator_us-gaap_EarningsPerShareDiluted_444" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_411" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_412" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_411" xlink:to="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_412" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_413" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_414" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_413" xlink:to="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_414" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperations_446" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_445" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperations_446" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_448" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_447" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_448" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_449" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_450" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_449" xlink:to="Locator_us-gaap_NetIncomeLoss_450" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_588" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_587" xlink:to="Locator_dei_LegalEntityAxis_588" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_592" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_591" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_592" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_608" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_607" xlink:to="Locator_us-gaap_ProfitLoss_608" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_609" xlink:to="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_613" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="Locator_us-gaap_DepreciationDepletionAndAmortization_614" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_613" xlink:to="Locator_us-gaap_DepreciationDepletionAndAmortization_614" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="Locator_us-gaap_ProvisionForDoubtfulAccounts_616" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_615" xlink:to="Locator_us-gaap_ProvisionForDoubtfulAccounts_616" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_618" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_617" xlink:to="Locator_us-gaap_ShareBasedCompensation_618" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionExpense" xlink:label="Locator_us-gaap_PensionExpense_620" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="Locator_us-gaap_PensionExpense_620" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_621" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_622" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_621" xlink:to="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_622" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_624" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_623" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_624" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_625" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_626" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_625" xlink:to="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_626" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_627" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_628" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_627" xlink:to="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_628" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_630" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_629" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_630" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_631" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_632" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_631" xlink:to="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_632" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_633" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_634" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_633" xlink:to="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_634" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_636" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635" xlink:to="Locator_us-gaap_AssetImpairmentCharges_636" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637" xlink:to="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_640" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_640" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_641" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_642" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_641" xlink:to="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_642" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_644" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_643" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_644" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_646" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_645" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_646" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_647" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_648" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_647" xlink:to="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_648" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_649" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_650" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_649" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_650" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_651" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_652" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_651" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_652" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_612" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_611" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_612" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_594" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_593" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_594" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_653" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_654" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_653" xlink:to="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_654" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_656" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_655" xlink:to="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_656" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_658" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657" xlink:to="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_658" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="Locator_us-gaap_PaymentsForProceedsFromInvestments_660" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_659" xlink:to="Locator_us-gaap_PaymentsForProceedsFromInvestments_660" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_662" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_661" xlink:to="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_662" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_663" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_664" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_663" xlink:to="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_664" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_665" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_666" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_665" xlink:to="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_666" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_667" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_668" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_667" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_668" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_595" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_595" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:label="Locator_us-gaap_IncreaseDecreaseInBookOverdrafts_670" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_669" xlink:to="Locator_us-gaap_IncreaseDecreaseInBookOverdrafts_670" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="Locator_us-gaap_ProceedsFromStockOptionsExercised_672" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_671" xlink:to="Locator_us-gaap_ProceedsFromStockOptionsExercised_672" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="Locator_us-gaap_ProceedsFromStockPlans_674" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_673" xlink:to="Locator_us-gaap_ProceedsFromStockPlans_674" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="Locator_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_676" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_675" xlink:to="Locator_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_676" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_678" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_677" xlink:to="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_678" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_679" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="Locator_amed_CashDistributionToNoncontrollingInterest_680" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_679" xlink:to="Locator_amed_CashDistributionToNoncontrollingInterest_680" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_681" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="Locator_us-gaap_ProceedsFromShortTermDebt_682" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_681" xlink:to="Locator_us-gaap_ProceedsFromShortTermDebt_682" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfShortTermDebt_684" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_683" xlink:to="Locator_us-gaap_RepaymentsOfShortTermDebt_684" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_685" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_686" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_685" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_686" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_687" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="Locator_us-gaap_PaymentsOfFinancingCosts_688" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_687" xlink:to="Locator_us-gaap_PaymentsOfFinancingCosts_688" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_689" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfLongTermDebt_690" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_689" xlink:to="Locator_us-gaap_RepaymentsOfLongTermDebt_690" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_691" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_692" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_691" xlink:to="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_692" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_693" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_694" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_693" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_694" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_597" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_598" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_597" xlink:to="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_598" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_600" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_599" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_600" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_602" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_601" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_602" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="Locator_us-gaap_SupplementalCashFlowInformationAbstract_604" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_603" xlink:to="Locator_us-gaap_SupplementalCashFlowInformationAbstract_604" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="Locator_us-gaap_SupplementalCashFlowInformationAbstract_695" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="Locator_us-gaap_InterestPaid_696" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SupplementalCashFlowInformationAbstract_695" xlink:to="Locator_us-gaap_InterestPaid_696" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="Locator_us-gaap_SupplementalCashFlowInformationAbstract_697" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="Locator_us-gaap_IncomeTaxesPaidNet_698" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SupplementalCashFlowInformationAbstract_697" xlink:to="Locator_us-gaap_IncomeTaxesPaidNet_698" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_606" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_605" xlink:to="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_606" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_699" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="Locator_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_700" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_699" xlink:to="Locator_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_700" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesIssued1" xlink:label="Locator_us-gaap_NotesIssued1_702" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_701" xlink:to="Locator_us-gaap_NotesIssued1_702" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_703" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="Locator_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_704" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_703" xlink:to="Locator_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_704" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_789" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_790" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_789" xlink:to="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_790" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_791" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="Locator_us-gaap_SignificantAccountingPoliciesTextBlock_792" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_791" xlink:to="Locator_us-gaap_SignificantAccountingPoliciesTextBlock_792" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ACQUISITIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="Locator_us-gaap_BusinessCombinationsAbstract_793" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="Locator_us-gaap_BusinessCombinationDisclosureTextBlock_794" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessCombinationsAbstract_793" xlink:to="Locator_us-gaap_BusinessCombinationDisclosureTextBlock_794" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_795" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="Locator_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_796" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_795" xlink:to="Locator_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_796" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_797" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_798" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_797" xlink:to="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_798" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_799" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="Locator_us-gaap_DebtDisclosureTextBlock_800" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_799" xlink:to="Locator_us-gaap_DebtDisclosureTextBlock_800" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_801" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_802" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_801" xlink:to="Locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_802" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="Locator_us-gaap_SegmentReportingDisclosureTextBlock_804" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_803" xlink:to="Locator_us-gaap_SegmentReportingDisclosureTextBlock_804" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="Locator_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_806" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_805" xlink:to="Locator_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_806" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_807" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="Locator_us-gaap_UseOfEstimates_808" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_807" xlink:to="Locator_us-gaap_UseOfEstimates_808" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComparabilityOfPriorYearFinancialData" xlink:label="Locator_us-gaap_ComparabilityOfPriorYearFinancialData_810" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_809" xlink:to="Locator_us-gaap_ComparabilityOfPriorYearFinancialData_810" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_811" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="Locator_us-gaap_ConsolidationPolicyTextBlock_812" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_811" xlink:to="Locator_us-gaap_ConsolidationPolicyTextBlock_812" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="Locator_us-gaap_EquityMethodInvestmentsPolicy_814" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813" xlink:to="Locator_us-gaap_EquityMethodInvestmentsPolicy_814" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_815" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="Locator_us-gaap_RevenueRecognitionPolicyTextBlock_816" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_815" xlink:to="Locator_us-gaap_RevenueRecognitionPolicyTextBlock_816" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_817" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock_818" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_817" xlink:to="Locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock_818" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_819" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="Locator_us-gaap_TradeAndOtherAccountsReceivablePolicy_820" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_819" xlink:to="Locator_us-gaap_TradeAndOtherAccountsReceivablePolicy_820" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_821" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_822" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_821" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_822" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_823" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_824" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_823" xlink:to="Locator_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_824" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="Locator_amed_DebtIssuanceCostsPolicyTextBlock_826" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825" xlink:to="Locator_amed_DebtIssuanceCostsPolicyTextBlock_826" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_827" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="Locator_us-gaap_FairValueOfFinancialInstrumentsPolicy_828" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_827" xlink:to="Locator_us-gaap_FairValueOfFinancialInstrumentsPolicy_828" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_829" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="Locator_us-gaap_IncomeTaxPolicyTextBlock_830" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_829" xlink:to="Locator_us-gaap_IncomeTaxPolicyTextBlock_830" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="Locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_832" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831" xlink:to="Locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_832" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="Locator_us-gaap_EarningsPerSharePolicyTextBlock_834" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833" xlink:to="Locator_us-gaap_EarningsPerSharePolicyTextBlock_834" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_835" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="Locator_us-gaap_AdvertisingCostsPolicyTextBlock_836" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_835" xlink:to="Locator_us-gaap_AdvertisingCostsPolicyTextBlock_836" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_837" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="Locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_838" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_837" xlink:to="Locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_838" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_839" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="Locator_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_840" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_839" xlink:to="Locator_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_840" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_841" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTextBlock_842" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_841" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTextBlock_842" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_843" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="Locator_amed_FinancialInstrumentDetailsTextBlock_844" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_843" xlink:to="Locator_amed_FinancialInstrumentDetailsTextBlock_844" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_845" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_846" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_845" xlink:to="Locator_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_846" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DISONTINUEDOPERATIONSANDASSETSHELDFORSALETables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_847" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="Locator_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_848" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_847" xlink:to="Locator_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_848" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureGOODWILLANDOTHERINTANGIBLEASSETSNETTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_849" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_850" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_849" xlink:to="Locator_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_850" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_851" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="Locator_us-gaap_ScheduleOfDebtInstrumentsTextBlock_852" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_851" xlink:to="Locator_us-gaap_ScheduleOfDebtInstrumentsTextBlock_852" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_853" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_854" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_853" xlink:to="Locator_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_854" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_855" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="Locator_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_856" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_855" xlink:to="Locator_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_856" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_857" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_858" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_857" xlink:to="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_858" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_965" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_966" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_965" xlink:to="Locator_us-gaap_SegmentDomain_966" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_971" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceInpatientMember" xlink:label="Locator_amed_HospiceInpatientMember_972" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_971" xlink:to="Locator_amed_HospiceInpatientMember_972" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_967" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_968" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_967" xlink:to="Locator_amed_HomeHealthMember_968" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_969" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_970" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_969" xlink:to="Locator_amed_HospiceMember_970" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_973" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_974" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_973" xlink:to="Locator_amed_PersonalCareMember_974" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_983" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_984" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_983" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_984" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_985" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_986" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_985" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_986" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="Locator_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_887" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_888" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_887" xlink:to="Locator_amed_OrganizationAndNatureOfOperationsTable_888" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_955" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_956" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_955" xlink:to="Locator_amed_OrganizationAndNatureOfOperationsLineItems_956" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_859" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="Locator_us-gaap_ConcentrationRiskPercentage1_860" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_859" xlink:to="Locator_us-gaap_ConcentrationRiskPercentage1_860" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_861" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingCareCenters" xlink:label="Locator_amed_OperatingCareCenters_862" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_861" xlink:to="Locator_amed_OperatingCareCenters_862" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_863" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_864" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_863" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_864" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_865" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_866" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_865" xlink:to="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_866" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_867" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="Locator_us-gaap_EquityMethodInvestmentAggregateCost_868" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_867" xlink:to="Locator_us-gaap_EquityMethodInvestmentAggregateCost_868" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_869" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="Locator_us-gaap_CostMethodInvestments_870" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_869" xlink:to="Locator_us-gaap_CostMethodInvestments_870" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_871" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_872" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_871" xlink:to="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_872" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_873" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_874" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_873" xlink:to="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_874" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_875" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_876" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_875" xlink:to="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_876" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_877" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_878" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_877" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_878" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_879" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_880" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_879" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_880" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_881" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_882" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_881" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_882" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_883" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_884" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_883" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_884" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_957" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_958" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_957" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_958" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_959" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_960" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_959" xlink:to="Locator_us-gaap_ConcentrationRiskByTypeAxis_960" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_975" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_976" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ConcentrationRiskByTypeAxis_975" xlink:to="Locator_us-gaap_ConcentrationRiskTypeDomain_976" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_977" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="Locator_us-gaap_CustomerConcentrationRiskMember_978" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_977" xlink:to="Locator_us-gaap_CustomerConcentrationRiskMember_978" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_979" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="Locator_us-gaap_SalesRevenueNetMember_980" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_979" xlink:to="Locator_us-gaap_SalesRevenueNetMember_980" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_981" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenueMember" xlink:label="Locator_amed_MedicareRevenueMember_982" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_981" xlink:to="Locator_amed_MedicareRevenueMember_982" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_961" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_962" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_961" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_962" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_963" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_964" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_963" xlink:to="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_964" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_987" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_988" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_987" xlink:to="Locator_us-gaap_EquityMethodInvesteeNameDomain_988" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_989" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HeritageHealthCareInnovationFundMemberMember" xlink:label="Locator_amed_HeritageHealthCareInnovationFundMemberMember_990" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityMethodInvesteeNameDomain_989" xlink:to="Locator_amed_HeritageHealthCareInnovationFundMemberMember_990" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1052" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1051" xlink:to="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1052" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1167" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1168" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1167" xlink:to="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1168" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_991" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_992" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_991" xlink:to="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_992" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_993" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_994" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_993" xlink:to="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_994" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_995" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_996" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_995" xlink:to="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_996" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_997" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_FirstThresholdOfTherapyServicesRequired_998" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_997" xlink:to="Locator_amed_FirstThresholdOfTherapyServicesRequired_998" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_999" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="Locator_amed_SecondThresholdOfServicesRequired_1000" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_999" xlink:to="Locator_amed_SecondThresholdOfServicesRequired_1000" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1001" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1002" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1001" xlink:to="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1002" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1003" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1004" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1003" xlink:to="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1004" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1005" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="Locator_amed_HistoricalCollectionRateFromMedicare_1006" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1005" xlink:to="Locator_amed_HistoricalCollectionRateFromMedicare_1006" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1007" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1008" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1007" xlink:to="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1008" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1009" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1010" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1009" xlink:to="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1010" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1011" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1012" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1011" xlink:to="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1012" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1013" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="Locator_amed_PercentageOfPatientReceivablesOutstanding_1014" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1013" xlink:to="Locator_amed_PercentageOfPatientReceivablesOutstanding_1014" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1015" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1016" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1015" xlink:to="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1016" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1017" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1018" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1017" xlink:to="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1018" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1019" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="Locator_amed_RevenueAdjustmentToMedicareRevenue_1020" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1019" xlink:to="Locator_amed_RevenueAdjustmentToMedicareRevenue_1020" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1021" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1022" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1021" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1022" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1023" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1024" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1023" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1024" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1025" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1026" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1025" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1026" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1027" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1028" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1027" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1028" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1029" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1030" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1029" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1030" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1031" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Percentageofpatientreceivablesoutstandingovertenpercent" xlink:label="Locator_amed_Percentageofpatientreceivablesoutstandingovertenpercent_1032" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1031" xlink:to="Locator_amed_Percentageofpatientreceivablesoutstandingovertenpercent_1032" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1033" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_1034" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1033" xlink:to="Locator_us-gaap_AssetImpairmentCharges_1034" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1035" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1036" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1035" xlink:to="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1036" order="23.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1037" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1038" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1037" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1038" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1039" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1040" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1039" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1040" order="25.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1171" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1172" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1171" xlink:to="Locator_amed_CapYearAxis_1172" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1189" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1190" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CapYearAxis_1189" xlink:to="Locator_amed_CapYearDomain_1190" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1191" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember" xlink:label="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember_1192" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CapYearDomain_1191" xlink:to="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember_1192" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1193" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember" xlink:label="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember_1194" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CapYearDomain_1193" xlink:to="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember_1194" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1173" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1174" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1173" xlink:to="Locator_amed_AssetImpairmentAxis_1174" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1195" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1196" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_AssetImpairmentAxis_1195" xlink:to="Locator_amed_AssetImpairmentDomain_1196" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1197" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="Locator_amed_Ams3HomecareAndHospiceMember_1198" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_AssetImpairmentDomain_1197" xlink:to="Locator_amed_Ams3HomecareAndHospiceMember_1198" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1176" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1175" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1176" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1183" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1184" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1183" xlink:to="Locator_us-gaap_SegmentDomain_1184" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1185" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1186" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1185" xlink:to="Locator_amed_HomeHealthMember_1186" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1187" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1188" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1187" xlink:to="Locator_amed_HospiceMember_1188" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1177" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1178" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1177" xlink:to="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1178" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="Locator_us-gaap_TypeOfAdoptionMember_1208" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1207" xlink:to="Locator_us-gaap_TypeOfAdoptionMember_1208" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="Locator_us-gaap_TypeOfAdoptionMember_1199" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="Locator_us-gaap_NewAccountingPronouncementMember_1200" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TypeOfAdoptionMember_1199" xlink:to="Locator_us-gaap_NewAccountingPronouncementMember_1200" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="Locator_us-gaap_NewAccountingPronouncementMember_1205" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AccountingStandardsUpdate201609Member" xlink:label="Locator_amed_AccountingStandardsUpdate201609Member_1206" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NewAccountingPronouncementMember_1205" xlink:to="Locator_amed_AccountingStandardsUpdate201609Member_1206" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1179" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_1180" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1179" xlink:to="Locator_us-gaap_StatementEquityComponentsAxis_1180" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_1201" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_1202" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementEquityComponentsAxis_1201" xlink:to="Locator_us-gaap_EquityComponentDomain_1202" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_1203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="Locator_us-gaap_RetainedEarningsMember_1204" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityComponentDomain_1203" xlink:to="Locator_us-gaap_RetainedEarningsMember_1204" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1055" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1056" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1055" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1056" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1057" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="Locator_us-gaap_AdvertisingExpense_1058" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1057" xlink:to="Locator_us-gaap_AdvertisingExpense_1058" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1059" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_1060" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1059" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_1060" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1061" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_1062" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1061" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_1062" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1063" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_1064" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1063" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_1064" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1053" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1053" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1181" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1182" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1181" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1182" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1170" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1169" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1170" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1043" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="Locator_amed_InternallyDevelopedComputerSoftware_1044" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1043" xlink:to="Locator_amed_InternallyDevelopedComputerSoftware_1044" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1045" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1046" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1045" xlink:to="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1046" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1047" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="Locator_us-gaap_Depreciation_1048" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1047" xlink:to="Locator_us-gaap_Depreciation_1048" order="3.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1214" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1213" xlink:to="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1214" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1230" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1229" xlink:to="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1230" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="Locator_us-gaap_LiabilitiesFairValueDisclosure_1210" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1209" xlink:to="Locator_us-gaap_LiabilitiesFairValueDisclosure_1210" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1231" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1232" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1231" xlink:to="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1232" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1233" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1234" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1233" xlink:to="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1234" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1235" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="Locator_us-gaap_FairValueInputsLevel1Member_1236" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1235" xlink:to="Locator_us-gaap_FairValueInputsLevel1Member_1236" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="Locator_us-gaap_FairValueInputsLevel2Member_1238" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1237" xlink:to="Locator_us-gaap_FairValueInputsLevel2Member_1238" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="Locator_us-gaap_FairValueInputsLevel3Member_1240" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1239" xlink:to="Locator_us-gaap_FairValueInputsLevel3Member_1240" order="3.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1242" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1241" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1242" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1243" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1244" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1243" xlink:to="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1244" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1245" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NonVestedStockAndStockUnits" xlink:label="Locator_amed_NonVestedStockAndStockUnits_1246" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1245" xlink:to="Locator_amed_NonVestedStockAndStockUnits_1246" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1247" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1248" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1247" xlink:to="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1248" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="Locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1250" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1249" xlink:to="Locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1250" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1320" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1319" xlink:to="Locator_us-gaap_SegmentDomain_1320" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1321" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1322" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1321" xlink:to="Locator_amed_HomeHealthMember_1322" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1323" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1324" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1323" xlink:to="Locator_amed_HospiceMember_1324" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1277" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1278" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1277" xlink:to="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1278" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1314" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1313" xlink:to="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1314" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1257" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="Locator_amed_NumberOfCareCentersConsolidated_1258" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1257" xlink:to="Locator_amed_NumberOfCareCentersConsolidated_1258" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1259" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersClosed" xlink:label="Locator_amed_NumberOfCareCentersClosed_1260" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1259" xlink:to="Locator_amed_NumberOfCareCentersClosed_1260" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1261" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1262" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1261" xlink:to="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1262" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1263" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersExited" xlink:label="Locator_amed_NumberOfCareCentersExited_1264" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1263" xlink:to="Locator_amed_NumberOfCareCentersExited_1264" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1265" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersAvailableForSale_1266" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1265" xlink:to="Locator_amed_NumberOfCareCentersAvailableForSale_1266" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1267" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_1268" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1267" xlink:to="Locator_amed_NumberOfCareCentersSold_1268" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1269" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1270" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1269" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1270" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1271" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1272" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1271" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1272" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1273" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1274" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1273" xlink:to="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1274" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1316" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1315" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1316" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1318" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1317" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1318" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1326" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1325" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1326" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="Locator_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1328" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1327" xlink:to="Locator_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1328" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfNetRevenuesAndOperatingResultsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1330" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1329" xlink:to="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1330" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1332" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1331" xlink:to="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1332" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1334" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1333" xlink:to="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1334" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1336" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1335" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1336" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1337" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1338" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1337" xlink:to="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1338" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1373" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1374" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1373" xlink:to="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1374" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1339" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1340" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1339" xlink:to="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1340" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1341" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1342" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1341" xlink:to="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1342" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1343" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1344" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1343" xlink:to="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1344" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1345" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1346" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1345" xlink:to="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1346" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1375" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1376" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1375" xlink:to="Locator_amed_CareCenterStatusAxis_1376" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1377" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1378" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CareCenterStatusAxis_1377" xlink:to="Locator_amed_CareCenterStatusDomain_1378" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1379" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1380" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CareCenterStatusDomain_1379" xlink:to="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1380" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1432" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1431" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1432" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1433" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1434" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1433" xlink:to="Locator_amed_TermLoanMember_1434" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1435" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1436" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1435" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1436" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1437" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1438" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1437" xlink:to="Locator_amed_SwingLineLoanMember_1438" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1440" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1439" xlink:to="Locator_us-gaap_LetterOfCreditMember_1440" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1443" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1444" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1443" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1444" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1445" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1446" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1445" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1446" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1441" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1442" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1441" xlink:to="Locator_amed_PromissoryNotesMember_1442" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="Locator_us-gaap_LongTermDebtAbstract_1393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1394" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongTermDebtAbstract_1393" xlink:to="Locator_us-gaap_DebtInstrumentTable_1394" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1428" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1427" xlink:to="Locator_us-gaap_DebtInstrumentLineItems_1428" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1386" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1385" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1386" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="Locator_us-gaap_LongTermDebtNoncurrent_1388" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1387" xlink:to="Locator_us-gaap_LongTermDebtNoncurrent_1388" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1390" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1389" xlink:to="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1390" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1384" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1383" xlink:to="Locator_us-gaap_LongTermDebt_1384" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1381" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1382" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1381" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1382" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1430" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1429" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1430" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1535" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1536" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_1535" xlink:to="Locator_us-gaap_RangeMember_1536" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1540" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1539" xlink:to="Locator_us-gaap_MinimumMember_1540" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1537" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1538" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1537" xlink:to="Locator_us-gaap_MaximumMember_1538" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1518" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1517" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1518" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1529" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1530" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1529" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1530" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1519" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1520" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1519" xlink:to="Locator_amed_TermLoanMember_1520" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1521" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1522" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1521" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1522" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1523" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1524" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1523" xlink:to="Locator_amed_SwingLineLoanMember_1524" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1525" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1526" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1525" xlink:to="Locator_us-gaap_LetterOfCreditMember_1526" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1531" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1532" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1531" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1532" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1533" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1534" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1533" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1534" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1527" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1528" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1527" xlink:to="Locator_amed_PromissoryNotesMember_1528" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="Locator_us-gaap_LongTermDebtAbstract_1463" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1464" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongTermDebtAbstract_1463" xlink:to="Locator_us-gaap_DebtInstrumentTable_1464" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1511" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1512" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1511" xlink:to="Locator_us-gaap_DebtInstrumentLineItems_1512" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1449" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1450" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1449" xlink:to="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1450" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1453" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="Locator_amed_InterestRateOnNotesPayableToBank_1454" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1453" xlink:to="Locator_amed_InterestRateOnNotesPayableToBank_1454" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1457" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1458" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1457" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1458" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1448" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1447" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1448" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1455" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1456" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1455" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1456" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1460" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1459" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1460" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1452" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1451" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1452" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1513" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1514" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1513" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1514" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1515" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1516" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1515" xlink:to="Locator_us-gaap_RangeAxis_1516" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1784" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_1783" xlink:to="Locator_us-gaap_RangeMember_1784" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1806" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1805" xlink:to="Locator_us-gaap_MinimumMember_1806" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1804" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1803" xlink:to="Locator_us-gaap_MaximumMember_1804" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1764" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1763" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1764" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1765" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1766" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1765" xlink:to="Locator_amed_TermLoanMember_1766" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1767" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1768" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1767" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1768" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1769" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1770" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1769" xlink:to="Locator_amed_SwingLineLoanMember_1770" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1772" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1771" xlink:to="Locator_us-gaap_LetterOfCreditMember_1772" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1775" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CreditAgreementMember" xlink:label="Locator_amed_CreditAgreementMember_1776" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1775" xlink:to="Locator_amed_CreditAgreementMember_1776" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1777" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1778" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1777" xlink:to="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1778" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1779" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1780" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1779" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1780" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1781" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1782" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1781" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1782" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1773" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1774" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1773" xlink:to="Locator_amed_PromissoryNotesMember_1774" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="Locator_us-gaap_LongTermDebtAbstract_1619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1620" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongTermDebtAbstract_1619" xlink:to="Locator_us-gaap_DebtInstrumentTable_1620" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1753" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1754" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1753" xlink:to="Locator_us-gaap_DebtInstrumentLineItems_1754" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1541" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="Locator_us-gaap_DebtInstrumentTerm_1542" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1541" xlink:to="Locator_us-gaap_DebtInstrumentTerm_1542" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1543" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WeightedAverageInterestRate" xlink:label="Locator_amed_WeightedAverageInterestRate_1544" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1543" xlink:to="Locator_amed_WeightedAverageInterestRate_1544" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1545" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TotalLeverageRatio" xlink:label="Locator_amed_TotalLeverageRatio_1546" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1545" xlink:to="Locator_amed_TotalLeverageRatio_1546" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1547" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FixedChargeCoverageRatio" xlink:label="Locator_amed_FixedChargeCoverageRatio_1548" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1547" xlink:to="Locator_amed_FixedChargeCoverageRatio_1548" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1549" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1550" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1549" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1550" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1552" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1551" xlink:to="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1552" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1553" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="Locator_us-gaap_LettersOfCreditOutstandingAmount_1554" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1553" xlink:to="Locator_us-gaap_LettersOfCreditOutstandingAmount_1554" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1555" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1556" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1555" xlink:to="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1556" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1557" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="Locator_amed_LineOfCreditFacilityDebtRestrictions_1558" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1557" xlink:to="Locator_amed_LineOfCreditFacilityDebtRestrictions_1558" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1559" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximumLeverageRatio" xlink:label="Locator_amed_MaximumLeverageRatio_1560" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1559" xlink:to="Locator_amed_MaximumLeverageRatio_1560" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1561" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="Locator_amed_MinimumFixedChargeCoverageRatio_1562" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1561" xlink:to="Locator_amed_MinimumFixedChargeCoverageRatio_1562" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1564" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1563" xlink:to="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1564" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1565" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="Locator_amed_RevolvingCreditFacilityTotal_1566" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1565" xlink:to="Locator_amed_RevolvingCreditFacilityTotal_1566" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1567" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1568" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1567" xlink:to="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1568" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1570" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1569" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1570" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1571" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1572" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1571" xlink:to="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1572" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1574" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1573" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1574" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="Locator_us-gaap_DeferredFinanceCostsNet_1576" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1575" xlink:to="Locator_us-gaap_DeferredFinanceCostsNet_1576" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1577" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1578" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1577" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1578" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1579" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1580" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1579" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1580" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1581" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1582" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1581" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1582" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1583" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="Locator_amed_DebtInstrumentInterestABRFlatRate_1584" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1583" xlink:to="Locator_amed_DebtInstrumentInterestABRFlatRate_1584" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1585" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1586" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1585" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1586" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1587" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="Locator_amed_ApplicableMarginRateOnBaseRate_1588" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1587" xlink:to="Locator_amed_ApplicableMarginRateOnBaseRate_1588" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1589" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="Locator_amed_ApplicableMarginRateOnEurodollarRate_1590" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1589" xlink:to="Locator_amed_ApplicableMarginRateOnEurodollarRate_1590" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1591" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="Locator_amed_EurodollarDepositsInterestPeriod_1592" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1591" xlink:to="Locator_amed_EurodollarDepositsInterestPeriod_1592" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1593" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="Locator_amed_DebtInstrumentInterestLiborFloor_1594" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1593" xlink:to="Locator_amed_DebtInstrumentInterestLiborFloor_1594" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1595" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="Locator_amed_PrepaymentPenaltyPercentage_1596" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1595" xlink:to="Locator_amed_PrepaymentPenaltyPercentage_1596" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1597" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1598" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1597" xlink:to="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1598" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1599" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1600" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1599" xlink:to="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1600" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1602" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1601" xlink:to="Locator_us-gaap_LongTermDebt_1602" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="Locator_us-gaap_OtherNotesPayable_1604" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1603" xlink:to="Locator_us-gaap_OtherNotesPayable_1604" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1606" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1605" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1606" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="Locator_us-gaap_RepaymentsOfLinesOfCredit_1608" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1607" xlink:to="Locator_us-gaap_RepaymentsOfLinesOfCredit_1608" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1610" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1609" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1610" order="35.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="Locator_us-gaap_DebtWeightedAverageInterestRate_1612" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1611" xlink:to="Locator_us-gaap_DebtWeightedAverageInterestRate_1612" order="36.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1613" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="Locator_amed_SeniorSecuredLeverageRatio_1614" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1613" xlink:to="Locator_amed_SeniorSecuredLeverageRatio_1614" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1616" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1615" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1616" order="38.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1756" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1755" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1756" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1758" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1757" xlink:to="Locator_us-gaap_RangeAxis_1758" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1759" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1760" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1759" xlink:to="Locator_amed_TimePeriodAxis_1760" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1785" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1786" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodAxis_1785" xlink:to="Locator_amed_TimePeriodDomain_1786" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1787" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneMonthMember" xlink:label="Locator_amed_OneMonthMember_1788" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1787" xlink:to="Locator_amed_OneMonthMember_1788" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1789" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoMonthMember" xlink:label="Locator_amed_TwoMonthMember_1790" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1789" xlink:to="Locator_amed_TwoMonthMember_1790" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1791" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThreeMonthMember" xlink:label="Locator_amed_ThreeMonthMember_1792" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1791" xlink:to="Locator_amed_ThreeMonthMember_1792" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1793" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SixMonthMember" xlink:label="Locator_amed_SixMonthMember_1794" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1793" xlink:to="Locator_amed_SixMonthMember_1794" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1795" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OneYearMember" xlink:label="Locator_amed_OneYearMember_1796" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1795" xlink:to="Locator_amed_OneYearMember_1796" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1797" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoYearMember" xlink:label="Locator_amed_TwoYearMember_1798" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1797" xlink:to="Locator_amed_TwoYearMember_1798" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1761" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1762" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1761" xlink:to="Locator_amed_FeeTypeAxis_1762" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1799" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1800" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FeeTypeAxis_1799" xlink:to="Locator_amed_FeeTypeDomain_1800" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1801" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ArrangerFeeMember" xlink:label="Locator_amed_ArrangerFeeMember_1802" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FeeTypeDomain_1801" xlink:to="Locator_amed_ArrangerFeeMember_1802" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentsAndContingenciesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2073" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2074" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2073" xlink:to="Locator_us-gaap_SegmentDomain_2074" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2077" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesMember" xlink:label="Locator_amed_MaximusFederalServicesMember_2078" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2077" xlink:to="Locator_amed_MaximusFederalServicesMember_2078" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2081" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="Locator_amed_MaximusFederalServicesAndHospiceMember_2082" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2081" xlink:to="Locator_amed_MaximusFederalServicesAndHospiceMember_2082" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2083" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassproAndHospiceMember" xlink:label="Locator_amed_MassproAndHospiceMember_2084" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2083" xlink:to="Locator_amed_MassproAndHospiceMember_2084" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2085" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfEmployeesInWageHourLitigationMember" xlink:label="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_2086" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2085" xlink:to="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_2086" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2087" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="Locator_amed_MaximusFederalServicesAndHomeHealthMember_2088" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2087" xlink:to="Locator_amed_MaximusFederalServicesAndHomeHealthMember_2088" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2075" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2076" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2075" xlink:to="Locator_amed_HomeHealthMember_2076" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2079" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2080" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2079" xlink:to="Locator_amed_HospiceMember_2080" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2071" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2072" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_2071" xlink:to="Locator_us-gaap_RangeMember_2072" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2149" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2150" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2149" xlink:to="Locator_us-gaap_MinimumMember_2150" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2151" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2152" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2151" xlink:to="Locator_us-gaap_MaximumMember_2152" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2131" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2132" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateAxis_2131" xlink:to="Locator_amed_StateDomain_2132" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2133" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IllinoisMember" xlink:label="Locator_amed_IllinoisMember_2134" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2133" xlink:to="Locator_amed_IllinoisMember_2134" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2135" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ConnecticutMember" xlink:label="Locator_amed_ConnecticutMember_2136" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2135" xlink:to="Locator_amed_ConnecticutMember_2136" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2137" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OhioMember" xlink:label="Locator_amed_OhioMember_2138" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2137" xlink:to="Locator_amed_OhioMember_2138" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2139" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SouthCarolinaMember" xlink:label="Locator_amed_SouthCarolinaMember_2140" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2139" xlink:to="Locator_amed_SouthCarolinaMember_2140" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2145" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MorgantownWestVirginiaMember" xlink:label="Locator_amed_MorgantownWestVirginiaMember_2146" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2145" xlink:to="Locator_amed_MorgantownWestVirginiaMember_2146" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2147" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="Locator_amed_ParkersburgWestVirginiaMember_2148" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2147" xlink:to="Locator_amed_ParkersburgWestVirginiaMember_2148" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2143" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_2144" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2143" xlink:to="Locator_amed_WestVirginiaMember_2144" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2141" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_2142" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2141" xlink:to="Locator_amed_MassachusettsMember_2142" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1879" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_1880" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1879" xlink:to="Locator_amed_CommimentsAndContingenciesTable_1880" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2055" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2056" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2055" xlink:to="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2056" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1807" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareRevenue" xlink:label="Locator_amed_MedicareRevenue_1808" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1807" xlink:to="Locator_amed_MedicareRevenue_1808" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_1810" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1809" xlink:to="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_1810" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1811" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_1812" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1811" xlink:to="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_1812" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1813" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_1814" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1813" xlink:to="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_1814" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1815" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_1816" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1815" xlink:to="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_1816" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1817" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfClaimsAppealed" xlink:label="Locator_amed_NumberOfClaimsAppealed_1818" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1817" xlink:to="Locator_amed_NumberOfClaimsAppealed_1818" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1819" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="Locator_amed_NumberOfRedeterminationDecisions_1820" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1819" xlink:to="Locator_amed_NumberOfRedeterminationDecisions_1820" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1821" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="Locator_amed_HealthInsuranceRetentionLimit_1822" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1821" xlink:to="Locator_amed_HealthInsuranceRetentionLimit_1822" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1823" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="Locator_amed_WorkersCompensationInsuranceRetentionLimit_1824" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1823" xlink:to="Locator_amed_WorkersCompensationInsuranceRetentionLimit_1824" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1825" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_1826" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1825" xlink:to="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_1826" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1827" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfBeneficiaries" xlink:label="Locator_amed_NumberOfBeneficiaries_1828" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1827" xlink:to="Locator_amed_NumberOfBeneficiaries_1828" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1829" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="Locator_us-gaap_LitigationSettlementAmount_1830" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1829" xlink:to="Locator_us-gaap_LitigationSettlementAmount_1830" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1831" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_1832" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1831" xlink:to="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_1832" order="13.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1833" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_1834" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1833" xlink:to="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_1834" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1835" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_1836" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1835" xlink:to="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_1836" order="15.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1837" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_1838" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1837" xlink:to="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_1838" order="16.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1839" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_1840" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1839" xlink:to="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_1840" order="17.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1841" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_1842" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1841" xlink:to="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_1842" order="18.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1843" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_1844" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1843" xlink:to="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_1844" order="19.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1845" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="Locator_us-gaap_LossContingencyAccrualProvision_1846" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1845" xlink:to="Locator_us-gaap_LossContingencyAccrualProvision_1846" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1847" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="Locator_amed_CorporateIntegrityAgreementTerm_1848" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1847" xlink:to="Locator_amed_CorporateIntegrityAgreementTerm_1848" order="21.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1849" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_1850" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1849" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_1850" order="22.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1851" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_1852" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1851" xlink:to="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_1852" order="23.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1853" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="Locator_amed_NumberOfMissingComputersAndLaptops_1854" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1853" xlink:to="Locator_amed_NumberOfMissingComputersAndLaptops_1854" order="24.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1855" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="Locator_amed_ThresholdOfIndividualsInDataBreach_1856" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1855" xlink:to="Locator_amed_ThresholdOfIndividualsInDataBreach_1856" order="25.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1857" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="Locator_amed_PercentageOfCompanyDevicesUsed_1858" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1857" xlink:to="Locator_amed_PercentageOfCompanyDevicesUsed_1858" order="26.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1859" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_YearOfDeparture" xlink:label="Locator_amed_YearOfDeparture_1860" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1859" xlink:to="Locator_amed_YearOfDeparture_1860" order="27.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1861" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_1862" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1861" xlink:to="Locator_amed_NumberOfCareCentersSold_1862" order="28.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1863" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfPatients" xlink:label="Locator_amed_NumberOfPatients_1864" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1863" xlink:to="Locator_amed_NumberOfPatients_1864" order="29.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1865" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest" xlink:label="Locator_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest_1866" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1865" xlink:to="Locator_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest_1866" order="30.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1867" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingCareCenters" xlink:label="Locator_amed_OperatingCareCenters_1868" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1867" xlink:to="Locator_amed_OperatingCareCenters_1868" order="31.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1869" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SuspensionOfMedicarePayments_days" xlink:label="Locator_amed_SuspensionOfMedicarePayments_days_1870" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1869" xlink:to="Locator_amed_SuspensionOfMedicarePayments_days_1870" order="32.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1871" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="Locator_us-gaap_LossContingencyNumberOfDefendants_1872" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1871" xlink:to="Locator_us-gaap_LossContingencyNumberOfDefendants_1872" order="33.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1873" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1874" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1873" xlink:to="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1874" order="34.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1875" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_1876" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1875" xlink:to="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_1876" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2057" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2058" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2057" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2058" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2059" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_2060" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2059" xlink:to="Locator_dei_LegalEntityAxis_2060" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_2089" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_2090" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_2089" xlink:to="Locator_dei_EntityDomain_2090" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_2091" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="Locator_amed_MedicareAdministrativeContractorMacMember_2092" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_EntityDomain_2091" xlink:to="Locator_amed_MedicareAdministrativeContractorMacMember_2092" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2061" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2062" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2061" xlink:to="Locator_us-gaap_LitigationStatusAxis_2062" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2093" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2094" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusAxis_2093" xlink:to="Locator_us-gaap_LitigationStatusDomain_2094" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2095" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="Locator_us-gaap_PendingLitigationMember_2096" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2095" xlink:to="Locator_us-gaap_PendingLitigationMember_2096" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2097" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FinalLitigationSettlmentMember" xlink:label="Locator_amed_FinalLitigationSettlmentMember_2098" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2097" xlink:to="Locator_amed_FinalLitigationSettlmentMember_2098" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2099" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FederalDerivativeActionsMember" xlink:label="Locator_amed_FederalDerivativeActionsMember_2100" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2099" xlink:to="Locator_amed_FederalDerivativeActionsMember_2100" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2101" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OigSelfDisclosureMember" xlink:label="Locator_amed_OigSelfDisclosureMember_2102" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2101" xlink:to="Locator_amed_OigSelfDisclosureMember_2102" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2103" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="Locator_amed_ErisaClassActionLawsuitMember_2104" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2103" xlink:to="Locator_amed_ErisaClassActionLawsuitMember_2104" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2105" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_2106" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2105" xlink:to="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_2106" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2107" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FrontierLitigationMember" xlink:label="Locator_amed_FrontierLitigationMember_2108" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2107" xlink:to="Locator_amed_FrontierLitigationMember_2108" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2109" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="Locator_amed_UsDepartmentOfJusticeMember_2110" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2109" xlink:to="Locator_amed_UsDepartmentOfJusticeMember_2110" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2111" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember" xlink:label="Locator_amed_SafeguardZoneProgramIntegrityContractorMember_2112" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2111" xlink:to="Locator_amed_SafeguardZoneProgramIntegrityContractorMember_2112" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2113" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_SecuritiesClassActionLawsuitMember" xlink:label="Locator_amed_SecuritiesClassActionLawsuitMember_2114" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2113" xlink:to="Locator_amed_SecuritiesClassActionLawsuitMember_2114" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2063" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2064" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2063" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2064" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2116" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2115" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2116" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2117" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_RelatedPartyMember" xlink:label="Locator_amed_RelatedPartyMember_2118" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2117" xlink:to="Locator_amed_RelatedPartyMember_2118" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2065" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2066" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2065" xlink:to="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2066" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2119" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2120" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2119" xlink:to="Locator_us-gaap_LossContingencyNatureDomain_2120" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2121" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ExtrapolatedMember" xlink:label="Locator_amed_ExtrapolatedMember_2122" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2121" xlink:to="Locator_amed_ExtrapolatedMember_2122" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2123" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableMember" xlink:label="Locator_amed_FavorableMember_2124" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2123" xlink:to="Locator_amed_FavorableMember_2124" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2125" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UnfavorableMember" xlink:label="Locator_amed_UnfavorableMember_2126" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2125" xlink:to="Locator_amed_UnfavorableMember_2126" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2127" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInFullMember" xlink:label="Locator_amed_FavorableInFullMember_2128" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2127" xlink:to="Locator_amed_FavorableInFullMember_2128" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2129" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FavorableInPartMember" xlink:label="Locator_amed_FavorableInPartMember_2130" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2129" xlink:to="Locator_amed_FavorableInPartMember_2130" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2067" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2068" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2067" xlink:to="Locator_amed_StateAxis_2068" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2069" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2070" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2069" xlink:to="Locator_us-gaap_RangeAxis_2070" order="7.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_2153" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="Locator_us-gaap_NumberOfReportableSegments_2154" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_2153" xlink:to="Locator_us-gaap_NumberOfReportableSegments_2154" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2230" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2229" xlink:to="Locator_us-gaap_SegmentDomain_2230" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="Locator_us-gaap_AllOtherSegmentsMember_2238" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2237" xlink:to="Locator_us-gaap_AllOtherSegmentsMember_2238" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2231" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2232" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2231" xlink:to="Locator_amed_HomeHealthMember_2232" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2233" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2234" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2233" xlink:to="Locator_amed_HospiceMember_2234" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2235" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2236" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2235" xlink:to="Locator_amed_PersonalCareMember_2236" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_2177" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2178" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_2177" xlink:to="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2178" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2226" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2225" xlink:to="Locator_us-gaap_SegmentReportingInformationLineItems_2226" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2155" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2156" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2155" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2156" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_2158" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2157" xlink:to="Locator_us-gaap_CostOfServices_2158" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2159" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="Locator_amed_GeneralAndAdministrativeExpenseSegment_2160" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2159" xlink:to="Locator_amed_GeneralAndAdministrativeExpenseSegment_2160" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2161" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2162" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2161" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2162" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2163" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2164" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2163" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2164" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2165" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_2166" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2165" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_2166" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2167" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AMS3writeoffcharge" xlink:label="Locator_amed_AMS3writeoffcharge_2168" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2167" xlink:to="Locator_amed_AMS3writeoffcharge_2168" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_2170" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2169" xlink:to="Locator_us-gaap_AssetImpairmentCharges_2170" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2171" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2172" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2171" xlink:to="Locator_us-gaap_CostsAndExpenses_2172" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2173" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_2174" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2173" xlink:to="Locator_us-gaap_OperatingIncomeLoss_2174" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2228" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2227" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2228" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EXITACTIVITIES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2240" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2239" xlink:to="Locator_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2240" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="Locator_us-gaap_SubsequentEventsAbstract_2241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="Locator_us-gaap_SubsequentEventsTextBlock_2242" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventsAbstract_2241" xlink:to="Locator_us-gaap_SubsequentEventsTextBlock_2242" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS">
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2243" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_2244" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2243" xlink:to="Locator_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_2244" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/INCOMETAXES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2245" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="Locator_us-gaap_IncomeTaxDisclosureTextBlock_2246" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2245" xlink:to="Locator_us-gaap_IncomeTaxDisclosureTextBlock_2246" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS">
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2247" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="Locator_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2248" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2247" xlink:to="Locator_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2248" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="Locator_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2250" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2249" xlink:to="Locator_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2250" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2251" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="Locator_us-gaap_QuarterlyFinancialInformationTextBlock_2252" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2251" xlink:to="Locator_us-gaap_QuarterlyFinancialInformationTextBlock_2252" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables">
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2253" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2254" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2253" xlink:to="Locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2254" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2255" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfOtherAssetsTableTextBlock_2256" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2255" xlink:to="Locator_us-gaap_ScheduleOfOtherAssetsTableTextBlock_2256" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2257" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2258" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2257" xlink:to="Locator_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2258" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2259" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_2260" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2259" xlink:to="Locator_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_2260" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/INCOMETAXESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2261" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="Locator_amed_ProvisionForIncomeTaxesTextBlock_2262" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2261" xlink:to="Locator_amed_ProvisionForIncomeTaxesTextBlock_2262" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2263" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="Locator_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_2264" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2263" xlink:to="Locator_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_2264" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2266" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2265" xlink:to="Locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2266" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2267" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="Locator_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_2268" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2267" xlink:to="Locator_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_2268" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2269" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2270" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2269" xlink:to="Locator_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2270" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2272" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2271" xlink:to="Locator_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2272" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2273" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="Locator_amed_InsuranceProgramsTableTextBlock_2274" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2273" xlink:to="Locator_amed_InsuranceProgramsTableTextBlock_2274" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EXITACTIVITIESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2275" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2276" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2275" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2276" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureVALUATIONANDQUALIFYINGACCOUNTSTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2277" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="Locator_amed_ValuationAndQualifyingAccountsTableTextBlock_2278" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2277" xlink:to="Locator_amed_ValuationAndQualifyingAccountsTableTextBlock_2278" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2279" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2280" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2279" xlink:to="Locator_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2280" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureAcquisitionsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2405" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2406" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2405" xlink:to="Locator_us-gaap_SegmentDomain_2406" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2407" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2408" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2407" xlink:to="Locator_amed_HomeHealthMember_2408" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2409" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2410" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2409" xlink:to="Locator_amed_HospiceMember_2410" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2411" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2412" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2411" xlink:to="Locator_amed_PersonalCareMember_2412" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="Locator_us-gaap_BusinessCombinationsAbstract_2309" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2310" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessCombinationsAbstract_2309" xlink:to="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2310" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2389" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2390" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2389" xlink:to="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2390" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2281" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2282" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2281" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2282" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2283" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="Locator_us-gaap_NumberOfBusinessesAcquired_2284" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2283" xlink:to="Locator_us-gaap_NumberOfBusinessesAcquired_2284" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2286" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2285" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2286" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2287" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2288" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2287" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2288" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2290" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2289" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2290" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2291" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2292" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2291" xlink:to="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2292" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2293" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2294" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2293" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2294" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2296" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2295" xlink:to="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2296" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2297" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2298" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2297" xlink:to="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2298" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="Locator_us-gaap_EscrowDeposit_2300" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2299" xlink:to="Locator_us-gaap_EscrowDeposit_2300" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2302" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2301" xlink:to="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2302" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2303" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_2304" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2303" xlink:to="Locator_us-gaap_LongTermDebt_2304" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2305" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2306" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2305" xlink:to="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2306" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2391" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2392" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2391" xlink:to="Locator_amed_StateAxis_2392" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2413" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2414" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateAxis_2413" xlink:to="Locator_amed_StateDomain_2414" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2415" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AlabamaMember" xlink:label="Locator_amed_AlabamaMember_2416" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2415" xlink:to="Locator_amed_AlabamaMember_2416" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2417" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NorthCarolinaMember" xlink:label="Locator_amed_NorthCarolinaMember_2418" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2417" xlink:to="Locator_amed_NorthCarolinaMember_2418" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2419" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_2420" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2419" xlink:to="Locator_amed_WestVirginiaMember_2420" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2421" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LouisianaMember" xlink:label="Locator_amed_LouisianaMember_2422" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2421" xlink:to="Locator_amed_LouisianaMember_2422" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2423" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FloridaMember" xlink:label="Locator_amed_FloridaMember_2424" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2423" xlink:to="Locator_amed_FloridaMember_2424" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2425" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_2426" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2425" xlink:to="Locator_amed_MassachusettsMember_2426" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2394" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2393" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_2394" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2428" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2427" xlink:to="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2428" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2433" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="Locator_amed_InHousePhysiciansPracticeMember_2434" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2433" xlink:to="Locator_amed_InHousePhysiciansPracticeMember_2434" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2435" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_2436" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2435" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_2436" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2437" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeStaffLlcMember" xlink:label="Locator_amed_HomeStaffLlcMember_2438" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_2437" xlink:to="Locator_amed_HomeStaffLlcMember_2438" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2396" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2395" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2396" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2398" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2398" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2430" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2429" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2430" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_2432" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2431" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_2432" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2400" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2399" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_2400" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2402" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_2401" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_2402" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2403" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_2404" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_2403" xlink:to="Locator_amed_PromissoryNotesMember_2404" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2481" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2482" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2481" xlink:to="Locator_us-gaap_SegmentDomain_2482" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2483" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2484" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2483" xlink:to="Locator_amed_HomeHealthMember_2484" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2485" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2486" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2485" xlink:to="Locator_amed_HospiceMember_2486" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2448" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2447" xlink:to="Locator_us-gaap_ScheduleOfGoodwillTable_2448" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2475" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2476" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2475" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2476" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2440" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2439" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2440" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2441" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_2442" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2441" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_2442" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2443" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2444" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2443" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2444" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2477" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2478" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2477" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2478" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2487" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2488" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2487" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_2488" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_2490" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2489" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_2490" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2491" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="Locator_amed_CareCentersClosedOrConsolidatedMember_2492" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2491" xlink:to="Locator_amed_CareCentersClosedOrConsolidatedMember_2492" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2493" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="Locator_amed_AnnualImpairmentTestStepOneMember_2494" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2493" xlink:to="Locator_amed_AnnualImpairmentTestStepOneMember_2494" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2479" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2480" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2479" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2480" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2583" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2584" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_2583" xlink:to="Locator_us-gaap_RangeMember_2584" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2600" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2599" xlink:to="Locator_us-gaap_MinimumMember_2600" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2602" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2601" xlink:to="Locator_us-gaap_MaximumMember_2602" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2521" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2522" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2521" xlink:to="Locator_us-gaap_IncomeTaxExaminationTable_2522" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2575" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2576" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_2575" xlink:to="Locator_amed_IncomeTaxDisclosureLineItems_2576" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2495" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="Locator_us-gaap_IncomeTaxesReceivable_2496" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2495" xlink:to="Locator_us-gaap_IncomeTaxesReceivable_2496" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2497" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="Locator_us-gaap_OperatingLossCarryforwards_2498" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2497" xlink:to="Locator_us-gaap_OperatingLossCarryforwards_2498" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2499" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_2500" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2499" xlink:to="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_2500" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_2502" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2501" xlink:to="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_2502" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_2504" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2503" xlink:to="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_2504" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2506" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2505" xlink:to="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2506" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_2510" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2509" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_2510" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2511" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2512" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2511" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2512" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2513" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_2514" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2513" xlink:to="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_2514" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2515" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="Locator_us-gaap_OpenTaxYear_2516" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2515" xlink:to="Locator_us-gaap_OpenTaxYear_2516" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2507" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_2508" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2507" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_2508" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_2517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_2518" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_2517" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_2518" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2577" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_2578" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_2577" xlink:to="Locator_us-gaap_IncomeTaxAuthorityAxis_2578" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_2585" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2586" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityAxis_2585" xlink:to="Locator_us-gaap_IncomeTaxAuthorityDomain_2586" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="Locator_us-gaap_StateAndLocalJurisdictionMember_2588" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_2587" xlink:to="Locator_us-gaap_StateAndLocalJurisdictionMember_2588" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="Locator_us-gaap_DomesticCountryMember_2590" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_2589" xlink:to="Locator_us-gaap_DomesticCountryMember_2590" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_2591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="Locator_us-gaap_ForeignCountryMember_2592" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_2591" xlink:to="Locator_us-gaap_ForeignCountryMember_2592" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2579" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2580" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_2579" xlink:to="Locator_us-gaap_RangeAxis_2580" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_2581" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_2582" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_2581" xlink:to="Locator_us-gaap_BalanceSheetLocationAxis_2582" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_2593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_2594" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BalanceSheetLocationAxis_2593" xlink:to="Locator_us-gaap_BalanceSheetLocationDomain_2594" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_2595" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherLongTermObligationsMember" xlink:label="Locator_amed_OtherLongTermObligationsMember_2596" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_2595" xlink:to="Locator_amed_OtherLongTermObligationsMember_2596" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_2597" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredIncomeTaxesMember" xlink:label="Locator_amed_DeferredIncomeTaxesMember_2598" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_2597" xlink:to="Locator_amed_DeferredIncomeTaxesMember_2598" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EmployeeBenefitPlansDetail">
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2603" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" xlink:label="Locator_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_2604" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2603" xlink:to="Locator_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_2604" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2605" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="Locator_amed_DefinedContributionPlanEmployerMatchingContribution_2606" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2605" xlink:to="Locator_amed_DefinedContributionPlanEmployerMatchingContribution_2606" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2607" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="Locator_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_2608" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2607" xlink:to="Locator_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_2608" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2609" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="Locator_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_2610" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2609" xlink:to="Locator_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_2610" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="Locator_us-gaap_DefinedContributionPlanCostRecognized_2612" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2611" xlink:to="Locator_us-gaap_DefinedContributionPlanCostRecognized_2612" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2613" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_2614" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2613" xlink:to="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_2614" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2615" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_2616" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2615" xlink:to="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_2616" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureFutureMinimumRentalCommitments">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2678" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_2677" xlink:to="Locator_us-gaap_RangeMember_2678" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2679" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2680" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2679" xlink:to="Locator_us-gaap_MinimumMember_2680" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2681" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2682" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2681" xlink:to="Locator_us-gaap_MaximumMember_2682" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2641" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_2642" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2641" xlink:to="Locator_amed_FutureRentalCommitmentsTable_2642" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_2673" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2674" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FutureRentalCommitmentsTable_2673" xlink:to="Locator_amed_OperatingLeaseObligationsLineItems_2674" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2618" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2617" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2618" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2620" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2619" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2620" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2621" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2622" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2621" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2622" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2624" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2623" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2624" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2625" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2626" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2625" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2626" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2627" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2628" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2627" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2628" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2630" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2629" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2630" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2631" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_2632" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2631" xlink:to="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_2632" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2633" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_2634" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2633" xlink:to="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_2634" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2635" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseTermYears" xlink:label="Locator_amed_OperatingLeaseTermYears_2636" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2635" xlink:to="Locator_amed_OperatingLeaseTermYears_2636" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_2637" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="Locator_amed_OperatingLeasesAgreementExpirationYear_2638" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_2637" xlink:to="Locator_amed_OperatingLeasesAgreementExpirationYear_2638" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_2675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2676" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FutureRentalCommitmentsTable_2675" xlink:to="Locator_us-gaap_RangeAxis_2676" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2683" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HealthInsurance" xlink:label="Locator_amed_HealthInsurance_2684" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2683" xlink:to="Locator_amed_HealthInsurance_2684" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2685" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_WokersCompensation" xlink:label="Locator_amed_WokersCompensation_2686" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2685" xlink:to="Locator_amed_WokersCompensation_2686" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2687" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ProfessionalLiability" xlink:label="Locator_amed_ProfessionalLiability_2688" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2687" xlink:to="Locator_amed_ProfessionalLiability_2688" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2689" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_2690" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2689" xlink:to="Locator_amed_EstimatedInsuranceTotal_2690" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2691" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="Locator_amed_EstimatedInsuranceLongTermPortion_2692" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2691" xlink:to="Locator_amed_EstimatedInsuranceLongTermPortion_2692" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2693" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="Locator_amed_EstimatedInsuranceExcludingLongTermPortion_2694" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2693" xlink:to="Locator_amed_EstimatedInsuranceExcludingLongTermPortion_2694" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ComponentsOfNetDeferredTaxAssetsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2702" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2701" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2702" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2703" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2704" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2703" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2704" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2705" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_2706" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2705" xlink:to="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_2706" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2707" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_2708" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2707" xlink:to="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_2708" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2709" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2710" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2709" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2710" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2711" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2712" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2711" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2712" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_2714" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2713" xlink:to="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_2714" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2716" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2715" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2716" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2717" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="Locator_amed_DeferredTaxAssetsOtherCurrent_2718" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2717" xlink:to="Locator_amed_DeferredTaxAssetsOtherCurrent_2718" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2719" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_2720" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2719" xlink:to="Locator_us-gaap_DeferredTaxAssetsGross_2720" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_2722" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2721" xlink:to="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_2722" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_2724" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2723" xlink:to="Locator_us-gaap_DeferredTaxAssetsNet_2724" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2726" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2725" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2726" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2728" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2727" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2728" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_2730" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2729" xlink:to="Locator_us-gaap_DeferredTaxLiabilities_2730" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2731" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_2732" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2731" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_2732" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSourcesOfTaxEffectDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2764" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2763" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2764" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2765" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2766" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2765" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2766" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2767" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2768" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2767" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2768" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2769" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2770" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2769" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2770" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_2772" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2771" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_2772" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2773" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2774" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2773" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2774" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2775" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2776" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2775" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2776" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureReconciliationOfUnrecognizedTaxBenefitsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2779" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2780" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2779" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2780" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2781" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2782" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2781" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2782" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2784" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2783" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2784" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2785" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2786" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2785" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2786" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_2788" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2787" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_2788" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2777" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_2778" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2777" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_2778" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2789" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_2790" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2789" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_2790" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_2797" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2798" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_2797" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2798" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2827" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2828" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2827" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2828" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2791" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_2792" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2791" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_2792" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2793" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2794" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_2793" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2794" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2829" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2830" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2829" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2830" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2835" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2836" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2835" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2836" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2841" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="Locator_us-gaap_BuildingMember_2842" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2841" xlink:to="Locator_us-gaap_BuildingMember_2842" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2843" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="Locator_us-gaap_LeaseholdImprovementsMember_2844" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2843" xlink:to="Locator_us-gaap_LeaseholdImprovementsMember_2844" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2845" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EquipmentAndFurnitureMember" xlink:label="Locator_amed_EquipmentAndFurnitureMember_2846" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2845" xlink:to="Locator_amed_EquipmentAndFurnitureMember_2846" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2847" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VehiclesMember" xlink:label="Locator_us-gaap_VehiclesMember_2848" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2847" xlink:to="Locator_us-gaap_VehiclesMember_2848" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2849" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_ComputerSoftwareMember" xlink:label="Locator_amed_ComputerSoftwareMember_2850" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_2849" xlink:to="Locator_amed_ComputerSoftwareMember_2850" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2831" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2832" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2831" xlink:to="Locator_us-gaap_RangeAxis_2832" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2833" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2834" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_2833" xlink:to="Locator_us-gaap_RangeMember_2834" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2837" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2838" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2837" xlink:to="Locator_us-gaap_MinimumMember_2838" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2839" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2840" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2839" xlink:to="Locator_us-gaap_MaximumMember_2840" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2851" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2852" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2851" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2852" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2853" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2854" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2853" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2854" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2855" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2856" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2855" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2856" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2857" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2858" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2857" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2858" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2859" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2860" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2859" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2860" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2861" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2862" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2861" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2862" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2863" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2864" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_2863" xlink:to="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_2864" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2909" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2910" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_2909" xlink:to="Locator_us-gaap_RangeMember_2910" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_2883" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_2884" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_2883" xlink:to="Locator_us-gaap_LineOfCreditFacilityTable_2884" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_2903" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_2904" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_2903" xlink:to="Locator_us-gaap_LineOfCreditFacilityLineItems_2904" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_2877" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_2878" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_2877" xlink:to="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_2878" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_2879" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2880" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_2879" xlink:to="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2880" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_2905" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2906" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_2905" xlink:to="Locator_us-gaap_RangeAxis_2906" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_2907" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="Locator_us-gaap_CreditFacilityAxis_2908" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_2907" xlink:to="Locator_us-gaap_CreditFacilityAxis_2908" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="Locator_us-gaap_CreditFacilityAxis_2915" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="Locator_us-gaap_CreditFacilityDomain_2916" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CreditFacilityAxis_2915" xlink:to="Locator_us-gaap_CreditFacilityDomain_2916" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="Locator_us-gaap_CreditFacilityDomain_2911" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_AbrLoansMember" xlink:label="Locator_amed_AbrLoansMember_2912" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CreditFacilityDomain_2911" xlink:to="Locator_amed_AbrLoansMember_2912" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="Locator_us-gaap_CreditFacilityDomain_2913" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_EurodollarLoansMember" xlink:label="Locator_amed_EurodollarLoansMember_2914" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CreditFacilityDomain_2913" xlink:to="Locator_amed_EurodollarLoansMember_2914" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2925" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2926" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2925" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2926" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2957" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2958" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2957" xlink:to="Locator_us-gaap_RestructuringCostAndReserveLineItems_2958" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2917" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="Locator_us-gaap_RestructuringReserve_2918" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2917" xlink:to="Locator_us-gaap_RestructuringReserve_2918" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2919" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="Locator_us-gaap_RestructuringCharges_2920" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2919" xlink:to="Locator_us-gaap_RestructuringCharges_2920" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2921" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="Locator_us-gaap_PaymentsForRestructuring_2922" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2921" xlink:to="Locator_us-gaap_PaymentsForRestructuring_2922" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2959" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2960" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2959" xlink:to="Locator_amed_OtherRestructuringCostsAxis_2960" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2963" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2964" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringCostsAxis_2963" xlink:to="Locator_amed_OtherRestructuringDomain_2964" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2965" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndElevenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndElevenExitActivityMember_2966" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_2965" xlink:to="Locator_amed_TwoThousandAndElevenExitActivityMember_2966" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2967" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndTwelveExitActivityMember" xlink:label="Locator_amed_TwoThousandAndTwelveExitActivityMember_2968" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_2967" xlink:to="Locator_amed_TwoThousandAndTwelveExitActivityMember_2968" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2969" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndThirteenExitActivityMember_2970" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_2969" xlink:to="Locator_amed_TwoThousandAndThirteenExitActivityMember_2970" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2971" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndFourteenExitActivityMember_2972" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_2971" xlink:to="Locator_amed_TwoThousandAndFourteenExitActivityMember_2972" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2961" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2962" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2961" xlink:to="Locator_us-gaap_RestructuringCostAndReserveAxis_2962" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2973" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="Locator_us-gaap_TypeOfRestructuringDomain_2974" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_2973" xlink:to="Locator_us-gaap_TypeOfRestructuringDomain_2974" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="Locator_us-gaap_TypeOfRestructuringDomain_2975" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_LeaseTerminationMember" xlink:label="Locator_amed_LeaseTerminationMember_2976" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TypeOfRestructuringDomain_2975" xlink:to="Locator_amed_LeaseTerminationMember_2976" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="Locator_us-gaap_TypeOfRestructuringDomain_2977" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="Locator_us-gaap_EmployeeSeveranceMember_2978" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TypeOfRestructuringDomain_2977" xlink:to="Locator_us-gaap_EmployeeSeveranceMember_2978" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2979" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Land" xlink:label="Locator_us-gaap_Land_2980" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2979" xlink:to="Locator_us-gaap_Land_2980" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2981" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Buildingandleaseholdimprovements" xlink:label="Locator_amed_Buildingandleaseholdimprovements_2982" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2981" xlink:to="Locator_amed_Buildingandleaseholdimprovements_2982" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2983" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_Equipmentandfurniture" xlink:label="Locator_amed_Equipmentandfurniture_2984" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2983" xlink:to="Locator_amed_Equipmentandfurniture_2984" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2985" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="Locator_us-gaap_CapitalizedComputerSoftwareGross_2986" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2985" xlink:to="Locator_us-gaap_CapitalizedComputerSoftwareGross_2986" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2987" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_2988" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_2987" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentGross_2988" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSHAREREPURCHASEPROGRAM">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_2997" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="Locator_us-gaap_TreasuryStockTextBlock_2998" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_2997" xlink:to="Locator_us-gaap_TreasuryStockTextBlock_2998" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ShareRepurchaseProgramDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_2999" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="Locator_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3000" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_2999" xlink:to="Locator_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3000" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_3001" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_3002" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_3001" xlink:to="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_3002" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_3003" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="Locator_us-gaap_TreasuryStockSharesAcquired_3004" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_3003" xlink:to="Locator_us-gaap_TreasuryStockSharesAcquired_3004" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_3005" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="Locator_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3006" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_3005" xlink:to="Locator_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3006" order="4.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="Locator_us-gaap_RelatedPartyTransactionsAbstract_3007" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="Locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3008" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionsAbstract_3007" xlink:to="Locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3008" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="Locator_us-gaap_RelatedPartyTransactionsAbstract_3009" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="Locator_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_3010" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionsAbstract_3009" xlink:to="Locator_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_3010" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="Locator_us-gaap_RelatedPartyTransactionsAbstract_3011" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="Locator_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3012" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionsAbstract_3011" xlink:to="Locator_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3012" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SubsequentEventDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_3043" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3044" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_3043" xlink:to="Locator_us-gaap_SegmentDomain_3044" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3045" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_3046" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_3045" xlink:to="Locator_amed_HomeHealthMember_3046" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3047" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_3048" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_3047" xlink:to="Locator_amed_HospiceMember_3048" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3049" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_3050" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_3049" xlink:to="Locator_amed_PersonalCareMember_3050" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_3051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3052" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_3051" xlink:to="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3052" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3053" />
        <loc xlink:type="locator" xlink:href="amed-20170331.xsd#amed_TenetHealthcareMember" xlink:label="Locator_amed_TenetHealthcareMember_3054" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAcquireeDomain_3053" xlink:to="Locator_amed_TenetHealthcareMember_3054" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="Locator_us-gaap_SubsequentEventsAbstract_3013" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="Locator_us-gaap_SubsequentEventTable_3014" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventsAbstract_3013" xlink:to="Locator_us-gaap_SubsequentEventTable_3014" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="Locator_us-gaap_SubsequentEventTable_3037" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_3038" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventTable_3037" xlink:to="Locator_us-gaap_SubsequentEventLineItems_3038" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_3015" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_3016" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventLineItems_3015" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_3016" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="Locator_us-gaap_SubsequentEventTable_3039" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_3040" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventTable_3039" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_3040" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="Locator_us-gaap_SubsequentEventTable_3041" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_3042" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventTable_3041" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_3042" order="2.0" />
    </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g371808g48q23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g371808g48q23.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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=* "@ H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762459152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Apr. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,728,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762983632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 48,334<span></span>
</td>
<td class="nump">$ 30,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable, net of allowance for doubtful accounts of $19,249, and $17,716</a></td>
<td class="nump">172,707<span></span>
</td>
<td class="nump">166,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,097<span></span>
</td>
<td class="nump">7,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">11,964<span></span>
</td>
<td class="nump">11,260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">243,102<span></span>
</td>
<td class="nump">214,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $142,185 and $138,650</a></td>
<td class="nump">36,676<span></span>
</td>
<td class="nump">36,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">292,793<span></span>
</td>
<td class="nump">288,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $28,557 and $27,864</a></td>
<td class="nump">46,220<span></span>
</td>
<td class="nump">46,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Deferred income taxes</a></td>
<td class="nump">98,943<span></span>
</td>
<td class="nump">107,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="nump">38,894<span></span>
</td>
<td class="nump">38,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">756,628<span></span>
</td>
<td class="nump">734,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">29,444<span></span>
</td>
<td class="nump">30,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">81,909<span></span>
</td>
<td class="nump">82,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">65,663<span></span>
</td>
<td class="nump">63,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">6,888<span></span>
</td>
<td class="nump">5,220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">183,904<span></span>
</td>
<td class="nump">181,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">85,472<span></span>
</td>
<td class="nump">87,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">3,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">273,682<span></span>
</td>
<td class="nump">272,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - Note 5</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common Stock, $0.001 par value, 60,000,000 shares authorized; 35,364,752, and 35,253,577 shares issued; and 33,693,027 and 33,597,215 shares outstanding</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">544,428<span></span>
</td>
<td class="nump">537,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock at cost 1,671,725 and 1,656,362 shares of common stock</a></td>
<td class="num">(47,531)<span></span>
</td>
<td class="num">(46,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="num">(14,967)<span></span>
</td>
<td class="num">(30,545)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders' equity</a></td>
<td class="nump">481,980<span></span>
</td>
<td class="nump">460,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">482,946<span></span>
</td>
<td class="nump">461,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 756,628<span></span>
</td>
<td class="nump">$ 734,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31928-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762526000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Patient accounts receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 19,249<span></span>
</td>
<td class="nump">$ 17,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">142,185<span></span>
</td>
<td class="nump">138,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 28,557<span></span>
</td>
<td class="nump">$ 27,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">35,364,752<span></span>
</td>
<td class="nump">35,253,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">33,693,027<span></span>
</td>
<td class="nump">33,597,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock at cost, shares</a></td>
<td class="nump">1,671,725<span></span>
</td>
<td class="nump">1,656,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763652800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 370,458<span></span>
</td>
<td class="nump">$ 348,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">215,785<span></span>
</td>
<td class="nump">201,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">74,459<span></span>
</td>
<td class="nump">76,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">3,874<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">40,417<span></span>
</td>
<td class="nump">46,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">4,417<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">345,293<span></span>
</td>
<td class="nump">337,754<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">25,165<span></span>
</td>
<td class="nump">11,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,068)<span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss from equity method investments</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">25,122<span></span>
</td>
<td class="nump">10,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(9,923)<span></span>
</td>
<td class="num">(4,388)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">15,199<span></span>
</td>
<td class="nump">6,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 15,130<span></span>
</td>
<td class="nump">$ 6,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding</a></td>
<td class="nump">33,443<span></span>
</td>
<td class="nump">32,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders</a></td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding</a></td>
<td class="nump">34,073<span></span>
</td>
<td class="nump">33,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Income Amounts Attributable To Reporting Entity Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 15,130<span></span>
</td>
<td class="nump">$ 6,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Doubtful Accounts For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionForDoubtfulAccountsForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationPatientServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for providing services to patients, net of provisions for contractual allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=d3e8184-115640<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=d3e8195-115640<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=SL9156442-115640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052803&amp;loc=SL9156464-115641<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=SL9156442-115640<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationPatientServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760922448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 15,199<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,417<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">3,874<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">401(k) employer match</a></td>
<td class="nump">2,227<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property and equipment</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">9,445<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of equity method investments</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity investment</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(12,493)<span></span>
</td>
<td class="num">(27,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(3,403)<span></span>
</td>
<td class="nump">7,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(990)<span></span>
</td>
<td class="num">(2,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">9,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="nump">576<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities</a></td>
<td class="nump">27,097<span></span>
</td>
<td class="nump">12,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of deferred compensation plan assets</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Purchase of investment</a></td>
<td class="num">(256)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,385)<span></span>
</td>
<td class="num">(6,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(4,099)<span></span>
</td>
<td class="num">(27,682)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(8,175)<span></span>
</td>
<td class="num">(34,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options and warrants</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld upon stock vesting</a></td>
<td class="num">(758)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Tax benefit from stock options exercised and restricted stock vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Non-controlling interest distribution</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from revolving line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of revolving line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,315)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(785)<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">18,137<span></span>
</td>
<td class="num">(19,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">30,197<span></span>
</td>
<td class="nump">27,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">48,334<span></span>
</td>
<td class="nump">7,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">$ 284<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents disclosure of the amount of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporation; these investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pension benefit costs recognized during the period for (1) defined benefit plans and (2) defined contribution plans. For defined benefit plans, pension expense includes the following components: service cost, interest cost, expected return on plan assets, gain (loss) on plan assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments. For defined contribution plans, the pension expense generally equals the firm's contribution to employees' accounts (if the firm contributes) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6924250560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. NATURE OF OPERATIONS</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">CONSOLIDATION </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">AND PRESENTATION </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">OF FINANCIAL STATEMENTS </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (&#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) </font><font style="font-family:Times New Roman;font-size:10pt;">are</font><font style="font-family:Times New Roman;font-size:10pt;"> a multi-state provider of home health</font><font style="font-family:Times New Roman;font-size:10pt;">, hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">personal care</font><font style="font-family:Times New Roman;font-size:10pt;"> services with </font><font style="font-family:Times New Roman;font-size:10pt;">approximately</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">79</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">of</font><font style="font-family:Times New Roman;font-size:10pt;"> our revenue derived from Medicare for</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">the three</font><font style="font-family:Times New Roman;font-size:10pt;">-month period</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> ended March 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2017</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">owned and operated</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">326</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare-certified home health care centers</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">79</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare-certified hospice </font><font style="font-family:Times New Roman;font-size:10pt;">care centers</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> personal</font><font style="font-family:Times New Roman;font-size:10pt;">-</font><font style="font-family:Times New Roman;font-size:10pt;">care care centers</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">in </font><font style="font-family:Times New Roman;font-size:10pt;">34</font><font style="font-family:Times New Roman;font-size:10pt;"> states within the United St</font><font style="font-family:Times New Roman;font-size:10pt;">ates</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> the District of Columbia</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Basis of Presentation</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated finan</font><font style="font-family:Times New Roman;font-size:10pt;">cial statements and related notes included in our Annual Report on Form 10-K for </font><font style="font-family:Times New Roman;font-size:10pt;">the year ended December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 1, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Use of Estimates</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our accounting and </font><font style="font-family:Times New Roman;font-size:10pt;">reporting policies conform with </font><font style="font-family:Times New Roman;font-size:10pt;">U.S.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">GAAP. </font><font style="font-family:Times New Roman;font-size:10pt;">In preparing the </font><font style="font-family:Times New Roman;font-size:10pt;">unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Reclassifications and Comparability </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current period'</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> presentation</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Principles of Consolidation </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">These </font><font style="font-family:Times New Roman;font-size:10pt;">unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;">c</font><font style="font-family:Times New Roman;font-size:10pt;">onsolidated financial statements include the accounts of Amedisys, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying</font><font style="font-family:Times New Roman;font-size:10pt;"> unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements, and business combinations accounted for as purchases have been included in our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are </font><font style="font-family:Times New Roman;font-size:10pt;">accounted for as set forth below</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Equity </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">Investments </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">%. </font><font style="font-family:Times New Roman;font-size:10pt;">Third party equity interests in our consolidated joint ventures are reflected as </font><font style="font-family:Times New Roman;font-size:10pt;">noncontrolling</font><font style="font-family:Times New Roman;font-size:10pt;"> interests in our </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% or less of the voting stock and the entity is not a variable interest entity in </font><font style="font-family:Times New Roman;font-size:10pt;">which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> as of March </font><font style="font-family:Times New Roman;font-size:10pt;">31</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">We account for investments in entities in which we have less than a </font><font style="font-family:Times New Roman;font-size:10pt;">20</font><font style="font-family:Times New Roman;font-size:10pt;">% ownership interest under the cost method</font><font style="font-family:Times New Roman;font-size:10pt;"> of accounting if we do not have the ability to exercise significant influence over the investee</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6924144064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We earn net service revenue through our home health</font><font style="font-family:Times New Roman;font-size:10pt;">, hospice </font><font style="font-family:Times New Roman;font-size:10pt;">and </font><font style="font-family:Times New Roman;font-size:10pt;">personal-care</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">care center</font><font style="font-family:Times New Roman;font-size:10pt;">s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> for services provided. We refer to home health revenue earned and billed on a </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episode of care as episodic-based revenue. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Home Health Revenue Recognition</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net service revenue is recorded under the Medicare prospective payment system (&#8220;PPS&#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits was fewer than five; (c)&#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&#160;changes in the base episode payments established by the Medicare Program; (h)&#160;adjustments to the base episode payments for case mix and geographic wages; and (i)&#160;recoveries of overpayments.   In addition, we make adjustments to Medicare revenue if we </font><font style="font-family:Times New Roman;font-size:10pt;">find that we </font><font style="font-family:Times New Roman;font-size:10pt;">are unable to produce </font><font style="font-family:Times New Roman;font-size:10pt;">appropriate </font><font style="font-family:Times New Roman;font-size:10pt;">documentation of a face to face encounter between the patient and physician.</font><font style="font-family:Times New Roman;font-size:10pt;">   </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">reflect</font><font style="font-family:Times New Roman;font-size:10pt;"> differences between estimated and actual payment amounts, </font><font style="font-family:Times New Roman;font-size:10pt;">our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">discovered </font><font style="font-family:Times New Roman;font-size:10pt;">inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of </font><font style="font-family:Times New Roman;font-size:10pt;">over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> on</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction</font><font style="font-family:Times New Roman;font-size:10pt;"> to patient accounts receivable. </font><font style="font-family:Times New Roman;font-size:10pt;">Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on </font><font style="font-family:Times New Roman;font-size:10pt;">the number of days elapsed during an episode of care</font><font style="font-family:Times New Roman;font-size:10pt;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa</font><font style="font-family:Times New Roman;font-size:10pt;">tient accounts receivable in our </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated balance sheets for such periods. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Episodic-based Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-episodic </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">b</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">ased Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Hospice Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver.  The four levels of care</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">are routine care, general inpatient care, continu</font><font style="font-family:Times New Roman;font-size:10pt;">ous home care and respite care. </font><font style="font-family:Times New Roman;font-size:10pt;">Routine care accounts </font><font style="font-family:Times New Roman;font-size:10pt;">for </font><font style="font-family:Times New Roman;font-size:10pt;">98</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">of our total net Medic</font><font style="font-family:Times New Roman;font-size:10pt;">are hospice service revenue for </font><font style="font-family:Times New Roman;font-size:10pt;">each of </font><font style="font-family:Times New Roman;font-size:10pt;">the three</font><font style="font-family:Times New Roman;font-size:10pt;">-</font><font style="font-family:Times New Roman;font-size:10pt;">month</font><font style="font-family:Times New Roman;font-size:10pt;"> period</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> ended March 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2017</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">. Beginning</font><font style="font-family:Times New Roman;font-size:10pt;"> January 1, 2016, </font><font style="font-family:Times New Roman;font-size:10pt;">the Centers for Medicare and Medicaid Services (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">CMS</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;"> has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or </font><font style="font-family:Times New Roman;font-size:10pt;">acceptable authorizations </font><font style="font-family:Times New Roman;font-size:10pt;">and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes </font><font style="font-family:Times New Roman;font-size:10pt;">a</font><font style="font-family:Times New Roman;font-size:10pt;"> historical collection rate </font><font style="font-family:Times New Roman;font-size:10pt;">of over 99% </font><font style="font-family:Times New Roman;font-size:10pt;">on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if </font><font style="font-family:Times New Roman;font-size:10pt;">we estimate a </font><font style="font-family:Times New Roman;font-size:10pt;">cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase </font><font style="font-family:Times New Roman;font-size:10pt;">in other accrued liabilities. </font><font style="font-family:Times New Roman;font-size:10pt;">Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their estimated cap liability by March 31</font><font style="font-family:Times New Roman;font-size:10pt;">st</font><font style="font-family:Times New Roman;font-size:10pt;"> of the following year. As of March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, w</font><font style="font-family:Times New Roman;font-size:10pt;">e have settled our Medicare </font><font style="font-family:Times New Roman;font-size:10pt;">hospice reimbursements for all fiscal years through October 31, 20</font><font style="font-family:Times New Roman;font-size:10pt;">12</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, we have recorded </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">0.9</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">f</font><font style="font-family:Times New Roman;font-size:10pt;">or</font><font style="font-family:Times New Roman;font-size:10pt;"> estimated amounts due back to Medicare in other accrued liabilities for the Federal </font><font style="font-family:Times New Roman;font-size:10pt;">cap years ended October 31, 2013 through October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> As of December 31, 2016, we had recorded $0.8 million for</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31, 2013 through October 31, 2016.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per </font><font style="font-family:Times New Roman;font-size:10pt;">day </font><font style="font-family:Times New Roman;font-size:10pt;">rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv</font><font style="font-family:Times New Roman;font-size:10pt;">able</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Personal Care Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Personal Care Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation, which are recognized as net service revenue at the time services are rendered</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Patient Accounts Receivable </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> and patients. </font><font style="font-family:Times New Roman;font-size:10pt;">As of March 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> t</font><font style="font-family:Times New Roman;font-size:10pt;">here is </font><font style="font-family:Times New Roman;font-size:10pt;">only </font><font style="font-family:Times New Roman;font-size:10pt;">one</font><font style="font-family:Times New Roman;font-size:10pt;"> single </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">, other than Medicare, that accounts for more than </font><font style="font-family:Times New Roman;font-size:10pt;">10</font><font style="font-family:Times New Roman;font-size:10pt;">% of our total</font><font style="font-family:Times New Roman;font-size:10pt;"> outstanding patient receivables</font><font style="font-family:Times New Roman;font-size:10pt;"> (</font><font style="font-family:Times New Roman;font-size:10pt;">approximately </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">%). T</font><font style="font-family:Times New Roman;font-size:10pt;">hus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection</font><font style="font-family:Times New Roman;font-size:10pt;"> of our patient accounts receivable. We fully reserve for accounts which are aged at </font><font style="font-family:Times New Roman;font-size:10pt;">36</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe the credit risk associated with our Medicare accounts</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">which </font><font style="font-family:Times New Roman;font-size:10pt;">represent </font><font style="font-family:Times New Roman;font-size:10pt;">58</font><font style="font-family:Times New Roman;font-size:10pt;">% and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">% of</font><font style="font-family:Times New Roman;font-size:10pt;"> our</font><font style="font-family:Times New Roman;font-size:10pt;"> net patient accounts receivable at </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively, is limited due to our historical collection rate of over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">from Medicare and the fact that Medicare is a U.S. government </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue </font><font style="font-family:Times New Roman;font-size:10pt;">adjustments as discussed above</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">During</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">the three</font><font style="font-family:Times New Roman;font-size:10pt;">-</font><font style="font-family:Times New Roman;font-size:10pt;">month periods ended March 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2017</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">we recorded </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> $</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.7</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">, in estimated revenue adjustments to Medicare revenue.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe there is a certain level of credit risk associated with non-Medicare </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;">. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Home Health </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">% of our estimated payment for the initial episode at the start of care or </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#8220;final billed&#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of </font><font style="font-family:Times New Roman;font-size:10pt;">120</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the start of the episode, or </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Hospice </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t</font><font style="font-family:Times New Roman;font-size:10pt;">hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. </font><font style="font-family:Times New Roman;font-size:10pt;">W</font><font style="font-family:Times New Roman;font-size:10pt;">e bill Medicare on a monthly basis for the services provided to the patient</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-Medicare Home Health, Hospice </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">and </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Personal Care</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Once the patient has been confirmed for eligibility, we will provide services to the patient </font><font style="font-family:Times New Roman;font-size:10pt;">and bill the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font><font style="font-family:Times New Roman;font-size:10pt;">Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> or groups of </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> with similar characteristics that would subject us to any significant credit risk.  </font><font style="font-family:Times New Roman;font-size:10pt;">We estimate an allowance for doubtful accounts</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of </font><font style="font-family:Times New Roman;font-size:10pt;">collectability</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 18px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Fair Value of Financial Instruments</font></td></tr><tr style="height: 8px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Fair Value at Reporting Date Using</font></td></tr><tr style="height: 51px"><td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">Financial Instrument</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Carrying Value as of
March 31, 2017</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Quoted Prices in Active Markets for Identical Items
(Level 1)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Other Observable Inputs (Level 2)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Unobservable Inputs (Level 3)</font></td></tr><tr style="height: 14px"><td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">94.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">96.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The </font><font style="font-family:Times New Roman;font-size:10pt;">fair value hierarchy</font><font style="font-family:Times New Roman;font-size:10pt;"> is</font><font style="font-family:Times New Roman;font-size:10pt;"> based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'></p><ul><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</font></li></ul><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. </font><font style="font-family:Times New Roman;font-size:10pt;">For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable</font><font style="font-family:Times New Roman;font-size:10pt;">, payroll and employee benefits</font><font style="font-family:Times New Roman;font-size:10pt;"> and accrued expenses</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> we estimate the carrying amounts' approximate fair value</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Weighted-Average Shares Outstanding</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">income</font><font style="font-family:Times New Roman;font-size:10pt;"> per share attributable to </font><font style="font-family:Times New Roman;font-size:10pt;">Amedisys</font><font style="font-family:Times New Roman;font-size:10pt;">, Inc. common stockholders, calculated on the treasury stock method, </font><font style="font-family:Times New Roman;font-size:10pt;">is</font><font style="font-family:Times New Roman;font-size:10pt;"> based on the weighted average</font><font style="font-family:Times New Roman;font-size:10pt;"> number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares </font><font style="font-family:Times New Roman;font-size:10pt;">used in our computation of the weighted-average shares outstanding, which are used to calc</font><font style="font-family:Times New Roman;font-size:10pt;">ulate our basic and diluted net </font><font style="font-family:Times New Roman;font-size:10pt;">income</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">attributable to </font><font style="font-family:Times New Roman;font-size:10pt;">Amedisys</font><font style="font-family:Times New Roman;font-size:10pt;">, Inc. common stockholders (amounts in thousands):</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;">&#160;</td><td colspan="3"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Three-Month Periods Ended March 31</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2017</font></td><td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - basic</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,443</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,920</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Effect of dilutive securities:</font></td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Stock options</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">239</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">82</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Non-vested stock and stock units</font></td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">391</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">506</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - diluted</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">34,073</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,508</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Anti-dilutive securities</font></td><td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">332</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">319</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Recently Issued Accounting Pronouncements</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;">, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued </font><font style="font-family:Times New Roman;font-size:10pt;">ASU </font><font style="font-family:Times New Roman;font-size:10pt;">2015-14, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Times New Roman;font-size:10pt;">, to defer the effective date of the standard from January 1, 2017 to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company </font><font style="font-family:Times New Roman;font-size:10pt;">does not expect an impact on its consolidated financial statements upon implementation of ASU 2014-09 and ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related </font><font style="font-family:Times New Roman;font-size:10pt;">disclosures</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;">, which will require</font><font style="font-family:Times New Roman;font-size:10pt;"> lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid</font><font style="font-family:Times New Roman;font-size:10pt;">ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still evaluating the overall impact on our consolidated financial statements and related disclosures and the effect of the standard on our ongoing financial reporting.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation (Topic 718):</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Times New Roman;font-size:10pt;">, which will simplify the accounting for share-based payment award transactions</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">including income tax consequences, classification of awards as either equity or liability and classification on the statement of cash flows. The ASU is effective for annual and interim</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">periods </font><font style="font-family:Times New Roman;font-size:10pt;">beginning after December 15, 2016. </font><font style="font-family:Times New Roman;font-size:10pt;">We adopted this ASU </font><font style="font-family:Times New Roman;font-size:10pt;">effective Ja</font><font style="font-family:Times New Roman;font-size:10pt;">nuary 1, 2017, and as a result, we recorded a $</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> million increase to our non-current deferred tax asset and retained earnings for tax benefits that were not previously recognized under the prior rules. Additionally, on a prospective basis, we recorded excess tax benefits as a discrete item in our income tax provision within our condensed consolidated statement of operations for the three-mo</font><font style="font-family:Times New Roman;font-size:10pt;">nth period ended March 31, 2017. </font><font style="font-family:Times New Roman;font-size:10pt;">Historically these amounts were recorded as </font><font style="font-family:Times New Roman;font-size:10pt;">addition</font><font style="font-family:Times New Roman;font-size:10pt;">al</font><font style="font-family:Times New Roman;font-size:10pt;"> paid-in capital </font><font style="font-family:Times New Roman;font-size:10pt;">in</font><font style="font-family:Times New Roman;font-size:10pt;"> our condensed consolidated balance sheet</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">We also elected to prospectively apply the change to the presentation of cash payments made to taxing authorities on the employees' behalf for shares withheld upon stock vesting on our condensed consolidated statements of cash flows for the three-month period ended March 31, 2017. We have also elected to continue our current policy of estimating forfeitures of stock-based compensation awards at grant date and revising in subsequent periods to reflect actual forfeitures</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In A</font><font style="font-family:Times New Roman;font-size:10pt;">ugust 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;">, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements </font><font style="font-family:Times New Roman;font-size:10pt;">and related disclosures and the effect of the standard on its ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In January 2017, the FASB issued ASU 2017-01, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Times New Roman;font-size:10pt;">, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The ASU is effective for annual and interim periods beginning after December 15, 2017. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In January 2017, the FASB issued ASU 2017-04, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;">, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference of the carrying amount to the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2017-04 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753199312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. ACQUISITIONS </font></p><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health</font><font style="font-family:Times New Roman;font-size:10pt;">, hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">personal care </font><font style="font-family:Times New Roman;font-size:10pt;">services. The purchase price paid for acquisitions is negotiated through arm's length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets. Preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On February</font><font style="font-family:Times New Roman;font-size:10pt;"> 1, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">we acquired the assets of Home Staff, L.L.C. which owns and operates three personal-care care centers servicing the state of Massachusetts for a total purchase price of $4.0 million (subject to certain adjustments), of which $0.4 million was placed in a promissory note to be paid over 24 months, subject to any offsets or withhold</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> for indemnification purposes. The purchase price was paid with cash on hand on the date of the transaction. During the three-month period ended March 31, 2017, we recorded goodwill ($3.8 million), </font><font style="font-family:Times New Roman;font-size:10pt;">other</font><font style="font-family:Times New Roman;font-size:10pt;"> intangibles &#8211; non-compete agreements ($0.2 million) and other assets and liabilities, net ($0.5 million) in connection with the acquisition</font><font style="font-family:Times New Roman;font-size:10pt;">. The non-compete agreements will be amortized over a weighted-average period of 2.8 years</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1497-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1490-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1486-128463<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1524-128463<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4922-128472<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4934-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4926-128472<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=SL65897772-128472<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1383-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6924144064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">4. LONG-TERM OBLIGATIONS</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2" rowspan="2" style="width: 90px; text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">March 31, 2017</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td colspan="2" rowspan="2" style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">December 31, 2016</font></td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$100.0 million Term Loan; principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.98% at March 31, 2017); due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">93.7</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">95.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$200.0 million Revolving Credit Facility; interest only payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Promissory notes</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.1</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred debt issuance costs</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (2.4)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (2.7)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">92.4</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">93.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Current portion of long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(6.9)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.2)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">85.5</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">87.8</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our weighted average interest rate for our $100.0 million Term Loan, under our </font><font style="font-family:Times New Roman;font-size:10pt;">Credit Agreement, was 2.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">2.4%</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">for the three-month period</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> ended March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> and 2016, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> Our weighted average interest rate for our $200.0 millio</font><font style="font-family:Times New Roman;font-size:10pt;">n Revolving Credit Facility was</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">2.7</font><font style="font-family:Times New Roman;font-size:10pt;">% for the three-month period ended March 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of March </font><font style="font-family:Times New Roman;font-size:10pt;">31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">our </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated</font><font style="font-family:Times New Roman;font-size:10pt;"> leverage ratio was </font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> our </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated </font><font style="font-family:Times New Roman;font-size:10pt;">fixed charge coverage ratio was </font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> we are in compliance with our Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, our </font><font style="font-family:Times New Roman;font-size:10pt;">availability under our $2</font><font style="font-family:Times New Roman;font-size:10pt;">00.0 million Revolving Credit Facility was $</font><font style="font-family:Times New Roman;font-size:10pt;">17</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> million as we had $</font><font style="font-family:Times New Roman;font-size:10pt;">29</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> million outstanding letters of credit.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6607367424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Legal Proceedings </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">- Ongoing</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We are involved in the following legal actions: </font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Securities Class Action Lawsuits </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As previously disclosed, between</font><font style="font-family:Times New Roman;font-size:10pt;"> June&#160;10 and July 28, </font><font style="font-family:Times New Roman;font-size:10pt;">2010, </font><font style="font-family:Times New Roman;font-size:10pt;">several</font><font style="font-family:Times New Roman;font-size:10pt;"> putative securities class action complaint</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">were</font><font style="font-family:Times New Roman;font-size:10pt;"> filed in the United States District Court for the Middle District of Louisiana (the &#8220;District Court&#8221;) against the Company and certain of our former senior executives.</font><font style="font-family:Times New Roman;font-size:10pt;"> The cases were consolidated into the first-filed action </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Bach, et al. v. </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Amedisys</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">, Inc., et al.</font><font style="font-family:Times New Roman;font-size:10pt;"> Case No. 3:10-cv-00395, and the District Court appointed as co-lead plaintiffs the Public Employees' Retirement System of Mississippi and the Puerto Rico Teachers' Retirement System (the &#8220;Co-Lead Plaintiffs&#8221;). They filed a consolidated, amended complaint which all defendants moved to dismiss. The District Court granted the defendants' motions to dismiss on June 28, 20</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">2, and the Co-Lead Plaintiffs appealed that ruling to the United States Court of Appeals for the Fifth Circuit (the &#8220;Fifth Circuit&#8221;). On October 2, 2014, a three-judge panel of the Fifth Circuit reversed the District Court's dismissal and remanded the case to the District Court for further proceedings. The defendants request for an </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">en banc</font><font style="font-family:Times New Roman;font-size:10pt;"> review was denied on December 29, 2014 and their Petition for a Writ of Certiorari from the United States Supreme Court was denied on June 29, 2015.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">After remand to the District Court, the Plaintiffs were granted leave to file a First Amended Consolidated Complaint (the &#8220;First Amended Securities Complaint&#8221;) on behalf of all purchasers or acquirers of </font><font style="font-family:Times New Roman;font-size:10pt;">Amedisys</font><font style="font-family:Times New Roman;font-size:10pt;">' securities between August 2, 2005 and September 30, 2011.  The First Amended Securities Complaint alleges that the Company and seven individual defendants violated Section 10(b), Section 20(a), and Rule 10b-5 of the Securities Exchange Act of 1934 by materially misrepresenting the Company's financial results and concealing a scheme to obtain higher Medicare reimbursements and additional patient referrals by (1) providing medically unnecessary care to patients, including certifying and re-certifying patients for medically unnecessary 60-day treatment episodes; (2) implementing clinical tracks such as &#8220;Balanced for Life&#8221; and wound care programs that provided a pre-set number of therapy visits irrespective of medical need; (3) &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">upcoding</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221; patients' Medicare forms to attribute a &#8220;primary diagnosis&#8221; to a medical condition associated with higher billing rates; and (4) providing improper and illegal remuneration to physicians to obtain patient certifications or re-certifications.  The First Amended Securities Complaint seeks certification of the case as a class action and an unspecified amount of damages, as well as interest and an award of attorneys' fees.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">All defendants moved to dismiss the</font><font style="font-family:Times New Roman;font-size:10pt;"> First Amended Securities Complaint on December 15, 2015. While that motion was pending the parties agreed to mediate the case. This mediation was not successful. On August 19, 2016, the District Court issued its ruling on the defendants' motions to dismiss, dismissing with prejudice all claims against two former officers, dismissing all except Section 20(a) claims against three former officers, and denying all other relief. The Company and four individual defendants then filed their answers to the First Amended Securities Complaint on October 20, 2016. The independent executrix of the estate of William F. Borne, who was substituted as a defendant in the case after Mr. </font><font style="font-family:Times New Roman;font-size:10pt;">Borne's</font><font style="font-family:Times New Roman;font-size:10pt;"> death, filed her answer on February 6, 2017. The case is currently in the early stages of discovery. The parties have agreed to mediate the case again on June 12, 2017.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Because the case is in the early stages of litigation, w</font><font style="font-family:Times New Roman;font-size:10pt;">e are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the securities litigation described above.&#160; The Company intends to continue to vigorously defend itself in the securities litigation matter but, if decided adverse to the Company, its impact could be material.&#160; No assurances can be given as to the timing or outcome of the securities matter described above or the impact of any of the inquiry or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Subpoena </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Duces</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Tecum</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> Issued by the U.S. Department of Justice</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On May 21, 2015, we received a Subpoena </font><font style="font-family:Times New Roman;font-size:10pt;">Duces</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Tecum</font><font style="font-family:Times New Roman;font-size:10pt;"> (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney's Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through </font><font style="font-family:Times New Roman;font-size:10pt;">May 21, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </font><font style="font-family:Times New Roman;font-size:10pt;">Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Civil Investigative Demand Issued by the U.S. Department of Justice</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On November 3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </font><font style="font-family:Times New Roman;font-size:10pt;">Based on the information currently available to us, we cannot predict the </font><font style="font-family:Times New Roman;font-size:10pt;">timing or outcome of this investigation</font><font style="font-family:Times New Roman;font-size:10pt;"> or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On June 27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January 1, 2011 through June 20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Other Investigative Matters</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> - Ongoing</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Corporate Integrity Agreement</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of</font><font style="font-family:Calibri;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Justice relating to certain of our clinical and business operations.  Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&#8220;CIA&#8221;) with the Office of Inspector General-HHS (&#8220;OIG&#8221;). The CIA formalizes various aspects of our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs.  The corporate integrity agreement has a term of five years.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Computer Inventory and Data Security Reporting</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On March 1 and March 2, 2015, we provided official notice under federal and state data privacy laws concerning the outcome of an </font><font style="font-family:Times New Roman;font-size:10pt;">extensive risk management process to locate and verify our large computer inventory. The process identified approximately 142 encrypted computers and laptops for which reports were required under federal and state data privacy laws. The devices at issue were originally assigned to Company clinicians and other team members</font><font style="font-family:Times New Roman;font-size:10pt;"> who left the Company between 2011 and 2014. We reported these devices to the U.S. Department of Health and Human Services, state agencies, and individuals whose information may be involved, as required under applicable law because we could not rule out unauthorized access to patient data on the devices. The Office of Civil Rights, U.S. Department of Health and Human Services (&#8220;OCR&#8221;) is reviewing our compliance with applicable laws, as is typical for any data breach involving more than 500 individuals. We are cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate with applicable regulatory authorities. In accordance with our CIA, we have notified the OIG of this matter.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Idaho and Wyoming Self-Report</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 2016, the Company engaged an independent auditing firm to perform a clinical audit of the hospice care centers acquired by Frontier Home Health and Hospice in April 2014. No assurances can be given as to the timing or outcome of the audit on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Third Party Audits</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> - Ongoing</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">From </font><font style="font-family:Times New Roman;font-size:10pt;">time to time, in the ordinary course of business, we are subject to audits under various governmental programs in whic</font><font style="font-family:Times New Roman;font-size:10pt;">h third party firms engaged by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;"> conduct extensive review of claims data to identify potential improper payments under the Medicare program.  </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor (&#8220;ZPIC&#8221;) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160; We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160; Based on the ZPIC's findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare Administrative Contractor (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">MAC</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;"> for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment.  We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An ALJ hearing was held in early January 2015. </font><font style="font-family:Times New Roman;font-size:10pt;">On January 18, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million </font><font style="font-family:Times New Roman;font-size:10pt;">with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160; No assurances can be given as to the timing or outcome of the Me</font><font style="font-family:Times New Roman;font-size:10pt;">dicare Appeals Council decision. As of June 30, 2016, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. </font><font style="font-family:Times New Roman;font-size:10pt;">In the event we </font><font style="font-family:Times New Roman;font-size:10pt;">are not able to recoup </font><font style="font-family:Times New Roman;font-size:10pt;">this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009.  As of </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;">, we have </font><font style="font-family:Times New Roman;font-size:10pt;">an indemnity receivable for the amount withheld related to the period prior to August 1, 2009.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In July 2016, </font><font style="font-family:Times New Roman;font-size:10pt;">the Company received a request for medical records from </font><font style="font-family:Times New Roman;font-size:10pt;">SafeGuard</font><font style="font-family:Times New Roman;font-size:10pt;"> Services, L.L.C (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">SafeGuard</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;), a ZPIC related to services provided by some of the care cente</font><font style="font-family:Times New Roman;font-size:10pt;">rs that the Company acquired fro</font><font style="font-family:Times New Roman;font-size:10pt;">m Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. Subsequent to the initial ZPIC letter, the Company received additional requests for information regarding its care centers in Florida including post </font><font style="font-family:Times New Roman;font-size:10pt;">payment claims reviews, </font><font style="font-family:Times New Roman;font-size:10pt;">communications regarding suspensions of payment, and letters notifying the Company that various care centers have been placed on prepayment review. As these matters continue to develop, the Company is cooperating with </font><font style="font-family:Times New Roman;font-size:10pt;">SafeGuard</font><font style="font-family:Times New Roman;font-size:10pt;">, responding to all requests for information, and working to resolve these matters.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Based on the information currently</font><font style="font-family:Times New Roman;font-size:10pt;"> available to the Company</font><font style="font-family:Times New Roman;font-size:10pt;"> and the uncertainty regarding the scope of this audit</font><font style="font-family:Times New Roman;font-size:10pt;">, the Company cannot predict the timing or outcome of this audit or reasonably estimate the amount or range of potential losses, which may arise from this matter</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Insurance </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We are obligated for certain costs associated with our insurance programs, including employee health, workers' compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">up to </font><font style="font-family:Times New Roman;font-size:10pt;">specified deductible limits</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not</font><font style="font-family:Times New Roman;font-size:10pt;"> reported</font><font style="font-family:Times New Roman;font-size:10pt;">. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. </font></p><p style='margin-top:4.5pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our health insurance has a retention limit of $</font><font style="font-family:Times New Roman;font-size:10pt;">0.9</font><font style="font-family:Times New Roman;font-size:10pt;"> million, our workers' compensation insurance has a retention limit of $</font><font style="font-family:Times New Roman;font-size:10pt;">0.5</font><font style="font-family:Times New Roman;font-size:10pt;"> million and our professional liability insurance has a retention limit of $</font><font style="font-family:Times New Roman;font-size:10pt;">0.3</font><font style="font-family:Times New Roman;font-size:10pt;"> million.</font><font style="font-family:Times New Roman;font-size:10pt;">  </font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6924164368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;margin-left:0px;">6</font><font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;">. Segment Information</font></p><p style='margin-top:9pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our operations involve servicing patients through our </font><font style="font-family:Times New Roman;font-size:10pt;">three</font><font style="font-family:Times New Roman;font-size:10pt;"> reportable business segments:  home health</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> and personal care</font><font style="font-family:Times New Roman;font-size:10pt;">.  Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with </font><font style="font-family:Times New Roman;font-size:10pt;">completing important personal tasks</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">Our hospice segment provides palliative care and comfort to terminally </font><font style="font-family:Times New Roman;font-size:10pt;">ill patients and their families. Our personal ca</font><font style="font-family:Times New Roman;font-size:10pt;">re segment</font><font style="font-family:Times New Roman;font-size:10pt;">, which was established with the acquisition of Associated Home Care during the three-month period ended March 31, 2016, </font><font style="font-family:Times New Roman;font-size:10pt;">provides</font><font style="font-family:Times New Roman;font-size:10pt;"> patients with assistance with the esse</font><font style="font-family:Times New Roman;font-size:10pt;">ntial activities of daily living</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">The &#8220;other&#8221; column in the following tables consist</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> of costs relating to </font><font style="font-family:Times New Roman;font-size:10pt;">executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">M</font><font style="font-family:Times New Roman;font-size:10pt;">anagement</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">evaluates performance and allocates resources based on the operating income of the reportable segments, </font><font style="font-family:Times New Roman;font-size:10pt;">which </font><font style="font-family:Times New Roman;font-size:10pt;">includes an allocation of </font><font style="font-family:Times New Roman;font-size:10pt;">corporate expenses</font><font style="font-family:Times New Roman;font-size:10pt;"> directly attribu</font><font style="font-family:Times New Roman;font-size:10pt;">table to the specific segment</font><font style="font-family:Times New Roman;font-size:10pt;"> and includes revenues and all other costs directly attributable to the specific segment</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">Segment assets are not reviewed by the company's chief operating decision maker and therefore are not disclosed below (amounts in millions).  </font></p><p style='margin-top:0pt; margin-bottom:9pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Three-Month Period Ended March 31, 2017</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">271.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">85.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">370.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">163.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">215.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">68.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">29.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">118.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">235.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">63.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">345.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.2)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(32.7)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">25.2</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Three-Month Period Ended March 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care (1)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">272.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">73.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">348.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">160.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">201.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">71.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">127.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">236.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">56.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">41.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">337.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">36.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(41.9)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 5px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="16"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">(1) Acquired March 1, 2016.</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753143824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">7.&#160; SUBSEQUENT EVENT</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On </font><font style="font-family:Times New Roman;font-size:10pt;">May 1, 2017, we acquired </font><font style="font-family:Times New Roman;font-size:10pt;">certain</font><font style="font-family:Times New Roman;font-size:10pt;"> home health and hospice operations </font><font style="font-family:Times New Roman;font-size:10pt;">from Tenet Healthcare </font><font style="font-family:Times New Roman;font-size:10pt;">in Arizona, Illinois, Massachusetts, and Texas</font><font style="font-family:Times New Roman;font-size:10pt;"> for a purchase price of $</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:8pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762503888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Basis of Presentation</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated finan</font><font style="font-family:Times New Roman;font-size:10pt;">cial statements and related notes included in our Annual Report on Form 10-K for </font><font style="font-family:Times New Roman;font-size:10pt;">the year ended December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 1, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</font></p><p style='margin-top:9pt; margin-bottom:0pt'>&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Use of Estimates</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our accounting and </font><font style="font-family:Times New Roman;font-size:10pt;">reporting policies conform with </font><font style="font-family:Times New Roman;font-size:10pt;">U.S.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">GAAP. </font><font style="font-family:Times New Roman;font-size:10pt;">In preparing the </font><font style="font-family:Times New Roman;font-size:10pt;">unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComparabilityOfPriorYearFinancialData', window );">Reclassifications and Comparability</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Reclassifications and Comparability </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current period'</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> presentation</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Principles of Consolidation </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">These </font><font style="font-family:Times New Roman;font-size:10pt;">unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;">c</font><font style="font-family:Times New Roman;font-size:10pt;">onsolidated financial statements include the accounts of Amedisys, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying</font><font style="font-family:Times New Roman;font-size:10pt;"> unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements, and business combinations accounted for as purchases have been included in our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">unaudited condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are </font><font style="font-family:Times New Roman;font-size:10pt;">accounted for as set forth below</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Investments</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Equity </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">Investments </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">%. </font><font style="font-family:Times New Roman;font-size:10pt;">Third party equity interests in our consolidated joint ventures are reflected as </font><font style="font-family:Times New Roman;font-size:10pt;">noncontrolling</font><font style="font-family:Times New Roman;font-size:10pt;"> interests in our </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% or less of the voting stock and the entity is not a variable interest entity in </font><font style="font-family:Times New Roman;font-size:10pt;">which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> as of March </font><font style="font-family:Times New Roman;font-size:10pt;">31</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">We account for investments in entities in which we have less than a </font><font style="font-family:Times New Roman;font-size:10pt;">20</font><font style="font-family:Times New Roman;font-size:10pt;">% ownership interest under the cost method</font><font style="font-family:Times New Roman;font-size:10pt;"> of accounting if we do not have the ability to exercise significant influence over the investee</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We earn net service revenue through our home health</font><font style="font-family:Times New Roman;font-size:10pt;">, hospice </font><font style="font-family:Times New Roman;font-size:10pt;">and </font><font style="font-family:Times New Roman;font-size:10pt;">personal-care</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">care center</font><font style="font-family:Times New Roman;font-size:10pt;">s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> for services provided. We refer to home health revenue earned and billed on a </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episode of care as episodic-based revenue. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Home Health Revenue Recognition</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net service revenue is recorded under the Medicare prospective payment system (&#8220;PPS&#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits was fewer than five; (c)&#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&#160;changes in the base episode payments established by the Medicare Program; (h)&#160;adjustments to the base episode payments for case mix and geographic wages; and (i)&#160;recoveries of overpayments.   In addition, we make adjustments to Medicare revenue if we </font><font style="font-family:Times New Roman;font-size:10pt;">find that we </font><font style="font-family:Times New Roman;font-size:10pt;">are unable to produce </font><font style="font-family:Times New Roman;font-size:10pt;">appropriate </font><font style="font-family:Times New Roman;font-size:10pt;">documentation of a face to face encounter between the patient and physician.</font><font style="font-family:Times New Roman;font-size:10pt;">   </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">reflect</font><font style="font-family:Times New Roman;font-size:10pt;"> differences between estimated and actual payment amounts, </font><font style="font-family:Times New Roman;font-size:10pt;">our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">discovered </font><font style="font-family:Times New Roman;font-size:10pt;">inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of </font><font style="font-family:Times New Roman;font-size:10pt;">over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> on</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction</font><font style="font-family:Times New Roman;font-size:10pt;"> to patient accounts receivable. </font><font style="font-family:Times New Roman;font-size:10pt;">Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on </font><font style="font-family:Times New Roman;font-size:10pt;">the number of days elapsed during an episode of care</font><font style="font-family:Times New Roman;font-size:10pt;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa</font><font style="font-family:Times New Roman;font-size:10pt;">tient accounts receivable in our </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated balance sheets for such periods. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Episodic-based Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-episodic </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">b</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">ased Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Hospice Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver.  The four levels of care</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">are routine care, general inpatient care, continu</font><font style="font-family:Times New Roman;font-size:10pt;">ous home care and respite care. </font><font style="font-family:Times New Roman;font-size:10pt;">Routine care accounts </font><font style="font-family:Times New Roman;font-size:10pt;">for </font><font style="font-family:Times New Roman;font-size:10pt;">98</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">of our total net Medic</font><font style="font-family:Times New Roman;font-size:10pt;">are hospice service revenue for </font><font style="font-family:Times New Roman;font-size:10pt;">each of </font><font style="font-family:Times New Roman;font-size:10pt;">the three</font><font style="font-family:Times New Roman;font-size:10pt;">-</font><font style="font-family:Times New Roman;font-size:10pt;">month</font><font style="font-family:Times New Roman;font-size:10pt;"> period</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> ended March 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2017</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">. Beginning</font><font style="font-family:Times New Roman;font-size:10pt;"> January 1, 2016, </font><font style="font-family:Times New Roman;font-size:10pt;">the Centers for Medicare and Medicaid Services (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">CMS</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;"> has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or </font><font style="font-family:Times New Roman;font-size:10pt;">acceptable authorizations </font><font style="font-family:Times New Roman;font-size:10pt;">and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes </font><font style="font-family:Times New Roman;font-size:10pt;">a</font><font style="font-family:Times New Roman;font-size:10pt;"> historical collection rate </font><font style="font-family:Times New Roman;font-size:10pt;">of over 99% </font><font style="font-family:Times New Roman;font-size:10pt;">on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if </font><font style="font-family:Times New Roman;font-size:10pt;">we estimate a </font><font style="font-family:Times New Roman;font-size:10pt;">cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase </font><font style="font-family:Times New Roman;font-size:10pt;">in other accrued liabilities. </font><font style="font-family:Times New Roman;font-size:10pt;">Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their estimated cap liability by March 31</font><font style="font-family:Times New Roman;font-size:10pt;">st</font><font style="font-family:Times New Roman;font-size:10pt;"> of the following year. As of March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, w</font><font style="font-family:Times New Roman;font-size:10pt;">e have settled our Medicare </font><font style="font-family:Times New Roman;font-size:10pt;">hospice reimbursements for all fiscal years through October 31, 20</font><font style="font-family:Times New Roman;font-size:10pt;">12</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, we have recorded </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">0.9</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">f</font><font style="font-family:Times New Roman;font-size:10pt;">or</font><font style="font-family:Times New Roman;font-size:10pt;"> estimated amounts due back to Medicare in other accrued liabilities for the Federal </font><font style="font-family:Times New Roman;font-size:10pt;">cap years ended October 31, 2013 through October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> As of December 31, 2016, we had recorded $0.8 million for</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31, 2013 through October 31, 2016.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per </font><font style="font-family:Times New Roman;font-size:10pt;">day </font><font style="font-family:Times New Roman;font-size:10pt;">rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv</font><font style="font-family:Times New Roman;font-size:10pt;">able</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Personal Care Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Personal Care Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation, which are recognized as net service revenue at the time services are rendered</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Patient Accounts Receivable </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> and patients. </font><font style="font-family:Times New Roman;font-size:10pt;">As of March 31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> t</font><font style="font-family:Times New Roman;font-size:10pt;">here is </font><font style="font-family:Times New Roman;font-size:10pt;">only </font><font style="font-family:Times New Roman;font-size:10pt;">one</font><font style="font-family:Times New Roman;font-size:10pt;"> single </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">, other than Medicare, that accounts for more than </font><font style="font-family:Times New Roman;font-size:10pt;">10</font><font style="font-family:Times New Roman;font-size:10pt;">% of our total</font><font style="font-family:Times New Roman;font-size:10pt;"> outstanding patient receivables</font><font style="font-family:Times New Roman;font-size:10pt;"> (</font><font style="font-family:Times New Roman;font-size:10pt;">approximately </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">%). T</font><font style="font-family:Times New Roman;font-size:10pt;">hus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection</font><font style="font-family:Times New Roman;font-size:10pt;"> of our patient accounts receivable. We fully reserve for accounts which are aged at </font><font style="font-family:Times New Roman;font-size:10pt;">36</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe the credit risk associated with our Medicare accounts</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">which </font><font style="font-family:Times New Roman;font-size:10pt;">represent </font><font style="font-family:Times New Roman;font-size:10pt;">58</font><font style="font-family:Times New Roman;font-size:10pt;">% and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">% of</font><font style="font-family:Times New Roman;font-size:10pt;"> our</font><font style="font-family:Times New Roman;font-size:10pt;"> net patient accounts receivable at </font><font style="font-family:Times New Roman;font-size:10pt;">March 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively, is limited due to our historical collection rate of over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">from Medicare and the fact that Medicare is a U.S. government </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue </font><font style="font-family:Times New Roman;font-size:10pt;">adjustments as discussed above</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">During</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">the three</font><font style="font-family:Times New Roman;font-size:10pt;">-</font><font style="font-family:Times New Roman;font-size:10pt;">month periods ended March 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2017</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">we recorded </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> $</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.7</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">, in estimated revenue adjustments to Medicare revenue.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe there is a certain level of credit risk associated with non-Medicare </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;">. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Home Health </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">% of our estimated payment for the initial episode at the start of care or </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#8220;final billed&#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of </font><font style="font-family:Times New Roman;font-size:10pt;">120</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the start of the episode, or </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Hospice </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t</font><font style="font-family:Times New Roman;font-size:10pt;">hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. </font><font style="font-family:Times New Roman;font-size:10pt;">W</font><font style="font-family:Times New Roman;font-size:10pt;">e bill Medicare on a monthly basis for the services provided to the patient</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-Medicare Home Health, Hospice </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">and </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Personal Care</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Once the patient has been confirmed for eligibility, we will provide services to the patient </font><font style="font-family:Times New Roman;font-size:10pt;">and bill the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font><font style="font-family:Times New Roman;font-size:10pt;">Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> or groups of </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> with similar characteristics that would subject us to any significant credit risk.  </font><font style="font-family:Times New Roman;font-size:10pt;">We estimate an allowance for doubtful accounts</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of </font><font style="font-family:Times New Roman;font-size:10pt;">collectability</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 18px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Fair Value of Financial Instruments</font></td></tr><tr style="height: 8px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Fair Value at Reporting Date Using</font></td></tr><tr style="height: 51px"><td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">Financial Instrument</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Carrying Value as of
March 31, 2017</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Quoted Prices in Active Markets for Identical Items
(Level 1)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Other Observable Inputs (Level 2)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Unobservable Inputs (Level 3)</font></td></tr><tr style="height: 14px"><td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">94.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">96.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The </font><font style="font-family:Times New Roman;font-size:10pt;">fair value hierarchy</font><font style="font-family:Times New Roman;font-size:10pt;"> is</font><font style="font-family:Times New Roman;font-size:10pt;"> based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'></p><ul><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</font></li></ul><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. </font><font style="font-family:Times New Roman;font-size:10pt;">For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable</font><font style="font-family:Times New Roman;font-size:10pt;">, payroll and employee benefits</font><font style="font-family:Times New Roman;font-size:10pt;"> and accrued expenses</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> we estimate the carrying amounts' approximate fair value</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Weighted-Average Shares Outstanding</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">income</font><font style="font-family:Times New Roman;font-size:10pt;"> per share attributable to </font><font style="font-family:Times New Roman;font-size:10pt;">Amedisys</font><font style="font-family:Times New Roman;font-size:10pt;">, Inc. common stockholders, calculated on the treasury stock method, </font><font style="font-family:Times New Roman;font-size:10pt;">is</font><font style="font-family:Times New Roman;font-size:10pt;"> based on the weighted average</font><font style="font-family:Times New Roman;font-size:10pt;"> number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares </font><font style="font-family:Times New Roman;font-size:10pt;">used in our computation of the weighted-average shares outstanding, which are used to calc</font><font style="font-family:Times New Roman;font-size:10pt;">ulate our basic and diluted net </font><font style="font-family:Times New Roman;font-size:10pt;">income</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">attributable to </font><font style="font-family:Times New Roman;font-size:10pt;">Amedisys</font><font style="font-family:Times New Roman;font-size:10pt;">, Inc. common stockholders (amounts in thousands):</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;">&#160;</td><td colspan="3"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Three-Month Periods Ended March 31</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2017</font></td><td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - basic</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,443</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,920</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Effect of dilutive securities:</font></td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Stock options</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">239</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">82</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Non-vested stock and stock units</font></td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">391</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">506</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - diluted</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">34,073</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,508</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Anti-dilutive securities</font></td><td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">332</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">319</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Recently Issued Accounting Pronouncements</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;">, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued </font><font style="font-family:Times New Roman;font-size:10pt;">ASU </font><font style="font-family:Times New Roman;font-size:10pt;">2015-14, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Times New Roman;font-size:10pt;">, to defer the effective date of the standard from January 1, 2017 to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company </font><font style="font-family:Times New Roman;font-size:10pt;">does not expect an impact on its consolidated financial statements upon implementation of ASU 2014-09 and ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related </font><font style="font-family:Times New Roman;font-size:10pt;">disclosures</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;">, which will require</font><font style="font-family:Times New Roman;font-size:10pt;"> lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid</font><font style="font-family:Times New Roman;font-size:10pt;">ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still evaluating the overall impact on our consolidated financial statements and related disclosures and the effect of the standard on our ongoing financial reporting.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation (Topic 718):</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Times New Roman;font-size:10pt;">, which will simplify the accounting for share-based payment award transactions</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">including income tax consequences, classification of awards as either equity or liability and classification on the statement of cash flows. The ASU is effective for annual and interim</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">periods </font><font style="font-family:Times New Roman;font-size:10pt;">beginning after December 15, 2016. </font><font style="font-family:Times New Roman;font-size:10pt;">We adopted this ASU </font><font style="font-family:Times New Roman;font-size:10pt;">effective Ja</font><font style="font-family:Times New Roman;font-size:10pt;">nuary 1, 2017, and as a result, we recorded a $</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> million increase to our non-current deferred tax asset and retained earnings for tax benefits that were not previously recognized under the prior rules. Additionally, on a prospective basis, we recorded excess tax benefits as a discrete item in our income tax provision within our condensed consolidated statement of operations for the three-mo</font><font style="font-family:Times New Roman;font-size:10pt;">nth period ended March 31, 2017. </font><font style="font-family:Times New Roman;font-size:10pt;">Historically these amounts were recorded as </font><font style="font-family:Times New Roman;font-size:10pt;">addition</font><font style="font-family:Times New Roman;font-size:10pt;">al</font><font style="font-family:Times New Roman;font-size:10pt;"> paid-in capital </font><font style="font-family:Times New Roman;font-size:10pt;">in</font><font style="font-family:Times New Roman;font-size:10pt;"> our condensed consolidated balance sheet</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">We also elected to prospectively apply the change to the presentation of cash payments made to taxing authorities on the employees' behalf for shares withheld upon stock vesting on our condensed consolidated statements of cash flows for the three-month period ended March 31, 2017. We have also elected to continue our current policy of estimating forfeitures of stock-based compensation awards at grant date and revising in subsequent periods to reflect actual forfeitures</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In A</font><font style="font-family:Times New Roman;font-size:10pt;">ugust 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;">, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements </font><font style="font-family:Times New Roman;font-size:10pt;">and related disclosures and the effect of the standard on its ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In January 2017, the FASB issued ASU 2017-01, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Times New Roman;font-size:10pt;">, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The ASU is effective for annual and interim periods beginning after December 15, 2017. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In January 2017, the FASB issued ASU 2017-04, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;">, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference of the carrying amount to the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2017-04 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComparabilityOfPriorYearFinancialData">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting any exceptions to the  comparability of prior year financial data with data shown for the most recent accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComparabilityOfPriorYearFinancialData</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. The accounting policy may include information such as: (1) initially recording an investment in the stock of an investee at cost; (2) adjusting the carrying amount of the investment to recognize the investor's share of the earnings or losses of the investee after the date of acquisition; and (3) adjustments to reflect the investor's share of changes in the investee's capital (dividends). This disclosure may also include a detailed description of the policy for determining the amount of equity method losses recognized after an investment has been reduced to zero as a result of previous losses, reasons for not using the equity method when the investor company owns 20 percent or more of the voting stock of the investee's company (including identification of the significant investee), reasons for using the equity method when the ownership percentage is less than 20 percent, and discussion of recognition of equity method losses when an investor's total investment in an investee includes, in addition to an investment in common stock, other investments such as preferred stock and loans to the investee. An entity also may describe how such investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753149632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTextBlock', window );">Financial Instruments Where Carrying Value and Fair Value Differ</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 18px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Fair Value of Financial Instruments</font></td></tr><tr style="height: 8px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Fair Value at Reporting Date Using</font></td></tr><tr style="height: 51px"><td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">Financial Instrument</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Carrying Value as of
March 31, 2017</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Quoted Prices in Active Markets for Identical Items
(Level 1)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Other Observable Inputs (Level 2)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Unobservable Inputs (Level 3)</font></td></tr><tr style="height: 14px"><td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">94.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">96.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;">&#160;</td><td colspan="3"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Three-Month Periods Ended March 31</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2017</font></td><td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - basic</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,443</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,920</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Effect of dilutive securities:</font></td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Stock options</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">239</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">82</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 350px; text-align:left;border-color:#000000;min-width:350px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Non-vested stock and stock units</font></td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">391</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">506</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - diluted</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">34,073</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,508</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 375px; text-align:left;border-color:#000000;min-width:375px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Anti-dilutive securities</font></td><td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">332</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">319</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6924352912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">4. LONG-TERM OBLIGATIONS</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2" rowspan="2" style="width: 90px; text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">March 31, 2017</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td colspan="2" rowspan="2" style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">December 31, 2016</font></td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$100.0 million Term Loan; principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.98% at March 31, 2017); due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">93.7</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">95.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$200.0 million Revolving Credit Facility; interest only payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Promissory notes</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.1</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred debt issuance costs</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (2.4)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (2.7)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">92.4</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">93.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Current portion of long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(6.9)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.2)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">85.5</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">87.8</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753092736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Income of Reportable Segments</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Three-Month Period Ended March 31, 2017</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">271.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">85.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">370.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">163.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">215.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">68.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">29.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">118.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">235.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">63.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">345.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.2)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(32.7)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">25.2</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td colspan="15"  style="width: 392px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:392px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Three-Month Period Ended March 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care (1)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">272.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">73.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">348.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">160.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">201.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">71.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">127.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">236.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">56.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">41.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">337.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">36.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(41.9)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 5px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="16"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">(1) Acquired March 1, 2016.</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762913120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number Of States With Facilities</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum percent ownership for controlling interest percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment Aggregate Cost | $</a></td>
<td class="nump">$ 27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum Percent Ownership For Equity Method Percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForCostMethodPercent', window );">Maximum Percent Ownership For Cost Method Percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember', window );">Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent Of Net Services Revenue Provided By Medicare</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForCostMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForCostMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OrganizationAndNatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OrganizationAndNatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763192704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>D </div>
<div>Number_of_Visits</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodeOfCareAsEpisodicBasedRevenue', window );">Episode of care as episodic-based revenue, days | D</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | Number_of_Visits</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FirstThresholdOfTherapyServicesRequired', window );">First threshold of therapy services required, visits | Number_of_Visits</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SecondThresholdOfServicesRequired', window );">Second threshold of services required, visits | Number_of_Visits</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ThirdThresholdOfTherapyServicesRequired', window );">Third threshold of therapy services required, visits | Number_of_Visits</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodesInProgressThatBeginDuringReportingPeriod', window );">Episodes in progress that begin during reporting period, days | D</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved', window );">Minimum days for accounts receivable outstanding to be fully reserved | D</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare', window );">Portion of accounts receivable derived from Medicare</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RevenueAdjustmentToMedicareRevenue', window );">Revenue adjustment to Medicare revenue | $</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare', window );">Rate of request for anticipated payment submitted for subsequent episodes of care</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode', window );">Maximum days to submit final bill from the start of episode | D</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid', window );">Maximum days to submit final bill from the date the request for anticipated payment was paid | D</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Percentageofpatientreceivablesoutstandingovertenpercent', window );">Percentage Of Patient Receivables Outstanding Over Ten Percent</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders Equity Including Portion Attributable To Noncontrolling Interest | $</a></td>
<td class="nump">$ 482,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 461,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amed_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders Equity Including Portion Attributable To Noncontrolling Interest | $</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember', window );">Cap Year Two Thousand Thirteen Through Two Thousand Sixteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember', window );">Cap Year Two Thousand Thirteen Through Two Thousand Seventeen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EpisodeOfCareAsEpisodicBasedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in a home health episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EpisodeOfCareAsEpisodicBasedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EpisodesInProgressThatBeginDuringReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in an episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EpisodesInProgressThatBeginDuringReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FirstThresholdOfTherapyServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the first threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FirstThresholdOfTherapyServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the start of the episode in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of days required before a patient accounts receivable must be outstanding to be fully reserved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumDaysAccountsReceivableOutstandingFullyReserved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageofpatientreceivablesoutstandingovertenpercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding over ten percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageofpatientreceivablesoutstandingovertenpercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PortionOfPatientAccountsReceivableDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RevenueAdjustmentToMedicareRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RevenueAdjustmentToMedicareRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SecondThresholdOfServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the second threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SecondThresholdOfServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ThirdThresholdOfTherapyServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the third threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ThirdThresholdOfTherapyServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amed_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amed_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749946368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Long-term obligations, excluding capital leases</a></td>
<td class="nump">$ 94.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Long-term obligations, excluding capital leases</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Inputs Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Long-term obligations, excluding capital leases</a></td>
<td class="nump">96.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Long-term obligations, excluding capital leases</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6924179248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Weighted Average Shares Outstanding (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic</a></td>
<td class="nump">33,443<span></span>
</td>
<td class="nump">32,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted</a></td>
<td class="nump">34,073<span></span>
</td>
<td class="nump">33,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762911232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2017 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.4<span></span>
</td>
<td class="nump">$ 93.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Home Staff, L.L.C. [Member] | Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Acquisition, recorded other assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Home Staff, L.L.C. [Member] | Personal Care [Member] | Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long Term Debt</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Home Staff, L.L.C. [Member] | Personal Care [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=73531372&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_MassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_MassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_HomeStaffLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_HomeStaffLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763650352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Deferred debt issuance costs</a></td>
<td class="num">$ (2,400)<span></span>
</td>
<td class="num">$ (2,700)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">92,400<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(6,888)<span></span>
</td>
<td class="num">(5,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">85,500<span></span>
</td>
<td class="nump">87,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember', window );">One Hundred Million Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">93,700<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember', window );">Two Hundred Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763942592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">$ 92.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Deferred debt issuance costs</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember', window );">One Hundred Million Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WeightedAverageInterestRate', window );">Weighted-average interest rate for five year Term Loan</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">$ 93.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember', window );">Two Hundred Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WeightedAverageInterestRate', window );">Weighted-average interest rate for five year Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Availability under the revolving credit facility</a></td>
<td class="nump">170.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes , depreciation and amortization plus rent expense to certain fixed charges (interest expense, required principal payments and capital expenditures).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762786416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt (Parenthetical) (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember', window );">One Hundred Million Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_InterestRateOnNotesPayableToBank', window );">Eurodollar Rate plus the applicable percentage</a></td>
<td class="nump">2.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 28,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember', window );">Two Hundred Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 28,  2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_InterestRateOnNotesPayableToBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate for the amounts borrowed under the Term Loan, including the terms and method for determining the interest rate at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_InterestRateOnNotesPayableToBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6766598256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">5 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1">74 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 02, 2015 </div>
<div>Computers </div>
<div>Residents</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>Claims</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>Agencies </div>
<div>D</div>
</th>
<th class="th"><div>May 21, 2015</div></th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>Beneficiary</div>
</th>
<th class="th"><div>Jun. 27, 2016</div></th>
<th class="th"><div>Aug. 19, 2016</div></th>
<th class="th"><div>Nov. 03, 2015</div></th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>Beneficiary</div>
</th>
<th class="th">
<div>Sep. 30, 2011 </div>
<div>D</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers' compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate Integrity Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number Of States With Facilities | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodeOfCareAsEpisodicBasedRevenue', window );">Episode Of Care As Episodic Based Revenue | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember', window );">Computer Inventory And Data Security Reporting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfMissingComputersAndLaptops', window );">Number of Missing Computers and Laptops | Computers</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ThresholdOfIndividualsInDataBreach', window );">Threshold of Individuals in Data Breach | Residents</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember', window );">Computer Inventory And Data Security Reporting [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_YearOfDeparture', window );">Year of Departure</a></td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember', window );">Computer Inventory And Data Security Reporting [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_YearOfDeparture', window );">Year of Departure</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_SecuritiesClassActionLawsuitMember', window );">Securities Class Action Lawsuit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Loss Contingency Number Of Defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodeOfCareAsEpisodicBasedRevenue', window );">Episode Of Care As Episodic Based Revenue | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_SecuritiesClassActionLawsuitMember', window );">Securities Class Action Lawsuit [Member] | Favorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Loss Contingency Number Of Defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_SecuritiesClassActionLawsuitMember', window );">Securities Class Action Lawsuit [Member] | Unfavorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Loss Contingency Number Of Defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_SecuritiesClassActionLawsuitMember', window );">Securities Class Action Lawsuit [Member] | Favorable In Part [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Loss Contingency Number Of Defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | South Carolina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Extrapolated [Member] | South Carolina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Unfavorable [Member] | South Carolina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest', window );">Recovery Amount Of Over Payment Made To Subsidiary Including Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | U.S. Department of Justice [Member] | Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfPatients', window );">Number of patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | U.S. Department of Justice [Member] | Morgantown, West Virginia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfPatients', window );">Number of patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | U.S. Department of Justice [Member] | Parkersburg, West Virginia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfPatients', window );">Number of patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CorporateIntegrityAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Integrity Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CorporateIntegrityAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EpisodeOfCareAsEpisodicBasedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in a home health episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EpisodeOfCareAsEpisodicBasedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfMissingComputersAndLaptops">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of missing computers and laptops</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfMissingComputersAndLaptops</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverPaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ThresholdOfIndividualsInDataBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of number of individuals involved in a data breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ThresholdOfIndividualsInDataBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_YearOfDeparture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year of departure from the company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_YearOfDeparture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_SecuritiesClassActionLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_SecuritiesClassActionLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableInPartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableInPartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_SouthCarolinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_SouthCarolinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_MassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_MassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753157536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765566464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Income of Reportable Segments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 370,458<span></span>
</td>
<td class="nump">$ 348,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">215,785<span></span>
</td>
<td class="nump">201,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="nump">118,800<span></span>
</td>
<td class="nump">127,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">4,417<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">345,293<span></span>
</td>
<td class="nump">337,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">25,165<span></span>
</td>
<td class="nump">11,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">271,300<span></span>
</td>
<td class="nump">272,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">163,000<span></span>
</td>
<td class="nump">160,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">235,600<span></span>
</td>
<td class="nump">236,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">35,700<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">85,600<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">42,400<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">63,200<span></span>
</td>
<td class="nump">56,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">22,400<span></span>
</td>
<td class="nump">16,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">10,400<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All Other Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="nump">29,500<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">32,700<span></span>
</td>
<td class="nump">41,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="num">$ (32,700)<span></span>
</td>
<td class="num">$ (41,900)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GeneralAndAdministrativeExpenseSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of each segment of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GeneralAndAdministrativeExpenseSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Doubtful Accounts For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionForDoubtfulAccountsForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationPatientServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for providing services to patients, net of provisions for contractual allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=d3e8184-115640<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=d3e8195-115640<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=SL9156442-115640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052803&amp;loc=SL9156464-115641<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=SL9156442-115640<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationPatientServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753190288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 01, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_TenetHealthcareMember', window );">Tenet Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="nump">$ 20.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_TenetHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_TenetHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["+M@[,[^8^.SH.S@U[^07U!+ P04    " #=0*-*F5R<(Q &  "<)P
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MB*>GHO2TF%>*H6?:#G@\K3B=%2 RE% \014EJ"7?XY2,P6*<<R*565M4YFB
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MR@R9'K?]*:*?*-D,)Z1D/*:M_@-02P,$%     @ W4"C2C";HF[_ P  -Q(
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M;J>CC.FF;Z[S,4UR/RO:_ M02P,$%     @ W4"C2A\JC[<%!0  H1D  !@
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M?W8VIOI3V97+15.?)LUYMH[E\%"8.^X'<SW<',=N_%^?;=O??5N:)%W,WX9
M%\WJK*%;S54Q[Z-?NR#4Q8I4<_K80:$5/L<],$R"Q_;\(0F/ U@8P(X![$V
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M9@VV5%92!1+%BD?&\&, /UF_KUA3;>9=)MUH56Q@(C^-0?5(\K<MZ\)0[MU
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MC_?A;,<Q&PV/W?2#V/R-BU]02P,$%     @ W4"C2N1:"EJU 0  T@,  !D
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M(F,'9::1GHOJ]E(M%"_KFYG77 _G_P!02P,$%     @ W4"C2D'=/,R? P
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M@WQ[H^2Q^Y/"Z_\I6?P%4$L#!!0    ( -U HTJ@]RYJ_@$  "0&   9
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M%+M.O_MOY$HJ 9=*!,>>5IWZ[^PO':=U[T5(J8L7?2T;=;WI-TG8F\$&N#?
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MGZ&9%W;="JYO=8'6/L&,8^PN?J)7K5 $C "6@OI&%+A&U#/2 :H(T"L8?$F
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MS:"9#$#8&!*.D,Z/G8XP^91$GX2-DE0+8^!(RB)%3D,8?DK23^!&2:QQ).T
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MNAH<&NNG=VZNY]LZ&U8-RT,DZ]^@_ M02P,$%     @ W4"C2B1C$C-.9
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M\%\D?Y8H3J9 N]M'5_@/)*L_L#_:W?IE6TV;TBV2>G+??FCK)U#*MOF8PAX
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MM^9(3.X3"IV7"",P^3K#*HYY;*"Y&&\<E6WZ'%C"Q @:/5%=DX<(<<RK^!A
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M24?S]9M#U^V;_O[]^8VT _WP!CN)8L.1LP]]W4:HGYOI*7!*$01!5_B&Z_(
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MX%7?AT+UVV(&.TS55&8$?(6SG6/YVQF'W.2=D1ADBKOJXE"*A#O/TED<?B4
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M%J#KH)6WVJ/LCT%X3,K'I3K*FEK[]<R395TL*X.3I>='T >D)&)C(F@JAS3
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MV#W<YJZ)O/6Y[+YJ$X'O99=/$1$9-!(YTIBP32Z=GL^0P,#L!3"\&DW9I[.
M=2H5(S(I8I-@:%<$%L9/L:S7?+[/"6@HWZH#O<>ST;L>W32MK:)ME0SLPT&@
M QX3C[#F+UW>C[!G6V%#3.ZQ[LVV$\:0:66E@;7%4S1EV#-NIX.M%+4E'JE-
MO$%JL/H>.X++N[H\3F,BW)M*/+=="6*""E)Z'@0JHPJR[&^KN2T /ZT8MNYG
M<^5Z".#X8EK9,E65?E'*85[UHVW@HX=4#I'?(LULV?#K1D-J605&I%@M1;.0
M55LA87V=S-*?&MS.8/H2Z$&X),(C>E5@40G>D';*O3>;Q2T+MH4K^Q+_55^
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MTKTL(DFMT]7D!T(:KV1@/W2B2<6/#\ K%6T7WC!=TZGLA@/7G!GJFS%@IK;
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MWWR"5X=$9'.A==-4WJU.9)/R\T&(9VP$%L"DM'V?$."7PS0DZ-A^J[03#R:
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M"14L2EP)".R[K]#?I<S-H8%,AIU/QT?=,*OY#T-W948+#(3S/<:.G\(4[.-
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MH*XEEJK.CC9T61$/B%NJ7@A4!AK<'624)EDZ04.8QT/P "<PB6*0/<9QGAF
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M?Z&EL&JK*E+/4C;AN/LEH]LX_$VZ_PE02P,$%     @ W4"C2G<"Y'%A 0
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MR:=SBWU]TOVZFGX#4$L! A0#%     @ W4"C2A\CSP/     $P(   L
M         ( !     %]R96QS+RYR96QS4$L! A0#%     @ W4"C2F;S"V""
M    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    " #=0*-*(5FWL>X    K @  $0              @ &9 0  9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    " #=0*-*F5R<(Q &  "<)P  $P
M            @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M -U HTIK[@'_B0(  $8)   8              "  ?<(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #=0*-*GMRY(DL$  "$%   &
M            @ &V"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ W4"C2H>>(#&C @  L@D  !@              ( !-Q   'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -U HTHPFZ)N_P,  #<2
M   8              "  1 3  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " #=0*-*'RJ/MP4%  "A&0  &               @ %%%P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ W4"C2DWM%L"O
M 0  T@,  !@              ( !@!P  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( -U HTJC,R*,M $  -(#   8              "
M 64>  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #=0*-*
MTJ5L6+4!  #2 P  &               @ %/(   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ W4"C2F/A(FNR 0  T@,  !@
M     ( !.B(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M -U HTKWJ.C5M $  -(#   9              "  2(D  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ W4"C2G"UUD.T 0  T@,  !D
M             ( !#28  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " #=0*-*Y%H*6K4!  #2 P  &0              @ 'X)P  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -U HTI82J(%+ (
M &P'   9              "  >0I  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ W4"C2NI>6=C( 0  -P0  !D              ( !
M1RP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #=0*-*
M5HP16K@!  #2 P  &0              @ %&+@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( -U HTI1TVO*M0$  -(#   9
M      "  34P  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ W4"C2E5%*CBH @  *@H  !D              ( !(3(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #=0*-*0=T\S)\#   U$0
M&0              @ $ -0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( -U HTJ@]RYJ_@$  "0&   9              "  =8X  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ W4"C2J@HG  V
M @  C08  !D              ( !"SL  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " #=0*-*UK#4_K0"  !("@  &0
M@ %X/0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -U
MHTI=2/FI9P(  *T(   9              "  6-   !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ W4"C2H3RR.X? P  OPP  !D
M         ( ! 4,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " #=0*-*0&!'(! "   R!@  &0              @ %71@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -U HTJIMI9)@ 0  -,8
M   9              "  9Y(  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ W4"C2OX@Q-Z[ 0  T@,  !D              ( !54T
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #=0*-*RD^P
MU[P$  !>&0  &0              @ %'3P  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( -U HTJ:HT_!R $  !D$   9
M  "  3I4  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MW4"C2B1C$C-.9   &' ! !0              ( !.58  'AL+W-H87)E9%-T
M<FEN9W,N>&UL4$L! A0#%     @ W4"C2E^*C\E6 @  6PP   T
M     ( !N;H  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #=0*-*PV(&EBL#
M  "\$@  #P              @ $ZO0  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ W4"C2G<"Y'%A 0  ^1$  !H              ( !DL   'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ W4"C2ABCGIV" 0
MPA(  !,              ( !*\(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     "4 )0#U"0  WL,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>59</ContextCount>
  <ElementCount>195</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000103 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000108 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>010109 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>010110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>010111 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>010115 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010118 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010122 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>010126 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>020010 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>030010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>030050 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>030110 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>040010 - Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail</Role>
      <ShortName>Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>040020 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>040023 - Disclosure - Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail</Role>
      <ShortName>Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>040024 - Disclosure - Schedule of Weighted Average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail</Role>
      <ShortName>Schedule of Weighted Average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>040030 - Disclosure - Acquisitions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureAcquisitionsDetail</Role>
      <ShortName>Acquisitions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>040070 - Disclosure - Long Term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureLongTermDebtDetail</Role>
      <ShortName>Long Term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>040071 - Disclosure - Long Term Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail</Role>
      <ShortName>Long Term Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>040072 - Disclosure - Long Term Debt (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail</Role>
      <ShortName>Long Term Debt (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>040100 - Disclosure - Commitments and Contingencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureCommitmentsAndContingenciesDetail</Role>
      <ShortName>Commitments and Contingencies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>040140 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>040141 - Disclosure - Operating Income of Reportable Segments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail</Role>
      <ShortName>Operating Income of Reportable Segments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>040170 - Statement - Subsequent Event (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SubsequentEventDetail</Role>
      <ShortName>Subsequent Event (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>amed-20170331.xml</File>
    <File>amed-20170331.xsd</File>
    <File>amed-20170331_cal.xml</File>
    <File>amed-20170331_def.xml</File>
    <File>amed-20170331_lab.xml</File>
    <File>amed-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001193125-17-155092-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-17-155092-xbrl.zip
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M6'Z<G=[PJ-WJ;4*F:[#>87<[\+9@O4N8R'"U0%@*5:O?ZW?Z[0I,I#3\<VC
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M?#D]/_ED7<.4'S_#S-?%6=_.Y:<R>AGNA%Q*J>,$)(@;/48'%A@FAP>6;7T
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MT'PO:1]3$H%M#V9N'$L_AW["Z50ZN.J\#ZV;*; 0F#H(88.F0>+!R3#XPB9
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MX9V(UY)/I@HU&1:P1+/(:S:4MF=V^WB886A-0H;:'>W5?>B2HV^<[E%)[8V
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MG.X?<B$^QJ7.]O%"H@ZAJ8 ALRLTS!L7AS(9-PLPE&DX_(OA@?VE,3YPVL7
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MRNP=H.6FF-2O6O*R5B$%=0XJ7.32$I9.-F)G1R%1W-6;#XPRG%EG&VZ4N;N
MK>+6J*AHN9-JGXIU<)XV;&M1A-22K"*S[C=LHKY;P5#C&*Q+40/..M4YRTN/
MQ"I?5<WY)8_OB4L#&7.EZK3J65B="J@BYH64U+U*ZK16U>,P@NI %,D TL6Z
MN)P!B]II/(A1^O3HED9-2&'Y:D8B:>,9!SLH%3?R!!-+P[NI;"[O?1F@(3]!
M9Z8O:Y? &6#UT0.,/8<_Q 5@$$YL7UYO'/#VI^&(M];$(,V0\T78\SL<'',<
M$MXPO:0$$.?D\*R/V2Y8^D;QSK2,C[A0@;_PU*(#>8LGSBU*^:>JTQ$RCV'
M.E\$>GMC="CJ=7]$>*E>YPL&'+L/?!0/;_X\6\2UTMV'%#HB?]$NKVPHLM5
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MBX4>)P%&$&&_ A;>4<<$+/TH5\U+7<+!P&YX'LPZ]^P1LV9!A+.Y$1VJA$7
M2J4G)XGK /9@@P#KZ^'UH?7KR<GEH77N6R?)!$;'P^T)/ .TD:AB=&<1;*,#
M(LP-)(^Z(>2Q]8':"P"MBIJ?_!X+E3YL'VX880%#J)T!S<343$308OY($#I?
M XB>Q X?+=&6&0?(?C4XX*L#W.<.?]Y18L["&08I8U%3VW<Y<MH./)*=Q(XL
M9H<@&NR(?@A 8P'NY>6 X]CLP^H0-4(V]CBYP)<8+!OA10-\;:/DQOX5"CL!
M% 1CQA@A/.#TWQ./>&7OT/K(9Y[//:SQ2ET=0A=)+E@&"V \]2'A2P3M@ .G
MEB27CD,D$>VK:)B"WX0L#H-H+L;#_B3)#,NKXE]\'D[MG!AYN5\^P2EMY:-9
MPG "QE?#.1 >HPO3X$6J;_$#],F,IIK$:2,)6&TL(I>3>4 O>3RR6-:OQ8,2
M<H#<NN)O)$,<NX!%MTF,.PN,"=@5PT8%=BRK]\J-T;>9V-K4QDWDD(:,%TXV
MNS^J7+K9BJR+VB;41-6QSMAM2.>#@5E%;B\.L]]HMG?.4S\Q.V**:0ZZ)2V>
M34AQ(29)E)O5]#P618QSP%0IP"XPL"[5%8>WU2%[K1&,&\@XJ+L,Z0 V@.:)
M;2!N2T3Q,&)S26W1- ACWL^7/_@&61]U!0EF0)=<P=9X*9X@D%O*VF@>'XB2
M]UIQ,3;/G:E"V+<,\,2G9C$^LBU[#+^#\!I1)P(+50*D8\54'2$-8(Y%C#+5
MFT M<=RQRYP<>RQPPH+&I?%N(;]02* .8_0,22&2)R&W9 X08 @CK.O;U/6X
MHB>YM-3HU$80>,3@Q/(!'>"HZ%_8 !NWFSKTC$)"#-?7^R?E.HJE[88"7]3E
M]@C&: J2[@!;PU"'IC)F&J Q"U^G?)Y7'U_%YPD_!8_5V*)J.\=4 $Z&3XOQ
M W\2( 3IT*"2 L["=W7GA3P\?Q4CW+VU<ZKWG]+[>O%XB\S/@EL>M08EM;QK
M8;<N6.3Y# R<.X%R0!H?9<\G<KHT*"_)$HE)FGVZ.Y$0H6KCCKE.::<&,76*
M(YAXNX.Y@,F^)^)&SH4=T\HB8+:#S>AP:0\P7G;?BNT'X@7 85%J8$\*#W@0
M]7F3?(R6&)'NSA5;9,?QH][DC8NS_*N^9 V<I^!8U&ULC"TE*\FE>N(TC2;%
M@]%!4_%;+GC[AAO(?6-<<F%#"91:QBWR](#_;AL=.&.O'O"F;JAB@*A*/"X:
MTUY]5K$7\39S-XNB;)OABOVGM\)R>-(CE4RJ&,!>433[@=\8)6%("J)L=HA\
M@"N@7.['MNMC7SR1#<M=4_",;,7'S?Y[)IIT@FYTYP9)!*J@TGD=*_$=809S
M0SM,0#<^M$X<AY0\[+=Y@%S"1B^7T@(Q%2#*'ASJOE&4!8!.&143 !;4)V Q
MLK.*QMI0N)"[@+P6JO,*P.5'U.)1TX(R?"H LB8N%J5>.4KHFP5FT1>T>\Y!
M+)9)#N0(;9C,?W.C. BQ=2WO=!I)3V7$CS*E%,/\S!9';G90SRS!S&W7:0".
MC.PYJBBF):]98)<@<L8X,.O&6']/7!\T!3=>*&V\*+ 8NO5X#R.- 0@?'=?
M1E/,19<N.F&"*<V$M FAB45@(3C\2?N!)&<")B2_19>JB.PH&OT$?&1J>^-4
MK>->VRGS'.[AXF&)&*THC> U.$>457$*K&,EM</.D(\KOSUX1^BBIYF@$,Q[
M3I>*Y'#D?4&%GCH&-8U,-704X#*$RIII:"N5NMB:A+9P%0C>CQR3.T^Q-3)I
MAK&R@LFK0?Y8[!",:IHVXY_*9W9B=+7JLF69U8G:WXX-LFM="IXB*I\1*@L+
ML]UIOCFV3@LVPBD+467@;^ %L#L7/@3Z1EAPIFTC;K>1D'?@<>0@"%5ZJ07
MT?UU2I1Y(X6VF/O$Y>LD'4%BA>C(H_L%[6)L.V=:N39_5,6-%DV#!)C4+>/>
M,%2SB%SME<ZTQ$?7)-X_PO!@YN)E%;6QQVNBP *.0]P0=2?AU>&;0[>!U.4=
M=I$=B M.8&"<Y7$F%T3R<>L^#V".N4=R>+P* NXLF(^$Y]9CV1L0W.H%%P3
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M__:N];EM(\E_WZK]'U"^7-FNDAB^'W;B*EFR$Z4D2R<IE]O]XH+((8D-"#
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M@XB)6'P,QX:OR0'TSW_\%=D!_-&=OD^^I; O#*#_>&?=48(?O827\,+'P'#
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MW4WD445$U,EAR+C<1>7Z2'_VHTG7'S&N$NW0QQ]/D?.=D=R#L3]!+ :'$LX
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MT[VAP7'"NJI14SJ>EG+NPFAF6XS#[EA!7?[:PP;2Z0;I3'??O9.%FK=].4Y
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M? D= DRHLDET)))C&1(IS^KM/(L!,OSTX_?'P'7>X7\__#]02P,$%     @
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M8T0'FVHXH$/5L$I+%W+?TX2++"S;K/76ZW4E:T BJ'OA:)RRD,+\5MD-J'0
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MZ4?]%ARZ]F:P[$5A3%&M#2&<"4,()O5G[E+8!F4@G.'(]BZ5LB;(Y^X!FF"
MGD&4,KX$F'&LP>K7:G&;'K,0YPE&#E79\X>?+6>G>*N:?<JU5F3))SOR+SCT
M)=\&!U'\]%<8.LE[>CT_D_W;YX2,%J?<%W\/XX3XOWU.*<3!FVBYP\[>[D*^
M(R,OG-]*=_X>B"X5W'KR^?#0+K_&K"4=9"_D"_LM1!#C2)%O:TK<)1L7BKF$
MBWWH?L_W%E_EDXQ PO7'F'B6 W8%(;[X&W+M7M-8JKAR4NPB*&/$?FYBY%[
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M-!,'SR;4KIXXI.#AJ%>UB*/B]<L@F6>WZ_O)]I$T>WD^/37)$.F+11<E:_3
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ML!B[]*8!4SG429:6<=_#FYF:FN?\'?&=OWUHJ_A G-;SG4.:]8>/P2@*AL'
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M>]:?!;VC64;OZE/ GA(4&,8>XZG2:))8F:]+SB?:%?]6S0 -FEB46.-\WDG
MM9""QRZ+6FU*]=U+,QJDLRLOU7-&UQL"(C03IECKJC0L@8<OA&" B&A..FVE
MJ-_3(!H$4R_4@L;K!)"BB9J*K:%*4 E4#.%[XQ.WP]C%IE3K1X#RPOP^,\>
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MP='3 X<N2Z6]>[N.BL5 9ZYJR4[Y&DC4RS^3>U6GAPXIR!6P2'L9RKXUA1X
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MXOG]Z'>/!N# /7@IZ4@@JG8#2R TR18J=N'S6!,RADV4Z_<@/1^DP6N^8?)
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MC,$EVQ9_^PHO??$2\A__'U!+ P04    " #=0*-*/L,T6<#/  #Z"PP %0
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M D4Y#+GMC-!<>+>6"S^]OZ@%BFDLH,R&46X0"\]30U3W_$G=6'WFZT<>EM!
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MVM=E3[$6O $@/6K/?4L?BDT87CLIH(G*OE91685"QD#RG&+Z;8D^](TPLH8
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MJI)(;%?>IBGI0S@$ E/0$G1H@Q]#G9LUUN-G>O'7+[/[V<-L?F-ZS8XA',R
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MD'RV(I-QEA G#'-@F*4D;/*EN4_BRZ-%SODJ"'F^SW$97417/-&U&,C[M/I
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MPA=WP;.7">3&'VLY)I&-RYXG7:I<ZK-XI'K>8(]HT'NZ#/J[-!K<M*2GV[V
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MFTJI28N?,2=F68UDZ7WC["#&'.; -#NW8?#B1FY0]I)ICRC'>]KD>&5KBKS
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MA9L"FZN<2(OZ041&PTS9B-X!/3T@ZNF!)CU=OX'E_=WY*U/=W<Q'>SN++/8
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M*KDJ^U??Q1V#U)PO\HYA$406W",@NA/&V! *X@<>OI2L?#OL$E5G5YOJA$W
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MN8O2(9@>4;3V-*UU<+A!Y9 4RK*TL'%>$"$+0]\&7HAZMJ=S<8,3H.%I4>.
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M\AC/?+DB8K*PP2$$B:,A0^VC(64-0KM84985"MO5#R)C'##\;6"&.* Q;&9
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M'B%J&T;>VHZIBA^BZQYI6E;]A!82+X-V@(98<IBB-H(V)HKRL<[UU-^#MN
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MHBY">V$\=:F;)X&X\N*EX_\?[D1? O>SDS3M4)P1:>ZL8YJ[KPN%W$7JE*P
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M".'34"P[/$2$U",=&^K_E)Y!X#,4QP[/$ GT2-O._$Z,(U.RN(5QBN<NX_9
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M0B7O$VVKTVD^V18^D6O^HAV?A"OF*Y^LK/ )ALVA+*9]0L7CDS[R4)QBF7)
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M9Y_FLBB395E>V+S^&!J#D3>B/Y64C?I8_WBT'Y3V\DTVVV87Y MM#H=_\Y;
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M'M>GQG$AJV"M)3#V"74P9HDI%8).^X"@[]HB4XQ10EW,680**Z?:8&4[7XC
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MT@A>;;&J$OM=5C/_7#S%<"840X\U/H<;QPL:+4%%FU,=ZV</=N=(*_R>E;;
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M9=Z/LJAY[3',!L-N0GLJ9!OWL83O77D!PVU0!@->F%!AVT3;81VM#: @>VD
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M?\I9H"S)5%&6E65Y88N& 82<(M$W8P(B(%4-:'JZ>(=.0/ F(H$9)Q IIFI
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M&U%$?"+^)?[C4=S<_M__/U!+ P04    " #=0*-*N2)P8>5^   HX0@ %0
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MXG?G"\<-TWP+ZM',A 'F\I<H$.2!YDMNH)F'ZG -Z\3F^3&< 4 5U*5+(7,
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M?'VD2U6[V[&V""T;5-,-X9&*:2R?6<=^D8K+HK$]<&>^.W7'3MI5>(-$V45
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M5W8O\F^_%6'2X?_,?['Y\S7\Y"TF_F35$W6+ S#1W.@]^G4<S#/]7]E/T O
MIZ1Y79]ZM4EJS']_(2%T< _?J=?[N^,E<)OYUG'#].\W[I3.M!O(+/!^WJ<@
MR[%>]V<SB#[8FP7&*,,+L;%[XD0)7=MZ?I] ()B23Q]X"/PP_^>U$[E2.9'&
MO@/\0F1W"07+GIVF68+! 6ZB.MEL@V$"A^R^;?1;E&^8VFF8UH=Z9^TF%S$X
M^4W6Q"\69W"!\H*I$HV] % (&,%_&=;U/9MCFU)CSS,IUC0[%M'$S5*OKXUA
M?EV_?_SUFTM"JLHO[W?@QDN<G\@- D@1':28EJ#$]B;#'E06YVZ4 H.KMA1X
M=I%YBURI2Q1*8P%N1"Z7DK D-%V!!:@4WH8:6+S@\$%6UU\D<90*^DCJH@WG
M3<"$**JM(P\)#6?B_O3Z;#%*72:=8VU]/E[)%5$,6T<>:OJ\CAN5(VU#GS&$
ML@K2.='6YY,/N6)JZZ(C#S5]7L>-Y;3F.W%G+S&9M.!^_"R[YQ;U5FTP]_%4
MYM2BI[O![X<$=*(WW>([.'9C 4BEL0 W(K]7*"#VY-*!W>QP4DW3P*+'FW:R
MAC76\=K!?![XF?36^UNM+MTN.\<7BW<(D%?_ ' (D6\L%"5[PACC1;/38VJ:
M1283PAX"_W<2T;4M;077\K/_/ODNOPDLYS6@$)$;+&0E(ZE+C/!PQ[Z$H1:=
M8,8N?>-Z"8AQ<[/6,W58HP%V1,ZR4$C*QHX >(6K^P'=)?9S,ECTH%N4J F(
MS'TE SB[28]WLFZ[9)(7#TDRY>Q-\^(ZCR1,)=R: RP1>!/?H'PZ0^25"P7*
MGC@FV6&V+L#NW/S5J3K\+0!&)F326]"E!#X!IXW9L>,WXDUN@W#@>*0UF:2U
M\R!_<QJ$\_1)NU& &B_5G1S9+,RH7[7_Y!C1+)7A,7NBEB'#<'I123HF.Y)6
MZ[9Q<HPHZE/&)X;%ST#2>,TP>1=.M]O&R3&BP$89AY@ZL0T#P\%0Z>ZZVDA7
MV["L(:L^(+54;';9Z/K4Z""KC<#Q'!^JYA$"%UQ**;]^I_]8!)'C?0V#9!%]
M]+HOMU5DTN%V1 7P&I%WJ:TLW(CA#AF)84W_9 I\8O-F4OTH[R33U7=("? <
MT:Z[6TVSN=)L2@!#_\A/.@..]8J^L@Y+EK'0-E7Z-H%;WU&;?B_P7&A+P;TG
M+W@5*$6TP>]>1JQ3&"FV-?NL_=-.3:U F,+4I"2J3\KT)4H=IFJTNY>+PG0L
M,JS9Q_6?=2+J%=P53,3',(@69 R'(4]^L" ^F12TAD(+XZ<%?6A,HJA(HLQ\
MU1T;L"**3>Y>RH)I79&OS4Z(^+2SWV1\N&2#Z+RYZK9Q]A)0]ZD\V$VYR&_#
M:PQK=A^%3SL1C>;U;:M(Z]5Q/0B1+,_=%:?DYNM ,:(\O]W+2GYR,EC7[.8/
MGW::UAQ1&@2>ZFX)KP!EGS:"=*X402JPJ]E-*#[M%*PY<I210B9=_X:Z0E'L
MQI1@J)VH."^9X\ QY*>-+Y57L];E8;,[;7S6&7Q11\B)H35EM%28R&7# :)/
M&UBZ$ >6U%FYG-:7AVG=J&E=<RRI3^;!:Y9+7]&;Y8P$.#YMU.E"*>HDYN)R
M'E\=YG$C<K0LUF2J]<[%IPI4%:7)SH.2X=DA3]*"U"PF5=\%_NR.NEG;E[2N
MW],?#2D%$O-1>AS ^ZFB5D4IL^>F*O\P7$FPH3O'%O<K-IT/U%R2NJHC,P2@
M1+1[J4I'1\>WP&/8AG8H;IOM;HIK&1 X#<((" SB\O5,JBB;YJC "T2;@X+X
MV%I?C15E$\%&#;<'$O?)*Z&4PHWN);'^K$^BA"J9W;O;I6S<]=6X$YN-0-9T
MC&^/+*6H,G^E!J0<P-320UN$DA-9A2?-3E;',;ML=@XH)3AS'.Z"*()86.DC
MUX0N]21[<.B\Z;!%_2O *T0'$]K"YLY#@XQJ=@([DLEI\:)G*<%4O)WIE(QC
MJ&)5\GL=)HC&!#X@.D30%J3BQ)-DBT:F^%4VS7PR@XM?AXD&G+08_9!882/J
M)?2FXJU.92A C2@:HBTV]K32X$:S:^\AF4LFLSHWPLB%+]X&H=SQ*>],PN@W
M #NB((NV\!B'UH;95$S9_JSJ8C3)PP!=HE08X]\!'B"P[>J0:WVS:)-[U8ZL
M]DN;]%JML-*F/F*STK1P<Z?4AZ.(,#1:J4M2K/0H;4;9B@CNUR32Z['"Y0%8
MX1MQ(@7BQ-BKC0^8$<3VZI(E=RLRPCE;P;X]FW?FS4$JS6OBDZD;=]X6Q(_,
M[&15QP:L>V3V;<J0.]\J<\U>Q&_/9IO)2^(9;5EE^M3G=OW9*LID<-)5_@0@
M1Q#WJTNBW+EGBGFVPH1[$O4P.?%6GP;:$EZ*._-YH&F/ID21SXSIP.%"M0S!
MFJ5D,K2\^0UNXB'G#: +0=A7Q#=)35C#M!-=J,)WD]$>N<DEKM>O,@[%<(DE
MOL/ELE![I+':3;Q<K:>0@SHDX?R&/,=VTRR!DGA)B4)F_^8KHZ-3F\E<FR1)
MYW%OOP1($(1C))C-/GSF(L.2A6]07B9#%S M[P+'%Z^UZT\"'0C""E+,8BRH
MI8#V4%U,N@!]\AIXK]2A:U,OS(UOG;'KI0WCQ/HC>!4H1> 82+&3H5!R"+'<
M>C.H829=A<$/%RZL^$1N52IY'"A"X"1(L8VA26Q4&+HR&-8>BW=.[D@<I\4A
MT@DK=2NL[!6* L/1L12K.684&UDQ"+<?6F?T_*?GDV^)/Z%\NW<]#Q**I:TJ
MP:M :1/,+,Y1C!S"8DG#/=$PDW;7\$>PSL1R6^-=PHQ7&@EP-,$JXQQ': $N
MUN?;$W4TF6CR2*7C1E$0OC\$L8SQ7_H"4(4X]K#&.H9R\7!5R[HUIT-YY$TR
M$;WLE='1R97-^U&4E*Y/24G@G$:F\$W)&X !V5;*8#/;1&/#PA"W,"2F4ZNE
M)-8HNI.L5\AX"[ @\D39W);5N$UD&&(9AB5V<FFY.L_'HN!/VL["A1P&XD2D
M]^RYLRR%HIV$('*5=5PT%N!&9.?QI<,_"5#%W/A;G:;UWW(EMUQ^#X$_5E;T
MU4N !.W:N\EO.8W> M?LCCG&%==F\9HUJIY\9QZ$L?L7F:0W Q.A#@O?!S,/
M48B1+P59<X*-L]E-9HQKMD7?J[@ *2S$0#4B;XO/6[GE=PFIPOT+#/?63:NF
MQ328XO(!!$91 H5/E[G^ DC\EP$9HM 4G_]L]94"J7&1#[$!7"'L8/,@TEQ>
M&EHKH<AG_HK+@(4QG?$Q9<8+B=VQX]G-;>P[_DQ&<3Z>&QV=V2S&D](A=>9>
M>!)H1A2HV.0E6Z^W,6 (V6K+P.):>>_Z[CR92U&]]BRE&U.:QC9'V=I3A@-#
M\%5;?RP&F>Z=-WG]*3X+=",**6USE*,_)3@PK#_&[)XSVPTHC)W4GV%J+<%A
MMKP)MX8,H]95DY>>W\!*?R7CP)_<N<3/LE-:LY"DMQ/E4\HDAX!5 -%NR&7O
MMJYI(-V[%+.S(Y.:IW\3Y.RX"7ITQ-:C4D![N%"93 &K\R;(V3&BV!N7G0R%
MDD.(P8 WK&$FLZI-W 0Y.T9T",%E&VN+8Z+:NYL@9U;[8IFZ"7*&K>\5D]4<
M YZ-;.]N@ISI7>2V<!/D#/-%[35V,M8R.81[EWI_9O;"MK6;(&=-N/!]QKOP
MK0.XV-)]/]11+[VZYIL@9Y@2I;FL8R@7#]=>W00Y/6_^39#3<V1+&8/-;!.-
M#0M#W,*0F,Z.;'9,,YLI=7:$R'IC<UM6XS:18?!&3=_=.4634'P;DO\DQ!^_
M]Z:/)'2#B3M^=-[GXMQXV6$HVC-$05R^3&1U5 @70P#.M-*>F2UL3<T@$L5]
M)R8]/S5L* =AN1@&UX[_)\_0$[T+M"+:A?D<91A]DA@/]S36^(GF>N?&JI!+
M4PD98PS B<BCX4M#=D'E8\5POFK<!$"CJ[?.F+3FRE>)5J\!FD9HY*F"1F[!
M:WB?:M-+K<43E76J[ITX"=WX_8;NE$IPBB\"(D2G*WR^RZIP"<##[;<U9J)Q
MPS;VO\?0]<?NPO&J& P?@T#XIA$NV)F""R8 B^&LQ[BZHHE9%;V3M,O!A(IC
M#/HT4UN#>0,!8K21K4VYR*JM!&"-LA%HU^@* 5K+-Y,-Y8ZCC4,4^<Q67@ZL
MO3H-L'U93?%RW1%:6[7(4;9:;6(I"Y?:OG^Y:K+=]:=!.$\_U[A[F!<V*SQH
MWN&ZP%3?89.7 J5>PX!AB=24P>47BTMBA7N8EU\0+8W;'&5K3QD.#*=(VOIC
M<=VI< _S\@NVM6>-HQS]*<&!8?TQ9DM?V,P.,IHG=X$M1XC!;'FW8 T91JVK
M*"^C!=>U;\-=G"/:V[C,8AQJEP+:0W4QF09;YVVXBW-$QW9<=C(42@XA!C/*
ML(89O1ANX#;<Q06B P8NVQB:Q$:%(?_0K/9<V&PP:>HVW,4%HK,!+JLY9A0;
MV=[=AKLPVS!\O2J#1#_?LA> JB:85+P>X!Q<&-*F#.N0T7Z K!H?VO?>]$8$
M7$VPPSC]QRL!QW!4;UA-39IG=5[\O<#0MUR*G0S%DT.X=S<M+_2*(Z.[^'N!
MJ10RE]FLB(8.X*4Z7NV/.EZ8O!IBZN+OQ07B,.L:ZQC*Q<.U5Q=_S_7*C:'*
M(3G'5JJ,P6:V-\J&A2%$:TA,%WJWV% FA%[@O>56Y+:LQFTBP[#$F;ZJK=<K
MM9891)<'M0E$7P $B"PV/I^E5[H5L,,=GS4FFK3JOA-W]A*32>N5A,Z,%/.@
M>;8=YS6@$.T"N,E'AHDGAE>A*= ^JJ31D_BT:Q+)6-\'G>'ZMEM/ SV(PL=\
MKK$<6!:J?;J%8$#O3 :>;]TW,FF_..&,M -)[6.] [0A"A[S.<C000&V0XV#
M-3ZB<94-W!L_:T1IF#.ETC";\ Y7;HNLM'F'$>C(#]OSP&R?0!S.]6?701@&
MD 32=A;T=_&[*)*E-!@@;X3CQ+_+J 6Z> Q]F  VXT]9ODF42["7Q%'L^!,J
M,JEU7/0ZH&N$0\:/2DG"+!Y;']1:KQX(PT N6V8ZTRD9Q^XK>9==J76& B2-
M<.G*ZX!4@%P\(S^HLUXE,05UAD_W"?VT.P:]8E$J_3[0W @_L+PJF"I.#$?H
MQG7.9-;0\CJ8='2K['E*4R/JQIR5UXT1X<J#_5\.2QXP\=QD2M'R-JM.I$OP
M*E#:"$_JG)TU) <QU\_#:53&3YN.4\G.M%Q93,0-6$,!ZD8X5(+;HNJ0<]T_
M''ME_#7I73%2%-.3(-["S'L/:&R$W\2YG2J!+U?+PZE8QLRZO:15#9[*3C]G
M*$#2"-^)<Q-6#W*NSX>SM8R_:,[6#!6U/<-T+9?/=]GSM1* N18?CMA2;NI=
M[V6LRNN?>4@@!7VKZ04W>B4W M#="+>N_$:O.M)<:0_'8AE;T:1EUUR*^0S3
MK12^/&279 '87-/WJ1;SF=YM=E-8LL7BUO4=?TS:011'#T2<A5/Z%F!IA.=6
M?@E>#EVN@H?3K8R5)OVV]<_D&<S%ZJG+GSP'K^264$$XWFWB3T29WU7&!8R-
M\.@X=^H-X,_5_NJ@]BFS31ZP*8FGDX3!)/ \)S2J]>O#4H28KO/SY6!"Z4OA
MY_<E#J=Z*:^-%@I0DD[KNF]4V9?C :9&.(J<J@$5<.?J?3@4S)AL\HH:0RS7
M_5O/$5Y4$[X,U#;"]2NO<JX$,M?2P_%=QE&3QW=*BT?/)_>!'[_49("4#P^(
M&^%27K(/ \VQ(9\+AS/#C.<F?<_68N&Y8Z@U<.^$,]?/NN5>.Q$1J3G_3:"S
M$?[C)=M_E$*8*^?A #!CITD/L5P \BNQS/N4YJM&^'R7;)]/ 6>NKH>3OI2I
M5R:=NQ7#;\@BB-PXRO>X++[/4U71NT!K(YRV*[;3)HDQ5]'#N5[&T/H=M#OW
M.0AOO6 UB+Q=NWH7:&V$>W:EZIYM8<Q5]'!U+6.H2>_L,22+Y3$HH6Y"_"YL
MC"IZ#2ALA#=UQ?:FQ/!RG3R<T&6\-.DEK9C=F_;)*_$3TO(GO6G'">'>=G1-
MID'X47MHZ+R1B&YQ(1F[F8+YD]8\"&/WK_2?MU0MOK_0C?"]]\,GDT'R'+D3
MUPE=PDT#VAD1P+U&^&Y7;-]MU\S*9]_AH#"3C$DWL"A+??GI3#,S7QL=G7]I
MA(MYQ78Q:^-*7B7K<-HX3UEBL[I+H>:M $#Q4:"Z":YIRMMM]>9 RG7S<%28
M\<]BAFDO?B%A6L3[T7F7*%V\]3S0WP3O])S?I)2%*U?5PWEAQD2KR:5E,02(
MP0ZHJI&)T)]5'P@0-\'#/>=W<%8&G&N]QLG@*PF?@_W3>RVOUPR6?AZAB'I3
MH.FC_I, #?,]P-,$/S3E.ENK1?AR)3Z<(&;,M'B%\#$,QH1,(O!5NE&40")\
M;RIA#[-?A*8137#^4KZSE5@(,-?B?6HV<'YDN=F >LEWR;<!6R-\MB-A&P(Q
MREPUK;9Q-*Z:)H\%!\1W@W! Q@GL/+(5K]AO 7V-<+:.V$>!0G2Y6AT. 3-6
M6G2YGGPGBS2224K@<H/JO"V('XF62O[+@*P1KM41U[62 IEKM,H1XE6FT3Z9
M@8>&2J<KM+BRJ,N;?>Y:;ZYH4I:] BC0ZFV1S_R(+ /67O53L^FS._Y,1L,^
MG@-ZT?KD18YR_/$-+,7^0(W7)9/GKD-W3K+,/(Z&E#Q)Z<!;];3(*8;E5XJF
MV,T' X>-WHA9C<[M8EOZ+-""8*-A<TDHY34<U7:6FOAK,I<IOVHCU?R\\"30
M@6#EY_&((>E2'"CE;'3U_A%(RGG]24H'A@L1/!ZQ9G09CFJ[>SUR-GKK8$A_
M*SNC-Y\%6A"$ 7E\8LFZ'$G-N[2>M(U&ZMPW25FO/PET((C(\7C$BL.5X2AV
MM$,C9Y,6&=VS_B!.*+5)KQX$*O#98FL<8N_16S"JM:^N2<@F33&Z8<D)>>U!
MH *Q(<9)RBZ#4>QMUG3OVV@#B%M"!.&_S<>  @2[N9A'#/78AE++,J_%6*,)
M[<NAQ0O0VH.CHTL,:>0,YO!ENH:@%M=+GZ<F)VTK#"&Z&-*/B%?UK8>!&@03
MF,DFAHQ9.,KD_+??BH#NZ'CY+S9_OH:4O,7$GY /@K>P B%N]![].@[FV8G4
MC1N-O2!*0M(.YG,W3C.P6OZD38U)EY+KCUVXKQ [KO>SI7TGS6H$NJZ3"!+#
MH@&9962*(_+<=T?'7VR6 UZ2PIV+I<\"W0B\%!4>L\\9RI!A.+>J)!V3YF_6
MP29:5MX<D/#5'9-(O&[RW@,:$1C'//XQ5E$)5!A.JJIHC]%2BN7\H@O\MR!:
MT+_JZM'F"$ W@DV9QU,EC6+@JV9J(] MDU&V>R>*%F&@IDREKP!EF':T$JXQ
MM8<'J%IL!H&ZF S6Y8TJ.O.%%[P3$G7][\Z,? N2\,Z-W5DJ:;$**0P#"! $
M^GC<9:B5.D@,$:)*JE:_S91.TCGY1AQ/YFA >A"@'K$UQ3GS5858[$7?1"73
MZZ;!4#(572KA)Z9N&&5\8J@, TGC73:3D4MI<VC+9D 0N>1QB*D3VS"JG3';
MRMND,"U>9DKIX&I-R9- ,R+/:Y.7[,C/-@8,BXBF#(Y.+5[(7/;YEJ)Z[5E*
M]QFB)6>;HVSM*</19/TYL[CN+)MDR^E/\5F@&]O:L\91COZ4X*@E"RX-CXN.
M43\>HI2<F(S_I0.+C_L*CP$%"&1:RA:&_;%-?2V'IWJ\-!EQZWKTF<"5B/ZO
M/PET((BO,=C#D&HI!$2"->E+M@/?)^/8'2>Q6+9;#P,U"+Q)!I,8XF6AJ&\1
M5I:PT0L%+VX@D:?X\11\'T%0B<$6ADRWR*\ETUA/F"8=_$&0Q"]MA_+0]1V)
M)./MQ\&^16!Y,QC%VF>9.&I)0=.2\ZG)9?F>LM3QX^"'_YU$\>\NM(UP)03.
M>P]HQ+E8G[(7:PE U6+#1E7 :%%K)_R3A-%S$L[4=(#[(E")<W4_Y52+ED"T
MU()+!%I@TO!6$WTY=W :X*=L YP)H]I9HU$AF\V5B2)G_))$)(ZE$JRV'@>*
M4/G.:XQBK>U,'!C2%WAIJ1^YJZWG* Z=L:C^G-)8HZ-+HX="Z<=+O\V[2B'S
M*J44T\&1#I>9/J(,\%IB C6*Z_B+7N4<'J4B?M\)*E=IC 0XL!BR<BSG:9DJ
M[%H,'6NB/+K4JXG+VDG)Q!U3R2U[BG!WT?5'@1(LAK$6#UF;;"G,^E8N2TID
M\1#T+HBB%8GO>0;=HT<-H-B=3L7EP03O4WP8:M3J2V9;-56Q%V.SNZSEB$_3
M;=:\W9!6:PS:1S>Z/XE__?XA,S5U9PP"2+$X-%HRDM9Y/@.*<>Q/KO@FPRKY
M0M.F[)Y'@^29TA*3R?7[1PND=Q[Q$J\#Q5@"+UJ\9M@3\M"+H?E/KKHFO:X^
M&0>O)'QOS8/$CWO3'OW'LH/!O3,APT!.A16& 02H_"U5WC-469T%Q;C4)U=I
MDU[;^IK26BR(XZTNDXL7X/P-H*NQ/MP1VX?CHBW&Q#^Y3IJ,FN8\[Y,)@2K'
MKI^JT T9NQ'8:S+:R7J7TGK<6(?NB!TUE<1=/+#]W!I[;/(4*;L<T_7I1Z!V
M?)^*P,^J=<R939[$+P*5C77$CMF'3S*@BZ'63ZZH1L^T@_0XGQ(!W0U2+=+0
M6OE1@/[&NF+'G&-R50XL]7GG3; 1ZK-)C^PQ#*8D@AW.\>Y<Y]GUW/A=0Z-5
MQ@$,C?7)CMD^F08/\K.,G;>H1JC6=7AEU\0G4W<L;LU>^@)0U5B?[%CLDY6!
MS35R;X[7CFT>KWV4G1B0./;2@E]9Q$9TT,!\D2(Z::S_=<P_4!.!SG73[#4'
MB[JI=VNMI@.Q<9@X7BMN.V'X3G_XN^,QDQ"4Q@"<C?7"RB_0Z>#/E=?LM0Z;
MRFOTDEYN)GUT@PW"/G'GSPFU<H"HWO2.S!SOEO#W<95Q $-C?2O>'4!U'N3*
M>3CPNC1Z1?$Q.Y)Y6@1^YXV,$U"KWO0INB%4+^),%O](HM@=D]6>Q_6S= 8$
M5(UUN#BW(:LP(]=XLRT ;.JM2?^IV.JXYU?05Z6! $5C_2W.#4\=)N3Z:?:^
MB$W]-%KFWO4=;SG]*ZVG2@-1%&CNGVKQGZ&?.DS(]=/LU46+^FGT5E36N*0W
MA28FU/HRIJY5Q@6,C?7#.%>Q#/ D5^:]N9B@=X^SEL!"A[)\#AO?])'^PGWV
M"#R@%E@H'P-P-M9_*[]"JH,_5]ZKO5%>JRW2RR(ZU)%^3=- M.)A'V\#ML;Z
M8>6%#M20YU<A#L==ET;K+;2#<!&$=($ 3V,6NO%[:Q:2=(<;DG#.)YS[*E#:
M6)>,4Y9!#G:NKWMS&&:SX&9^ZIC>L8?:["_N^*5#28[?>PL"LA!9!1(C4(P8
MBG/J2X>]Q,JCS]5V;\[)].I\"G(#NO[$?74G=)N*OKN03C<-PGFJ)#W_WJ5F
MEC^[(6EM=YG$ ?G1 $]C_;#R^J#5.)&KZ]Z<C)W5<=UKR3K(F$O &**DW#F+
M.%A(J2?[;:"WL5[4F?BREQ!YKGYFZ[#95#^3)UC0#3UZ";S)VL3N^C=.[%R'
MQ!F_\&@7OPWT-M8GXM3'D$:>J]_>'$2=&:TD1\(QJ,*,]*8PA1W_?;EY/$7\
M:U;\-X'.QOHU9YQR<S*H<Y7;F[.E,Y-G2]!'O#?-PL;T.SQ"-QZEE)PWUODX
M8Y\/E</,M6AO3H",]EC_N/=(Q=4F<  <#0)/[F+H^BM 66/]!4Y/=C[<7+OV
MYDCFO ZGX)%J ) @HU;YLT!+8PW^<['!OX$S5Z2].1XYK[LBPV-Y'8&N/_:2
M"24N3V?AH:HR+F!LK$MPKE:S09$G>4F=+WNCS$;;!:1A4'#V5UL*C]JRYX&F
MQCH&YYPN VRLN5+MS2G'N=&V!4D$5U33U-+[94'"Y:R-1A/GG=^B2/0RE')M
MK,MPSNEZ( D\U[V].:JPV0J149'PADR)/W'89J+T^X"OL:X(O[&B+/9<8??F
ML.+"I%_26;A1,"&94]>*LG^ZXVLG(A.)NK82KP/%C?5>+MC>BSST7 /WYKS"
M:(/IW,AV4B,[F :KPFAS:F3'].NYD>WF1K:[-+)_N/'+"^$':4R,#Y@;Z^!P
MVEP;Y$VNY*C*U95RR41E>RTGR%#_;\@F >JNDXA*.8J6+:PCB1;0W'<!%RI'
M2B@"MG$@ [2!#14J)X-%9/SK+'C];4)<T+A3^ N@."TH&OW1*+UNFJ4J<=2J
MY$E*):X3%2%#MY6(#:M:U\9="^)R9^J2?9;;UFCS,4K?%0)%87.N7"]*()CK
MQUTSNXUVD5J&"%J3N>N[T.4F=E\)3#+H=Q.$]\Y8HK>4["! /0(WEL%4AG&E
MBJYY^Y'>^:OQ2CU4!Q(9ZZ?L%4"!0+,4&,Z)B+#Q5>M0BTUB5S8ORVV0Q%V%
M^2\!$@21$0EFR^O<&C)S.R,:>5F\Z?9(?/"_5[1Q-UC!6X %041#BN%L[>.#
M*ZK?+B,2*!77Y+%M>F-[H_A;>B@NM/CX;P*=""(04LQD&'U2 ,VYD6C4RVBM
M$$+9XW@W)'1?4YMYV;5(0KVX;XZ.C[X@<#FEF,E2+QF &(V]2NIU],6DZ]IS
M9P/B35?!<K%>,5X!RA X#U+L8R@4'UFQJ]*>:)+1P]/0C9RVYT11-@WOG!]1
MXDIL@]P7@4K$;L$:*UEGHQ+X,+3=-JQ;AOL=I]??NOXK%500OK?\"5Q%&I!Q
M K??^V01A! A$&N;XE" I &N0<INAO[I(2XV-]H3C31J]8<0DB*AI /*?0=H
M:X"E?\3I=2R 5NP[M"?*9-+&+RWS)=8GSFN40@R-BZ78R% I,;IJ_=@Q:I5>
MBV%6ZJ\S);/$"2?_'?A03'D6.O./>C&%DQ>AGBD-!"B:X :4=PK6QEML\+,G
MNFC2.5C:&BZ)=#P$\=M ;Q/<!$Y[7VF0:UUW&G(V:O&,*FLW!WFIO7#F^.Y?
MJ5R62:F#( G'1.;T37880(M $Q4$PSY14,2,(4"R<VD?Z;68WAU:J5U ?B!
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MT3Y 0[>B^.,W^ O3,!-__@=02P$"% ,4    " #=0*-*Q*:G/:.J   XEP<
M$0              @ $     86UE9"TR,#$W,#,S,2YX;6Q02P$"% ,4
M" #=0*-*GJNY6@,@  "X9 $ $0              @ '2J@  86UE9"TR,#$W
M,#,S,2YX<V102P$"% ,4    " #=0*-*#C1A0#8:  #ZI $ %0
M    @ $$RP  86UE9"TR,#$W,#,S,5]C86PN>&UL4$L! A0#%     @ W4"C
M2NI(-D:V6@  IQP& !4              ( !;>4  &%M960M,C Q-S S,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( -U HTH^PS19P,\  /H+#  5
M  "  59  0!A;65D+3(P,3<P,S,Q7VQA8BYX;6Q02P$"% ,4    " #=0*-*
MN2)P8>5^   HX0@ %0              @ %)$ ( 86UE9"TR,#$W,#,S,5]P
<<F4N>&UL4$L%!@     &  8 B@$  &&/ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
